Department of Medicine Annual Report
July 1, 2011 – June 30, 2012
Sunnybrook DEPARTMENT OF MEDICINE DEPARTMENT OF MEDICINE
ANNUAL REPORT
July 1, 2011 – June 30, 2012 Table of Contents Appendixes
MESSAGE FROM THE PHYSICIAN-IN-CHIEF 3 APPENDIX I: LIST OF FACULTY 36
EXECUTIVE SUMMARY 4 APPENDIX II: SUMMARY ACTIVITY REPORTS OVERALL DEPARTMENTAL SUMMARY 39 MEMBERS OF THE EXECUTIVE COMMITTEE 6 DIVISION OF CARDIOLOGY 40 COMMITTEE REPORTS 7 DIVISION OF CARDIOLOGY 46 9 FACULTY DIVISION OF DERMATOLOGY 50 Promotions 10 DIVISION OF ENDOCRINOLOGY New Appointments 11 AND METABOLISM 53
2012 Department of Medicine Award Recipients 12 DIVISION OF GASTROENTEROLOGY 56
External Leadership Positions 12 DIVISION OF GENERAL INTERNAL MEDICINE 59
Faculty Well-Being Committee 13 DIVISION OF GERIATRIC MEDICINE 66 DIVISION OF INFECTIOUS DISEASES 68 STRATEGIC PLAN 14 DIVISION OF MEDICAL ONCOLOGY 16 DIVISION REPORTS AND HEMATOLOGY 77 Cardiology 17 DIVISION OF NEPHROLOGY 99 Dermatology 19 DIVISION OF NEUROLOGY 105 Endocrinology 20 DIVISION OF REHABILITATION MEDICINE 123 Gastroenterology 22 DIVISION OF RESPIROLOGY AND CLINICAL General Internal Medicine 23 IMMUNOLOGY 125
Geriatric Medicine 24 DIVISION OF RHEUMATOLOGY 129
Infectious Diseases 26 MISSION, VISION & VALUES STATEMENTS 132 Medical Oncology & Clinical Hematology 27 ORGANIZATION CHART 132 Nephrology 28
Neurology 29
Obstetrical Medicine 30
Rehabilitation Medicine 31
Respirology & Clinical Immunology 33
Rheumatology 34
2 MESSAGE FROM THE PHYSICIAN-IN-CHIEF It has been a busy and productive year for the Sunnybrook Department of Medicine. We continue to see changes to our infrastructure and physical plant, most notably the merger this year of Sunnybrook with St John’s Rehabilitation Hospital, a change that offers us tremendous opportunity for regional and national leadership in rehabilitation services. Our researchers have had great success in obtaining peer-reviewed grant funding and publications, including five New England papers this year. Our educators have also had a great year, with outstanding teaching scores and rotation scores and a growing profile in Educational Scholarship, Research and Leadership. A record number of our faculty have been recognized this year by external organizations for their contributions locally, provincially, nationally and internationally.
This is my second annual report to you as Physician-in-Chief. When I took on this role three years ago, we developed together a Strategic plan, “Sharpening Our Focus” which was guided by three principles: 1) That we would strategically focus our efforts, 2) That we could align our priorities with the Hospital, Research Institute, and the University of Toronto, and 3) That we would maximize our impact through partnerships with our Toronto Academic Health Science Network and community partners. These principles guided the development of our long-term priorities and short-term goals. Dr. Kevin Imrie When we published this plan, I committed to updating you on our progress. This exercise is as much for me as it is for you as it allows me to reflect upon our shared accomplishments and helps me to focus on what we need to get done together in the year ahead.
I am immensely proud of our ourstanding faculty for all of their hard work and dedication in clinical care, research, education, and administration. I am particularly grateful to our Division Heads and senior committee chairs for their leadership. Finally I want to thank Denise Campbell for her work in preparing this report.
Thank you
Kevin
Kevin Imrie MD FRCPC
Physician-in-Chief, Department of Medicine, Sunnybrook Health Sciences Centre
Vice-Chair Education, Department of Medicine, University of Toronto
3 EXECUTIVE SUMMARY
About us:
The Department of Medicine is Sunnybrook’s largest Department on integration with primary care and community providers. We with 103 full time and 187 part-time physician members. We are have continued to expand our rapid referral clinic to provide an organized into 15 Divisions, including uniquely specialized services alternative to admission for many acute general internal medical such as Clinical Pharmacology and Obstetrical Medicine. Our problems and are working with other clinical departments and members work in all eight of Sunnybrook’s Programs, including programs to develop a common infrastructure to support integrated playing an important role in the new St. John’s rehab program. urgent episodic care. This QUICK clinic will bring together existing clinics including Rapid Referral, TIA, and RADAR clinics and will Clinical Care: Clinically, our divisions operate approximately 180 inpatient beds as well as numerous specialized outpatient clinics. add a new focus on acute ambulatory cardiac care including CHF These include unique services such as the Thromboembolism, (Congestive Heart Failure), chest pain and rhythm abnormalities. ALS, and HIV clinics as well as an increasing focus on acute The mid to long-term plans include expansion of these urgent outpatient services such as our Rapid Referral, TIA (Transient ambulatory services to include Respiratory Diseases, Cancer and Ischemic Attack), RADAR (Rapid Diabetes Assessment and Gastroenterology among others. Referral), TRAPP (Treatment of Respiratory and Pleural Problems) The second clinical priority has been a renewed emphasis on and EPIC (Effusion Procedure Interprofessional Clinic) Clinics. improving integration with primary care physicians and other
In 2011-12, our two main clinical priorities have been to continue the providers within our community. These efforts began in summer development of ambulatory acute care as well as a new emphasis of 2012 and have been facilitated by the recent announcement by
4 the Ministry of Health and Long-Term Care of the HEALTHLINKS such as Academic Medicine and Medical Education. They will initiative, which is designed to encourage communication among be joined in 2012 by Dr. Umberin Najeeb, a clinician educator family care providers, specialists, hospitals, long-term care, home with a focus on improving the experience and development of care and other providers. Sunnybrook’s leadership in clinical internationally-trained health professionals. We are also please information technology development, including the e-Discharge to be joined this year by three outstanding young teachers, Drs. system implemented within General Internal Medicine will be a Esther Bui (Neurology), Dov Gandell (Geriatrics), and Graham key asset as this initiative moves forward. Slaughter (General Internal Medicine).
Research: Our members have had a highly productive year. As Sustainability and accountability: Our main priority in this domain evidence of this, they now hold over $70 million in peer-reviewed this year has been to improve transparency and communication grant funding and this year, authored 633 publications, including within the Department and beyond. The Sunnybrook Department 5 papers in the New England Journal of Medicine. We continue of Medicine Partnership has completed its second successful to be guided by our cross-cutting focus on Health-Services year and has focused on improving its governance. This has Research, Quality and Patient Safety and Education Research included revising the partnership agreement as well as developing and Scholarship. We increased our practice plan investment in and approving explicit policies on confidentiality, pregnancy and research this past year by nearly 20% to further build upon last parental leave, non-partner members as well as career transitions. year’s growth. Particularly notable this past year has been the We have continued our poster campaign to promote the work external recognition our members have received for their work. We of the researchers and educators in the Department and have are also pleased to have been joined this year by two promising launched a series of videos, accessible on-line, that tell the stories researchers, Dr. Alex Leber, a clinician-investigator whose field of our researchers.
The future: 2012-13 promises to be a busy year. The recent merger of Sunnybrook with St John’s Rehab offers incredible potential for enhanced leadership in Physiatry and Rehabilitation Medicine. Sunnybrook’s ambulatory strategy offers the potential to build innovative new models of acute care which bridge the spectrum from inpatient to outpatient care while the Healthlink initiative will allow us to collaborate with primary care physicians in our community and other providers to provide more integrated and patient-centered care. We look forward to continued growth of our research enterprise with a continued focus on our cross- cutting priorities in Health Services Research, Quality & Patient Safety, Educational Scholarship and we look forward to the postgraduate accreditation visit by the Royal College of Physicians is cardiac imaging and Dr. Andrew Lim, a Clinician-Scientist in and Surgeons of Canada in April 2013. It should be a fun year! sleep medicine.
Education: Our two major priorities in this past year have been to improve the experience of our learners and advance educational research and scholarship. The investments we have made in partnership with the Hospital to improve the learner experience have had measurable impact as evidenced by the successful undergraduate accreditation visit this year and the significant gains we have made in teaching and rotation effectiveness measures at the postgraduate level. We continue to work with the Sunnybrook VP Education on improvements to our educational infrastructure and look forward to the 2013 postgraduate accreditation site visit. On the scholarship front, our cadre of educational researchers has had a very productive year securing peer-reviewed funding for their work and publishing in prominent medical education journals
5 L-R: Drs. David Berbrayer, RobFowler, James Perry, Richard Jay, Steve Shadowitz, Kevin Imrie, Maureen Trudeau, Greg Choy, Andy Simor, Ivy Fettes, Rajin Mehta, Neil Shear, Khalil Sivjee Absent: Drs. Johane Allard, Michelle Hladunewich David Juurlink, Christopher Morgan, Dr. Brad Strauss
MEMBERS OF THE EXECUTIVE COMMITTEE
Chair Dr. Andrew Simor – Infectious Diseases
Dr. Kevin Imrie – Physician-in Chief Dr. Maureen Trudeau – Medical Oncology/Haematology Dr. Michelle Hladunewich – Nephrology and Obstetrical Medicine Division Heads Dr. David Berbrayer – Rehabilitation Medicine Dr. Bradley Strauss – Cardiology Dr. Khalil Sivjee – Respirology & Clinical Immunology Dr. David Juurlink – Clinical Pharmacology & Toxicology Dr. Greg Choy (Interim) – Rheumatology Dr. Neil Shear – Dermatology Committee Chairs Dr. Ivy Fettes – Endocrinology
Dr. Johane Allard – Gastroenterology Education – Dr. Richard Jay
Dr. Steve Shadowitz – Deputy Physician-in-Chief Finance – Dr. Chris. Morgan & Division Head General Internal Medicine Research – Dr. Rob. Fowler
Dr. Rajin Mehta – Geriatric Medicine Faculty Well- Being – Dr Ivy Fettes & Liesly Lee (co-chairs)
6 COMMITTEE REPORTS
Education – Chair, Dr. Richard Jay
EDUCATION: The Department S. Shumak, G. Piliotis, C. Morgan, B. Wong and D. Juurlink of Medicine has had another who placed among the top 10% of teachers in the Department outstanding year in our academic city-wide (a disproportionally high number). Our clinician teachers mission of Medical Education, have also garnered nine nominations and 14 awards across the building on our strengths in entire spectrum of academic teaching endeavors ranging from Education Scholarship, Research the international/national to regional-provincial/local stage. Special and Excellence in Teaching. commendations to Ed Etchells (Colin Woolf Award – Continuing Education) and Anita Rachlis (W T Aitkins-Faculty Teaching Education Scholarship and Award - Undergraduate Education) who received two of the major Research: We continue to expand and embellish our leadership role in teaching awards for the Faculty of Medicine – University of Toronto Education Scholarship and Medical Education Leadership: Sunnybrook continues to play a major Dr. Richard Jay Education research. Several of our education leadership role at the University and Faculty of Medicine DOM members are Principal or Co-Investigators in both external level: Senior Academic Leaders: Brian Wong - Director of grants (e.g. RCPSC – Medical Education Research grants, AMS/ Faculty Development and Continuing Education in Quality and CanMEDS Research and Development grants) as well as internal Safety, Brian Murray - Director of Integrative Medicine. University grants (e.g. University of Toronto - Education Development grants Division Directors: Dermatology (N Shear), Gastroenterology (J. for Innovations in Education). Our members have published Allard), Clinical Pharmacology (D. Juurlink) and Medical Oncology extensively in high impact Medical Education journals such as (K. Pritchard). Postgraduate Program Directors: Dermatology Academic Medicine and Medical Education. As well, several of (S. Walsh), Hematology (G. Piliotis), Geriatrics (B. Liu)), Medical our clinician educators/scientists have been invited speakers at Oncology (S. Berry), Peters-Boyd Academy Director (M. Cooper) international and national forums for Medical Education Research. and the U of T lead for the Toronto Addis Ababa Academic We continue to be a recognized national leader in Patient Safety Collaboration (G. Piliotis) and Quality Improvement. Special mention should be made of Education Symposium: The second annual Education Ayelet Kuper who recently received a prestigious CIHR New Symposium was held on September 20, 2011 on Simulation Investigator Award. Umberin Najeeb (General Internal Medicine) and Other Technologies in Medical Education. It attracted a is a new clinician educator who will join the Department in the large audience not only from Sunnybrook but the University of coming year and will certainly augment our on-going education Toronto Medical Education Research community as a whole. This scholarly activities in years to come. annual event is the highlight of education scholarship activities Teaching: This year we welcomed several new education of our Department because of the focused format and the local, faculty members to the Department. Graham Slaughter national and international quality of our guest speakers. (General Internal Medicine), (Geriatric Medicine) Dov Gandel It has been a genuine pleasure to lead, facilitate and coordinate and Shirley Chow (Rheumatology) are all clinician teachers who the academic activities of an exceptional group of dedicated have already demonstrated and have been recognized for their clinician-teachers, educators and scientists throughout 2011- excellent teaching abilities and will surely enhance the Sunnybrook 12. We can all look forward to continued success and further Department of Medicine’s continued reputation for outstanding outstanding achievements in the on-going education mission of teaching excellence. We are particularly proud of of our nine the Department of Medicine. clinician teachers/educators: U. Najeeb, K. Sivjee, J. Hsiao,
7 Research
The Department of Medicine at Many members of the Department received external salary Sunnybrook Hospital celebrates a support for their research success, including Canada Research very productive year of research Chair holders Jack Tu, Don Redelmeier, and Kaveh Shojania; activities and accomplishments. Of Nick Daneman, a CIHR Phase II Clinician-Scientist; Dennis our departmental faculty, half are Ko, a CIHR New Investigator; Harindra Wijeysundera, a CIHR clinician-scientists or investigators, Institute of Health Services and Policy Research Fellow; Rob and the newest is Dr. Alex Leber Fowler, Heart and Stroke Foundation Phase II Clinician-Scientist; who joins the Division of Cardiology. Ayelet Kuper, a CIHR New Investigator; Urban Emmenegger,
Department researchers received over a Clinician-Scientist Awardee from the Prostate Cancer Canada; 340 peer-reviewed grants totaling $70 Richard Swartz, a Focus on Stroke Research Scholarship, from the Heart and Stroke Foundation, CIHR, and the Canadian Stroke Dr. Robert Fowler, Chair million, in addition to another 142 industry-sponsored and non-peer- Network; Sandra Black, the Deborah Ivy Christiani Brill Chair reviewed grants totaling nearly $10 million. Department members in Neurology and Andrea Gershon, a CIHR New Investigator authored 633 peer-reviewed and another 88 non-peer-reviewed Awardee for Pharmacologic Management of Chronic Disease publications. in Older Adults.
Due to this productivity and impact, members received over Department partners have been generous in their support of researchers and research activities and we have been able 118 individual awards, including Sandra Black (the Order of to successfully leverage this support via the federal Scientifi c Ontario), Mario Masellis (Early Researcher Award from the Research and Experimental Development program. The Ontario Ministry of Research and Innovation), Dennis Ko (C. Verma Young Investigator Award, Heart and Stroke Foundation department continues to enjoy a very collaborative relationship with Sunnybrook Research Institute and the Institute for Evaluative of Canada), Baiju Shah (Research Award for Diabetes, South Clinical Sciences: partnering with clinical programs to help improve Asian Professional Network for Health Awareness), Fred Saibil (Crohn’s and Colitis Foundation of Canada Finkelstein Prize), our collective research space on K3-West; working with SRI to create more seamless accounting and research administration Donald Redelmeier (Award for Outstanding Contributions, International Traffi c Medicine Association and the Anne and Neil interactions; and ensuring departmental research employees McArthur Award for Outstanding Canadian Research, McMaster have an appropriate home within SRI. We are thrilled to promote research activities internally with our ongoing scientist poster University), Maureen Trudeau (Best Paper Award, Journal of series, and a new investigator video link to help the world learn Oncology Pharmacy Practice), David Spaner (Governor General’s Research Award, Leukemia and Lymphoma Society of Canada), more about researchers at Sunnybrook. Ellen Warner (U of T Division of Medical Oncology Investigator Award), Lorne Zinman (ALS Queen Elizabeth II Diamond Jubilee Medal), Andrea Gershon (Ontario Lung Association/Pfi zer Canada Smoking Cessation and COPD Award and the Department of Medicine Junior Investigator Award), Brad Strauss (Department of Medicine Senior Investigator Award and Rob Fowler (Commonwealth Fund Harkness Fellowship in Healthcare Policy).
8 FACULTY
Full-Time Faculty by Division
Our faculty consists of 103 full-time and 187 part-time members FULL-‐TIME FACULTY by * DIVISION 25 25 20 20
15 13 10 11 5 6 5 3 4 6 0 3 4 1 2 Cardiology Dermatology Endocrinology
Gastroenterology Geriatric Medicine Nephrology Neurology Infec7ous Diseases
General Internal Medicine Rheumatology Rehabilita7on Medicine Respirology & Clinical Medical Oncology/Haematology
The OB Medicine and* Clinical The Pharmacology OB Medicine and & Toxicology Clinical divisions Pharmacology are &Toxicology divisions not are represented not represented on the chart on the as all members chart as are all cross-appointed members are cross-‐appointed
Full-Time Faculty by University Rank
19% of the full-time faculty are full-professors and this compares with 25% across the University-wide Department of Medicine. FULL-‐TIME FACULTY by UNIVERSITY RANK
Professor, 20
Lecturer, 6
Assistant Professor, 55
Associate Professor, 22 University Rank Sunnybrook UofT Professor 19% 25% Associate Professor 21% 26% Assistant Professor 53% 43% Lecturer 6% 6% TOTAL 100% 100%
9 Full-Time Faculty by Job Description 49% of the faculty are researchersFULL-‐TIME FACULTY by JOB DESCRIPTION
Clinician Administrator, 3
Clinician Educator, 9
Clinician Teacher, 41
Clinician Inves7gator, 26
Clinician Scien7st, 24
Promotions
Congratulations to our physicians who were promoted effective July 1, 2011.
Professor Associate Professor
Dr. Craig Earle Dr. Scott Berry Dr. Liesly Lee
10 New Appointments We welcomed the following new faculty:
Cardiology Geriatric Medicine
Dr. Alex Leber is an interventional Dr. Gandell is a Geriatic Medicine Cardiology staff member participating consultant in the Division of Geriatric in the PCI and STEMI program as Medicine. He is a Lecturer and a well as in the TAVI program. He is an Clinician-Teacher at the University of Associate Profofessor and a Clinician- Toronto. His area of academic interest Investigator at the University of Toronto. is the role of comprehensive geriatric He is also the Clinical Director of the assessment in older trauma patients. Imaging Research Centre for Cardiac Interventions (IRCCI). His area of academic interest is advanced cardiac Dr. Dov Gandell Dr. Alex Leber imaging using MSCT and MRI to characterize atherosclerosis and to guide cardiac interventions. Neurology He pioneered in cardiac CT research and was part of the team Dr. Esther Bui is an epilepsy developing the first in men coronary MSCT exams back in 1999. consultant in the Division of Neurology. She is a Lecturer and a Clinician- General Internal Medicine Teacher at the University of Toronto. Her area of academic interest is Dr. Slaughter is an internal medicine consultant in the Division epilepsy in pregnancy, women’s health of General Internal Medicine. He is in epilepsy and medical education. a Lecturer and Clinician-Teacher at the University of Toronto. His area of academic interest is ambulatory Dr. Esther Bui medicine, and diversion of patients and daughter from inpatient medicine. Dr. Andrew Lim is a neurology and sleep medicine consultant in the Division of Neurology. He is an Assistant Professor and a Clinician- Dr. Graham Slaughter Scientist at the University of Toronto. His area of academic interest is the genetic dissection of sleep and circadian traits using contemporary statistical genetic approaches, and the elucidation of their relationship to Dr. Andrew Lim the risk, presentation, and treatment of common medical diseases, including stroke, heart disease, neurodegenerative disease, and cancer.
11 2012 Department of Medicine Award Recipients
Teaching Research
Young Teacher Award Junior Investigator Award • Dr. Brian Wong • Dr. Andrea Gershon
In-Patient Teaching Award Senior Investigator Award • Dr. Gemini Tanna • Dr. Bradley Strauss Pre-Clerkship Teaching Award • Dr. Grant Chen Leadership
Ambulatory Teaching Award Department Of Medicine Leadership Award • Dr. Janey Hsiao • Dr. Michelle Hladunewich
Part-Time Teaching Award Mentorship • Dr. Andrew Smaggus William J. Sibbald Faculty Mentoring Award Continuing Education Award • Dr. Kaveh Shojania • Dr. Ilan Lashevsky External Leadership Positions
Peters-Boyd Academy Director • Dr. Brian Wong, Director, Faculty Development & Continuing Education • Dr. Mary Anne Cooper in Quality & Safety
U of T Division Directors U of T Division Directors • Dr. Johane Allard – Gastroenterology • Dr. Johane Allard – Gastroenterology • Dr. David Juurlink – Clinical Pharmacology • Dr. David Juurlink – Clinical Pharmacology • Dr. Neil Shear – Dermatology • Dr. Neil Shear – Dermatology • Dr. Kathy Pritchard – Medical Oncology • Dr. Kathy Pritchard – Medical Oncology • Dr. Khalil Sivjee (interim) – Respirology U of T Program Directors U of T Program Directors • Scott Berry • Gena Piliotis • Scott Berry • Gena Piliotis • Barb Liu • Scott Walsh • Barb Liu • Scott Walsh Director, Toronto Dementia Research Alliance U of T Educational Leaders • Sandra Black • Dr. Anita Rachlis, Lead Scientist, Colo Cancer Check program, CCO Faculty of Medicine Clerkship Director • Jill Tinmouth • Dr. Brian Murray, DOM Director of Integrated Medical Education Canadian Hypertension Education Program Chair • Sheldon Tobe
12 Faculty Well-Being Committee
The Department has established a Faculty Well-Being committee with the aim to further enhance the environment of the department physicians by focusing on issues relating to their personal, academic and social lives. The Committee is led by Drs. Ivy Fettes and Liesly Lee and will advise the Physician-in-Chief on issues relating to faculty well being and satisfaction.
Last year, five meet and greet luncheons were held; these were hosted by the divisions of Cardiology, Endocrinology, Medical Oncology/Hematology, Nephrology and Neurology. Feedback continues to be very supportive and the plan is to have luncheons in the upcoming academic year. A retirement planning seminar was also held and an information session for incorporated members, to give information about the practical aspects of managing their corporations is being planned. L-R: Drs. E. Piliotis, B. Shah, A. Zahirieh, L. Lee (co-chair), A. Tandon Seated: Dr. I. Fettes (co-chair) Absent - Drs. K. Imrie and M. Myers
13 STRATEGIC PLAN Our Strategic Plan 2010-2015, “Sharpening our Focus” was developed in 2009 and we accomplished most of our goals outlined for 2010-2012. The following goals for 2013-2014 have been developed and are currently being worked on.
14 SHORT-TERM GOALS 2013-2014
Quality Sustainability/ Clinical Care Research Education Accountability
• Ensure all divisions • Establish named • Make process for • Develop and implement a make outpatient notes professorship and dinner awarding teaching late career transition policy accessible in EPR for the DOM Resident stipends more transparent, • Develop and implement a • Ensure all divisions Research Day focused and merit-based global budgeting model for implement processes for • Establish a funded • Develop and deploy a the academic budgets expedited access from the research chair for DOM regular Departmental • Implementing performance ED, RRC, and inpatient • Complete the transfer education newsletter assessment for wards of research staff from • Nominate at least four Management Committee • Formalize discharge clinic Sunnybrook Department (4) DOM members for members and committee visits in order to improve of Medicine partnership external awards each year chairs care transition from (SDMP) to Sunnybrook • Ensure each rotation has • Revise the SDMP inpatient to outpatient Research Institute (SRI) a structured orientation partnership agreement • Enter formal partnerships • Increase DOM research as well as updated goals • Implement a new with 20 community contributions to SRI and and a rotation manual pregnancy and parental primary care physicians the SRED program by 20% accessible online leave policy • Decrease patient census • Establish a mechanism to • Develop and implement per team on GIM to < 25 find adequate work space a policy for non- (15% reduction) for DOM and affiliated partner members of the Programs’ clinical research department staff in the hospital • Explore the feasibility of • Increase support for DOM implementing stipends for Clinician Scientists and division heads Investigators, in line with • Develop and report one other University of Toronto measure of access, one hospitals measure of process and • Improve visibility and one measure of outcome promotion for DOM for each division Research within and • Improve physician hand outside Sunnybrook hygiene compliance to through deployment of over 90% videos on the web • Deploy a departmental • Conduct an external portal to improve review of the DOM communications research activities and committee functioning
15 DIVISION REPORTS There are 15 subspecialty divisions in the Department of Medicine. Appendix 1 lists faculty by Division.
16 Cardiology
The Division of Cardiology consists of 20 full-time cardiologists, 1 major part- time cardiologist, and four part-time community cardiologists. The division works with the Schulich Heart Program to provide care of patients with cardiac and vascular diseases, focusing on coordinated and integrated cardiovascular services; cardiac interventional and structural procedures, acute coronary syndromes, and ambulatory care.
Division Head: Dr. Bradley Strauss Clinical: Education:
Over 3300 diagnostic cardiac angiograms, 1800 coronary The division is one of three University of Toronto teaching units, angioplasties, 50 Transaortic valvular implants, 25 Mitra clips, attracting trainees in Interventional Cardiology, Electrophysiology, 360 pacemakers, 230 ICDs and over 240 EP studies/ablations and Cardiac Imaging (Echocardiography, MRI, CT scanning) are performed annually. Inpatient activities include emergency from the University of Toronto as well as from other prestigious care, an active cardiology ward and CICU and hospital-wide institutions, nationally and internationally. The teaching program cardiac consultation services. In the past year, the CICU has involves undergraduate and postgraduate trainees (residents and now expanded its activities to include full ventilation. Outpatient subspecialty fellows). activities involve supporting a large ambulatory interventional/ We have reorganized the clinical rotation of PGY1 in the past diagnostic catheterization program as well as leading edge echo year to provide additional exposure to cardiac critical care and services, where over 9600 echocardiographic procedures are cardiac consultations. performed annually. Sunnybrook echo lab is one of only 3 echo labs in Canada accredited by the Intersocietal Accreditation Research: Commission (sponsored by American College of Cardiology/ American Society of Echocardiography) for adult echo, trans Major research foci are image-guided cardiovascular interventions esophageal echo and stress echo. Cardiology Clinics, including and cardiovascular outcomes and health care utilization. Collectively, the Arrhythmia Clinic and the Device Clinic (pacemaker, ICD) the division members hold almost $59 million in peer-reviewed record over 6900 visits annually. funding as principal investigators and co-investigators. In partnership with other members of the Schulich Heart Program Our STEMI program has >400 activations annually. We held the and the Sunnybrook Research Institute, the division has access first annual THAC (Toronto Heart Attack Collaboration) STEMI to the Imaging Research Centre for Cardiovascular Intervention conference at Vaughan Estates in September 2012 with 150 (IRCCI), which was funded several years ago by a major national participants and Dr. Brahmajee Nallamutho from University of peer-reviewed CFI grant, The Cardiology faculty produced over Michigan as the key-note speaker. 80 peer reviewed publications over the past year and held over $8.7 Million in research grants the last year.
17 Recent Achievements: Future Plans:
The Cardiology division has now completed the D3 renovations, The structural heart disease program will shortly be starting a new including the Odette Family In-Patient ward, the Brian W. Gilbert procedure, renal artery denervation for patients with uncontrolled Cardiac Intensive Care Unit and the Short Stay Unit. The Cardiology hypertension. division shares the in-patient ward with Schulich Heart Centre partners, Cardiovascular Surgery and Vascular Surgery, in an innovative care model.
The expertise and efficient health care delivery of the cardiac interventional and EP services continue to be recognized by the Ministry of Health with further expansion of some clinical volumes. We are one of six provincial sites recently awarded funding from the Ministry of Health for tranaortic valvular implants.
Sunnybrook cardiology recently performed the first-in-man collagenase trial for patients requiring angioplasty procedures for chronic total occlusions. A large international trial of collagenase for >400 patients, CTO-2, will be initiated in spring 2013 and Sunnybrook will be a leading centre.
The structural heart disease program continues to grow and expand. Currently we are performing 50 TAVI (transcatheter aortic valve implantations) annually and with the recent provincial funding support, will be able to increase TAVI volume to 75 cases next year and 90 cases the following year. We have an established program in mitra clips for patients with mitral insufficiency, approximately 25 cases annually. The structural program continues to mature, and we now have a dedicated structural heart disease clinical/ research fellow.
Dr. Alex Leber joined the Division of Cardiology in February 2012. Dr. Leber, from Munich, is an interventional cardiologist with an international reputation in cardiac imaging, particularly CT angiography.
A number of Cardiology divisional members have received special awards and recognitions: • Dept. of Medicine CME event – Dr. Ilan Lashevsky • Dept. of Medicine Senior Investigator Award – Dr. Bradley Strauss • Fifth Annual Leo N. Steven Excellence In Leadership Award.– Dr. Chris Morgan • MDMSA Distinguished Service Award – Dr. Chris Morgan • The Queen Elizabeth II Diamond Jubilee Medal in recognition of his contributions to Canada - Dr. Brian Gilbert
18 Dermatology
The Division of Dermatology consists of 3 full-time members, 2 clinical associates and 5 part-time members. Services include treatment of skin, hair and nail-related conditions such as eczema, psoriasis, hair loss, skin cancers, acne, and rosacea. The Division provides specialized testing and offers a comprehensive service for cosmetic concerns and records approximately 40,000 patient visits per year in its outpatient clinics.
Division Head: Dr. Neil Shear
Clinical: • Dr. Hara Keelan (MRCP(I) Dublin University, Ireland) is completing a 1 year research fellowship on the newest treatments for The division is the leading clinic in Canada for patients with skin pemphigus vulgaris, a life-threatening blistering skin disease. blistering diseases and skin lymphoma. Working closely with the Odette Cancer Centre, members care for patients with skin • Dr. Jennifer Salsberg (Dermatology FRCPC University of cancers, as well as people at high risk of developing skin cancer, Toronto), is competing a 1-year fellowship with Dr. Kucy Pon and patients experiencing skin side effects of chemotherapy. The in aesthetic dermatology and a focus in Education. division has facilities for laser care, camouflage makeup, injections, patch testing and surgical skin treatments. Research: Members are continually working to improve therapies and the Education: safe use of medications and this work has translated into many Sunnybrook Dermatology provides training for all medical students areas of research. New treatments for disease such as pemphigus at the University of Toronto, and for all dermatology residents. The and psoriasis have been pioneered in the clinics. We are excited undergraduate University program in Dermatology is directed by at the opportunity to recruit Dr. Raed Alhusayen and Dr. Akerke Dr. Perla Lansang. The new program is now in its second year Baibergenova to our Dermatology division as Clinical Associates. and has been innovative and well received. Dr. Alhusayen’s clinical focus is in the field of Advanced Medical Dermatology; his investigative work has varied from large database The postgraduate University program directed by Dr Scott Walsh studies to better understand if there is a relationship among is the largest in Canada with 38 trainees over 5 years. Scott has isotretinoin, severe acne and inflammatory bowel disease. This latter received many accolades for his superb teaching and leadership. work was published in the Journal of Investigative Dermatology Dermatology Fellows: (the highest impact dermatology publication). Dr. Baibergenova • Dr. Ru’aa Al Harithy (Dermatology FRCPC University of has also just published in the same journal describing work that Toronto; Saudi Arabia) is completing a Masters degree in Public she completed at the top dermatoepidemiology institute in the Health and is continuing research activity into mechanisms United Kingdom, in Nottingham.. and treatment of hair loss. • Dr. Roni Dodiuk-Gad (Dermatology staff, Technion University, Future Plans: Israel) is completing a 2 year fellowship in Advanced Medical Sunnybrook is the focus of skin epidemiology research in Canada. Dermatology with a focus on Clinical Pharmacology. The knowledge and skills of this field are much needed in the • Dr. Phil Laws (Dermatology FRCP (UK) Manchester) is doing specialty. On-going excellence in education at all levels is a a 2 year fellowship in Advanced Medical Dermatology with priority of the division. a focus on Critical Thinking and Cutaneous Lymphomas.
19 Endocrinology
The Endocrine Division comprises five full-time Endocrinologists plus Community and Women’s College Hospital Associated Endocrinologists, a nurse practitioner, nurse educators and dieticians.
The full-time Endocrinologists are: Dr. Ivy Fettes (Division Head) Dr. Julia Lowe, and Dr. Jay Silverberg Dr. Jeremy Gilbert Dr. Baiju Shah
Division Head: Dr. Ivy Fettes Clinical: Education:
The Division offers outpatient clinics in General Endocrinology, Staff from the Endocrine Division is involved in local, national diabetes mellitus including diabetes in pregnancy, polycystic and global education programs. We participate in the training ovarian syndrome, thyroid problems including thyroid issues in of undergraduate medical students, postgraduate residents, pregnancy and post partum, and pituitary disease. graduate students and other physicians and health professionals, including nurses, nurse practitioners and dieticians. A new Rapid Diabetes Assessment and Referral (RADAR) Clinic was established in 2012, and provides urgent care for patients A structured program with specific training objectives is offered to with uncontrolled Diabetes Mellitus. medical residents and Endocrine residents/Fellows. From Monday to Thursday the residents spend one-half day in clinic and one-day The Endocrine Division and the Department of Family Practice work closely together to provide ambulatory patient care and seeing in-patients. Friday mornings they attend Endocrinology education through the Sunnybrook Diabetes Education Program academic half-day lectures at the University of Toronto. Friday (SUNDEC). Patients can refer themselves to SUNDEC. Special afternoons are spent seeing and discussing in-patients with the programs are provided for older patients with diabetes, for people Endocrinologist on call. Informal teaching is conducted on a with PCOS and pre-diabetes, and for patients on the insulin pump. regular basis during the various Endocrine clinics. Formal teaching sessions are held throughout the week. On Monday mornings The Division provides clinical support for all of Sunnybrook’s from 8 to 9 a.m. Dr. Silverberg talks about thyroid issues. On strategic priority programs including the Women & Babies program, Thursday mornings from 8 to 9 a.m. the Endocrinologist on the Schulich Heart Centre program, the Odette Cancer Centre call teaches on a variety of Endocrine topics. Dr. Gilbert does program, and the Trauma Emergency & Critical Care program. a one-hour session called “Gab with Gilbert” with residents on We provide rapid turnaround glucose management for same-day a weekly basis. Sunnybrook Endocrine Rounds are held every surgery patients with diabetes on insulin. Wednesday from 8 to 9 a.m. The presentations may be clinical We do consultations offered to northerly and rural general or research related, and are done by residents, Fellows and practitioners via Telemedicine Ontario. staff from a variety of disciplines in Endocrinology or related to Endocrinology. City-wide Endocrine rounds are research rounds We have an Endocrine test centre in which we perform diagnostic based at the University of Toronto, and are held every Friday from testing, primarily for adrenal and pituitary problems. 8 to 9 a.m. prior to the academic half-day lectures.
20 Dr. Fettes, Dr. Silverberg and Dr. Gilbert are actively involved in Recent Achievements program planning of Endocrine Education at the national level, In 2011 Dr. Gilbert received the George L. A. From Post-graduate through the Canadian Society of Endocrinology & Metabolism Teaching Award in Endocrinology & Metabolism from the University (CSEM) and the Canadian Diabetes Association (CDA). Dr. Gilbert of Toronto. In October 2011, Dr. Fettes received the Canadian is the Faculty Advisor for the Residents Council of the CSEM. This Society of Endocrinology & Metabolism Robert Volpe Distinguished involves organization of an Annual Residents Educational Program Service Award. and facilitation of the participation of residents in the Annual Professional Conference of the Canadian Diabetes Association/ The Sunnybrook Endocrine Division continues to be highly rated for Canadian Society of Endocrinology & Metabolism. Dr. Silverberg the training program for rotating Medical and Endocrine residents. is the President Elect of the CDA Clinical & Scientific section. Two of the important publications from Endocrine Division staff in Dr. Lowe is involved in educational programs in Ethiopia, Guyana 2012 related to Diabetes in Pregnancy. Dr. Shah was the Senior and Australia. She is the academic lead for the University of Author of a paper describing the increased risk of subsequent Toronto Division of Endocrinology in the global partnership diabetes after gestational diabetes in different ethnic groups with Addis Ababa University. Dr. Lowe is also the University of (Diabetologia 2012; 55: 2148-53). Dr. Lowe was a contributing Toronto Endocrine lead in the Multidisciplinary Guyana Diabetic author to a paper for the HAPO Study Cooperative Research Group Foot project, which is a collaborative effort between Canada and in a recent hyperglycemia and adverse pregnancy outcome study, Guyana to develop a multi-educational program in diabetes and suggesting an A1C measurement was not a useful alternative to hypertension in Guyana. an OGTT in pregnant women (Diabetes Care 2012; 35: 574-580). The Endocrine Division underwent an External Review in January Research 2012. The plans are for recruitment of a new Division Head since Dr. Fettes has completed her two terms, and for recruitment of a Our research focuses on diabetes mellitus and quality improvement Junior Endocrinologist with an interest in Quality Improvement. initiatives. The division undertakes basic research into the genetics and immunology of Type 1 diabetes mellitus, and health services in Epidemiology research in diabetes mellitus, through the Institute of Clinical Evaluative Sciences (ICES).
21 Gastroenterology
The Division of Gastroenterology consists of six full time faculty members and one clinical-associate who share a clinical focus on all aspects of gastroenterology and hepatology, in addition to the Division Head who holds an administrative position. Faculty members have particular expertise in gastrointestinal oncology, inflammatory bowel disease nutritional support and therapeutic endoscopy.
Division Head: Dr. Johane Allard Clinical: Recent Achievements: Working with Sunnybrook’s care programs, including Odette Cancer Research funding: Centre, Trauma, Emergency & Critical Care and Veterans & Community, • Assessing quality of colonoscopy. Canadian Cancer Society, members provide inpatient and outpatient consultative services and CCO. Dr Tinmouth endoscopic procedures. The division’s gastrointestinal endoscopy • Assessing incidence and prevention of esophageal adenocarcinoma in persons with gastroesophageal reflux. service provides state of the art diagnostic and therapeutic intervention Connaught Foundation. Dr Tinmouth for gastrointestinal bleeding, pancreatico-biliary diseases, colorectal • Improving gastric cancer survival: development and cancer screening and prevention, and palliative endoluminal stenting measurement of quality indicators. NCIC. Dr Tinmouth for malignant disease. New endoscopic programs in development • Colorectal cancer screening. CIHR Dr. Tinmouth include endoscopic ultrasound and enteroscopy (including both • Anal cancer screening. NCIC. Dr Tinmouth video capsule and push optical enteroscopic imaging). • Investigating impact of ColonCancerCheck feasibility. CCO. Dr Tinmouth • Dr Tinmouth: New Investigator Award in HIV/AIDS Biomedical/ Education: Clinical Research. CIHR • Several clinical trials in IBD, UGI bleed and polyp prevention Members provide expertise and training for medical students, (as participating site) Dr Saibil, Dr Cohen and Dr Bernstein residents in internal medicine, gastroenterology, general surgery • Quality assessment of simulator-based endoscopy curriculum. and specialty gastroenterology fellows. Students at all levels are DOM U of T. Dr MA Cooper, Dr Yong and Dr Tinmouth exposed to a wide range of clinical issues within the outpatient New positions: and inpatient services. Excellent teaching rounds and clinical conferences are provided on an ongoing basis. This year, the • Academy Director for Peters-Boyd Academy : Dr MA Cooper • Dr Tinmouth as Clinical-Scientist Lead for CCO Division of Gastroenterology at Sunnybrook had the highest ColonCancerCheck teaching rotation score across the city, for gastroenterology. Future Plans include: Research: • Recruiting a clinician-teacher with a Master in Education to further improve the education program in GI and expand The research accomplishments of the division include leading the research program in education edge research projects in colon cancer and epidemiology with the • Recruiting a clinician-scientist to conduct epidemiologic Institute for Clinical Evaluative Sciences, as well as anal cancer, research to assess the impact of new technology in screening esophageal adenocarcinoma & gastric cancer. The division is a and treating gastrointestinal cancers. partner with the Ministry of Health & Long Term Care Ontario on • Patient Safety and Quality-Improvement initiatives are being an innovative nurse flexible sigmoidoscopy program, which aims developed by Dr Bernstein who is a member of the newly to increase colorectal cancer screening capacity in Ontario. In formed Quality Improvement and Patient Safety Committee addition, there is an active clinical trials program in inflammatory within the University of Toronto GI Division. bowel disease and research on the quality of and education in • In addition to current endoluminal stenting procedures, it is planned to add other endoscopic stenting procedures gastrointestinal endoscopy. The division is also actively involved such as esophageal, gastroduodenal and colonic stenting in research regarding endoscopy simulation. procedures in the coming year.
22 General Internal Medicine
The Division of General Internal Medicine (GIM) has 12 full-time faculty members who deal with preventing, diagnosing and treating adults with complex multi- system illness in the inpatient and ambulatory setting. The division is the largest admitting service in the hospital and is responsible for the majority of patients admitted to the Department of Medicine at Sunnybrook. Members also provide consultative services for medical issues in all areas of the hospital.
Division Head: Dr. Steve Shadowitz
Clinical: Recent Achievements:
Approximately 5,000 patients are admitted to GIM annually. In In the last year, the division in cooperation with the University of addition, the Division performs about 1,300 consultations each Toronto Department of Medicine, has developed a fifth clinical year for other departments. The GIM Division is responsible teaching unit (Silver Team). This team was initiated to improve for two unique and highly innovative programs, the Hospitalist the service to education ratio on GIM, and to improve the clinical Training Program as well the Sunnybrook Patient Safety Unit. experience of students and trainees. Other achievements include Both undertakings are firsts in Canada and both have attracted the purchase of a portable ultrasound machine to improve the considerable external attention. safety of bedside diagnostic procedures. Under the leadership of Dr Graham Slaughter, we are studying the clinical and educational Education: impact of bedside portable ultrasound. We have recruited Dr Graham Slaughter, a clinician teacher whose interests include In addition to its major clinical presence, the GIM Division is also ambulatory care GIM. We have recruited Dr Umberin Najeeb, home to many outstanding educators. Members have been the a clinician educator whose interests include the international recipients of numerous prestigious awards for medical education. medical graduate educational experience. Some of these awards include the PAIRO Clinical Teaching Excellence Award, and such Faculty level honours as the W.T. Future Plans: Aikins Award, the “Silver Shovel” Award, the E. Mary Hollington Award, and the Deans’ Postgraduate Teaching Excellence Award. Our division continues to work with the hospital to improve the At the University Department of Medicine level, GIM members flow and care of patients admitted through the ER. have won the Department of Medicine Teaching Excellence Award and the William Goldie Award.
Research:
Together GIM members hold over $2 million of peer-reviewed funding as principal investigators and more than $1 million as co-investigators. Members have publications in peer-reviewed journals such as the New England Journal of Medicine, JAMA, The Lancet, CMAJ, and Annals of Internal Medicine. In recent years, members have been awarded two Canada Research Chairs in Health Services Research, Career Scientist Awards from the Ontario Ministry of Health and Long Term Care, and a Senior Scientist Award from the Canadian Institute for Health Research.
23 Geriatric Medicine
The Division of Geriatric Medicine consists of four full-time members as well as several part-time physician members. The division was pleased to welcome Dr. Dov Gandell to our group in 2012. Dr. Gandell is a clinician-teacher with a strong reputation as a teacher and will also be involved with quality improvement. The group works closely with the Brain Sciences Program, the Veterans and Community Program and the Regional Geriatric Program of Toronto to provide a full spectrum of patient care for seniors from comprehensive, interprofessional assessments to outreach and in-home treatments. The Director of the Regional Geriatric Program of Toronto is a member of the division.
Division Head: Dr. Rajin Mehta
The program underwent an external review this year. Key findings Clinical: included: The division provides consultations to all areas of the hospital. 1. The provision of “patient centred, easily accessible and Members also provide specialized geriatric ambulatory consultation, well rated services” including the multidisciplinary memory clinic and specialized falls 2. “Dedicated” and “hard working division members who go prevention program, as well as the Day Hospital. The geriatric beyond their call of duty” outreach team provides in-home multidisciplinary assessment of 3. A “Strong interprofessional team (which) is unparalled in the frailest homebound seniors. many jurisdictions in Canada” with “high work satisfaction” The division has several new services this year. They include a 4. There is a “very positive learning environment” “and its Geriatric Trauma Consultation Service that is the subject of an members have consistently exceeded expectations in onging multi-hospital study. Additionally, and in line with provincial fulfilling their teaching mandate” directives, participation in the Impact Clinic, a multidisciplinary collaboration with Family Practice, Allied Health and Geriatric Medicine for frail seniors has also been instituted. Across the spectrum of our services we provide over 6,000 total patient visits per year.
Key areas for development relate to the limited number of division members and limited funding for Geriatric Medicine. Suggestions included a strategic alignment with hospital priority programs to focus the division’s limted resources and this strategy is currently being implemented.
24 Education: Leadership:
Members of the division are sought after teachers, both locally Division members provide leadership to geriatric initiatives including and internationally with multiple elective trainees. We provide leading the RGP and various senior friendly strategies that range inter-professional education at all levels and have been recognized in scope from local, regional, provincial and national initiatives. through several awards. Several members are involved at a national Members are also involved in a number of physician management level including involvement on the Royal College Examination committees including the Sunnybrook Department of Medicine Board. The University of Toronto Program Director for Geriatric Management Committee and Vice Chair of the Sunnybrook AFP. Medicine is located at Sunnybrook as is the co-director for Additionally, they are involved with ongoing work for the CPSO. undergraduate education. The division provides direct supervision for over 100 students annually. The education program is the Future Plans: highest rated Geriatric Medicine program amongst the internal The division is looking to establish further linkages with programs medicine trainees at U of T. where preliminary evidence suggests improved outcomes through Research: such collaborations. Our next focus will be on geriatric oncology, this will provide for further research opportunities, while studying The division’s research focuses on health services evaluation and such models of care. quality improvement initiatives, such as the early mobilization, multisite project, and The Virtual Ward project. This is a CIHR funded UofT collaborative RCT looking at improving the transition of care from the hospital to the community. Our Proactive Geriatric Trauma Consultation Service study was also implemented this year and is going well. We are also active collaborators on a number of studies on falls prevention and patient safety. In total, there is more than 3.5 million dollars in peer reviewed funding relating to the division’s research.
25 Infectious Diseases
The division has two full-time and three part-time members who focus on the diagnosis, treatment, and prevention of infectious diseases, specializing in hospital-acquired infections, antimicrobial resistance, and HIV infection.
Division Head: Dr. Andrew Simor
Clinical: surveillance to better understand the epidemiology and outcome of significant healthcare-associated infections. Division members The division provides inpatient and outpatient consultations in continue to be successful in garnering peer-reviewed funding, infectious diseases. The interdisciplinary HIV Ambulatory Clinic and as a result of their investigations, there were numerous peer- provides HIV-related infectious diseases, renal, endocrinology and reviewed publications in high impact medical journals. nursing care, with social work counseling. The division plays an active role in the hospital’s Antimicrobial Stewardship Program, Recent Achievements: and works closely and collaboratively with the Department of Microbiology and the hospital’s Infection Prevention and Control A new divisional ambulatory-care clinic (one-half day per week) for service. general infectious diseases became operational this past year. In partnership with the Department of Pharmacy, the division led the Education: initiative to implement an Antimicrobial Stewardship program in order to ensure the most appropriate use of antimicrobial agents The division provides training for the Infectious Diseases Residency to decrease antimicrobial resistance and drug costs. The program Training Program, Core Internal Medicine trainees, Medical was initially instituted in the hospital’s critical care units, and in Microbiology trainees, Family Medicine, Dermatology, Orthopedic, the past year it has been rolled out to several other medical and and Critical Care residents, and elective undergraduate medical surgical units. The program has been enormously successful, with students. Elective residents and students are drawn to the division greater than 15% reductions in broad-spectrum antibiotic use, from across Canada and internationally. and associated decreases in C. difficile infection rates. Research: In the past year, a member of our division was awarded the Faculty of Medicine W.T.Aikins Faculty teaching Award for outstanding The division includes two Clinician Scientists. Research methodologies teaching and service in Undergraduate Education. Another employed by investigators in the division span the spectrum divisional member was successful this past year in garnering a from basic science studies and utilization of animal models, to CIHR Clinician Scientist Phase 2 Award. observational and clinical trials, epidemiologic studies, and health services research. The content of the research undertaken is also Future Plans: diverse, including studies of HIV infection, influenza transmission, hospital epidemiology, healthcare-associated infections, antimicrobial In the next year, we plan to to complete a more formal and resistance (including methicillin-resistant Staphylococcus aureus rigorous evaluation of the impact of the hospital’s Antimicrobial and Clostridium difficile), and antimicrobial stewardship. A member Stewardship program. We also plan to recruit a new physician of the division is an active member of the Canadian Nosocomial to the division. Infection Surveillance Program, which conducts prospective
26 Medical Oncology & Clinical Hematology
The division provides consultation, diagnosis and treatment services for a wide variety of cancers and is a key partner of the Odette Cancer Centre. The division consists of 25 full-time Medical Oncologists and Hematologists who work in multidisciplinary teams across the hospital and at the Odette Cancer Centre providing highly specialized and individualized care for unique cases. Dr. Kathy Pritchard leads the U of T Division as Director for Medical Oncology.
Division Head: Dr. Maureen Trudeau Clinical: Research:
Care is provided in a multidisciplinary outpatient setting with over The division’s clinical trial programs offer many patients from all 4,300 new patients and 23,000 chemotherapy visits annually. The tumour sites the opportunity to participate in leading edge research opening of the newly renovated pharmacy and chemotherapy unit and care options. Medical oncologists and hematologists within provides more space and privacy, and enables us to meet our the group hold leadership positions as site group chairs for the patients needs more efficiently and safely. More chemotherapeutic Cancer Care Ontario, Program in Evidence-Based Care (CCO- regimens have been introduced since last year, demonstrating the PEBC), and the National Cancer Institute of Canada-Clinical Trials great advances that have been made in the adjuvant, metastatic Group (NCIC-CTG). Dr. Craig Earle heads the Ontario Institute for and targeted therapy areas, especially new treatments guided Cancer Research (OICR) Health Services Research (HSR) section by the presence or absence of biologic markers. and is highly involved with HSR at ASCO as well. Members also Programs such as the Myelodysplastic Syndrome Program, serve on ASCO committees. Economic outcomes and research the Locally Advanced Breast Cancer Program, and the PYNK is another developing area of research in the group and Dr. Kelvin program for young women with breast cancer provide patients Chan is pursuing a PhD in biostatics, he will be the sole Canadian with focused, leading-edge care. The presence of ethicist Dr. Scott oncologist with this training. Dr. Georg Bjarnason also pursues Berry in the division allows a focus on end of life care. Many of studies in chronobiology, he works closely with the European these programs are unique in Canada, and are among the ways Organization for Research and Treatment of Cancer (EORTC) Sunnybrook is leading the future of cancer care. Several division in this important area of research, especially in renal cell cancer. members participate in National and Provincial cancer drug funding committees (pCODR, CED-CCO subcommittee and CED). Future plans: The division plans to maintain its academic excellence in education Education: and research while increasing its focus on patient centred care The division is a leader in training and academics, both in the and clinic care redesign. The presence of the Women and Babies traditional educational model, and in the online and web-based Program at the Sunnybrook Campus will foster collaborative environments. The OncologyEducation.ca website has achieved research between our programs. The recruitment of a clinician national and international attention. The post graduate training as in quality improvement to our staff (Dr Sonal Gandhi), will help to well as programs developed for medical oncology and hematology meet the goals of quality improvement both at the CCO level and residents nation-wide, and the development & implementation of within the hospital. Our future goals include the development of an training guidelines, particularly through the participation in the Program health technology assessment unit, a program in collaboration with of Evidence-Based Care at Cancer Care Ontario (CCO-PEBC), Geriatrics, and greater collaboration with SRI with the recruitment continue to set Sunnybrook and the University of Toronto apart as of Dr. David Andrews. leaders in oncology and hematology education. The postgraduate training program directors for both Medical Oncology and Hematology (Drs. Berry and Piliotis) are Sunnybrook division members.
27 Nephrology
The Division of Nephrology has six full-time Nephrologists who provide a full range of services to patients with kidney disease. These services encompass chronic in-centre dialysis services and home dialysis services, consultation services throughout the hospital including the initiation of acute dialysis and continuous renal replacement therapy with citrate regional anticoagulation, as well as outpatient clinical services to a wide range of patients with chronic kidney disease. Specialty clinics dedicated to hypertension (Dr. Sheldon Tobe), pregnancy and kidney disease (PreKid Clinic – Dr. Hladunewich), glomerulonephritis clinic (Dr. Hladunewich), HIV kidney disease (Dr. Zahirieh) and progressive diabetic kidney disease (Dr. Naimark) that support research and teaching initiatives. As such, the nephrology staff at Sunnybrook Health
Division Head: Sciences Centre is recognized as national and international experts in their respective fields. Dr. Michelle Hladunewich
Clinical: 3. Drs Tanna and Zahirieh continue to co-ordinate Renal Week for the second year medical student MMMD course. There Our clinical program provides excellent care to our patients, was a significant improvement in the teaching scores - with both in hospital and within the community. Our many innovations a ranking in the top 5 weeks of the entire course. continue to improve program delivery and benefit the quality of life for the many patients we work with. Through our multidisciplinary 4. Our core rotation for medicine residents continues to rank kidney care clinic and nocturnal dialysis program, we are positively highly. The number of trainees for the 2012-2013 year has impacting patient care. Our newest initiatives involve the creation significantly increased. of a vascular access clinic wherein patients are seen in a single clinic visit by a vascular access coordinator nephrologist (Dr. Research: Oliver) and a vasular surgeon. All members of the division are actively conducting research Further, we have a wider impact with respect to quality of care with recent funding in the areas of hypertension, acute kidney through the efforts of Dr. Oliver. The Dialysis Measurement Analysis injury and glomerular-based disease. Dr. Tobe is leading studies and Reporting (DMAR) system is a web-based quality assurance in hypertension as the head of CHEP (Canadian Hypertension system housed at the Institute for Clinical Evaluative Sciences. It Educational Program). He is integral within DREAM Global, which accurately collects performance and quality assurance data from will utilize established HIV infrastructure to bring chronic disease nine dialysis programs across Canada so they can compare their management to the 3rd world. Dr. Hladunewich is the co-chair of practice and improve patient care. Data collected in the system recruitment for an international consortium funded by the NIH for is also used for peer reviewed research. $10.5 million to develop a database and biobank for the study of nephrotic syndrome (Neptune Study). Dr. Naimark is an integral Education: member of the Chronic Kidney Disease Prognosis Consortium, which results in numerous high impact publications yearly. The division has a number of successful education initiatives. 1. Nephrology Now, The Ultimate Guide toKidney Disease Future Plans: Research, developed by Dr. Tanna and her partners, reviews and highlights leading edge international nephrology literature. The nephrology team was disappointed with the MOH decision Nephrology Now has over 4000 subscribers worldwide (www. not to support our new kidney care centre, but plans are ongoing nephrologynow.com). This year it was expanded to create for a satellite alternative. a separate website for transplant literature, Transplant Now (www.transplantnow.com). 2. Drs Tanna and Zahirieh organize the renal curriculum for the newly created PGY1 and 2 core internal medicine half days.
28 Neurology
The Neurology division has 11 full-time members known for significant local, national, and international leadership and leading knowledge translation expertise from a wide spectrum of neurologic specialties. Neurology is an important leader in the Brain Sciences Program but has important roles across other priority programs at Sunnybrook including Oncology (brain tumours), Trauma (Neuro-ICU consulatation and EEG), Women and Babies (neonatal EEG, obstetrical medicine, management of seizures, stroke, and sleep disorders). Known for leading research in stroke medicine, vascular cognitive impairment, and neurodegenerative disease several scientists and investigators in the division are active participants in large multicentre grants, city-wide and provincial centres of excellence, and attract students at all levels of education. Division Head: Dr. James Perry Clinical: Leadership positions and Awards: The Neurology division has 11 full-time members known for Members of the division of neurology are often national and significant local, national, and international leadership and international leaders in their field of expertise. leading knowledge translation expertise from a wide spectrum Some highlights include: of neurologic specialties. Neurology is an important leader in • Dr Brian Murray – Appointed as Director of Integrated the Brain Sciences Program but has important roles across Medical Education for the University of Toronto Department other priority programs at Sunnybrook including Oncology (brain of Medicine. Also appointed as Vice-Chair of the Sunnybrook tumours), Trauma (Neuro-ICU consulatation and EEG), Women Research Ethics Board. and Babies (neonatal EEG, obstetrical medicine, management of seizures, stroke, and sleep disorders). Known for leading • Dr Liesly Lee – Received the MOHLTC 2012 Achievement, research in stroke medicine, vascular cognitive impairment, and Commitment and Excellence (ACE) award for contributions neurodegenerative disease several scientists and investigators to provincial guidelines in multiple sclerosis in the division are active participants in large multicentre grants, • Dr Lorne Zinman – Queen Elizabeth II Diamond Jubilee Medal city-wide and provincial centres of excellence, and attract students in recognition of leadership in ALS and remains founder and at all levels of education. Chair of the Canadian ALS Consortium • Dr Mario Masellis – received the prestigious Early Researcher Education: Award from the Ministry of Economic Development and Innovation. The division has a strong reputation for teaching, and is one of • Dr Sandra Black – received the Order of Ontario and was the most popular training sites at the University of Toronto. Five named as a Fellow of the Royal Society of Canada. Also members of the division’s faculty have received teaching awards appointed as Executive Director of the Toronto Dementia in the last two years. Research Alliance Research: • Dr Rick Swartz - appointed the Medical Director for the North & East GTA Stroke Network Members are actively involved in Research. Feature research includes: Future Goals: • Heart and Stroke Centre for Stroke Recovery, devoted to optimizing cognitive and sensorimotor recovery after stroke. The Division is in a recruitment phase and the addition of an • Stroke Research Unit Urgent Care Neurologist and a Stroke Medicine Specialist are anticipated in 2013. • LC Campbell Cognitive Neurology Research Unit (including the Memory Disorders Clinical Trials Unit) • Motor Neuron Disease Translational Research Unit • Neuro-oncology program through the Crolla Brain Tumour Unit
29 Obstetrical Medicine
The Division of Obstetrical Medicine was formed to provide support to medically ill mothers and to further the educational and research directives of the Women’s and Babies Program. The goal of the Division of Obstetrical Medicine is to provide a service that aspires to clinical excellence with safe, collaborative multidisciplinary care.
Division Head: Dr. Michelle Hladunewich
Recent Achievements: • Drs. Jeremy Gilbert, Julia Lowe, Baiju Shah and Ivy Fettes – Division of Endocrinology (SHSC) We developed a safe sustainable system to provide this care by integrating obstetrical medicine into existing established services. • Drs. Shoba Kumar and Lorraine Lipscombe – Division of All potential medical services exist to accept consultation. Each Endocrinology (Cross-appointed WCH) division has identified an expert/champion who is available to • Drs. Brian Murray, Richard Swartz and Ester Bui – Division assist front line individuals and continue the education process. of Neurology (SHSC)
Outpatient consultations exist for all subspecialties. Areas wherein it is best to provide care in a combined MFM/OB Medicine clinic, have clinic time within the Mother’s and Babies Program. To date, Endocrinology is a busy combined clinic and this year Nephrology and a hypertension clinic along with a General OB Medicine Clinic were added. The Pregnancy and Kidney Disease Clinic (PreKid) is operating twice a month, and this busy clinic is a huge draw for trainees. The Hypertension and Pregnancy Clinic is embedded within this clinic and received support from the DOM strategic initiatives fund.
Clinical Faculty: • Dr. Michelle Hladunewich – Head Obstetric Medicine and Division of Nephrology (SHSC) Education and Research: • Dr. Anne McLeod – Division of Hematology (SHSC) We have integrated four lectures a year dedicated to obstetrical • Drs. Jack Colman, Candice Silversides and Rachel Wald – medicine into Medical Grand Rounds. We are teleconferencing Division of Cardiology (Cross-appointed MSH) citywide obstetrical medicine rounds from MSH. The members • Dr. Perla Lansang – Division of Dermatology (SHSC) of the division are involved in three CIHR funded multicenter • Dr. Vanessa Allen – Division of Infectious Disease (SHSC) research studies and a study nurse has just been recruited. The upcoming year’s activities will concentrate on the ongoing growth • Dr. Carl Laskin – Division of Rheumatology (Cross-appointed of educational and research activities. MSH)
30 Rehabilitation Medicine
The division of Rehabilitation Medicine has one full-time and a number of part-time physicians (Physiatrists) who treat injuries or illnesses that affect how you move. By taking the whole body into account, they are able to accurately pinpoint problems and enhance performance - without surgery.
Division Head: Dr. David Berbrayer
Clinical: as an adjudicator. Dr. Berbrayer also serves as a mentor for undergraduate students both in Toronto as well as at the American Members provide consultation for long-term care as well as Academy of Physical Medicine and Rehabilitation (AAPM&R). orthopaedic, neurology, family practice and rheumatology. The He assisted the CAPM&R in undergoing re-accreditation by the division also provides clinical care management in Sunnybrook RCPSC in March 2012 and also participates in the Medicine Centre for Independent Living (SCIL). Several outpatient programs Grand Rounds Committee at Sunnybrook. have been established which include Head Injury, Spinal Cord, Multiple Sclerosis, Amputee Management, Foot Care Management, Research: Orthotics Care, Sports Injury Management, and Muscular Dystrophy Management. The division has established links with St. John’s The division explores a number of areas in practice-based Rehab and Toronto Rehab. research and program evaluation. This includes recognition and evaluation of mild head injury patients, evaluating function of Education: ALS patients, improving mobility of patients with chronic foot pain, providing a multidisciplinary approach to management of We are actively involved in undergraduate training, postgraduate patients with multiple sclerosis and evaluating chronic spinal training as well as participating in fellowship training. A formal cord patients. The division has also recently begun rehab work fellowship was developed by Dr. Berbrayer for Sunnybrook with burn patients. In 2012, Dr. Berbrayer was appointed to the rehabilitation medicine and advertised on the University of Toronto Performance Metrics Committee (a sub-committee of the evidence website. In collaboration with the University of Toronto a fellow based committee of the American Academy of Physical Medicine from University of Montreal will be rotating in amputee care in and Rehabilitation) as well as PCPI representative ( one of two 2014. Members of the division are involved in undergraduate AAPMR members). He was also appointed editor of Knowledge teaching at the U of T such as ASCM-1, DOCH-2, Pain Week Now of PMR (journal of AAPMR). Dr. Berbrayer was asked by University of Toronto Year 2, Clerkship Year 3 and Transition to AAPMR to review research papers for CAPMR at their annual Residency Year 4. Students also spend time rotating throughout meeting as well as abstracts. Dr. Berbrayer also reviewed several the department from other universities. abstracts which were selected for the annual AAPMR meeting In 2012, Dr. Berbrayer was appointed a member of the Educational in Atlanta Georgia. Dr. Berbrayer reviewed several papers for Task Force of the Association of Academic Physiatrists and is Family Practice journal, Spinal Cord, PMR, Journl of Rehabilitation the current CPD chair of CAPMR and Vice Chair of Education Medicine. Dr. Berbrayer worked with the specialty committee of of CAPMR. He was elected as a delegate for OMA at the CMA PM&R to examine underserviving of Physiatry across Canada.Dr. annual meeting, August 2011 in St. John’s Newfoundland and Berbrayer participated as a member of the research committee produced a motion that was adopted and passed at the meeting. of the Department of Medicine at Sunnybrook. He participated in a medical student contest at Cleveland Clinic
31 Recent Achievements: Future Plans:
The division has recorded a number of achievements over the The division anticipates exciting opportunities for collaboration past year: (a) Dr. Berbrayer received the “Advocate for Student with St. John’s Hospital. Plans include (a) expanding work in award” from the Ontario Medical Association and in May 2012 he amputee management to include core rotation both at Sunnybrook also received the Ontario Medical Association Physiatry Service and St. John’s. (b) Increasing treatment/consult of stroke rehab Award (b) a Spasticity Clinic was established and the the division and developing expedited referral to St. John’s as well as stroke received further funding from Allergan for Spasticity research (c) network. It also intends to work closer with Orthopaedics to deal Physiatry Educational Rounds is now webcast and part of core with multiple trauma treatment and develop opportunities for teaching at the UofT division of Physiatry. integrated education with allied health staff.
32 Respirology & Clinical Immunology
The Division of Respirology and Clinical Immunology consists of five full-time members who along with part-time members provide comprehensive clinical care for a full range of respiratory conditions. The division runs a number of ambulatory clinics and offers a 24-hour hospital based consultation service. Specific clinical interests of members include: Asthma, COPD, Lung cancer, Blood Clots, Musculoskeletal related breathing disorders and Sleep disorders.
Division Head: Dr. Khalil Sivjee
Clinical: and are involved with analyzing provincial wide data bases to measure the impact of respiratory diseases in Ontario. They are Ambulatory programs include clinics in general respirology, integral in the development of metrics being used prospectively thromboembolic disorders, lung cancer diagnosis and management, in the Ontario Health Study. neuro-muscular respiratory insufficiency and sleep. The division offers on-site bronchoscopic investigation including fluoroscopic Recent Achievements: guided biopsy and transbronchial needle aspiration, performs ultrasound guided diagnostic and therapeutic thoracentesis With the recruitment of a full time clinican researcher and a part and in conjunction with interventional radiology, coordinate CT time clinician educator, the division has been able to produce guided lung biopsies and tunnelled pleural catheter placement. a nice balance of research, teaching, and clinical services. A hospital based pulmonary function laboratory is used primarily The exceptional quality of our faculty is evidenced by ongoing for patients that fall within the hospital priorities but accepts publications in high impact journals, teaching ratings that are in community based referrals. the top 10% city wide, and the creation of two new ambulatory clinics. One of these clinics is based in the Odette Cancer Centre Education: and will teach residents how to perform advanced techniques in managing pleural diseases. The division is strongly committed to teaching/offering leading-edge training programs for undergraduates, postgraduates as well as Future Plans: practicing clinicians. With a clinical focus on thromboembolism, lung cancer, sleep disordered breathing, and respiratory complications With the economic realities of the day, the division will continue in neuromuscular disease, the division offers a vast array of clinical to explore ways to continue to perform at a high level while being experiences - including ambulatory and acute care Respirology fiscally prudent. Using e-technology and novel therapeutics, we - valuable at both the undergraduate and postgraduate level of will continue to shift traditionally inpatient activity to the outpatient training. Our teachers and our respirology rotation have become arena. These efforts have been shown to be drastically less costly among the most popular in the city. while producing equivalent outcomes.
. Research:
Our research interests center on: Epidemiology and prevention of venous thromboembolism in fractures, COPD diagnosis and management, lung cancer, non-invasive positive pressure ventilation and hospital systems issues. Our researchers are cross appointed at the Institue of Clinical Evaluative Services (ICES)
33 Rheumatology
The Division of Rheumatology consists of three full-time members and several part- time members who work to provide diagnosis, treatment and follow-up care to patients throughout the province. The division cares for patients with rheumatologic diseases throughout outpatient clinics and inpatient consultation service. We also provide education, counselling and management plans to support patients as they help themselves with increased mobility and good health.
Interim Division Head: Dr. Gregory Choy Clinical: other sites within the University of Toronto and with other groups across the country. Members have won several awards for The division provides general rheumatology services to both the educational activities in undergraduate medicine, occupational immediate catchment area, several northern Ontario communities therapy, and CME. through the Ontario Telemedicine Network, and outreach clinics. There is ongoing partnerships with the Arthritis Society Client Research: Services team allowing for comprehensive management of rheumatic disease patients. Research activities include health services and quality of care research in arthritis management, clinical trials in advanced Education: therapeutics in inflammatory arthritis, and research in innovative methods of delivering MSK education. Both peer-review and The division is committed to teaching at the level of undergraduate, contract research is performed within the division. postgraduate and continuing education in collaboration with
34 APPENDIXES
35 APPENDIX I: LIST OF FACULTY
Cardiology Gastroenterology
Ahmed Shaheeda Assistant Professor Bernstein Michael Assistant Professor
Cohen Eric Associate Professor Cohen Lawrence Associate Professor
Crystal Eugene Associate Professor Cooper Mary Anne Assistant Professor
Dubbin James Assistant Professor Saibil Fred Professor
Gilbert Brian Professor Tinmouth Jill Assistant Professor
Hansen Mark Asssistant Professor Yong Elaine Assistant Professor
Joyner Campbell Professor General Internal Medicine Ko Dennis Associate Professor Cheung Mark Associate Professor Lashevsky Ilan Assistant Professor Etchells Edward Associate Professor Leber Alex Associate Professor Fowler Robert Associate Professor Madan Minakshi Assistant Professor Juurlink David Associate Professor Morgan Christopher Associate Professor Kuper Ayelet Assistant Professor Myers Martin Professor Redelmeier Donald Professor Myers Robert Assistant Professor Shadowitz Steven Assistant Professor Pang Jeffrey Assistant Professor Shojania Kaveh Associate Professor Radhakrishnan Shyam Assistant Professor Shumak Steven Professor Singh Sheldon Assistant Professor Slaughter Graham Lecturer Strauss Bradley Professor Stroud Lynfa Assistant Professor Tu Jack Professor Wong Brian Assistant Professor Wijesundera Harindra Assistant Professor
Dermatology Geriatric Medicine Gandell Dov Lecturer Lansang Perla Assistant Professor Liu Barbara Associate Professor Shear Neil Professor Mehta Rajin Assistant Professor Walsh Scott Assistant Professor Norris Mireille Assistant Professor Endocrinology Infectious Diseases Fettes Ivy Professor Daneman Nick Assistant Professor Gilbert Jeremy Assistant Professor Rachlis Anita Professor Lowe Julia Associate Professor Simor Andrew Professor Shah Baiju Assistant Professor
Silverberg Jay Professor
36 Medical Oncology & Hematology Neurology
Berry Scott Associate Professor Black Sandra Professor
Bjarnason Georg Associate Professor Bui Esther Lecturer
Buckstein Rena Assistant Professor Gladstone David Assistant Professor
Chan Kelvin Assistant Professor Hopyan Julia Assistant Professor
Cheng Susanna Assistant Professor Lee Liesly Associate Professor
Cheung Matthew Assistant Professor Lim Andrew Assistant Professor
Dent Rebecca Assistant Professor Masellis Mario Lecturer
Earle Craig Professor Murray Brian Associate Professor
Eisen Andrea Assistant Professor Perry James Associate Professor
Emmenegger Urban Assistant Professor Swartz Rick Assistant Professor
Hsiao Janey Lecturer Zinman Lorne Assistant Professor
Imrie Kevin Professor Rehabilitation Medicine Jay Richard Associate Professor Berbrayer David Assistant Professor Ko Yoo-Joung Assistant Professor McLeod Anne Assistant Professor Respirology & Clinical Immunology Petrella Teresa Assistant Professor Geerts William Professor Piliotis Eugenia Assistant Professor Gershon Andrea Assistant Professor Pritchard Kathleen Professor Sivjee Khalil Assistant Professor Selby Rita Assistant Professor Tandon Anu Assistant Professor Singh Simron Assistant Professor (adjunct)
Spaner David Associate Professor Rheumatology
Trudeau Maureen Professor Bell Mary Associate Professor
Verma Sunil Associate Professor Choy Gregory Assistant Professor
Warner Ellen Professor
Wells Richard Assistant Professor
Nephrology
Hladunewich Michelle Assistant Professor
Naimark David Assistant Professor
Oliver Matthew Associate Professor
Tanna Gemini Assistant Professor
Tobe Sheldon Associate Professor
Zahirieh Alireza Assistant Professor
37 APPENDIX II: SUMMARY ACTIVITY REPORTS1
1. A special thanks to the WebCV Team for providing the summary information for this report. This was a manual process and we have deleted some of the information submitted by the Team, thus there may be discrepancies between the departmental/divisional summary tables and the listed information for all the categories. OVERALL DEPARTMENTAL SUMMARY Number of Faculty: 103 Number of Clinician Investigators: 26 Number of Clinician Teachers: 41 Number of Clinician Scientists: 24 Number of Clinician Educators: 9 Number of Clinician Administrators: 3
Grants Number Amount Peer Reviewed Funding Principal Investigator: 68 $5,821,667 CAD Co-Principal Investigator: 30 $2,248,290 CAD 2 $502,390 USD 1 $147,198 AUD Co-Investigator / Collaborator: 175 $34,647,780 CAD 6 $3,663,906 USD Other: 55 $11,812,502 CAD 4 $2,326,784 USD Total Peer Reviewed Funding: 328 $54,530,239 CAD 12 $6,493,080 USD 1 $147,198 AUD
Non Peer Reviewed Funding Total Non Peer Reviewed Funding: 139 $8,204,272 CAD 3 $992,500 USD Publications Number Peer Reviewed Publications Principal Author 105 Co-Principal Author 24 Senior Responsible Author 89 Collaborator / Co-Author 361 Other Role 56 Total Peer Reviewed Publications: 633 Total Non Peer Reviewed Publications: 88 Honours and Awards Nominated Received Total International Totals: 0 17 17 National Totals: 4 34 38 Provincial / Regional Totals: 1 21 22 Local Totals: 7 28 35 Other: 0 18 18 Total Honours and Awards: 12 118 130
39 DIVISION OF CARDIOLOGY
Number of Faculty: 20
Grants Number Amount Peer Reviewed Funding Principal Investigator: 6 $1,182,965 CAD Co-Principal Investigator: 2 $31,065 CAD Co-Investigator / Collaborator: 22 $10,115,305 CAD Other: 11 $594,808 CAD 1 $20,667 USD Total: 41 $11,924,143 CAD 1 $20,667 USD
Non Peer Reviewed Funding Total: 29 $3,744,768 CAD Publications Number Peer Reviewed Publications Principal Author 21 Co-Principal Author 3 Senior Responsible Author 12 Collaborator / Co-Author 45 Other Role 5 Total 86 Honours and Awards Received National: 4 Provincial: 1 Local: 1 Total Honours and Awards 6
40 Grants, Contracts and Clinical Trials
Peer Reviewed Funding Other Peer Reviewed Funding
Division Member is Principal Investigator 1. Crystal, Eugene. Asymptomatic AF and stroke evaluation in PPM patients and AF reduction A pacing trial. S Connolly, SJM. 1. Crystal, Eugene. Three-dimensional Catheter Tracking using ($15,000 July 2006-July 2011 Prorated: $246) [Clinical Trial] a Single Two-dimensional Image. Peter Austin, Susan Bronskill, 2. Crystal, Eugene. Magnetic Resonance Imaging for Ischemic Rick Glazier, Dennis Ko, Douglas Lee, Therese Stukel, Jack Heart Disease. Graham Wright: Canadian Institutes of Tu, Walter Wodchis: Canadian Institutes of Health Research Health Research (CIHR). ($830,540 July 2009-Mar 2014 (CIHR). Operating Grant - Secondary Analysis of Databases. Prorated: $174,851) [Clinical Trial] ($142,000 Apr 2010- Mar 2012 Prorated: $53,250) [Grant] 3. Crystal, Eugene. T wave alternans severity assessment in 2. Improving the Assessment and Treatment Ko, Dennis. cardiomyopathy (TASC). V Chauhan: AFP innovation fund. of Severe Aortic Stenosis by Evaluating Care Gaps and Innovation Funds. (July 2010-July 2012) [Grant] Advancing Risk Predictions (First ranked proposal in clinical 4. Crystal, Eugene. The impact of a Post Cardiac Arrest Consult committee). D Alter, P Austin, B Borgundvaag, J Brehaut, Team (PACT) on process and clinical outcomes in patients M Edmonds, S Friedman, J Grimshaw, J Lee, M Schull, T resuscitated from out-of-hospital cardiac arrest. Brooks Stukel, J Tu, H Wijeysundera: Heart and Stroke Foundation SC, W. Beattie, V. Chan, B. Croal, J. Granton, J. Hoch, M. of Canada. Operating Grant. ($331,058 Apr 2012-Mar 2015 Mamdan, D. Mazer, C. Mccartney, P. Oh, R. Pearse, A. Smith, Prorated $27,588) [Grant] K. Thorpe, H. Wijeysundera: Heart and Stroke. Operating. 3. Strauss, Bradley. Microvascular Injury in Acute Myocardial ($200,000 Jan 2011-Dec 2012 Prorated: $100,000) [Grant] Infarction. Paul Grootendorst, Luciano Ieraci, Márcio Machado, 5. Crystal, Eugene. Viability Analysis and Visualization for Mike Paulden, Jack Tu, Gabrielle van der Velde, Harindra Fluoroscopy-guided Arrhythmia Therapy. Wright, Graham, Wijeysundera, William Witteman: Heart & Stroke Foundation David Alter, Peter Austin, Warren Cantor, Asim Cheema, of Canada. Research Grant. ($279,426 July 2011-June 2014 Michael Chu, Stephen Fremes, Madhu Natarajan, Mark Prorated: $93,142) [Grant] Peterson, Marc Ruel, Therese Stukel, Jack Tu, Harindra 4. Tu, Jack. Canadian Cardiovascular Outcomes Research Wijeysundera: Ontario Centres of Excellence (OCE) – MaRS Team II: Access to Quality Cardiac Care. One year extension Innovation (MI). ($90,000 Mar 2012- Mar 2013 Prorated: granted 2012. Graham Wright, Andrew Ganton, Normand $27,692) [Grant] Robert: Canadian Institutes of Health Research (CIHR). Proof 6. Hansen, Mark Silvin. Comparison of the Hemodynamic of Principle Program - Phase I. ($4,214,550 Apr 2006- Mar Performance of the CoreValve and Edwards Valve for the 2012 Prorated: $526,819) [Grant] Treatment of Severe Aortic Stenosis. Pibarot, Phillippe, 5. Tu, Jack. Measuring and improving the quality of ambulatory Crystal, Eugene Radau, Perry: Canadian Heart and care for people with cardiovascular risk factors and/or chronic Stroke Foundation. Institutional Proof-of- Principle (CIPoPP) cardiovascular disease. Silver F, Tu JV, Hall R, Phillips S, Hill Application. ($10,000 July 2010-present Prorated: $4444) M, Willis K: Canadian Institutes of Health Research (CIHR). [Grant] ($1,998,740 Dec 2011-Nov 2016 Prorated: $233,186) [Grant] 7. Ko, Dennis. Canada Data Definitions and Quality Indicators. 6. Tu, Jack. Measuring and improving the quality of ST-segment Humphries, Karin: Public Health Agency of Canada (PHAC). elevation myocardial infarction (STEMI) care. Canadian Health Services and Policy Research. ($350,000 2012-2013 Institutes of Health Research (CIHR). Resuscitation & Prorated: $87,500) [Grant] Knowledge Transfer & Exchange 2010 Initiative. ($995,920 8. Ko, Dennis. Canada Data Definitions and Quality Indicators. Apr 2011- Mar 2015 Prorated: $248,980) [Grant] Buller, Christopher, Alter D, Atzema C, Austin P, Bhatia S, Booth G, Garg A, Gershon A, Glazier R, Hillmer M, Hogg W, Kapral M, Ko D, Lee D, Lewis M, Manuel D, Palmer L, Stukel T, TU JV, Tu K, Walton N, Wijeysundera H, You J: Public Health Agency of Canada (PHAC). ($350,000 2010-2012 Prorated: $116,667) [Grant]
41 9. Ko, Dennis. CIHR Team in Assessment and Treatment of 18. Madan, Minakshi. The PACT (Post-Cardiac Arrest Center Occlusive Vascular Disease. Graham Wright and Bradley of Excellence) study. Dr. SC Brooks, Austin P, Birnie D, Strauss, David Alter, Clare Atzema, Peter Austin, Gillian Cameron D, Crystal E, Dorian P, Harris I, Healey J, Khaykin Booth, Maria Chu, Richard Glazier, Moira Kapral, Dennis Y, Krahn A, Mangat I, Simpson C, Tu JV, Yee R: Heart and Ko, Douglas Lee, Douglas Manuel, Jillian Oderkirk, Claudi Stroke Foundation of Canada. Operating Grant. ($198,726 Sanmartin, Gustavo Saposnik, Baiju Shah, Therese Stukel, 2010-2013 Prorated: $49,682) [Grant] Karen Tu, : Harindra Wijeysundera Canadian Institutes 19. Pang, Jeffrey. AQUARIUS. Cohen, Eric, Anderson G, Tu . Team Grant: Chronic Disease of Health Research (CIHR) JV: NOVARTIS/Cleveland. Operating Grant. (2009-present) Risk and Intervention Strategies. ($2,193,864 Apr 2007-Mar [Grant] 2012 Prorated: $329,080) [Grant] 20. Pang, Jeffrey. FREEDOM: Optimal management of multivessel 10. Ko, Dennis. Measuring and Improving the Quality of disease to evaluate whether PCI with DES is more or less Ambulatory Care for People with Cardiovascular Risk Factors effective than CABG. Cyr C, Rivera T, Arthur HM, Chessex and/or Chronic Cardiovascular Disease. , Normand Tu, Jack C, O’Neill B, Reid R, Suskin N, Tu JV: National Institutes Robert PhD, Graham Wright PhD: Canadian Institutes of for Health. CIHR Meetings, Planning & Dissemination Health Research (CIHR). Proof of Principal. ($1,998,740 (2007-present) [Grant] Dec 2011-Mar 2016 Prorated: $269,061) [Grant] 21. Pang, Jeffrey. RIVAL Study. Jolly, Sanjit S, Brooks SC, 11. dal-PLAQUE study. , Madan, Minakshi. Dr. Eric Cohen Madan M: (Mar 2010-Dec 2012) [Grant] Graham A. Wright, Peter Burns, & Alexander Dick: Hoffmann- 22. Pang, Jeffrey. TRACER. Madan, Mina: SPRI. Health la Roche Inc, USA. Grant-in-aid. ($44,595 Jan 2011-Aug Services and Policy Research. (2009-present) [Grant] 2013 Prorated: $16,723) [Grant] 23. Strauss, Bradley. Inflammation and Brain-Derived Neurotrophic 12. Madan, Minakshi. EVITA. Investigator initiated project/ Factor: At the Heart of Cardiovascular Risk among Adolescents Pfizer USA. Grant-in-aid. ($639,000 May 2009-present with Bipolar Disorder. Goldstein, Benjamin, Crean A; Lee, Prorated: $191700) [Grant] D; Andrew Y; Wright G; Crystal.E; Pinter A: Heart & Stroke 13. EXPLORE study. Madan, Minakshi. Dr. B Strauss: Abbott Foundation of Canada. ($104,136 July 2011-June 2013 Vascular, Belgium. Division of Cardiology Collaborative Prorated: $52,068) [Grant] Initiative. ($12,000 Jan 2011-present Prorated: $8,000) [Grant] 24. Tu, Jack. Assessing the appropriateness of coronary 14. Madan, Minakshi. FREEDOM. David Alter, Clare Atzema, revascularization for patients with coronary artery disease. Peter Austin, Gillian Booth, Maria Chu, Richard Glazier, Canadian Institutes of Health Research (CIHR). ($455,118 Moira Kapral, Dennis Ko, Douglas Lee, Douglas Manuel, Apr 2010-Mar 2013 Prorated: $151,706) [Grant] Jillian Oderkirk, Claudi Sanmartin, Gustavo Saposnik, Baiju 25. Tu, Jack. CANadian NEtwork and Centre for Trials Internationally Shah Therese Stukel, Karen Tu, Harindra Wijeysundera: (CANNECTIN). Canadian Institutes of Health Research National Institutes for Health. Team Grant: Chronic Disease (CIHR). Operating Grant. ($9,582,529 Apr 2008-Mar 2013 Risk & Intervention Strategies ($10,800 Feb 2007-Mar 2012 Prorated: $1,916,506) [Grant] Prorated: $1,568) [Grant] 26. Tu, Jack. CANadian NEtwork and Centre for Trials Internationally 15. Madan, Minakshi. OAT: Occluded Artery Trial/Long-Term (CANNECTIN). Jack Tu, Therese Stukel, Peter Austin, David Follow up. C. Atzema, P. Austin, J. Cox, T. Huynh, C. Alter, Harindra Wijeysundera: University of Toronto. Jackevicius, D. Ko, L. Lambert, D. Lee, M. Natarajan, D. So, Operating Grant-3 year term. ($6,000,000 Apr 2008-Mar T. Stukel, H Wijeysundera: NIH/MRC. Operating Grants. 2013 Prorated: $1,200,000) [Grant] ($124,000 USD Jan 2007-2012 Prorated: $20,667) [Grant] 27. Tu, Jack. Effects of immigration and acculturation on 16. Madan, Minakshi. REMINDER study. Pfizer Inc. (USA). cardiovascular risk profiles of Ontario’s four major ethnic ($52,650 Jan 2011-July 2012 Prorated: $33,253) [Grant] groups. Chiu, Maria: Heart and Stroke Foundation of 17. SIGNIFY. , Atzema Madan, Minakshi. Dr. S. Radhakrishnan Ontario. Operating Grant. ($50,000 Aug 2010-July 2012 C, Austin P, Cox J, Huynh T, Jackevicius C, Ko D, Lambert Prorated: $25,000) [Grant] L, Lee DS, Natarajan M, So D, Stukel T, Wijeysundera H: Servier Canada Inc. Operating Grant. ($11,642 Sept 2010 present Prorated: $6,350) [Grant]
42 28. Tu, Jack. Improving Cardiovascular Disease Surveillance in 36. Wijeysundera, Harindra. Measuring and Improving the Canada’s Ethnic Minority Groups. David Alter, Peter Austin, Quality of ST-segment Myocardial Infarction (STEMI) Care. Therese Stukel, Jack Tu, Harindra Wijeysundera: Public Jack V Tu, TU JV, Ghali WA, Pilote L, Cox JL, Humphries Health Agency of Canada (PHAC). Health Services Evaluation KH, et al. Canadian Institutes of Health Research (CIHR) & Interventions Research. ($495,540 Apr 2011-Mar 2013 Team Grant Program ($995,920 Apr 2011-Mar 2015 Prorated: Prorated: $247,770) [Grant] $248,980) [Grant] 29. Statistical Methods for Health Service Research. Tu, Jack. Non Peer Reviewed Funding Austin, Peter: Canadian Institutes of Health Research. Operating Grant. ($122,994 Apr 2011-Mar 2014 Prorated: 1. Crystal, Eugene. Ontario Research Fund, Research Excellence $40,998) [Grant] Fund. Imaging for Cardiovascular Therapeutics. G Wright:
30. Wijeysundera, Harindra. ACUTE Study: Acute Congestive The Ministry of Research and Innovation Research Fund . ($14,490,484 Heart Failure Urgent and Transitional Care Evaluation. Lee, Research Excellence (ORF-RE) program 2007-2012 Prorated: $2,415,081) [Clinical Trial] Douglas: Canadian Institutes of Health Research (CIHR). ($518,688 Oct 2011-Sept 2015 Prorated: $129,672) [Grant] 2. Crystal, Eugene. ELECTRA: Elective Cardioversion for prevention of symptomatic Atrial Fibrillation Occurrence. 31. Wijeysundera, Harindra. Assessing the Appropriateness . ($1,000 July 2011-June 2012) [Clinical Trial] of Coronary Revascularization for Patients with Coronary Sanofi Artery Disease. Dennis T. Ko, Canadian Institutes of 3. Crystal, Eugene. FLeCX: Fidelis Lead Canadian X-Ray Health Research (CIHR). Canadian Foundation Innovation Study. University de Laval. ($2,500 July 2011-June 2012) Infrastructure funds HHSC. ($455,118 Apr 2010-Mar 2013 [Clinical Trial] Prorated: $151,706) [Grant] 4. Crystal, Eugene. IRASE- AF: Irrigated Albation System 32. Wijeysundera, Harindra. Closing the quality feedback Evaluation for Atrial Fibrillation. Andre D’Avila, Young Hoon loop: A web-based forum to improve the quality of care and Kim, Michael Mangrum, Gregory Michaud, Arash Aryana, outcomes of the Toronto Heart Attack Collaborative (THAC) David Callans: St Jude Medical. (July 2011-June 2012) Regional STEMI Program. Wijeysundera, Harindra; Fam, [Clinical Trial] Neil; Overgaard Chris, University of Toronto, Division of 5. Crystal, Eugene. OPTIMISE: Optimal Programming to Cardiology. ($60,000 July 2011-July 2013 Prorated: $3,373) Improve Mechanical Indices, Symptoms and Excerise in [Grant] Cardiac Resynchronization Therapy. St Jude Medical. (July 33. Wijeysundera, Harindra. Closing the Quality Feedback 2011-June 2012) [Clinical Trial] Loop: A Web-Based Forum to Improve the Quality of Care and 6. Crystal, Eugene. OPTIMISE: Optimal Programming to Outcomes of the Toronto Heart Attack Collaborative (THAC) Improve Mechanical Indices, Symptoms and Excerise in Regional STEMI Program. Sunnybrook Medical Services Cardiac Resynchronization Therapy. St Jude Medical. (July Alternative Funding Plan (AFP) Association. $80,961 June 2011-June 2012) [Clinical Trial] 2012-May 2014 Prorated: $60,000 [Clinical Trial] 7. Crystal, Eugene. RAAFT: First Line Radiofrequency Ablation 34. Wijeysundera, Harindra. Heart Failure (Multi-Disciplinary Versus Antiarrhythmic Drugs fror Atrial Fibrillation Treatment. Community Care) Clinics Field Evaluation. Murray Krahn: July 2011-June 2012 Ministry of Health and Long Term Care of Ontario. ($240,449 8. Crystal, Eugene. Aid for determination of medical device July 2010-June 2012 Prorated: $120,225) [Clinical Trial] position and orientation from a single two-dimensional image. 35. Wijeysundera, Harindra. Measuring and improving the Mars Innovations. ($50,000 Sept 2011-Aug 2012 Prorated: quality of ambulatory care for people with cardiovascular risk $41,667) [Clinical Trial] factors and/or chronic cardiovascular diseases. Jack Tu, 9. Crystal, Eugene. Novel Catheter Tracking System. MARS Canadian Institutes of Health Research (CIHR). ($1,998,739 Innovations. ($150,000 May 2010-Dec 2011 Prorated: Dec 2011-Nov 2016 Prorated: $262,295) $45,000) [Clinical Trial]
10. Crystal, Eugene. Atrial Fibrillation Fish Oil Reserach Study. Canadian Institutes of Health Research (CIHR). (July 2009-present) [Clinical Trial]
43 11. Ko, Dennis. Assessing the Appropriateness of Coronary 23. Singh, Sheldon. Development of a standardized data collection Revascularization for Patients with system for ambulatory patients referred for atrial fibrillation 12. Coronary Artery Disease. Canadian Institutes of Health management: A city-wide collaboration of the University of Research (CIHR). ($455,118 Jan 2010-Mar 2013 Prorated: Toronto teaching hospitals. Ha, Andrew, Mangat, Iqwal: $140,036) [Grant] University of Toronto. Division of Cardiology Collaborative Innovation and Research. ($60,000 Jan 2012-Dec 2012 13. Ko, Dennis. Socioeconomic status, quality of primary care, Prorated: $30,000) [Grant] and survival following acute myocardial infarction: A ten-year follow-up of the Socio-Economic Status and Acute Myocardial 24. Singh, Sheldon. Modified Ablation Guided by Ibutilide administration in Chronic Atrial Fibrillation Trial. Reddy, Vivek, Infarction Study. Alter, David: Canadian Institutes of Health Electrophysiology sites through Canada: Mount Sinai School Research (CIHR). ($120,000 Apr 2012-Sept 2014 Prorated: $12,000) [Industrial Grant] of Medicine. $10,000 USD July 2010-present Prorated: $2,500 [Clinical Trial] 14. Ko, Dennis. Measuring and Improving the Quality of ST- 25. Promoting systematic inpatient cardiac rehabilitation segment Elevation Myocardial Infarction (STEMI) Care. Tu, Jack: Tu, Jack. referral. Canadian Institutes of Health Research (CIHR). ($995,919 Grace, SL: Canadian Institutes of Health Research Jan 2011-Mar 2015 Prorated: $234,334) [Clinical Trial] (CIHR). ($100,000 Mar 2011-Feb 2012 Prorated: $66,667) [Grant] 15. Lashevsky, Ilan. Identifying Genetic Determinants of Human Circadian Rhythms and Determining their Impact 26. Tu, Jack. The Registry of the Canadian Stoke Network on the Triggering of Stroke and Life-Threatening Cardiac (Renewal). Kapral, M: Canadian Stroke Network. ($1,871,711 Jan 2010-Dec 2013 Prorated: $467,928) [Clinical Trial] Arrhythmia. Andrew S. Lim, Dr. Dorian, Dr. Nanthakumar, Dr. Lashevsky, Dr. Kennedy, Dr. Buchman, Dr. De Jager, 27. Tu, Jack. Implantable Cardioverter Defibrillator Selection to Dr. Sole, Dr. Bjarnason (July 2011-June 2012) Improve Survival in Left Ventricular Systolic Dysfunction: ISIS LVSD Study (Ontario ICD Database Phase 2). 16. Lashevsky, Ilan. Prolonged Monitoring to Detect Ventricular Lee, Douglas: Arrhythmias in Presymptomatic ARVC Patients - the PREPARE Canadian Institutes of Health Research (CIHR). ($589,044 Apr 2011-Mar 2015 Prorated: $147,261) [Clinical Trial] study. Krahn Andrew: St. Jude Medical Clinical Studies. (Sept 2010-Sept 2016) [Clinical Trial] 28. Wijeysundera, Harindra. Measuring and improving the quality of care for patients with cardiovascular risk factors 17. Madan, Minakshi. dal-OUTCOMES study. Dr. Shaheeda and/or chronic cardiovascular disease. Ahmed: Hoffmann-la Roche Inc, USA. ($49,200 May 2009- Tu, Jack: Canadian June 2013 Prorated: $11,808) [Clinical Trial] Institutes of Health Research (CIHR). ($10,000 June 2011- Aug 2011 Prorated: $10,000) [Clinical Trial] 18. Madan, Minakshi. CAIN-003 study. Dr. Eric Cohen: 29. The METS (Measurement of Canadian Institutes of Health Research (CIHR). ($44,595 Wijeysundera, Harindra. Jan 2011-present Prorated: $25,483) [Clinical Trial] Exercise Tolerance before Surgery) Study: An International Multicentre Prospective Cohort Study of Cardiopulmonary 19. Madan, Minakshi. COAPT study: Canadian Observational Exercise Testing For Improving Preoperative Risk Stratification Antiplatelet study. Cohen, Eric: Eli Lilly Canada Inc. for Major Non-Cardiac Surgery. Wijeysundera, Duminda ($22,570-present Prorated: $22,570) [Clinical Trial] N. & Cuthbertson, Brian H: Canadian Institutes of Health 20. Pang, Jeffrey. OAT, TOSCA-2, OAT-NUC: Occluded Artery Research (CIHR). ($987,068 Apr 2012-Mar 2016 Prorated: Trial. NIH/’MRC. ($64,400 Dec 1998-June 2012 Prorated: $61,692) $4,741) [Clinical Trial]
21. Pang, Jeffrey. Protection-AMI. Cohen, Eric: KAI/CHRC. (2009-present) [Clinical Trial]
22. Singh, Sheldon. Ventricular Tachycardia (VT) Ablation Versus Enhanced Drug Therapy (VANISH). Canadian Institutes of Health Research (CIHR). (July 2011) [Clinical Trial]
44 Publications 9. Blom K, How M, Dai M, Baker B, Irvine J, Abbey S, Abramson BL, Myers MG, Perkins N, Tobe SW. Hypertension Analysis Peer Reviewed Publications of stress Reduction using Mindfulness meditatiON and Yoga (The HARMONY Study): study protocol of a randomised 1. Abrahamyan L, Austin PC, Donovan LR, Tu JV. Standard control trial. BMJ Open. 2012;2:e000848. doi:10. 1136/ admission orders can improve the management of acute bmjopen-2012-000848. myocardial infarction. Int J Qual Health Care. 2012 May 16; Epub ahead of print. 10. Boom NK, Lee DS, TU JV. Comparison of processes of care and clinical outcomes for patients newly hospitalized 2. Abrahamyan L, Boom N, Donovan LR, TU JV; Canadian for heart failure attended by different physician specialists. Cardiovascular Society Quality Indicators Steering Committee. Am Heart J. 2012; Feb 1; 163(2):252-259. An international environmental scan of quality indicators for cardiovascular care. Can J Cardiol. 2011 Dec 10; 28(1):110- 11. Chiu M, Austin PC, Manuel DG, TU JV. Cardiovascular 118, 2011. Risk Factor Profiles of Recent Immigrants vs Long-Term Residents of Ontario: A Multi-Ethnic Study. Can J Cardiol. 3. Al Khdair D, Alshengeiti L, Elbarouni B, Yan RT, Grondin FR, 2011 Aug 3; 28(1):20-6. Spencer FA, Pallie S, Brieger D, Eagle KA, Mangat I, Singh S, Goodman SG, Yan AT; Global Registry of Acute Coronary 12. Chun S, Tu JV, Wijeysundera HC, Austin PC, Wang X, Levy Events (GRACE/GRACE2) and the Canadian Registry of D, Lee DS. Lifetime analysis of hospitalizations and survival Coronary Events (CANRACE) Investigators. Management of patients newly-admitted with heart failure. Circ Heart Fail. and outcome of acute coronary syndrome patients in 2012 May 2; Epub ahead of print. relation to prior history of atrial fibrillation. Canadian Journal 13. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, of Cardiology. 2012; 28: 443-449. Amerena J, Atar D, Avezum A, Blomstrom P, Borggrefe M, 4. Alter DA, Ko DT, Tu JV, Stukel TA, Lee DS, Laupacis A, Chong Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy A, Austin PC. The Average Lifespan of Patients Discharged JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, from Hospital with Heart Failure. Journal of General Internal Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel Medicine. 2012 May 2. [Epub ahead of print]. H, Kautzer J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters 5. Alter DA, Ko DT, Tu JV, Stukel TA, Lee DS, Laupacis A, Chong NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsayni A, Austin PC. The average lifespan of patients discharged J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier from hospital with heart failure. J Gen Intern Med. 2012 May D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, 2; Epub ahead of print. Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH; the PALLAS 6. Alter DA, Franklin B, Austin PC, Chong Wijeysundera HC, investigators. Dronedarone in High-Risk Permanent Atrial A, Oh PI, Stukel TA. Obesity, lifestyle risk-factors, Tu JV, Fibrillation. N Engl J Med. 2011 Nov 14. [Epub]. and health service outcomes among healthy middle-aged 14. D MacFadden, MD; MD; AD Krahn, MD; I Mangat, adults in Canada. BMC Health Services Research. 2012 E Crystal, MD; JS Healey, MD, MSc; P Dorian, MD; D Birnie, MBChB; CS Aug 4;12(1):238. Simpson, MD; Y Khaykin, MD; A Pinter, MD; K Nanthakumar, 7. Atzema CL, Austin PC, Huynh T, Hassan A, Chiu M, Wang MD; AJ Calzavara, MSc; PC Austin, PhD; JV Tu, MD, PhD; JT, . Effect of marriage on duration of chest pain TU JV DS Lee, MD, PhD. Sex differencesin implantable cardioverter associated with acute myocardial infarction before seeking defibrillator outcomes: findings from a prospective defibrillator care. Can Med Assoc J. 2011 Jul 18; 183(13):1482-91. database. JAMA 2011 Nov 20. 8. Atzema CL, Schull MJ, Austin PC, TU JV. Temporal changes 15. Dukkipati SR, d’Avila A, Soejima K, Bala R, Inada K, Singh in emergency department triage of patients with acute S, Stevenson WG, Marchlinski FE, Reddy VY. Long term myocardial infarction and the effect on outcomes. Am Heart outcomes of combined epicardial and endocardial ablation of J. 2011 Aug 29; 162(3):451-9, 2011. monomorphic ventricular tachycardia related to hypertrophic cardiomyopathy. Circulation Arrhythmia and Electrophysiology. 2011; 4(2): 185-94.
45 16. Essebag V, Champagne J, Birnie DH, Verma A, Healey JS, 23. Lawrence J, Pogue J, Synhorst D, Adalet K, Atar D, Avezum Simpson CS, Kus T, Thibault B, Mangat I, Tung S, Sterns A, Budaj A, Commerford PJ, Dans AL, De Caterina R, Diener L, Exner DV, Davies T, Coutu B, Crystal E, Stephenson HC, Eidelboom J, Connolly SJ, Joyner CD, Hart RG, Lip GY, EA, Connors S, Paredes FA, Parkash R, Krahn AD. Non- O’Donnell M, Hohnloser SH, Hankey GJ, Shestakovska O, physiologic noise early after defibrillator implantation in Yusuf S; AVERROES steering committee and investigators. Canada - incidence and implications: A report from the Apixaban versus aspirin in patients with atrial fibrillation and Canadian Heart Rhythm Society Device Committee. Heart previous stroke or transient ischaemic attack: a predefined Rhythm. 2011 Oct 21. [Epub ahead of print]. subgroup analysis from AVERROES, a randomized trial. Lancet Neurol. 2012 Mar;11(3):225-31 [Epub - 2012 Feb 1]. 17. Ho JE, Gona P, Pencina MJ, Tu JV, Austin PC, Vasan RS, Kannel WB, D’Agostino RB, Lee DS, Levy D. Discriminating 24. Leite LR, Santos SN, Maia H, Henz BD, Giuseppin F, Oliveira clinical features of heart failure with preserved vs. reduced A, Zanatta AR, Peres AK, Novalolsi C, Barreto JR, Vassalo ejection fraction in the community. Eur Heart J. Apr 16, F, d’Avila A, Singh SM. Luminal esophageal temperature 2012 - Epub ahead of print. monitoring with a deflectable esophageal temperature probe 18. Huynh T, Birkhead J, Huber K, O’Loughlin J, Stenestrand and intracardiac echocardiography may eliminate esophageal U, Weston C, Jernberg T, Schull M, Welsh RC, Denktas AE, injury during atrial fibrillation ablation procedure – results of a pilot study. Circulation Arrhythmia and Electrophysiology. Travers A, Sookram S, Theroux P, TU JV, Timmis A, Smalling R, Danchin N. The pre-hospital fibrinolysis experience in Europe 2011; 4(2): 149-56. and North America and implications for a wider dissemination. 25. Macfadden DR, Crystal E, Krahn AD, Mangat I, Healey JACC Cardiovasc Interv. 2011 Aug 9; 4(8):877-83, 2011. JS, Dorain P, Birnie D, Simpson CS, Khaykin Y, Pinter A, 19. Kaufman ES, Israel CW, Nair GM, Armaganijan L, Divakaramenon Nanthakumar K, Calzavara AJ, Austin PC, TU JV, Lee DS. Sex differences in implantable cardioverter-defibrillator S, Mairesse GH, Brandes A, Crystal E, Costantini O, Sandhu RK, Parkash R, Connolly SJ, Hohnloser SH, Healey JS; outcomes: findings from a prospective defibrillator database. ASSERT Steering Committee and Investigators. Positive Ann Intern Med. 2012 Feb 7; 156(3):195-203. predictive value of device-detected atrial high-rate episodes 26. Myers MG, Godwin M. Automated office blood pressure. at different rates and durations: An analysis from ASSERT. Canadian Journal of Cardiology. 2012;28:341-346. Heart Rhythm. 2012 Mar 20. 27. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, 20. Ko DT, Guo H, Wijeysundera HC, Zia MI, Dzavik V, Chu Kaczorowski J. Conventional versus automated measurement MW, Fremes SE, Cohen EA, Tu JV. Long Term Safety and of blood pressure in the office (CAMBO) trial. Family Practice. Effectiveness of Drug Eluting Stents for the Treatment of 2011 Nov;0:1-7 doi:10.1093/fampra/cmr113. Saphenous Vein Grafts Disease: A Population-Based Study. 28. Myers MG, Valdivieso M. Evaluation of an automated JACC Cardiovasc Intervention. 2011 Sep;4(9): 965-73. sphygmomanometer for use in the office setting. Blood 21. Ko DT, Wijeysundera HC, Yun L, Austin PC, Cantor WJ, Tu Pressure Monitoring. 2012 Mar;17:116-119. Effectiveness of preprocedural statin therapy on clinical JV. 29. Myers, MG. Automated office blood pressure - Eliminating outcomes for patients with stable coronary artery disease white coat hypertension in clinical practice. Current Hypertension after percutaneous coronary interventions. Circulation CV Reviews. 2012 Mar;8:136-140. Quality and Outcomes. 2011 Jul;4(4):459-66. 30. Natarajan MK, Strauss BH, Rokoss M, Buller CE, Mancini 22. Lavi S, Cantor WJ, Casanova A. Tan MK, Yan AT, Dzavik GBJ, Xie C, Sheth TN, Goodhart D, Cohen EA, Seidelin P, V, Fitchett D, Cohen EA, Borgundvaag B, Heffernan M, Harper W, Gerstein HC. Randomized trial of insulin versus Ducas J, Goodman SG. Efficacy and safety of enoxaparin usual care in reducing restenosis after coronary intervention in compared with unfractionated heparin in the pharmacoinvasive patients with diabetes. The STent Restenosis and Metabolism management of acute ST-segment elevation myocardial (STREAM) study. Cardiovascular Revascularization Medicine. infarction: Insights from the TRANSFER-AMI Trial. Am Heart Cardiovasc Revasc Med. 2012 Mar;13(2):95-100. Epub J. 2012 Feb;163(2):176-81.e2. 2012 Jan 30.
46 31. Oduneye S, Biswas L, Ghate S, Ramanan V, Barry J, Laish- 38. Singh SM, Goodman SG, Yan RT, Dery JP, Wong GC, Gallo Farkash A, Kadmon E, Zeidan Shwiri T, Crystal E, Wright R, Grondin FR, Lai K, Lopez-Sendon J, Fox KAA, Yan AT, for G. The Feasibility of Endocardial Propagation Mapping the Canadian GRACE and CANRACE investigators. Relation Using Magnetic Resonance Guidance in a Swine Model, Between Prior Angiotensin Converting Enzyme Inhibitor Use and Comparison with Standard Electroanatomic Mapping. and In-Hospital Outcomes in Acute Coronary Syndromes. IEEE Trans Med Imaging. 2011 Nov 4. American Journal of Cardiolgy. 2012; 109: 332-336
32. Pop M, Sermesant M, Mansi T, Crystal E, Ghate S, Peyrat 39. Singh SM, Neuzil P, Skoka J, Kriz R, Popelova J, Love BA, JM, Lashevsky I, Qiang B, McVeigh E, Ayache N, Wright GA. Mitnacht AJC, Reddy VY. Percutaneous trans-heaptic venous Correspondence between simple 3D MRI-based computer access for catheter ablation procedures in patients with models and in-vivo EP measurements in swine with chronic interruption of the inferior vena cava. Circulation Arrhythmia infarctions. IEEE Trans Biomed Eng. 2011 Sep 15. [Epub and Electrophysiology. 2011; 4(2): 235-241. ahead of print]. 40. Strauss BH, Osherov AB, Radhakrishnan S, Mancini 33. Saposnik G, Fang J, Kapral MK, TU JV, Mamdami M, Austin GBJ, Manners A, Sparkes JD, Chisholm RJ. Collagenase P, Johnston SC; on behalf of the Investigators of the Registry Total Occlusion-1 (CTO-1) Trial: A Phase I, Dose-Escalation, of the Canadian Stroke Network (RCSN) and the Stroke Safety Study. Circulation. 2012 Jan 24;125(3):522-8. Outcomes Research Canada (SORCan) Working Group. 41. Stukel TA, Fisher ES, Alter DA, Guttmann A, Ko DT, Fung K, The iScore predicts effectiveness of thrombolytic therapy for Wodchis WP, Baxter NN, Earle CC, Lee DS. Association of acute ischemic stroke. Stroke. 2012 Feb 3; 43(5):1315-1322. hospital spending intensity with mortality and readmission rates 34. Saposnik G, Raptis S, Kapral MK, Liu Y, TU JV, Mamdani in Ontario hospitals. JAMA. 2012 Mar 14;307(10):1037-45. M, Austin PC; on behalf of the Investigators of the Registry 42. Tardif JC, Gregoire J, L’Allier PL, Ibrahim R, Lavoie MA, Lemay of the Canadian Stroke Network and the Stroke Outcome M, Cohen E, Levesque S, Keller PF, Heinonen T, Guertin MC. Research Canada (SORCan – www.sorcan.ca) Working Effect of atherosclerotic regression on total luminal size of Group. The iScore predicts poor functional outcomes early coronary arteries as determined by intravascular ultrasound. after hospitalization for an acute ischemic stroke. Stroke. Am J Card. 2011 July 1. 2011 Oct 2; 42(12):3421-3428, 2011. 43. Tsadok MA, Jackevicius CA, Rahme E, Essebag V, Eisenberg 35. Shehata N, Rothwell D, Li, L, Forster A, Wilson K, Mazer MJ, Humphries KH, TU JV, Behlouli H, Joo J, Pilote L. C.D, Naglie G, Fowler R, TU JV, Henry D Hebert PC, Rubens Amiodarone-induced thyroid dysfunction: brand-name F. Anemia: Does it Impact Hospital Readmissions Following versus generic formulations. Can Med Assoc J. 2011 Jul Coronary Artery Bypass Surgery. Transfusion. 2011 Oct 6; 11; 183(12):E817-23. 51 Suppl 183A. 44. Tsang W, Alter DA, Wijeysundera HC, Zhang T, Ko DT. The 36. Singh SM, d’Avila A, Kim YH, Aryana A, Mangrum M, Michaud impact of cardiovascular disease prevalence on women’s G, Dukkipati S, Callans D, Barrett CD, Jovine M, Reddy V. enrollment in landmark randomized cardiovascular trials: The Modified Ablation Guided by Ibutilide use in Chronic a systematic review. Journal of General Internal Medicine. Atrial Fibrillation (MAGIC-AF) study: Clinical Background and 2012 Jan;27(1):93-8. Study Design. Journal of Cardiovascular Electrophysiology. 45. Tu JV, Ko DT, Guo H, Richards JA, Walton N, Natarajan MK, 2012: 23; 352-358. Wijeysundera HC, So D, Latter DA, Feindel CM, Kingsbury 37. Douglas PS, Reddy VY. The incidence and Singh SM, K, Cohen EA. Determinants of Variations in Coronary long term clinical outcome of iatrogenic atrial septal defects Revascularization Practices in Ontario. CMAJ. 2012 Feb secondary to transseptal catherization with a 12Fr transseptal 7;184(2):179-186. Epub 2011 Dec 12. sheath. Circulation Arrhythmia and Electrophysiology. 2011; 46. Van Spall HGC, Atzema C, Schull MJ, Newton GE, Mak S, 4(2): 166-171. Chong A, TU JV, Stukel TA, Lee DS. Prediction of emergent heart failure death by semi-quantitative triage risk stratification. PLos ONE. 2011 Aug 10; 6(8):e23065.
47 47. Welsh RC, Rao SV, Zeymer U, Thompson VP, Huber K, 53. Zia MI, Wijeysundera HC, Tu JV, Lee DS, Ko DT. Percutaneous Kochman J, McClue MW, Gretler DD, Bhatt DL, Gibson CM, Coronary Intervention With Versus Without On-Site Cardiac Angiolillo DJ, Gurbel PA, Berdan LG, Paynter G, Leonardi Surgery Backup: A Systematic Review and Meta-analysis. S, Madan M, French WJ, Harrington RA; on behalf of the Canadian Journal Cardiology. 2011 Sep-Oct;27(5):664.e9- Innovate PCI Investigators. A Randomized Double Blind 16. Epub 2011 May 5. Review. Active-controlled Phase 2 Trial to Evaluate a Novel Selective 54. Zia MI, Wijeysundera HC, Tu JV, Lee DS, Ko DT. Percutaneous and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel coronary intervention with vs without on-site cardiac surgery Versus Clopidogrel in Patients Undegoing Nonurgent backup: a systematic review and meta-analysis. The Canadian Percutaneous Coronary Intervention The Innovate-PCI Trial. Journal of Cardiology. 2011 Sep-Oct;27(5):664.e9-16. Epub Circulation Cardiovascular Interventions. 2012;5:00-00 2011 May 5. Review. Published online May 29,2012. 48. Wijeysundera HC, Mitsakakis N, Witteman W, Paulden M, Honours and Awards van der Velde G, TU JV, Lee DS, Goodman SG, Petrella R, O’Flaherty M, Capewell S, Krahn M. Achieving quality National indicator benchmarks and potential impact on coronary heart disease mortality. Can J Cardiol. 2011 Aug 30; 27(6):756- Distinctions and Research Awards 62, 2011. Received
49. Wijeysundera HC, Mitsakakis N, Witteman W, Paulden 1. Ko, Dennis. New Investigator Award, Canada. (Research Award). M, van der Velde G, Tu JV, Lee DS, Goodman SG, Petrella July 2009 – June 2014. Canadian Institutes of Health Research. R, O’Flaherty M, Capewell S, Krahn M. Achieving Quality Ranked first in competition across Canada. Total Amount: Indicator Benchmarks and Potential Impact on Coronary $300,000.00. Heart Disease Mortality Canadian Journal of Cardiology. 2. Tu, Jack. 2010 CSIM Dr. David Sackett Senior Investigator 2011 Nov-Dec;27(6):756-62. Award, Canadian Society of Internal Medicine, Toronto, Ontario, 50. Wijeysundera HC, Wang X, Tomlinson G, Ko DT, Krahn Canada. (Research Award). October 2010 – September 2011. MD. Techniques for Estimating Health Care Costs with To recognize excellence in research by a senior Canadian Censored Data: An overview for the health services researcher general internist. The award is intended to increase awareness ClinicoEconomics and Outcomes Research. 2012 Apr;4:145-55. of high quality reserah by general internists in Canada and . 51. Yan AT, Yan RT, Cantor WJ, Borgundvaag B, Cohen to foster such research. Total Amount: $2,500.00 CAD EA, Fitchett DH, Dzavik V, Ducas J, Tan M, Casanova 3. Wijeysundera, Harindra. Fellowship Award, Canadian A, Goodman SG; for the TRANSFER-AMI Investigators. Institute for Health Research (CIHR), Institute of Health Relationship between risk stratification at admission and Services and Policy Research, Canada. (Research Award) treatment effects of early invasive management following 2007- 2011. $50,000/yr for 4 years, Supervisor: M. Krahn. fibrinolysis: insights from the Trial of Routine Angioplasty and Total Amount: $200,000.00 CAD. Stenting After Fibrinolysis to Enhance Reperfusion in Acute 4. Wijeysundera, Harindra. 2011 CCS Young Myocardial Infarction. (TRANSFER-AMI). Eur Heart J. 2011 Investigator Award - Clinical Science Category, Feb 8. (Epub ahead of print) PMID: 21307037 Eur Heart J Canadian Cardiovascular Society, Canada. (Research 2011 Aug;32(16):1994-2002. Award, Specialty: Cardiology). July 2011 – July 2012. 52. Zia MI, Ghugre NR, Connelly KA, Joshi SB, Strauss BH, Total Amount: $1,000.00 CAD. Cohen EA, Wright GA, Dick AJ. Thrombus aspiration during primary percutaneous coronary intervention is associated with reduced myocardial edema, hemorrhage, microvascular obstruction and left ventricular remodeling. J Cardiovasc Magn Reson. 2012 Mar 26;14(1):19.
48 Provincial Local
Distinctions and Research Awards Distinctions and Research Awards
Received Received
1. Ko, Dennis. S. C. Verma Young Investigator 1. Ahmed, Shaheeda. Division of Cardiology Collaborative Award, Heart and Stroke Foundation of Canada, Initiative Award. University Joint Collaboration with Dr.J. Edwards Ontario, Canada. (Research Award). April 2012. (SMH) and Dr. G. Nesbitt (Mount Sinai). Dept of Medicine, Prize recognizes exceptional achievement in the cardiovascular Faculty of Medicine, University of Toronto, Ontario, Canada. sciences by Junior faculty members at the University of (Innovation, Specialty: Cardiology). November, 2011 – present. Toronto. Total Amount: $1,500.00 CAD. Awarded for the development of an online echo-case based teaching tool for the Cardiology Trainees
49 DIVISION OF DERMATOLOGY
Number of Faculty: 3 Grants Number Amount Peer Reviewed Funding Principal Investigator: 1 $7,500 CAD Co-Principal Investigator: 0 $0 CAD Co-Investigator / Collaborator: 0 $0 CAD Other: 1 $2,500 CAD Total: 2 $10,000 CAD
Non Peer Reviewed Funding Total: 1 $25,819 CAD
Publications Number Peer Reviewed Publications Principal Author 0 Co-Principal Author 0 Senior Responsible Author 0 Collaborator / Co-Author 12 Other Role 0 Total 12
Honours and Awards Received International: 7 National: 1 Provincial : 2 Total Honours and Awards 10
50 Grants, Contracts and Clinical Trials 5. Lynde C, Guenther L, Diepgen TL, Sasseville D, Yves Poulin Y, Gulliver W, Agner T, Barber K, Bissonnette R, Ho V, Shear NH, Peer Reviewed Funding Toole J. Canadian hand dermatitis management guidelines. J. Cutan Med Surg 2011;14, 267–284. Division Member is Principal Investigator 6. Matsukura T, Knowles SK, Walsh S, Shear NH. Effect of 1. Shear, Neil. Whole exome mutation screening in patients a single cycle of an alternative dosing regimen for rituximab with drug-induced Stevens-Johnson Syndrome or Toxic for recalcitrant pemphigus: A case series of nine patients. Epidermal Necrolysis. Dr. George S. Williamson Research perpub on-line: doi:10.1001/archdermatol.2011.3320. Arch Grant (CDF), Sunnybrook Research Institute ($15,000 Dermatol 2012. 2011-2012 Prorated: $7,500) [Grant] 7. Nanwa N, Mittmann N, Knowles S, Bucci C, Selby R, Other Peer Reviewed Funding Shear N, Walker SE. The Direct Medical Costs Associated with Suspected Heparin-Induced Thrombocytopenia. 1. Shear, Neil. Dr. Jennifer M. Salsberg - The impact of skin Pharmacoeconomics. Complement Altern Med. 2011 Apr camouflage on the quality of life of children with skin disease 7. doi: 10.2165/11584330-000000000-00000. [Epub ahead and their parents. The Hospital for Sick Children. CDF of print]. Research Grant. ($5,000 2011-2012 Prorated $2,500) [Grant] 8. Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for Non Peer Reviewed Funding the treatment of vitiligo vulgaris: an open label pilot clinical trial. 11(1): 21 (Full text: http://www.ncbi.nlm.nih.gov/ 1. Rituximab for severe pemphigus: Shear, Neil. pmc/articles/PMC3065445/). BMC Complement Altern Pharmacoeconomic analysis for Ontario Ministry of Health Med 2011. and Longterm Care. Shear NH, Walsh S, Knowles S, 9. Tan J, Stacey D, Barankin B, Bissonnette R, Gulliver W, Lui Mittman N, Hitzig S: Hoffman LaRoche Canada. ($51,638 H, Shear N, Bhatti S. Support needed to involve psoriasis 2012 Prorated: $25,819 [Grant] patients in treatment decisions: Survey of dermatologists. Publications J Cut Med Surg 2011;15 (4): 192-200. 10. Tan J, Stacey D, Fung K, Barankin B, Gulliver W, Lui H, Peer Reviewed Publications Shear N, Jackson C, Zhang X. Treatment decision needs of psoriasis patients: Cross-sectional survey. J Cutan Med Journal Articles 2011;14(5): 233-9.
1. Baibergenova A, Shear NH. Skin conditions that bring 11. Yeung M, Balma-Mena A, Shear N, Simor A, Pope E, Walsh patients to emergency departments. 147 (1):118-20. Arch S, McGavin MJ. Identification of major clonal complexes Dermatol 2011. Baibergenova A. and Walsh S. Use of and toxin producing strains among ataphylococcus aureus pioglitazone in patients with lichen planopilaris. J. Cutan. associated with atopic dermatitis. Microbes and Infection Med. Surg 2012;16(2): 97-100. 2011;13(2): 189 - 97.
2. Baibergenova A. and Walsh S. Use of pioglitazone in patients 12. Yeung M, Balma-Mena A, Shear N, Simor A, Pope E, with lichen planopilaris. 1 J. Cutan. Med. Surg 2012;6(2): Walsh S, and McGavin MJ. Identification of major clonal 97-100. complexes and toxin producing strains among Staphylococcus aureus associated with atopic dermatitis. Microbes Infect. 3. Dalle S, Thomas L, Shear NH. How pharmacogenomics of 2011;13(2): 189-97 biological response modifiers will influence clinical response and toxicity in dermatology. Int J Dermatol 2011;50: 114 – 18. 4. Foldvari M, Badea I, Kumar P, Wettig S, Batta R, King MJ, He Z, Yeboah E, Gaspar K, Hull P, Shear NH. Topical Delivery of Interferon alpha in Human Volunteers and Treatment of Patients with Human Papillomavirus Infections. Curr Drug Deliv. 2011;Feb 3. [Epub ahead of print].
51 Honours and Awards Teaching Awards Received International 1. Shear, Neil. The William “Joe” B. Moores Lecture, Dermatology, Distinctions and Research Awards Dept of Medicine, Faculty of Medicine, Indiana Academy of Received Dermatology and the Indiana University School of Medicine. (Postgraduate MD, Core Program). 2011. 1. Shear, Neil. Visiting Professor, Dubai Health Authority, University of Louisville Dermatology, United States. 2011. National 2. Shear, Neil. Visiting Professor, Dubai Health Authority, St. John’s Institute (King’s University), United Kingdom. 2012. Distinctions and Research Awards Received 3. Shear, Neil. Visiting Professor, Dubai Health Authority, University of Nottingham, United Kingdom. 2012. 1. Shear, Neil. Dr. David Hawkins Lectureship, Department of 4. Shear, Neil. Visiting Professor, Dubai Health Authority, The Medicine, Memorial University, St. John’s NL, Canada. 2012. University of Manchester, United Kingdom. 2012. Provincial / Regional 5. Shear, Neil. Visiting Professor, Dubai Health Authority, Cardiff University, Canada. 2012. Distinctions and Research Awards
6. Shear, Neil. 28th Stiefel Visiting Professor, Dubai Health Received Authority, Royal Society of Medicine, London UK, United 1. Shear, Neil. Amgen Keynote Lecturer, Quebec Deramtology Kingdom. 2012. Residents Retreat, Canada. 2011.
2. Shear, Neil. Dr. Barry Zimmerman Memorial Lectureship, Allergy Asthma and Immunology Society of Ontario, Canada. 2012.
52 DIVISION OF ENDOCRINOLOGY AND METABOLISM
Number of Faculty: 5
Grants Number Amount Peer Reviewed Funding Principal Investigator: 4 $197,512 CAD Co-Principal Investigator: 2 $59,943 CAD
1 $147,198 AUD Co-Investigator / Collaborator: 9 $828,719 CAD Other: 2 $411,051 CAD Total: 17 $1,497,225 CAD 1 $147,198 AUD
Non Peer Reviewed Funding Total: 0 $0 CAD
Publications Number Peer Reviewed Publications Principal Author 3 Co-Principal Author 2 Senior Responsible Author 0 Collaborator / Co-Author 10 Other Role 1 Total 16
Non Peer Reviewed Publications Total 2
Honours and Awards Received National: 2 Total Honours and Awards 2
53 Grants, Contracts and Clinical Trials 5. Lowe, Julia. The effect of a low glycemic index (GI) diet on maternal glycemic control and maternal and neonatal Peer Reviewed Funding markers of postpartum diabetes risk in women with gestational hyperglycemia. Wolever, Thomas, Barre, Ed; Darling, Pauline; Division Member is Principal Investigator Lowe, Julia; El-Sohemy Ahmed; Feig Denice; Josse Robert; 1. Shah, Baiju. Diabetes care and outcomes for people with Luthra, Meera; O’Connor Deborah; Ray, Joel, Thorpe, Kevin: Chinese and South Asian origins. Shah BR, Zwarenstein M ($229,876 July 2012-June 2014 Prorated: $76,625) Hux JE, Manuel D, Anand SS, Austin PC: Heart and Stroke 6. Lowe, Julia. Youth Out Reach for Diabetes (YOuR-Diabetes): Foundation of Ontario. ($301,703 July 2008-June 2012 Implementation and evaluation of a Systems Navigation Prorated: 75,426) [Grant] Model of Transition and Care for Non-Metropolitan Young 2. Shah, Baiju. Glycemic Risk of Adverse Clinical Events Adults with Type 1 Diabetes. Perry, Lin: NHMRC. Partnership (GRACE) Scale Development. Shah Baiju Lowe J, Bruce Grant. ($735,989 July 2013-June 2016 AUD Prorated: E: ASHC AFP Innovation Fund. ($70,208 Apr 2011-June $147,198) [Grant] 2012 Prorated: $56,166) [Grant] 7. Shah, Baiju. Evaluation of a strategy to improve cardiovascular 3. Shah, Baiju. RApid Diabetes Assessment and Referral disease screening and treatment for people with diabetes (RADAR) Clinic. Shah, Baiju: Sunnybrook Health Sciences (HSFC). Shah BR, Zwarenstein M (Co-Principal Investigator), Centre Ambulatory Services Pilot Project. ($85,000 Oct Mamdani M, Straus S, Parsons J, Bhattacharyya O, Yu 2011-Sept 2013 Prorated: $31,875) [Grant] C: Heart and Stroke Foundation of Canada. Operating Grant: Intervention Research. ($50,000 Oct 2009-Mar 2012 4. Shah, Baiju. The influence of language and ethnicity on stroke Prorated: $15,000) [Grant] care. Shah BR, Kapral M, Khan N, O’Donnell M: Canadian Institutes of Health Research (CIHR). Operating Grant. 8. Shah, Baiju. Evaluation of a strategy to improve cardiovascular ($102,136 Apr 2010-Mar 2013 Prorated: $34,045) [Grant] disease screening and treatment for people with diabetes. Shah BR, Zwarenstein M (Co-Principal Investigator), Other Peer Reviewed Funding Mamdani M, Straus S, Parsons J, Bhattacharyya O, Yu C: . Operating 1. Lowe, Julia. Glycemic Risk of Adverse Clinical Events Canadian Institutes of Health Research (CIHR) Grant: Intervention Research ($149,809 Oct 2009-Mar 2012 (GRACE) scale development. Shah, Baiju, Erin Bruce: AHSC AFP. ($47,676 July 2011-June 2012 Prorated: $47,676) Prorated: $44,943) [Grant] [Clinical Trial] 9. Shah, Baiju. Healthcare System Sustainability through Longitudinal Efficiency: Improved Quality and Lower Costs. 2. Lowe, Julia. Hypertensive Disorders of Pregnancy and Future Risk of Diabetes in Affected Women and Their Offspring. Stukel T, Alter D, Bierman A, Glazier R, Guttman A, Katz A, Laport A, Lee D, Manuel D, , Smith M, Tu Feig, Denice, Shah Baiju, Wu, Fangyun; Hwee, Jeremiah, Shah BR Ray Joel, Lipscombe Lorraine, Booth Gillian: Canadian K: Canadian Institutes of Health Research – Emerging Diabetes Association. ($98,081 July-July 2012 Prorated: Team Grant: Applied Health Services and Policy Research. $47,079) [Grant] ($1,460,779 Dec 2008-Nov 2013 Prorated: $292,156) [Grant] 10. Mobile Diabetes Education Teams in Primary 3. Lowe, Julia. MiTy trial (Metformin in Women with Type 2 Shah, Baiju. Care. Diabetes in pregnancy). Feig D: Canadian Institutes of Gucciardi, Enza: Canadian Institutes of Health ($277,601 July 2014-June 2014 Prorated: Health Research (CIHR). ($1,700,000 June 2010-June Research (CIHR). 2015 Prorated: $334,426) [Grant] $92,534) [Grant] 11. South Asian HeArt Risk Assessment (SAHARA) 4. Lowe, Julia. RApid Diabetes Assessment and Referral (RADAR) Shah, Baiju. Project. Clinic. Shah, Baiju, Dr Ivy Fettes, Dr Jay Silverberg, Dr Anand, Sonia: Heart and Stroke Foundation of . Grant in Aid. ($140,000 Sept 2010-Aug Jeremy Gilbert: AHSC AFP. ($72,000 Jan 2012-Dec 2012 Canada (HSFC) Prorated: $36,000) [Clinical Trial] 2012 Prorated: $70,000) [Grant] 12. Shah, Baiju. South Asian Heart Risk Assessment (SAHARA) Project. Anand, Sonia: Canadian Institutes of Health Research (CIHR). Operating Grant. ($714,514 June 2012-Mar 2015 Prorated: $21,015) [Grant]
54 13. Shah, Baiju. START- SouTh Asian biRth cohorT. Anand, 7. Perry L, Lowe J, Steinbeck K, & Dunbabin J. Doing the best Sonia: Heart and Stroke Foundation of Canada (HSFC). they can: experiences of adult diabetes services of young ($375,000 Apr 2011-Mar 2014 Prorated: $125,000) [Grant] adults with type 1 diabetes mellitus in rural Australia. Journal of Clinical Nursing 2012 June;21:1955–1963. 14. Shah, Baiju. Understanding the determinants of adiposity among newborns of Indian ancestry in Canada and India. 8. Shah BJ, Lipscombe L, Feig DS, Lowe J M. Missed Anand S, Beyene J, Gupta M, Dunn J, McDonald S, Ray J, opportunities for type 2 diabetes screening following gestational Irvine J, Teo K, Saigal S, Pare G, Persad V, Mente A, Morrison diabetes. British Journal of Obstetrics and Gynaecology. K, Retnakaran R, Hynie M, Shah BR: Canadian Institutes 2011 Aug 22;118:1484-1490. . Team Grant. ($375,000 Apr of Health Research (CIHR) 9. Shah BR, Cauch-Dudek K, Anand SS, Austin PC, Manuel 2011-Oct 2014 Prorated: $97,259) [Grant] DG, Hux JE. Absence of disparities in the quality of primary diabetes care for South Asians and Chinese in an urban Publications Canadian setting. Diabetes Care 2012 Apr, 359(4):794–796. (80% Contribution). Peer Reviewed Publications 10. Shah BR, Cauch-Dudek K, Pigeau L. Diabetes prevalence 1. Amed S, Dean HJ, Hadjiyanakis S, Sellers ECA, Panagiotopoulos and complications in the Métis population of Ontario. Diabetes C, Laubscher TA, Dannenbaum D, Shah BR, Booth GL, Care 34(12):2555–2556, 2011 Dec (85% contribution). Hamilton JK. Risk factors for medication-induced diabetes 11. Shah BR, Lipscombe LL, Feig D, Lowe J. Missed opportunities and type 2 diabetes. J Pediatr. 159(2):291-296, 2011 Aug for type 2 diabetes screening following gestational diabetes. (5% contribution). Impact Factor 4.042. BJOG 118(12):1484-1490, 2011 Nov. (75% contribution) 2. Amed S, Hamilton JK, Sellers EAC, Panagiotopoulos C, Impact Factor 3.349. Hadjiyannakis S, Shah BR, Booth GL, et. al. Differing clinical 12. Yamashita S, Ng E, Brommecker F, Silverberg J, Adhikari N. features in Aboriginal vs. non-Aboriginal children presenting Implementation of the Glucommander Method of Adjusting with type 2 diabetes. Pediatric Diabetes. 2012 Feb. E-published Insulin Infusions in Critically Ill Patients. Can J Hosp Pharm. ahead of print. doi:10.1111/j.1399-5448.2012.00859.x. 2011 Sept;64(5):333-339. 3. Chiu M, Austin PC, Manuel DG, Shah BR, Tu JV. Body mass index and incidence of diabetes in Whites, South Asians, Honours and Awards Chinese and Blacks living in Ontario, Canada. Diabetes Care 34(8): 1741-1748, 2011 Aug (15% contribution). Impact National Factor 6.718. Distinctions and Research Awards 4. Kiran T, Victor JC, Kopp A, Shah BR, Glazier RH. The relationship between financial incentives and quality of diabetes Received care in Ontario. Diabetes Care. 2012 Apr; 35:1038-1046. 1. Fettes, Ivy Marlys. Robert Volpe Distinguished Service (10% Contribution). Award, Canadian Society of Endocrinology and Metabolism. 5. Lowe LP, Metzger BE, Dyer AR, Lowe J, McCance DR, (Distinction). 2011. Lappin TRJ, Trimble ER, Coustan DR, Hadden DR, Hod Teaching Awards M, Oats JJN, Persson B, for the HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Received Outcome (HAPO) Study: Associations of A1c and Glucose with 1. Gilbert, Jeremy David. The 2011 George From Pregnancy Outcomes. Diabetes Care 2012 Mar;35:574-580. Postgradue Endocrinology Teaching Award, Division 6. Mukerji G, Chiu M, Shah BR. Impact of gestational diabetes of Endocrinology, Department of Medicine, University on the risk of diabetes following pregnancy among Chinese of Toronto. (Postgraduate MD). September 2011. and South Asian women. Diabetologia. 2012 Apr, 55(8):2148- For outstanding teaching by Faculty Member in Endocrinology 2153. (contribution 50%). at University of Toronto who excels in teaching and CANMED roles.
55 DIVISION OF GASTROENTEROLOGY
Number of Faculty: 6
Grants Number Amount Peer Reviewed Funding Principal Investigator: 2 $93,379 CAD
Co-Principal Investigator: 3 $181,866 CAD Co-Investigator / Collaborator: 5 $717,193 CAD Other: 1 $16,296 CAD Total: 11 $1,008,734 CAD
Non Peer Reviewed Funding Total: 12 $491,536 CAD
Publications Number Peer Reviewed Publications Principal Author 1 Co-Principal Author 1 Senior Responsible Author 2 Collaborator / Co-Author 13 Other Role 0 Total 16
Honours and Awards Received National: 1 Local: 1 Total Honours and Awards: 2
56 Grants, Contracts and Clinical Trials 8. Tinmouth, Jill. Team Grant - Emerging: Colorectal Cancer Screening. Canadian Institutes of Health Research (CIHR). Peer Reviewed Funding $2,443,467 Oct 2007-Sept 2012 Prorated: $488,693 [Grant] 9. The TRACE Anal Cancer Screening Study: Division Member is Principal Investigator Tinmouth, Jill. Progression and Transmission. Irving Salit: National Cancer 1. Cooper, Mary Anne. Developing Quantitative Tools to Evaluate Institute of Canada (NCIC). ($504,430 2007-2012 Prorated: Endoscopic Performance Using a High Fidelity Simulator. $84,072) [Grant] Dr. Mary Anne Cooper, Dr. Heather Carnahan, Dr. Samir Grover, Dr. Jill Tinmouth, Dr. Elaine Yong: University of Non Peer Reviewed Funding . (2010-present) [Grant] Toronto, Division of Gastroenterology 1. Cohen, Lawrence B. Change in Adipocytokines profiles 2. Tinmouth, Jill. Improving the quality of colonoscopy: in obese patients treated with intragastric balloon therapy. Development and pilot testing of an endoscopist audit Private Donation. ($125,000 June 2012-present Prorated: and feedback tool derived from health administrative data. $41,667) [Donation] . ($186,758 Canadian Cancer Society Research Institute 2. Cohen, Lawrence B. ICE Trials The Efficacy of Open Label Feb 2011-Jan 2013 Prorated: $93,379) [Grant] Infliximab for the induction and maintenance of Mucosal Healing Other Peer Reviewed Funding in small bowel Crohn’s Disease assessed through wireless capsule endoscopy. Merck, Canada. (Apr 2011-present) 1. Cohen, Lawrence B. Polyp Prevention Study and Extension [Industrial Grant] Studies. Saibil, Fred: NCI (USA). ($377,435 July 1995-present) 3. Cohen, Lawrence B. PYRAMID (Humira Registry Project). [Clinical Trial] Saibil, Fred: Abbott Laboratories. ($19,206 July 2008-present) 2. Cooper, Mary Anne. Biomarkers for Assessment Of Liver [Industrial Grant] Fibrosis. Ms. Tammie Taylor, MLT, Dr.Lei Fu Dr. David Cole: 4. Cohen, Lawrence B. PURSUIT Trial (Induction Phase). Sunnybrook Practice Based Research (PBR). ($9,526 Apr Saibil, Fred: Centocor Inc. ($23,782 Apr 2008-present) 2007-present Prorated: $1,786) [Grant] [Industrial Grant] 3. Saibil, Fred. GEM project: A multidisciplinary Human Study 5. Cohen, Lawrence B. PERSUIT Trial (Maintenance Phase). of the Genetic., Environmental and Microbial Interactions Saibil, Fred: Centocor Inc. ($38,528 Apr 2008-present) that Cause Inflammatory Bowel Disease. Croituru, Ken: [Industrial Grant] Canadian Institutes of Health Research (CIHR). ($40,000 Mar 2010-present Prorated: $16,296) [Grant] 6. Saibil, Fred. Pyramid trial: Adalimumab for Crohn’s disease; monitoring study. Dr. L. Cohen: Abbott Laboratories. ($4,940 4. Saibil, Fred. Polyp prevention trial extension studies (DNA July 2008-present Prorated: $1,156) [Grant] methylation; thromboxane B2, others). Dr. L. Cohen: NCI 7. PURSUIT trial: Golimumab for active ulcerative (USA). ($24,494 1995-present Prorated: $1,289) [Grant] Saibil, Fred. colitis. Induction study. Dr. L. Cohen: Centocor. ($10,269 5. Tinmouth, Jill. A population-based study of cancer incidence 2008-present)[Grant] and mortality in patients with solid organ transplants. Baxter, 8. PURSUIT trial: Golimumab for active ulcerative Nancy: Canadian Institutes of Health Research (CIHR). Saibil, Fred. ($682,732 Oct 2011-2016/09 Prorated: $102,410) [Grant] colitis. Maintenance study. Dr. L. Cohen: Centocor. $2,538 2008-present [Grant] 6. Tinmouth, Jill. Identifying barriers to participation in colorectal 9. Assessing the quality of colonoscopy: cancer screening. Nancy Baxter: Canadian Cancer Society Tinmouth, Jill. Validation of NEW colonoscopy data elements from the Research Institute. ($204,847 July 2011-June 2013 Prorated: $102,424) [Grant] Colonoscopy Interim Reporting Tool (CIRT). Ontario Institute for Cancer Research. ($15,000 Jan 2012-Dec 2012 Prorated: 7. Tinmouth, Jill. Treatment of Anal Dysplasia: Acceptability $7500) [Contract] and Outcomes. Salit, Irving: Canadian Cancer Society 10. Pilot Evaluation of Fecal Immunologic Test Research Institute. ($193,009 Feb 2011-Jan 2013 Prorated: Tinmouth, Jill. $96,505) [Grant] in Ontario. Cancer Care Ontario. ($401,000 Mar 2011-Apr 2012 Prorated: $286,429) [Contract]
57 11. Tinmouth, Jill. Increasing the uptake of colorectal cancer Honours and Awards screening in Ontario. Ontario Institute for Cancer Research. ($457,427 Jan 2011-Dec 2013 Prorated: $152,475) [Contract] National 12. Current status of screening programs for anal Tinmouth, Jill. Distinctions and Research Awards cancer precursors in HIV-infected persons: An environmental scan. Salit, I: Ontario HIV Treatment Network. ($10,000 Sept Received
2010-Sept 2011 Prorated: $2,307) [Contract] 1. Saibil, Fred. CCFC Finkelstein Prize for 2011, Crohn’s and Colitis Foundation of Canada, Canada. (Distinction). 2011. Publications Local Peer Reviewed Publications Teaching Awards 1. Cardoso R, Coburn N, Seevaratnam R, Sutradhar R, Gomes Received Lourenco L, Mahar A, Law C, Yong E, Tinmouth J. A systematic review and meta-analysis on the utility of EUS 1. Bernstein, Michael. SHSC Department of Medicine for preoperative staging for gastric cancer. Gastric Cancer Young Teacher Award for 2011, Dept of Medicine, Faculty 2012 Jan 12. Epub ahead of print. doi:10.1007/s10120- of Medicine, Sunnybrook Hospital Department of Medicine. 011-0115-4. (Multilevel Education). September 2011.
2. Murthy SK, Steinhart AH, Tinmouth J, Austin P, Nguyen GC. Impact of Gastroenterologist Care on Health Outcomes of Hospitalized Ulcerative Colitis Patients. Gut 2012. June 8, Epub ahead of print. doi:10.1136/gutjnl-2011-301978.
3. Neuman MG, Nanau MR, Cohen L, Hwang P. Genetic and Immune Predictors for Hypersensitivity Syndrome to Antiepileptic Drugs. Translation Res, J Clinical and Lab Medicine, 159, 397-406, 2012 DOI 101016/j. trsl 201201.004. 4. Neuman, MG., Schmilowitz-Weiss H. Hilzenrat N, Bourliere M, Marceling P, Trepo C, Mazulli T, Moussa G, Patel, Baig AA, Cohen, L. Markers of inflammation and fibrosis in alchoholic heptitis and viral heptitis C. World J Hepatol, special issues on Alcoholic Hepatitis, doi: 10.115/2012/231210.2011.
5. Udell JA, Wang CS, Tinmouth J, FitzGerald Jm, Ayas NT, Schulzer M, Mak E, Yoshida EM. The rational clinical exam: Does this patient have cirrhosis? JAMA 2012;307:832-42.
6. Yogeswaran K, Chen G, Cohen L, Cooper M, Yong E, Hsieh E, Rowsell C, Saibil F, Tinmouth J. How well is Helicobacter pylori treated in usual practice? Canadian Journal of Gastroenterology. 2011 Oct; 25(10):543-6.
58 DIVISION OF GENERAL INTERNAL MEDICINE
Number of Faculty: 13
Grants Number Amount Peer Reviewed Funding Principal Investigator: 11 $805,432 CAD Co-Principal Investigator: 6 $333,424 CAD Co-Investigator / Collaborator: 22 $1,954,357 CAD 2 $252,710 USD Other: 3 $203,361 CAD Total: 42 $3,296,574 CAD 2 $252,710 USD
Non Peer Reviewed Funding Total: 2 $40,931 CAD
Publications Number Peer Reviewed Publications Principal Author 13 Co-Principal Author 2 Senior Responsible Author 10 Collaborator / Co-Author 19 Other Role 0 Total 44
Honours and Awards Received Distinctions and Research Awards: 2 International: 2 National: 4 Local: 7 Total Honours and Awards 15
59 Grants, Contracts and Clinical Trials 9. Wong, Brian. Characterizing facilitators and barriers in order to promote the successful implementation of a quality Peer Reviewed Funding improvement and patient safety curriculum for postgraduate trainees and medical students. M. Mamdani: University Division Member is Principal Investigator of Toronto. Education Development Fund for Innovation 1. Fowler, Robert. E-PROTECT. The Economic Evaluation of in Education. ($1,750,000 Aug 2010-July 2011 Prorated: the PROTECT trial. Redelmeier, Don, Laskin C, Librach C, $218,750) [Grant] Udell J: Heart and Stroke Foundation of Canada. ($97,307 10. Wong, Brian. A Virtual Ward to Reduce Re-admissions 2008-2011 Prorated: $24,327) [Grant] After Hospital Discharge. Alternate Funding Plan. Innovation 2. Fowler, Robert. Pregnant women: who is at risk and is the Fund (Multi-site request). ($230,563 Jan 2010-Dec 2012 H1N1 flu vaccine safe for the baby?Canadian Institutes of Prorated: $28,820) [Grant] Health Research (CIHR). ($99,208 2009-2011 Prorated: 11. Wong, Brian. Development and Evaluation of a Clinical $33,069) [Grant] Messaging System for Interprofessional Team-Based Care in 3. Fowler, Robert. Influenza-and H1N1-Related Critical Illness the Outpatient Setting. Kuper, Ayelet, Mathieu Albert, Brian - Demand and Capacity in the Health Care System: the David Hodges: Department of Medicine and Department of Canadian ICU-Flu Study. Redelmeier, Don, Shadowitz Family and Community Medicine. BRIDGES (Building Bridges S, Etchells E: Public Health Agency of Canada (PHAC). to Integrate Care). ($111,138 Jan 2012-Mar 2013 Prorated: ($90,000 2009-2011 Prorated: $30,000) [Grant] $20,838) [Grant]
4. Fowler, Robert. Planning meeting for the PREEDICCT Other Peer Reviewed Funding study. Redelmeier, Donald, Laskin C, Librach C, Udell J: 1. Promoting Real-Time Improvements Canadian Institutes of Health Research (CIHR). ($97,307 Etchells, Edward. 2011-2012 Prorated: $32,436) [Grant] in Safety for the Elderly (PRISE) Study. Stroud, Lynfa and Wong, Brian, Matreiya Coffey, Guisseppe Papia, Markku 5. Juurlink, David. Real-World Effects of Bisphosphonates: Nousiainen, Adelle Atkinson, Heather McDonald-Blumer, Anne Using Innovation to Link Datasets. Phase 1. Edward Etchells, Matlow, Wendy Levinson: Canadian Patient Safety Institute. Kaveh Shojania, Ayelet Kuper: Canadian Institutes of ($24,804 June 2010-Dec 2011 Prorated: $24,804) [Grant] Health Research, Catalyst Grant: Post Market Drug Safety and Effectiveness. ($7,500 2010-2011 Prorated: $625) [Grant] 2. Etchells, Edward. A SMART adverse Events Tracking System for Physicians. Rob Wu, Amna Husain, Trevor Jamieson, 6. Kuper, Ayelet. The origins and development of medical Irfan Dhalla, Dante Morra, Tara O’Brien, Brian Wong, education research: A sociohistorical study (410-2008-0227). David Frost, Lydia Lee, Joe Cafazzo, Nancy Martin-Ronson, Brian Wong, Ed Etchells, Ross Baker, Jocelyn Charles, Sherman Quan, Jennifer Stinson: Alternate Funding Plans. Barbara Liu, et al: Social Sciences and Humanities Research ($201,377 Mar 2010-May 2012 Prorated: $80,551) [Grant] Council of Canada (SSHRC). Standard Operating Grant. ($260,000 Apr 2008-Mar 2012 Prorated: $120,000) [Grant] 3. Etchells, Edward. Multi-Center Medication Reconciliation Quality Improvement Study - MARQUIS. Matlow, Anne, Tina 7. Shojania, Kaveh G. Informing the decision to participate in Borschel, Brian M. Wong, Heather McDonald-Blumer: a clinical trial: Can decision aids improve the quality of trial Agency for Health Care Research & Quality (AHRQ) (formerly participation decisions? David Juurlink: Canadian Institutes Agency for Health Care Policy and Research). ($10,275 Oct of Health Research (CIHR). ($1,379,400 Feb 2008-2011 2010-Sept 2013 Prorated: $10,275) [Grant] Prorated: $229,900) [Grant] 4. Fowler, Robert. Influenza-and H1N1-Related Critical 8. Stroud, Lynfa. Towards contextualized performance Illness - Demand and Capacity in the Health Care System: assessments: The importance and influence of environmental the Canadian ICU-Flu Study. Redelmeier, Don and Scales, factors on evaluation. Fowler, Robert: Royal College of Damon, Markel F: Canadian Institutes of Health Research Physicians and Surgeons of Canada. Medical Education (CIHR). ($90,000 2009-2011 Prorated: $30,000) [Grant] Research Grant. ($400,000 July 2010-Dec 2012 Prorated: $66,667) [Grant]
60 5. Fowler, Robert. Impact of H1N1 pandemic on critical 13. Juurlink, David. The Ontario Drug Policy Research Network care services for children. Albert, Mathieu, Ayelet Kuper: (ODPRN). Shojania, Kaveh, Susan VanDeVelde-Coke (Decision Canadian Institutes of Health Research (CIHR). ($51,900 Maker Lead), Brian Wong (Co-PI), Edward Etchells, 2010-2011 Prorated: $17,300) [Grant] Barbara Liu, Deborah Brown-Farrell, G. Ross Baker, Rajin Rupinder Taggar, Sandra Knowles, Jocelyn Charles, 6. Fowler, Robert. EPITEC - Epidemiology of ThromboEmbolism Mehta, : in Critical Care. Christian, Michael, Fisman D, Fowler R, Ayelet Kuper Ontario Ministry of Health and Long-Term . MOHLTC Drug Innovation Fund. ($240,000 2008-2011 Marshall J, Zygun D: Canadian Institutes of Health Research Care Prorated: $102,857) [Grant] (CIHR). ($23,842 2010-2011 Prorated: $31,950) [Grant] 14. Safety of pregnancy exposure to 7. Fowler, Robert. Influenza-and H1N1-Related Critical Illness - Juurlink, David. Demand and Capacity in the Health Care System: the Canadian antidepressants. Canadian Institutes of Health Research, Catalyst Grant: Post Market Drug Safety and Effectiveness. ICU-Flu Study. Morris, Andrew, Bell C, Fowler R, Burry L, Daneman N, Dresser L, Elligsen M, Herridge M, Mehta S, ($438,568 USD 2010-2011 Prorated: $146,189) [Grant] Muller M: Canadian Institutes of Health Research (CIHR). 15. Juurlink, David. Canadian Drug Safety and Effectiveness ($768,000 Oct 2009-Oct 2011 Prorated: $256,000) [Grant] Research Network (CDSERN). Udell JA: Canadian Institutes , Emerging Team Grant: Health Services 8. Fowler, Robert. Age of Blood Evaluation (ABLE) Trial in the of Health Research and Policy Research. ($165,000 2009-2014 Prorated: Resuscitation of Critically Ill Patients. Ray, JG, Guttman A, $55,000) [Grant] You J, McDonald S, Redelmeier DA: ($49,120 2008-2013 Prorated: $24,560) [Grant] 16. Kuper, Ayelet. History of Professionalism. Brian Wong, , Barabara Liu: 9. Fowler, Robert. Council of Academic Hospitals of Ontario Kaveh Shojania Social Sciences and (CAHO) Implementation of Antimicrobial Stewardship Humanities Research Council of Canada (SSHRC). SSHRC Programs (ASP) in Intensive Care Units in Ontario Academic Institutional Grant (SIG) to University of Toronto. ($260,000 Apr 2009-Mar 2012 Prorated: $82,105) [Grant] Hospitals. Slaughter, Graham, Jordan Chenkin, Mark Cheung, Brian Wong, Lynfa Stroud: ($19,984 2011-2013 17. Kuper, Ayelet. Promoting Real-Time Improvements in Safety Prorated: $17,129) [Grant] for the Elderly (PRISE) Study. Shojania, Kaveh, Susan VanDeVelde-Coke, Barbara 10. Fowler, Robert. A National Comparison of Intensity of End- Brian Wong, Edward Etchells, of-Life Care in Canada: Defining Changing Patterns, Risk Liu, Deborah Brown-Farrell, G. Ross Baker, Rajin Mehta, Rupinder Taggar, Sandra Knowles, Jocelyn Charles, Ayelet Factors and Targets for Intervention. Slaughter, G, Stroud Kuper: . ($130,000 L, Chenkin J, Cheung M, Wong B: Canadian Institutes of Canadian Patient Safety Institute (CPSI) July 2010-Mar 2012 Prorated: $55,714 [Grant] Health Research (CIHR). ($19,984 2011-2013 Prorated: $15,987) [Grant] 18. Kuper, Ayelet. Knowledge Production Practices and Legitimization Strategies Used by Social Scientists and 11. Fowler, Robert. DECIsion-making about goals of care for hospitalized meDical patiEnts: a multicentre, mixed-methods Humanities Scholars Working in Faculties of Medicine. study, The DECIDE Study. Fowler R, Heyland D, You J, Stroud L, Ginsburg S, McIlroy J, Bryden P, McKnight D: Albert M, Brazil K, Day A, Downar J, Ilan R, Jayaraman Social Sciences and Humanities Research Council of D, Kryworuchko J, Lamontagne F, Ma I, Palepu A, Shik J, Canada (SSHRC). Standard Operating Grant. ($32,870 Apr Strachan P: $100,000 2012-2014 Prorated: $16,667 [Grant] 2011-Mar 2014 Prorated: $13,148) [Grant] 19. Childhood Cerebral Palsy and Maternal 12. Fowler, Robert. Pilot KT intervention to address gender Redelmeier, Donald. Cardiovascular Disease. differences in access to post arrest care Funds. Rac, Valeria, Wen, Shi Wu: Ontario Federation Slutsky A, Abramson B, Dorian P, Bierman A, Parsons J, for Cerebral Palsy. ($94,718 2011-2012 Prorated: $23,680) Scales DC, Fowler R, Gray S, Dainty K, Zwarenstein M, Kiss [Grant] A: Canadian Institutes of Health Research (CIHR). ($218,994 20. Redelmeier, Donald. Clinical Scientist Award for Nick 2012-2014 Prorated: $36,499) [Grant] Daneman. Fowler, Robert; Jouvet, Philippe: Canadian Institutes of Health Research (CIHR). ($599,673 July 2009- June 2012 Prorated: $95,948) [Grant]
61 21. Redelmeier, Donald. A New Model for General Internal 30. Wong, Brian. Teaching medical error disclosure skills to Medicine Teaching Units. Dhalla, Irfan (overall study PI), postgraduate internal medicine, surgery and pediatrics Rajin Mehta (Sunnybrook Lead), Chaim Bell, Wee-Shian trainees. Royal College of Physicians and Surgeons of Chan, Steven Hwang, Ophyr Mourad, Steven Shadowitz, Canada (The). AMS/CanMEDS Research and Development Brian Wong: Alternative Funding Plan. Innovation Fund. Grant. ($500,000 Mar 2012 Prorated: $98,361) [Grant] ($91,800 2011-2013 Prorated: $30,600) [Grant] 31. Wong, Brian. Integrating a focus on quality of care into a 22. Redelmeier, Donald. Organ Donation after Brain Death in longitudinal ambulatory care rotation. Fowler, Robert; Jouvet, Ontario. Jouvet, Philippe André, Fowler, R; Hutchison, J; Philippe, Dr. Anand Kumar, Dr. Allison McGeer, Dr. Jamie Kissoon, N; Menon, K: Trillium Gift of Life Network (Ontario). Hutchison, Dr. Kusum Menon, Dr. Deborah Cook, Dr. John ($99,972 2011-2013 Prorated: $24,993) [Grant] Marshall: University of Toronto. Education Development Fund for Innovation in Education. ($400,000 May 2012 Prorated: 23. Redelmeier, Donald. Fellowship Award for Jay Udell. Cook $66,667) [Grant] DJ, Crowther P, Devereaux P, Dodek P, Fowler R, Hall R, Herridge M, Jacka M, Lauzier F, Marshall J, Meade M, Mehta 32. Wong, Brian. Promoting Real-Time Improvements in Safety S, Muscedere J, Turgeon A: Canadian Institutes of Health for the Elderly (PRISE). Canadian Patient Safety Institute Research (CIHR). ($63,899 July 2010-June 2013 Prorated: (CPSI). Research Competition. ($4,020,189 July 2010-May $15,975) [Grant] 2012 Prorated: $670,032) [Grant]
24. Redelmeier, Donald. General Reproductive Assistance 33. Wong, Brian. Implementing a Bedside Ultrasound Curriculum and Vascular Illness Downstream. Caderette, Suzanne: for Procedures into an Internal Medicine Residency Program. Canadian Institutes of Health Research (CIHR). ($100,000 Jamie Brehaut: University of Toronto. Education Development 2011-2014 Prorated: $25,000) [Grant] Fund for Innovation in Education. ($298,215 June 2011-July 2013 Prorated: $38,070) [Grant] 25. Redelmeier, Donald. Resuscitation Outcomes Consortium (ROC) Regional Clinical Centre - Toronto Regional Coordinating Non Peer Reviewed Funding Centre. Morrison, Laurie: Canadian Institutes of Health Research (CIHR). Institute of Circulatory and Respiratory 1. Redelmeier, Donald. Generalized Reproductive Assistance Health. ($1,002,000 Dec 2009-Nov 2015 Prorated: $167,000) and Vascular Illness Downstream (GRAVID). Coburn, Natalie, [Grant] Andrew Smith, Ru Taggar: Canadian Institutes of Health Research (CIHR). ($99,760 July 2011-June 2014 Prorated: 26. Redelmeier, Donald. Toronto Regional resuscitation $40,643) [Grant] research out of hospital network. Morrison, Laurie: Heart and Stroke Foundation of Canada. Resuscitation Outcomes 2. Shojania, Kaveh G. Tier 2 Canada Research Chair in Consortium (ROC). ($1,500,000 Dec 2009-Nov 2015 Prorated: Patient Safety and Quality Improvement. Kuper, Ayelet: $250,000) [Grant] Government of Canada Research Chairs Program. ($1,152 Oct 2008-Oct 2013 Prorated: $288) [Grant] 27. Redelmeier, Donald. Toronto Regional resuscitation research out of hospital network. Morrison, Laurie: National Institutes of Health (NIH) (USA). Resuscitation Outcomes Publications Consortium (ROC). ($648,000 USD Dec 2009-Dec 2015 Peer Reviewed Publications Prorated: $106,521) [Grant] 1. Ackery A, McLellan BA, Bicyclist deaths 28. Shojania, Kaveh G. Promoting Real-Time Improvements in Redelmeier DA. and striking vehicles in the United States. Injury Prevention. Safety for the Elderly (PRISE) Study. Daneman N: Canadian 2012;18:22-6. Patient Safety Institute (CPSI). CPSI 2009 Research Competition. ($150,000 June 2010-July 2012 Prorated: 2. Banfield JM, Gomez M, Kiss A, Redelmeier DA, Brenneman $50,000) [Grant] F. Effectiveness of the PARTY program in preventing traumatic injuries. Journal of Trauma 2011; 70:732-5. 29. Stroud, Lynfa. Implementing a bedside ultrasound curriculum for procedures into an internal medicine residency program. 3. Becker T, Hux JE. Risk of acute complications of diabetes McGeer, Allison: Faculty of Medicine, University of Toronto. among people with schizophrenia in Ontario, Canada. Education Development Fund & Department of Medicine. Diabetes Care. 2011; 34 (2):398-402. ($385,628 Apr 2011-June 2012 Prorated: $64,271) [Grant]
62 4. Berger E, Kuper A, Albert M, Shouldice M. The CanMEDS 14. Hill AD, Fowler RA and Nathens AB. Impact of interhospital Portfolio: A Tool for Reflection in a Fellowship Program. transfer on outcomes for trauma patients: a systematic review. Clin Teach 8 (3): 151-5, September 2011 (Contribution: co- J Trauma. 2011 Dec;71(6):1885-900; discussion 1901. supervised the design of the study; supervised the analysis Hodges BD, Kuper A. Theory and Practice in the Design of the study; revised drafts of the paper). and Conduct of Graduate Medical Education. Acad Med 87 (1): 25-33, January 2012 (Contribution: wrote portions 5. Chan J, Shojania KG, Easty AC, Etchells EE. Usability evaluation of order sets in a computerised provider order of the manuscript, revised the manuscript). entry system. BMJ Qual Saf. 2011 Nov;20(11):932-40. 15. Hodges BD, Kuper A. Theory and Practice in the Design Epub 2011 Jul 31. and Conduct of Graduate Medical Education. Acad Med 87 (1): 25-33, January 2012 (Contribution: wrote portions 6. Chan WK, Redelmeier DA. Simpson’s Paradox and the Association between Vitamin D Deficiency and Increased of the manuscript, revised the manuscript). Heart Disease. American Journal of Cardiology. 2012 Mar 16. Kitto S, Bell M, Peller J, Sargeant J, Etchells E, Reeves S, 29; e pub ahead of print. Silver I. Positioning continuing education: boundaries and intersections between the domains continuing education, 7. Daneman N, Shore K, Pinto R and Fowler R. Antibiotic treatment duration for bloodstream infections in critically ill knowledge translation, patient safety and quality improvement. patients: a national survey of Canadian infectious diseases Adv Health Sci Educ Theory Pract. 2011 Dec 14. [Epub and critical care specialists. Int J Antimicrob Agents. 2011 ahead of print]. Dec;38(6):480-5. Epub 2011 Oct 7. 17. Kuster SP, Katz KC, Blair J, Downey J, Drews SJ, Finkelstein 8. Dodek PM, Wong H, Jaswal D, Heyland DK, Cook DJ, S, Fowler R, Green K, Gubbay J, Hassan K, Lapinsky SE, Mazzulli T, McRitchie D, Pataki J, Plevneshi A, Powis Rocker GM, Kutsogiannis DJ, Dale C, Fowler R and Ayas NT. Organizational and safety culture in Canadian intensive care J, Rose D, Sarabia A, Simone C, Simor A and McGeer A. units: relationship to size of intensive care unit and physician When should a diagnosis of influenza be considered in management model. J Crit Care. 2012 Feb;27(1):11-7. Epub adults requiring intensive care unit admission? Results of 2011 Sep 29. population-based active surveillance in Toronto. Crit Care. 2011 Jul 28;15(4):R182. 9. Etchells E, Adhikari NK, Wu R, Cheung M, Quan S, Mraz 18. Mandourah Y, Al-Radi A, Ocheltree AH, Ocheltree SR R, Wong B, Pinto R, Mehta R, Morra D, Fowler R, Sibbald W, Abrams H and Rossos PG. Real-time automated paging and Fowler RA. Clinical and Temporal Patterns of Severe and decision support for critical laboratory abnormalities. Pneumonia Causing Critical Illness during Hajj. BMC Infect BMJ Qual Saf. 2011 Nov;20(11):924-30. Epub 2011 Jul 1. Dis. 2012 May 16;12(1):117. 19. Mandourah Y, Ocheltree A, Al Radi A and The 10. Etchells E, Koo M, Daneman N, McDonald A, Baker M, Fowler R. epidemiology of Hajj-related critical illness: lessons for Matlow A, Krahn M, Mittmann N. Comparative economic analyses of patient safety improvement strategies in acute deployment of temporary critical care services*. Crit Care care: a systematic review. BMJ Quality and Safety. 2012 Med. 2012 Mar;40(3):829-34. Jun;21(6):448-56. Epub 2012 Apr 22. 20. Quinn RR, Laupacis A, Hux JE, Oliver MJ, and Austin PC. 11. Evans TW, Nava S, Mata GV, Guidet B, Estenssoro E, Predicting the risk of 1-year mortality in incident dialysis patients: accounting for case-mix severity in studies using Fowler R, Scheunemann LP, White D and Manthous CA. Critical care rationing: international comparisons. Chest. administrative data. Med Care. 2011; 49 (3):257-266. 2011 Dec;140(6):1618-24. 21. Redelmeier DA, Chan WK, Mullainathan S, Shafir E. Social benefit payments and acute injury in low income mothers. 12. Fowler RA, Shafazand S. Anthrax Bioterrorism: Prevention, Diagnosis, and Management Strategies. J Bioterrorism & Open Medicine. 2012. 5:101-8. Biodefense 2011, 2:107. 1.3. 22. Redelmeier DA, Dickinson VM. Judging whether a patient is actually improving: more pitfalls from the science 13. Goligher EC, Leis JA, Fowler RA, Pinto R, Adhikari NK and Ferguson ND. Utility and safety of draining pleural effusions of perception. Journal of General Internal Medicine. 2012. in mechanically ventilated patients: a systematic review and 27:1195-9. meta-analysis. Crit Care. 2011;15(1):R46. Epub 2011 Feb 2.
63 23. Redelmeier DA, Katz D, Lu H, Saposnik G. Roadway crash 34. Westcott M, Martiniuk AL, Fowler RA, Adhikari NK and risks in recent immigrants. Accident Analysis & Prevention. Dalipanda T. Critical care resources in the Solomon Islands: 2011; 43:2128-33. a cross-sectional survey. BMC Int Health Hum Rights 2012 Mar 1;12:1. 24. Redelmeier DA, Vermeulen M. Emergency department visits during an Olympic Gold Medal broadcast. Open Medicine. 35. Wong B, Hollenberg E, Etchells E, Kuper A, Levinson 2011;5:112-9. W, Shojania K. The Emergence of Quality Improvement (QI) and Patient Safety Training in Postgraduate Medical 25. Redelmeier DA, Yarnell CJ. Road crash fatalities on US income tax days. JAMA. 2012; 307(14):1486-88. Education: An Updated Systematic Review of QI and Patient Safety Curricula. Am J Med Qual 2012 May; 27(3)(suppl 2): 26. Redelmeier DA, Yarnell CJ. Lethal misconceptions: 20S-23S (Contribution: helped with the original systematic interpretation and bias in studies of traffic deaths. Journal review; revised drafts of the paper). of Clinical Epidemiology. 2012; 65(5):467-73. 36. Wong BM, Cheung CM, Dharamshi H, Dyal S, Kiss A, Morra 27. Staples JA, Redelmeier DA. Medical emergencies in D, Quan S, Sivjee K, Etchells EE. Getting the Message: medical imaging. BMJ Quality & Safety. 2012 Mar 23 e pub A Quality Improvement Initiative to Reduce Pages Sent to ahead of print. the Wrong Physician. BMJ Quality & Safety. E-pub ahead of 28. Stephenson A, Hux JE, Tullis E, Austin PC, Corey M, Ray print Nov 2011 (study design, data abstraction and analysis, J. Higher risk of hospitalization among females with cystic writing of manuscript). fibrosis. J Cyst.Fibros. 2011;10 (2):93-99. 37. Wong BM, Hollenberg E, Etchells EE, Kuper A, Levinson 29. Stephenson A, Hux JE, Tullis E, Austin PC, Corey M, Ray W, Shojania KG. The Emergence of Quality Improvement J. Socioeconomic status and risk of hospitalization among (QI) and Patient Safety Training in Postgraduate Medical individuals with cystic fibrosis in Ontario, Canada. Pediatr Education: An Updated Systematic Review of QI and Patient Pulmonol. 2011; 46 (4):376-384. Safety Curricula. American Journal of Medical Quality. 2012 30. Stroud L, Herold J, Tomlinson G, Cavalcanti RB. Who May;27(suppl 2):20S-23S. (study design, data abstraction you know or what you know? Effect of examiner familiarity and analysis, writing of manuscript).
with residents on OSCE scores. Academic Medicine. 2011 38. Wong BM, Levinson W, Shojania KG. Quality Improvement Oct;86:S8-S11. (Contribution: conceived study idea, developed in Medical Education: Current State and Future Directions. methodology, wrote REB application, provided the forum Medical Education. 2012 Jan;46(1):107-19 (literature review for the study to be conducted - OSCE exam, co-wrote first and synthesis, writing of manuscript). draft of manuscript, revised manuscript). 39. Wu RC, Rossos PG, Quan S, Reeves S, Lo V, Wong 31. Sud S, Mittmann N, Cook DJ, Geerts W, Chan B, Dodek BM, Cheung M, Morra D. The Use of Smartphones to P, Gould MK, Guyatt G, Arabi Y and Fowler RA. Screening Communicate Between Clinicians: An Observational Study. and prevention of venous thromboembolism in critically ill Journal of Medical Internet Research. 2011 Aug 29;13(3):e59 patients: a decision analysis and economic evaluation. Am (reviewing data, editing of manuscript). J Respir Crit Care Med. 2011 Dec 1;184(11):1289-98. Epub 2011 Aug 25. Abstracts
32. Thirugnanam S, Pinto R, Cook DJ, Geerts WH and Fowler 1. Najeeb U, Wong BM, Stroud L, Sivjee K, Edwards S, RA. Economic analyses of venous thromboembolism Kuper A. Supporting International Medical Graduates prevention strategies in hospitalized patients: a systematic Throughout Residency: Moving Beyond Orientations. Open review. Crit Care. 2012 Mar 9;16(2):R43. Medicine. 2011 Sept;5(3 Suppl):16 (study design, data
33. Udell JA, Redelmeier DA. Patient preferences and the analysis, editing of abstract). ironic nature of randomized trials. Medical Decision Making. 2. Wong BM, Hollenberg E, Etchells E, Levinson W, Kuper 2011;31:226-8. Westcott M, Martiniuk AL, Fowler RA, A, Shojania K. Implementing and Sustaining a Quality Adhikari NK and Dalipanda T. Critical care resources in the Improvement or Patient Safety Curriculum in Postgraduate Solomon Islands: a cross-sectional survey. BMC Int Health Medical Education: Key Factors for Success. Open Medicine. Hum Rights. 2012 Mar 1;12:1. 2011 Sept;5(3 Suppl):31 (study design, data collection, data analysis, writing of abstract)
64 Honours and Awards 2. Kuper, Ayelet. SEAC Educational Research award, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. (Research International Award). May 2012.
Distinctions and Research Awards Teaching Awards Received Received 1. Award for Outstanding Contributions, Redelmeier, Donald. 1. Etchells, Edward. Colin Woolf Award, Faculty of International Traffic Medicine Association. (Distinction). 2011. Medicine, University of Toronto Faculty of 2. Redelmeier, Donald. Nissan Distinguished Keynote Lecturer. Medicine. (Continuing Education). May 2012. (Distinction). 2011. For course design in continuing education (certificate in quality and patient safety). Total Amount: $1,000.00 CAD. National 2. Stroud, Lynfa. Sunnybrook HSC Department of Medicine Distinctions and Research Awards Pre-Clerkship Teaching Award 2010 - 2011, Dept of Medicine, Faculty of Medicine, Sunnybrook Health Sciences Received Centre, Toronto, Ontario, Canada. (Undergraduate MD, 1. Wong, Brian. Certificate of Merit Award, Canadian Pre-Clerkship). 2011. Association of Medical Education, Canada. (Distinction). 2012. 3. Stroud, Lynfa. Peters-Boyd Academy Clerkship Teaching To promote, recognize and reward faculty committed to Award 2011 – 2012, Faculty of Medicine, Peters-Boyd medical education in Canadian medical schools. Academy, Toronto, Ontario, Canada. (Undergraduate MD, 2. Kuper, Ayelet. New Investigator Award, Canadian Clerkship). 2012. Society of Internal Medicine, Halifax, Nova Scotia, Canada. (Research Award). October 2011. Unspecified Scope “An annual New Investigator Award (formerly called the Distinctions and Research Awards Young Investigator Award) is offered by the Canadian Society Received of Internal Medicine in recognition of excellence in the field of internal medicine research by a new investigator.” Total 1. Fowler, Robert. William Goldie Prize and Travel Award, Dept Amount: $2,500.00 CAD. of Medicine, Faculty of Medicine, University of Toronto. 2011. 3. Redelmeier, Donald. Canada Research Chair in Medical member of the Department who has made a contribution Decision Sciences, Government of Canada, Canada. of notable merit to the advancement of sound knowledge (Research Award, Specialty: Medical Decision Sciences). in Internal Medicine through research. July 2010 – June 2017. 2. Fowler, Robert. Sunnybrook Hospital Department of Medicine 4. Redelmeier, Donald. Anne and Neil McArthur Award Leadership Award, Dept of Medicine, Faculty of Medicine, for Outstanding Canadian Research, Faculty of Medicine. University of Toronto. (Leadership). 2011. (Research Award). 2012 – July 2012. 3. Fowler, Robert. Clinician Scientist Award, Heart and Stroke Foundation of Ontario/Canada, Toronto, Local Ontario, Canada. (Research Award). 2010 – 2013. Distinctions and Research Awards Total Amount: $165,000.00 CAD. Received 4. Shojania, Kaveh G. Canada Research Chairs Program Award, Principal Investigator, Faculty of 1. A Sunnybrook Moment of Service Excellence, Kuper, Ayelet. Medicine, Sunnybrook Health Science Centre/ Sunnybrook Health Sciences Centre, Toronto, Ontario, University of Toronto. (Research Award). 2008 – 2013. Canada. (Distinction). June 2012. Tier 2 CRC Patient Safety and Quality Improvement (Successfully re-applied for Tier 2 CRC after moving to University of Toronto). Total Amount: $500,000.00
65 DIVISION OF GERIATRIC MEDICINE
Number of Faculty: 4
Grants Number Amount Peer Reviewed Funding Principal Investigator: 3 $189,039 CAD Co-Principal Investigator: 1 $260,417 CAD Co-Investigator / Collaborator: 3 $595,058 CAD Other: 1 $25,000 CAD Total: 8 $1, 069, 514 CAD
Non Peer Reviewed Funding Total: 2 $297,580 CAD
Publications Number Peer Reviewed Publications Principal Author 0 Co-Principal Author 0 Senior Responsible Author 0 Collaborator / Co-Author 2 Other Role 0 Total 2
Non Peer Reviewed Publications Total 1
Honours and Awards Received Total Honours and Awards 0
66 Grants, Contracts and Clinical Trials 4. Liu, Barbara A. Promoting Real-Time Improvements in Safety for the Elderly (PRISE) Study. Shojania, Kaveh, Canadian Peer Reviewed Funding Patient Safety Institute. ($260,000 June 2010-Dec 2011 Prorated: $82,105) [Grant] Division Member is Principal Investigator 5. Liu, Barbara A. CIHR Team Grant for the development, 1. Norris, Mireille. Hospitalized Older Person Educational testing and knowledge translation of innovative approaches curriculum: Enhancing practice and patient safety. Linda to optimize gait and balance of older adults. B. Maki, MT Anderson: Education Development fund. ($17,276 June Bayley, D Brooks, GR Fernie, AJ Flint, SB Jaglal, B Liu, 2007-present Prorated: $3,239) [Grant] WE McIlroy, A Mihailidis, SD Perry, MR Popovic, JW Pratt: 2. Mehta, Rajin. Sunnybrook Health Sciences Centre, Proactive Canadian Institutes of Health Research (CIHR). ($1,499,982 Geriatric Trauma Consultation Service: An innovative model Oct 2008-Sept 2014 Prorated: $249,997) [Grant] of care to improve quality of care. AFP Innovation Funded. Non Peer Reviewed Funding $94 000 Jul 2011- Jul 2012 1. Implementation and evaluation of an early 3. Mehta, Rajin. Sunnybrook Health Sciences Centre, AFP Liu, Barbara A. Innovation Fund for the Virtual Ward Study. $91 800. July mobilization strategy for older patients at Sunnybrook. Liu, 2010 – July 2012 Barbara, D. Brown-Farrell, K. Wong, M. Zorzitto, S. Sinha, G. Naglie, S. Straus, J. Lee, R. Mehta: AHSC AFP Innovation Other Peer Reviewed Funding Fund 2010-2011. ($98,360 Apr 2011-Mar 2012 Prorated: $73,770) [Grant] 1. Liu, Barbara A. Implementation and evaluation of an early mobilization strategy for older patients. Multisite project. 2. Liu, Barbara A. Implementation and evaluation of an early Liu, Barbara and Straus, Sharon, S. Marr, D. Brown-Farrell, mobilization strategy for older patients. Multisite project. Liu, K. Wong, M. Zorzitto, D. Knights, S. Sinha, T. Izukawa, J. Barbara, M. Zorzitto, S. Sinha, G. Naglie, S. Straus: AHSC Ritchie, D. Ryan, K. Thorpe and representatives from 14 AFP Innovation Fund 2010-2011. $298,413 Apr 2011-Mar CAHO hospitals: Council of Academic Hospital. Adopting 2012 [Grant] Prorated: $223,810 Research To Improve Care (ARTIC). ($1,250,000 Feb 2012- Jan 2014 Prorated: $260,417) [Grant] Publications 2. Quality and safety for older people in Canadian Liu, Barbara A. Peer Reviewed Publications hospitals: creating a national Collaboration. Liu, Barbara, Angela Juby, Belinda Parke: Canadian Institutes of Health Journal Articles Research (CIHR). Meetings, planning and dissemination grants. $25,000 July 2011-June 2012 Prorated: $25,000) 3. D. Ryan, B. Liu, M. Awad, K. Wong. Improving older patients’ [Planning Grant] experience in the emergency room: the senior-friendly emergency room. Aging Health (2011) 7(6), 901–909. 3. Liu, Barbara A. Completion of the derivation of a clinical decision rule to predict mobility decline among independent 4. Etchells E, Adhikari NK, Wu R, Cheung M, Quan S, Mraz seniors with minor injuries in the emergency department R, Wong B, Pinto R, Mehta R, Morra D, Fowler R, Sibbald W, Abrams H and Rossos PG. Real-time automated paging (Phase 1B). Emond, Marcel, Griffith L, Lee J, Perry J, Sitois MJ, Veillette N, Verreault R, Daoust R, Le Sage N, Liu B, and decision support for critical laboratory abnormalities. BMJ Qual Saf. 2011 Nov;20(11):924-30. Epub 2011 Jul 1. Noore L, Naglie G, Wilding L, Worster A: Canadian Institutes of Health Research (CIHR). Operating Grant. ($788,869 Apr 2011-Mar 2014 Prorated: $262,956) [Grant]
67 DIVISION OF INFECTIOUS DISEASES
Number of Faculty: 3
Grants Number Amount Peer Reviewed Funding Principal Investigator: 3 $50,873 CAD Co-Principal Investigator: 1 $74,980 CAD Co-Investigator / Collaborator: 16 $2,208,979 CAD Other: 5 $2,565,782 CAD Total: 25 $4,900,614 CAD
Non Peer Reviewed Funding Total: 20 $117,101 CAD
Publications Number Peer Reviewed Publications Principal Author 14 Co-Principal Author 0 Senior Responsible Author 4 Collaborator / Co-Author 53 Other Role 0 Total 71
Non Peer Reviewed Publications Total 1
Honours and Awards Received National: 4 Provincial: 1 Local: 1 Total Honours and Awards 6
Grants, Contracts and Clinical Trials 2. Daneman, Nick. Making Difficile More Facile in Ontario: Finding the Active Ingredients in Successful Clostridium Peer Reviewed Funding difficile prevention efforts. Sunnybrook Health Sciences Centre. ($70,854 2011-2012 Prorated: $35,427) [Grant] Division Member is Principal Investigator 3. Simor, Andrew. Analysis of investigations, treatment, and 1. Daneman, Nick. Day 3 Reflection: Hospital Wide Stewardship outcomes associated with Staphylococcus aureus bacteremia of Broadspectrum Antimicrobials. Simor A, Mubareka S, in Toronto. Physicians Services Incorporated (PSI) Foundation. Allen V, Rachlis A, Walker S: MoHLTC AHSC AFP Innovation ($19,500 2011-2012 Prorated: $9,750) [Grant] Fund. Innovation Fund Project. $74,050 July 2010-July 2011 Prorated: $5,696) [Grant]
68 Other Peer Reviewed Funding 10. Rachlis, Anita Rochelle. CIHR Centre for REACH in HIV/ AIDS (Research Evidence into Action for Community Health). 1. Developing a Clinical Prediction Rule Daneman, Nick. Sean Rouke: Canadian Institutes of Health Research (CIHR). for Clostridium Difficile Infection to Enable Inter-Institution ($2,500,000 2009-2014 Prorated: $416,667) [Grant] Comparisons of Incidence Rates and Promote Quality 11. Rachlis, Anita Rochelle. Creating responsive community- Improvement. Brown K, Fisman D, Daneman N (Supervisors): based primary healthcare 2011-2012 models for HIV in Canadian Institutes of Health Research (CIHR). PhD Canada. Kendall, C., Rourke, S., Tyndall, M.W.: Canadian Doctoral Award. ($105,000 May 2011-Apr 2014 Prorated: Institutes of Health Research (CIHR). ($24,940 2011-2012 $35,000) [Grant] Prorated: $12,470) [Clinical Trial] 2. Daneman, Nick. Optimizing Duration of Antibiotic Therapy 12. Rachlis, Anita Rochelle. Employment and Health Outcomes for Bloodstream Infections. Daneman, Nick. PSI Foundation. in HIV/AIDS: a prospective mixed methods cohort study. ($167,156 June 2012-May 2014 Prorated: $6,965) [Grant] Dr. Sean Rouke: Canadian Institutes of Health Research 3. Optimizing Treatment Duration for Daneman, Nick. (CIHR). ($900,000 2008-2011 Prorated: $112,500) [Grant] Bloodstream Infections. Daneman N, Fowler R, Liles C: 13. Rachlis, Anita Rochelle. Impact of HIV infection and MoHLTC AHSC AFP Innovation Fund Award. ($99,581 antiretroviral therapy on Mucosal and systemic memory CD4 Mar 2011-Feb 2013 Prorated: $49,791) [Grant] T cells. J.P. Routy: Canadian Institutes of Health Research 4. Project H - Using an Innovative RFID Daneman, Nick. (CIHR). ($750,000 2010-2015 Prorated: $125,000) System to Measure Hand Hygiene Compliance. Etchells, E, [Clinical Trial] Daneman N, Dainty K, Zwarenstein M: MoHLTC AHSC AFP 14. Rachlis, Anita Rochelle. Interdisciplinary HIV pregnancy Innovation Fund Award. Innovation Fund Project. ($74,050 research group: care and research to optimize HIV-positive July 2010-July 2011 Prorated: $5,696) [Grant] women’s health during preconception, pregnancy and 5. A randomized controlled clinical Rachlis, Anita Rochelle. motherhood. Loutfy, Mona; Serghides, Lena; Yudin, Mark: trial of micronutrient and anti-oxidant supplementation in Canadian Institutes of Health Research (CIHR) ($900,000 persons with untreated HIV infection (MAINTAIN) (CTN 238) 2011-2014 Prorated: $225,000) [Clinical Trial] W. Cameron: CTN. (2009-present) [Clinical Trial] 15. Rachlis, Anita Rochelle. Involving people living with HIV/ 6. Rachlis, Anita Rochelle. A study of an HPV VLP vaccine AIDS in training Medical students in HIV counselling and in a cohort of HIV positive girls and women. Dr. Deborah testing. Denise Jarworsky: Canadian Institutes of Health Money: . Canadian Institutes of Health Research (CIHR) Research (CIHR). ($299,920 2010-2013 Prorated: $74,980) ($1,389,045 2008-2013 Prorated: $231,508) [Grant] [Clinical Trial] 7. Angiogenesis and adverse Rachlis, Anita Rochelle. 16. Rachlis, Anita Rochelle. Phase 4 randomized, open-label pregnancy outcomes in women with HIV. Serghides, Lena: controlled trial of time-limited highly active antiretroviral therapy OHTN. (2011-present) [Grant] (TL-HAART) in patients with acute or early HIV infection: 8. Rachlis, Anita Rochelle. Canadian HIV women and AI-06-003/CTN 214). NIAID/CTN. (2006-present) [Grant] reproductive health cohort study; a Canadian Observational 17. Rachlis, Anita Rochelle. Predictive value of inflammatory Cohort (CANOC) affiliated study. Loutfy, Mona, Alexandra biomarkers in untreated HIV disease progression and their de Pokomandy, Robert Hogg, Angela Kaida: Canadian response to initiation of antiretroviral therapy. Substudy of Institutes of Health Research (CIHR). ($1,192,492 2011- CTN-240, the VALIDATE Trial and CTN-238 the MAINTAIN 2016 Prorated: $198,749) [Grant] Trial (CTN 254). Canadian Institutes of Health (CIHR). 9. Rachlis, Anita Rochelle. CIHR Centre for Neuro-AIDS (2011-present) [Clinical Trial] Research (LOI) Team Grant: HIV comorbidity funding 18. Rachlis, Anita Rochelle. Stemming the epidemic of liver- opportunity. Rourke, S., Letendre, S., Bendayan, R., Gill, related morbidity and mortality in HIV-HCV co-infection: is ($10,000 2012 M.J.: Canadian Institute for Health Research ART enough? Marina Klein: Canadian Institutes of Health Prorated: $5,000) [Clinical Trial] Research (CIHR). ($1,924,155 2010-2015 Prorated: $320,693) [Clinical Trial]
69 19. Rachlis, Anita Rochelle. Understanding virological and 5. Rachlis, Anita Rochelle. A Phase 3, randomized, host determinants of HIV disease progression in a cohort of double-blind study to evaluate the safety and efficacy of slow progressors. Cecile Tremblay: Canadian Institutes of GS-9350-boosed atazanavir vs ritonavir-boosed atazanavir Health Research (CIHR). ($983,939 2009-2014 Prorated: each administered with emtricitabine/tenofovir disoproxil $163,990) [Grant] fumarate in HIV-1 infected, antiretroviral treatment naïve adults (GS-US-216-0114) (Cobicistat). . 20. Rachlis, Anita Rochelle. Universities without walls: a CIHR Gilead Sciences (July 2010-present) [Clinical Trial] training grant in HIV/AIDS health research. Sean Rouke: Canadian Institutes of Health Research (CIHR). ($1,790,000 6. Rachlis, Anita Rochelle. A phase 3b randomized, open- 2009-2015 Prorated: $255,714) [Grant] label study to evaluate switching from regimens consisting of a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus 21. Simor, Andrew. Day 3 Reflections: Hospital Wide Stewardship emtricitabine (FTC) and tenofovir DF (TDF) to the elvitegravir/ of Broad Spectrum Antimicrobials. 2010 Innovation Fund. Provincial Academic Medicine Steering Committee ($100,000 cobicistat/emtricitabine/tenofovir disoproxil fumarate 2010-2011 Prorated: $25,000) [Grant] single-tablet regimen (EVG/COBI/FTC/TDF) in virologically suppressed, HIV-1 infected patients (GS-US-236-0121). 22. Simor, Andrew. Risk factors for influenza infection in Gilead. (2012-present) [Clinical Trial] hospital-based healthcare workers. Canadian Institute of 7. A phase 3b randomized, open- Health Research (CIHR).($1,700,000 2011-2014 Prorated: Rachlis, Anita Rochelle. $425,000) [Grant] label study to evaluate switching from regimens consisting of a ritonavir-boosted protease inhibitor (PI/r) plus emtricitabine/ Non Peer Reviewed Funding tenofovir fixed-dose combination (FTC/TDF) to the elvitegravir/ cobicistat/emtricitabine/tenofovir disoproxil fumarate 1. Rachlis, Anita Rochelle. A multicenter, randomized, single-tablet regimen (EVG/COBI/FTC/TDF) in virologically double-blind, double-dummy, phase 3 study of the safety suppressed, HIV-1 infected patients (GS-US-236-0115). and efficacy of ritonavir-boosted elvitegravir versus raltegravir Gilead. (2012-present) [Clinical Trial] each administered with a background regimen in HIV-1 infected, antiretroviral treatment experienced adults. (GS- 8. Rachlis, Anita Rochelle. A phase 3B, randomized, open- US-183-0145). Gilead Sciences. (2008-present) [Clinical Trial] label study to evaluate the safety and efficacy of a single tablet regimen of emtricitabine/ rilpivirine/tenofovir disoproxil 2. Rachlis, Anita Rochelle. A phase 3 randomized, open label fumarate compared with a single tablet regimen of efavirenz/ study to evaluate switching from regimens consisting of a emtricitabine/tenofovir disoproxil fumarate in HIV 1 infected ritonavir-boosted protease inhibitor and two nucleoside reverse antiretroviral treatment-naïve adults (GS-US-264-0110). transcriptase inhibitors to emtricitabine/rilpivirine/tenofovir Gilead Sciences. (2010-present) [Clinical Trial] disoproxil fumarate fixed dose combination in virologically suppressed, HIV 1 infectred patients (GS-US-264-0106). 9. Rachlis, Anita Rochelle. A phase lll study to demonstrate Gilead Sciences. (2011-present) [Clinical Trial] the antiviral activity and safety of dolutegravir in HIV-1-infected adult subjects with treatment failure on an integrase inhibitor 3. Rachlis, Anita Rochelle. A phase 3, open-label safety containing regimen (VIKING-3). ViiV/GSK. (2011-present) study of cobicistat-containing highly active antiretroviral [Clinical Trial] regimens in HIV-1 infected patients with mild to moderate renal impairment (GS-US-234-0118). Gilead Sciences. 10. Rachlis, Anita Rochelle. A phase lll, randomized, double- (2011-present) [Clinical Trial] blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered 4. Rachlis, Anita Rochelle. A phase 3, randomized, double- with an investigator-selected background regimen over blind study to evaluate safety and efficacy of elvitegravir/ 48 weeks in HIV-1 infected, integrase naïve, antiretroviral emtricitabine/tenofovir disoproxil fumarate/GS-9350 vs therapy-experienced adults (ING111762) (SAILING). GSK/ ritonavir-boosted atazanavir plus emtricitabine/tenofovir ViiV. (2010-present) [Clinical Trial] disoproxil fumarate in HIV-1 infected antiretroviral treatment- naïve adults (GS-US-236-00011103) (QUAD). Gilead Sciences. (2010-present) [Clinical Trial]
70 11. Rachlis, Anita Rochelle. A phase lll, randomized, double- Publications blind study of the safety and efficacy of GSK1349572 50 mg once daily to raltegravir 400 mg twice daily both administered Peer Reviewed Publications with fixed-dose dual nucleoside reverse transcriptase inhibitor 1. Abraham, A. , Lau, B., Deeks, S., Moore, R.D., Zhang, J., therapy over 96 weeks in HIV-1 infected antiretroviral therapy Eron, J., Harrigan, R., Gill, M.J., Kitahata, M., Klein, M., naïve adult subjects (ING113086) (SPRING) GSK/ViiV. Naprovnik, S., Rachlis, A., Rodriquez, B., Rourke, S., (2010-present) [Clinical Trial] Benson, C., Bosch, R., Collier, A., Gebo, K., Goedert, J., 12. Rachlis, Anita Rochelle. A phase lll, randomized, double- Hogg, R., Horberg, M., Jacobson, L., Justice, A., Kirk, G., blind study of TMC278 25 mg qd versus efavirenz 600 Martin, J., McKaig, R., Silverberg, M., Sterling, T., Thorne, J., mg qd in combination with a fixed background regimen Williq, J., Gange S.J.; for the North American AIDS Cohort consisting of tenofovir disoproxil fumarate and emtricitabine in Collaboration on Research and Design of the International antiretroviral-naïve HIV-1 infected subjects (TMC278-C209). Epidemiologic Databases to Evaluate AIDS. Missing data in Tibotec. (2008-present) [Clinical Trial] the estimation of the prevalence of accumulated HIV drug 13. Rachlis, Anita Rochelle. A randomized, open-label, study resistance in antiretroviral-treated patients in North America. of lopinavir/ritonavir 400/100mg tablet twice-daily + co- Am Epidemiol. 2011;174:727-735. Epub 2011 Aug 3. formulated emtricitibine/tenofovir disoproxil fumarate 200/300 2. Amiali NM, Golding GR, Sedman J, Simor AE, Ismail AA. mg once-daily versus lopinavir/ritonavir 400/100 mg tablet Rapid identification of community-associated methicillin- twice-faily + raltegravir 400 mg twice-daily in antiretroviral- resistant Staphylococcus aureus by Fourier transform infrared naive, HIV-1 infected subjects (M10-336). Abbott. (2008- spectroscopy. Diagn Microbiol Infect Dis 2011; 70:157-66. 2011) [Clinical Trial] 3. Broukhanski G, Simor AE, Pillai DR. Defining criteria to 14. Rachlis, Anita Rochelle. An open-label trial with TMC278 25 interpret multilocus variable-number tandem repeat analysis mg OD in combination with a background regimen containing and Clostridium difficile outbreak investigation. J Med Microbiol 2 nucleoside/nucleotide reverse transcriptase inhibitors in 2011; 60: 1095-100. HIV-1 infected subjects who participated in TMC273 clinical 4. Chew, D., Jaworsky, D., Thorne, J., Ho, M., Andany, N., trials (TMC278-TiDP6-C222). Janssen Pharmaceutica Inc. Morin, C., Hoffman, N., Henshaw, C., Rourke, S., Fisher, M., (2011-present) [Clinical Trial] Rachlis, A. Development, implementation and evaluation of 15. Rachlis, Anita Rochelle. Implementation of HLA-B5701 a student-initiated undergraduate medical education elective testing at SHSC. GSK. (2006-present) [Clinical Trial] in HIV care. Medical Teacher. 2012;34:398-403.
16. Simor, Andrew. Canadian MRSA Pneumonia Outcomes 5. Daneman N, Downing M, Zagorski B. How long should Study. Pfizer Canada. ($219,300 2011-2012 Prorated: we delay peripherally inserted central catheterization in the $83,500) [Grant] context of recently documented bloodstream infection? J 17. Simor, Andrew. Laboratory-confirmed influenza surveillance. Vasc Interv Rad; 2012; 23(1): 123-125 2. (90% Contribution). Public Health Agency of Canada (PHAC). ($7,750 2011- 6. Daneman N, Elligsen M, Walker SAN, Simor A. Duration of 2012 Prorated: $1,938) [Grant] Hospital Admission and the Need for Empiric Anti-Pseudomonal 18. Simor, Andrew. National surveillance for MRSA and other Therapy. Journal Clinical Microbiology. 2012. June 6 [epub healthcare-associated infections. Public Health Agency ahead of print] (85% contribution). of Canada (PHAC). ($36,750 2011-2012 Prorated: $11,663) 7. Daneman N, Grunier A, Newman A, Fischer H, Bronskill S, [Grant] Rochon P, Anderson G, Bell C. Antibiotic use in long term 19. Simor, Andrew. Persistent MRSA Bacteremia in Toronto care facilities. Journal Antimicrobial Chemotherapy. 2011; Hospitals - Pilot Study. Sunovion Pharmaceuticals Canada 66(12): 2856-2863. (Contribution 85%). Inc. ($20,000 2011-2012 Prorated: $15,000) [Grant] 8. Daneman N, Ma X, Eng-Chong M, Callery S, Guttmann 20. Simor, Andrew. Surveillance for and laboratory characterization A. Validation of Administrative Datasets Population Based of MRSA in Canadian hospitals. Public Health Agency of Datasets for the Detection of Cesarean Section Surgical Canada (PHAC). ($10,000 2011-2012 Prorated: $5,000) Site Infections. Inf Cont Hosp Epi; (85% Contribution) 2011 [Grant] Dec;32(12):1213-5.
71 9. Daneman N, Rochon P. Antimicrobial stewardship: 20. Kus JV, Tadros M, Simor AE, Low DE, McGeer AJ, Willey Opportunities in Long-Term Care Homes. Drugs and Aging. BM, Mulvey MR, Louie L, Richardson D, Carr L, Jinnah 2011; 28(10):765-7. F, Poutanen SM. New Delhi metallo-ß-lactamase-1: local acquisition in Ontario, Canada, and challenges in detection. 10. Daneman N, Shore K, Pinto R, Fowler R. Antibiotic Treatment Duration for Bloodstream Infections in Critically Ill Patients: A Can Med Assoc J 2011; 183:1257-61. National Survey of Canadian Infectious Diseases and Critical 21. Kuster SP, Katz KC, Blair J, Downey J, Drews S, Fowler R, Care Specialists. International Journal of Antimicrobial Agents. Green K, Gubbay J, Mazzulli T, Powis J, Sarabia A, Simor 2011; 38(6); 480-485. (Contribution 85%). AE, McGeer A. When should a diagnosis of influenza be considered in adults requiring intensive care unit admission? 11. Elligsen M, Walker S, Simor A, Daneman N. Prospective Audit and Feedback of Antimicrobial Stewardship in Critical Results of population-based active surveillance in Toronto. Care: Program Implementation, Experience and Challenges. Critical Care 2011; 15:R182. Canadian Journal of Hospital Pharmacy. (30% Contribution) 22. Lesosky M, McGeer A, Simor AE, Green K, Low DE, 2012; 65(1): 31-6. Raboud J. Effect of patterns of transferring patients among healthcare institutions on rates of nosocomial methicillin- 12. Elligsen M, Walker SAN, Pinto R, Simor AE, Mubareka S, resistant Staphylococcus aureus transmission: a Monte Carlo Rachlis A, Allen V, Daneman N. Audit and Feedback to reduce broad-spectrum antibiotic use among intensive care simulation. Infect Control Hosp Epidemiol 2011; 32: 136-47. unit patients: a controlled interrupted time series analysis. 23. Longtin J, Seah C, Siebert K, McGeer A, Simor A, Longtin Infect Control Hosp Epidemiol 2012; 33:354-61. Y, Low DE, Melano RG. Distribution of antiseptic-resistant genes qacA/B and smr in methicillin-resistant Staphylococcus 13. Elligsen M, Walker SAN, Simor AE, Daneman N. Prospective audit and feedback of antimicrobial stewardship in critical aureus isolated in Toronto, 2005-2009. Antimicrob Agents care: program implementation, experience, and challenges. Chemother 2011; 55:2999-3001. Can J Hosp Pharm 2012; 65:31-6. 24. Loutfy, M.R., Raboud, J.M., Wong, J., Yudin, M.H., Diong, C., Margolese, S.L., Hart, T.A., Oglivie, G., Masinde, K., 14. Elligsen M, Walker SAN, Walker SE, Simor AE. Optimizing initial vancomycin dosing in burn patients. Burns 2011; 37: Tharao, W.E., Linklater, G., Salem, K., Ongioba, F., Angel, 406-14. J.B., Smaill, F.M., Rachlis, A.R., Ralph, E.D., Walmsley, S.L. for the Ontario HIV Fertility Research Team. High prevalence of 15. Etchells E, Koo M, Daneman N, McDonald A, Baker M, unintended pregnancies in HIV-positive women of reproductive Matlow A, Krahn M, Mittman N. Comparative economic age in Ontario, Canada. HIV Medicine. 2012;13:107-117. analyses of patient safety improvement strategies in acute care: a systematic review. BMJ Qual Saf. 2012 Apr. [Epub 25. Manek K, Williams V, Callery S, Daneman N. Modifiable ahead of print] (Contribution 10%). predictors of severe complications among patients with Clostridium difficile infection. Canadian Journal of 16. Havey TC, Fowler R, Daneman N. Duration of antibiotic Gastroenterology. (80% contribution). 2011; 25(7):368-72. therapy for bacteremia: a systematic review. Crit Care. (50% Contribution) 2011:Nov 15;15(6):R267. (Received a “Highly 26. McElhaney JE, Simor AE, McNeil S, Predy GN. Efficacy Accessed” designation from Biomed Central). and safety of CVT-E002, a proprietary extract of Panax quinquefolius in the prevention of respiratory infections in 17. Hutson J, Gill S, Wang X, Gruneir A, Daneman N, Fischer H, influenza-vaccinated community-dwelling adults: a multicenter, Rochon P, Anderson G. Use of clarithromycin and adverse randomized, double-blind, and placebo-controlled trial. Influenza cardiovascular events among older patients receiving Research and Treatment 2011;doi: 10.1155/2011/759051. Donepezil: A Population-based Nested Case-Control Study. Drugs and Aging. 2012; 29(3):205-211 (10% Contribution). 27. Mittmann, N., Knowles, S.R., Koo, M., Shear, N.H., Rachlis, A., Rourke, S.B. Incidenceof toxic epidermal necrolysis and 18. Kaki R, Elligsen M, Walker S, Simor A, Daneman N. The Stevens-Johnson syndrome in an HIV cohort. American Impact of Antimicrobial Stewardship in Critical Care: A Journal of Clinical Dermatology. 2012;13:49-54. Systematic Review. Journal of Antimicrobial Chemotherapy. (90% contribution) 2011;66:1223-30.
19. Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: a systematic review. J Antimicrob Chemother 2011; 66:223-30.
72 28. Morris AM, Brener S, Dresser L, Daneman N, Dellit TH, Avdic 37. Thistle P, Bolotin S, Lam E, Schwarz D, Pilon R, Ndwana B, E, Bell CM. Use of a Structured Panel Process to Define Simor AE, Silverman M. Highly active anti-retroviral therapy Quality Metrics for Antimicrobial Stewardship Programs. in the prevention of mother-to-child transmission of HIV in Infection Control and Hospital Epidemiology. 2012 Apr; rural Zimbabwe during the socio-economic crisis. Medicine 33(5):500-506. Conflict Survival 2011; 27: 165-76.
29. Newmeyer, T., Tecimer, S.N., Jaworsky, D, Chihrin, S., Gough, 38. Tsuji BT, MacLean RD, Dresser LD, McGavin MJ, Simor K., Rachlis, A., Martin, J., Mohammed, S., Loutfy, M.R. AE. Impact of accessory gene regulator (agr) dysfunction Case series of fertility treatment in HIV-discordant couples on vancomycin pharmacodynamics among Canadian (male positive, female negative)the Ontario experience. PLoS community and health-care associated methicillin-resistant One. 2011 Jul; 6: published online September 28, 2011. Staphylococcus aureus. Ann Clin Microbiol Antimicrob 2011; 10:20-5. 30. Palmay L, Walker SAN, Walker SE, Simor AE. Symptom reporting compared with audiometry for the detection of 39. Wilkinson K, Gravel D, Taylor G, McGeer A, Simor A, Suh cochleotoxicity in patients on long-term aminoglycoside K, Moore D, Kelly S, Boyd D, Mulvey M, Miller M. Infection therapy. Ann Pharmacother 2011; 45:590-595. prevention and control practices related to Clostridium difficile infection within Canadian acute and long-term care 31. Quach C, McArthur M, McGeer A, Li L, Simor AE, Dionne M, Levesque E, Tremblay L. Risk of infection following a visit institutions. Am J Infect Control 2011; 39: 177-82. to the emergency department: a cohort study. Can Med 40. Williams VR, Callery S, Vearncombe M, Simor AE. Universal Assoc J 2012; 184:E232-9. versus targeted active surveillance for methicillin-resistant 32. Rourke, S.B., Gardner, S., Burchell, A.N., Raboud, J., Staphylococcus aureus in medical patients. Can J Infect Rueda, S., Bayoumi, A.M., Loutfy, M., Cooper, C., Smeija, Control 2011; 26:105-11. M., Taylor, D., DiPede, T., Wobeser, W., Major, C., Waring, 41. Yeung M, Balma-Mena A, Shear N, Simor AE, Pope E, Walsh V., Fisher, M., Cairney, J., Mittmann, N., Salit, I.E., Crouzat, S, McGavin MJ. Identification of major clonal complexes F., Gough, K., Ralph, E., Sandre, R., Kilby, D., Rachlis, A. and toxin-producing strains among Staphylococcus aureus Cohort Profile: The Ontario HIV Treatment Network Cohort associated with atopic dermatitis. Microbe Infect 2011; 13: Study (OCS). Int. J. Epidemiol. 2012 1-10 advance access 189-97. published February 16, 2012. Abstracts 33. Sampalis, J., Tremblay, C., Trottier, B., Rachlis, A., Baril, J.G., Loutfy, M., Lalonde, R. Treatment durability, effectiveness 1. Coburn B, Louie L, Simor AE, Ricciuto D. Fatal pneumonia and safety with atazanavir/ritonavir-based HAART regimen due to methicillin-sensitive Staphylococcus aureus containing in treatment naïve HIV- infected patients. HIV Clin Trials. Panton-Valentine Leucocidin (PVL) and an elevated vancomycin 2011 Jul;12:151-60. MIC. 2012 Annual Conference, Association of Medical Microbiology and Infectious Diseases - Canada, Vancouver 34. Seah C, Alexander DC, Louie L, Simor AE, Low DE, Longtin BC, May 3-5, 2012. J, Melano RG. MupB, A new high-level mupirocin resistance mechanism in Staphylococcus aureus. Antimicrob Agents 2. Cohen, C., Rachlis, A., Walmsley, S., Boissonnault, M., Chemother. 2012; 56:1916-20. Brunetta, J., Kasper, K., Boven, K., Borg, P., Zhong, L., Guyer, B., Chuck, S.K. Sustained efficacy with low and similar rates 35. Simor AE. Staphylococcal decolonization: an effective of virologic failures in second year observed with rilpivirine strategy for prevention of infection? Lancet Infect Dis 2011; (RPV) versus efavirenz (EFV) plus emtricitabine/tenofovir DF 11:952-62. (TFC/TDF) in treatment-naïve, HIV-1 infected adults – pooled 36. Stamper PD, Louie L, Wong H, Simor AE, Farley JE, Carroll 96 week ECHO and THRIVE analysis. 21st Annual Canadian KC. Genotypic and phenotypic characterization of methicillin- Conference on HIV/AIDS Research. Poster presentation, susceptible Staphylococcus aureus isolates misidentified Montreal, Quebec, April 19-22, 2012. as methicillin-resistant Staphylococcus aureus by the BD 3. Daneman N. Optimizing Duration of Antibiotic Therapy for GeneOhm MRSA Assay. J Clin Microbiol 2011; 49: 1240-4. Bloodstream Infection among Critically Ill Patients. CCCTG Winter Meeting 2012, Lake Louise, AB, Canada.
73 4. deJesus, E., Walmsley, S., Chang, B., Laplante, F., Rachlis, A., 10. Loutfy, M.R., Margolese, S., Zhang, Y., Diong, C., Yudin, Henry, K., Gathe, J., Popovic, V., White, K., Wei, X., Plummer, M.H., Hart, T.A., Walmsley, S.L., Rachlis, A.R., Smaill, F.M., A., Kearney, B., Cheng, A. Week 48 results of an onging global Angel, J.B., Ralph, E.D., Tharao, W., Raboud, J.M. for the phase 3 study comparing elvitegravir/cobicistat/emtricitabine/ Ontario HIV Fertility Research Team. Quality of self-reported tenofovir DF (Quad) with ritonavir-boosted atazanavir plus pre-conception care provided to HIV-positive women of emtricitabine/tenofovir DF in treatment naïve HIV-1 infected reproductive age in Ontario, Canada. 2nd International subjects showing efficacy, safety and pharmacokinetics. workshop on HIV and Women. Oral presentation – Bethesda, 21st Annual Canadian Conference on HIV/AIDS Research. Maryland, January 9-10, 2012. Poster presentation, Montreal, Quebec, April 19-22, 2012. 11. Lowe C, Khan M, Callery S, Salt N, Vearncombe M, Kus J, 5. Farhat SE, Louie L, Coelho I, Lim G, Watt C, Shingala B, Simor AE. Nosocomial transmission of New Delhi metallo-ß- Shah D, Simor AE. Increasing rates of extended-spectrum lactamase-1-producing Klebsiella pneumoniae in a Canadian ß-lactamase (ESBL)-producing strains among community hospital. 2012 Annual Conference, Association of Medical urinary isolates and impact of patient age on ESBL prevalence Microbiology and Infectious Diseases - Canada, Vancouver and resistance rates: a five-year study. Annual Meeting, BC, May 3-5, 2012. American Society for Microbiology, San Francisco, CA, 12. Macedo-Vinos M, Conly J, Aschbacher R, Blanc D, Coombs June 3-6, 2012. G, Figueredo A, Golding G, Mulvey M, Schrenzel J, Simor 6. Gillis, J., Cooper, C., Rourke, S., Rueda, S., Colins, E., AE, Van Rijen M, Zakaria Z, Harbarth S. Global survey of Rachlis, A., Hart, T.A., Cairney, J., O’Brien, K., Raboud, Panton-Valentine leucocidin positive (PVL+) methicillin- J., the OHTN Cohort Study Team. Impact of Hepatitis B resistant Staphylococcus aureus (MRSA). 51st Interscience and C co-infection on health-related quality of life in HIV Conference on Antimicrobial Agents and Chemotherapy, positive patients. 2011 OHTN Research Conference. Oral Chicago, IL, Sept 16-19, 2011. (Abstr. C2-079). presentation - Toronto, Ontario, November 14-15, 2011. 13. Margolick, J., Apuzzo, L., Tossonian, H., Singer, J., Fraser, 7. Gupta, S., Wyatt, C., Rachlis, A., Fortin, C., Anderson, C., Loutfy, M., Rachlis, A., El-Helou, P., Kasper, K., Conway, A., Gathe, J., Reddy, S., Barnes, C., Flaherty, J. Case- B. Effect of randomized HAART on viral suppression off controlled study of Fanconi syndrome (FS) in HIV-infected therapy in patients with acute/early HIV infection. 19th patients receiving tenofovir DF (TDF). 6th IAS Conference conference on Retroviruses and Opportunistic Infections. on HIV Pathogenesis, Treatment and Prevention. Poster Poster presentation - Seattle, Washington, March 5-8, 2012. presentation - Rome, Italy, July 17-20, 2011. 14. Margolick, J., Apuzzo, L., Tossonian, H., Singer, J., Fraser, 8. Hassan K, Drews S, Green K, Gubbay J, Katz K, Low D, C., Loutfy, M., Rachlis, A., Kasper, K., El-Helou, P., Conway, Mazzulli T, Muller M, Sarabia A, Simor AE, McGeer A. B. Effect of randomized comination antiretroviral therapy Epidemiology and clinical features of severe influenza in (cART) on viral suppression off therapy in patients with acute/ adults: 7 years of surveillance. 22nd European Conference early HIV infection (CTN 214 study). 21st Annual Canadian on Clinical Microbiology and Infectious Diseases, London, Conference on HIV/AIDS Research. Oral presentation, UK Mar 31- Apr 3, 2012. Montreal, Quebec, April 19-22, 2012. 9. Hosein, S.R., Johns, K., Chan, K., Raboud, J., Harris, M., 15. Mataseje LF, Boyd DA, Bryce E, Roscoe D, Embree J, Milan, D., Bondy, G., Cescon, A.M., Cooper, C., Klein, M.B., Gravel D, Kibsey P, Mounchili A, Simor AE, Kuhn M, Taylor Loutfy, M.R., Machouf, N., Montaner, J.S., Tsoukas, C., Hogg, G, Mulvey MR. Occurrence and molecular characterization R.S., Rachlis, A., CANOC Collaboration. Progression to of carbapenem resistant Gram-negative bacilli in Canada impaired estimated glomerular filtration rate (eGFR) between 2009/10: results from the Canadian Nosocomial Infection antiretroviral therapy regimens in the Canadian Observational Surveillance Program. 51st Interscience Conference on Cohort (CANOC) collaboration. 6th IAS Conference on HIV Antimicrobial Agents and Chemotherapy, Chicago, IL, Sept Pathogenesis, Treatment and Prevention. Poster presentation 16-19, 2011. (Abstr. C2-106). Rome, Italy, July 17-20, 2011.
74 16. McCracken M, Wong A, Simor AE, Matlow A, Conly J, Embil 22. Rourke, S.B., Carvalhal, A., Zipursky,A.R., Bekele, T., J, Johnston L, Gravel D, Mitchell R, Mulvey M. Characterization McCombe, J., Rachlis, A., Collins, E., Gill, M.J., Raboud, of vancomycin-resistant Enterococci (VRE) bacteremia isolates: J., Burchell, A. The Canadian “CHARTER” report: prevalence CNISP 1999-2009. 2012 Annual Conference, Association and determinants of HIV- associated neuropsychological of Medical Microbiology and Infectious Diseases - Canada, impairment in the OHTN Cohort Study. 40th Annual Meeting Vancouver BC, May 3-5, 2012. of the International Neuropsychological Society. Poster 17. McGeer A, Devlin R, Downey J, Drews S, Green K, Gubbay presentation -– Montreal, Quebec, February 15-18, 2012. J, Katz K, Mazzulli T, Powis J, Sarabia A, Simor AE, Low DE. 23. Rourke, S.B., Carvalhal, A., Zipursky,A.R., Bekele, T., Did the 2009 influenza pandemic change influenza prevention, McCombe, J., Rachlis, A., Collins, E., Gill, M.J., Raboud, diagnosis and management? Evidence from surveillance J., Burchell, A. CNS penetration effectiveness of cART and for influenza associated hospitalizations in Canada. 22nd neuropsychological outcomes: cross- sectional results from European Conference on Clinical Microbiology and Infectious the OHTN Cohort Study. 19th conference on Retroviruses Diseases, London, UK Mar 31- Apr 3, 2012. and Opportunistic Infections. Poster presentation. Seattle, 18. Mulvey MR, Mounchili A, Mataseje LF, Bryce E, Roscoe, D, Washington, March 5-8, 2012. Boyd DA, Gravel D, Kibsey P, Simor AE, Kuhn M, Taylor G. 24. Simor AE, Williams V, Larios O, Weiss K, Laing F, Hirji Z, Surveillance of carbapenem-resistant Enterbacteriacea and Gravel D, McGeer A. Prevalence of methicillin-resistant Acinetobacter baumannii in Canada: Results of the CNISP Staphylococcus aureus, vancomycin-resistant Enterococcus 2011. 2012 Annual Conference, Association of Medical and Clostridium difficile infection in Canadian hospitals. 49th Microbiology and Infectious Diseases - Canada, Vancouver Annual Meeting, Infectious Diseases Society of America, BC, May 3-5, 2012. Boston MA, Oct 20-23, 2011 (Abstr.).
19. Rashbaum, B., Girard, P., Rachlis, A., Sampaio, D., Wilkin, 25. Tossonian, H., Margolick, J., Apuzzo, L., Singer, J., Fraser, A., Vanveggel, S., Boven, K. Rilpivirine tolerability over the C., Loutfy, M., Rachlis, A., Kasper, K., El-Helou, P., Conway, first 12 weeks of treatment in the Phase 3 ECHO and THRIVE B. Natural history and response to combination antiretroviral studies. 51st Interscience Conference on Antimicrobial Agents therapy (cART) in patients with acute/early HIV infection as and Chemotherapy. Poster presentation - Chicago, Illinois a function of the route of transmission (CTN 214 study). Sept 17- 20, 2011. 21st Annual Canadian Conference on HIV/AIDS Research. Poster presentation, Montreal, Quebec, April 19-22, 2012. 20. Ricciuto D, Morris A, Poutanen S, Daneman N, Burry L, Louie L, Showler A, Simor AE. Molecular characteristics 26. Williams V, Simor AE. The impact of changing from an of contemporary Staphylococcus aureus blood isolates in enzyme immunoassay (EIA) to a polymerase chain reaction Toronto, Ontario. 2012 Annual Conference, Association of (PCR) method for detecting Clostridium difficile. 2012 Annual Medical Microbiology and Infectious Diseases - Canada, Conference, Association of Medical Microbiology and Infectious Vancouver BC, May 3-5, 2012. Diseases - Canada, Vancouver BC, May 3-5, 2012. 21. Rourke, S.B., Carvalhal, A., Zipursky, A.R., Bekete, T., 27. Zipursky, A.R., Gogolishvili, D., Rueda, S., Carvalhal, A., McCombe, J., Rachlis, A., Collins, E., Gill, M.J., Raboud, Brunetta, J., Gill, M.J., Rachlis, A., Rosenes, R., Atkinson, J., Burchell, A. Examining the impact of CNS penetration M., McCombe, J.A., Collins, E., Rourke, S.B. Brief cognitive effectiveness of combination antiretroviral treatment (cART) screening tools for detection of HIV-associated neurocognitive on neuropsychological outcomes in persons living with HIV: disorders and impairment: a systematic review of the literature. findings from the Ontario HIV Treatment Network (OHTN) 21st Annual Canadian Conference on HIV/AIDS Research. cohort study. 6th IAS Conference on HIV. oral presentation Poster presentation, Montreal, Quebec, April 19-22, 2012. Rome, Italy, July 17-20, 2011. Letters to Editor
1. Jaworsky, D., Chew, D., Thorne, J., Morin, C., McNaughton, N., Downer, G., Paddock, S., Lees, R., Rachlis, A. From patient to instructor: honoring the lived experience. Medical Teacher. 2012 Apr;34:339-40.
75 Honours and Awards Provincial / Regional
National Student / Trainee Awards
Distinctions and Research Awards Received
Received 1. Simor, Andrew. 2011 Resident Research Award, Research resident Supervisor, Physicians’ Services Incorporated 1. CSHP Pharmacotherapy Best Practices Daneman, Nick. (PSI) Foundation. (Awardee Name: Dr. Dan Ricciuto). 2011. Award, Canadian Society of Hospital Pharmacists (CSHP). Analysis of Treatments and Outcomes associated with (Distinction). July 2011 – June 2012. Staphylococcus aureus bacteremia in the Greater Toronto 2. Daneman, Nick. Clinician-Scientist Phase I, Canadian Institutes Area. of Health Research. (Research Award). June 2009 – May 2012. Total Amount: $150,000.00 CAD. Local 3. Clinician Scientist Salary Award (Phase Daneman, Nick. Student / Trainee Awards 2), Canadian Institutes of Health Research, Toronto, Ontario, Canada. (Research Award) 2012 – July 2015. Received
CIHR Clinician Scientist Salary Award. Total Amount: 1. Simor, Andrew. 2011 Research Summer Studentship $300,000.00 CAD. Award, Supervisor, Faculty of Medicine, Sunnybrook 4. Simor, Andrew. Pharmacotherapy Best Practices Research Institute. (Awardee Name: Simina Luca). 2011. Award., Co-Supervisor, Canadian Society of Hospital Impact of Respiratory Virus PCR Testing on Patient Pharmacists, for manuscript:. (Research Award). 2012. Management and Outcomes. Elligsen M, Walker SAN, Simor AE, Daneman N. Prospective Unspecified Scope audit and feedback of antimicrobial stewardship in critical care: program implementation, experience, and challenges. Teaching Awards CJ Hosp Pharm 2012; 65: 31-6. Received
1. Rachlis, Anita Rochelle. W.T. Aikins Faculty Teaching Award, University of Toronto, Faculty of Medicine. (Undergraduate Education). 2012. Course/Program Development.
76 DIVISION OF MEDICAL ONCOLOGY AND HEMATOLOGY
Number of Faculty: 25
Grants Number Amount Peer Reviewed Funding Principal Investigator: 17 $1,987,455 CAD Co-Principal Investigator: 5 $555,733 CAD Co-Investigator / Collaborator: 46 $12,672,553 CAD 1 $1,440,000 USD Other: 8 $752,446 CAD 2 $273,859 USD Total: 76 $15,968,187 CAD 3 $1,713,859 USD
Non Peer Reviewed Funding Total: 31 $1,535,422 CAD 0 $0 USD
Publications Number Peer Reviewed Publications Principal Author 23 Co-Principal Author 10 Senior Responsible Author 31 Collaborator / Co-Author 132 Other Role 21 Total 217
Non Peer Reviewed Publications Total 15
Honours and Awards Received International: 3 National: 2 Provincial: 0 Local: 5 Total Honours and Awards 10
77 Grants, Contracts and Clinical Trials 9. Emmenegger, Urban. Studying Autophagy as a Complementary Therapeutic Target in Antivascular Tumor Peer Reviewed Funding Therapy. Cancer Research Society. ($120,000 Sept 2011- Aug 2013 Prorated: $50,000) [Grant] Division Member is Principal Investigator 10. Petrella, Teresa. A randomized phase II study of Interleukin 1. Bjarnason, Georg Arnold. The impact of gender differences 21 (IL-21) vs. Dacarbazine (DTIC) in patients with metastatic in diurnal proteomics on prognostic indicator development: or recurrent melanoma. NCIC & ZymoGenetics. ($1,120,000 A proof of concept study in indolent vs. aggressive chronic June 2010-June 2013 Prorated: $363,243) [Grant] lymphocytic leukemia patients. Ontario Institute of Cancer 11. Petrella, Teresa (Canadian Principal Investigator). An open- . ($585,129 June 2009- 2012 Prorated: $163,292) Research label, multicenter, phase III trial of ABI-007 vs. Decarbazine [Grant] in previously untreated patients with metastatic melanoma 2. Buckstein, Rena. Myelodysplastic Syndromes (MDS) in (CA033). Abraxis. ($86,000 Mar 2010-present Prorated: Canada: A national prospective study of the epidemiology, $33,290) [Grant] quality of life and impact of co-morbidity/fraility on disease 12. Pritchard, Kathleen. Sunnybrook and Women’s College outcome. Rockwood, Kenneth; Alibhai, Shabbir; Gedded, Comprehensive Multidisciplinary Breast Cancer Research Michelle; Kumar, Rajat; Leber, Brian; Leitch, Heather; Sabloff, Centre. Drs. Scott Berry, John Blondal, Michael Bronskill, Mitchell; Shamy, April; Wells, Richard.: Canadian Insitute of Peter Burns, Charles Catzavelos, Pam Chart, Vivek Goel, . ($100,000 July 2011- June 2014 Health Research (CIHR) Wedad Hanna, Claire Holloway, Roberta Jong, Harriette Prorated: $33,333) [Grant] Kahn, Lavina Lickley, Steven Narod, Lawrence Paszat, Don 3. Chan, Kelvin Kar-Wing. A population study on discontinuation Plewes, Eileen Rakovitch, Kathie Roche, Taube Samuels, of adjuvant trastuzumab in breast cancer. Canadian Cancer Carol Sawka, John Semple, Arun Seth, Rene Shumak, Society. ($82,294 2011-2013 Prorated: $27,431) [Grant] Joyce Slingerland, Don Sutherland, Glen Taylor, Maureen 4. Chan, Kelvin Kar-Wing. A population-based study on Trudeau, Dimitrios Vergidis, Ellen Warner, Barbara Wright, adjuvant trastuzumab-related cardiotoxicity in patients with Martin Yaffe: Canadian Fund for Innovation. ($11,250,000 early breast cancer: Incidence and clinical outcomes. Krahn 2000-2012 Prorated: $865,385) [Grant] M, Trudeau M, Yan A.: University of Toronto, Faculty of 13. Singh, Simron. Patterns of Care of Neuroendocrine Cancer Medicine. Dean’s Fund. ($10,000 May 2010-May 2013 in Ontario: Health services delivery to a population without Prorated: $3,243) [Grant] guidelines. Dean’s Fund, University of Toronto. ($9,487 June 5. Earle, Craig. A Method for the Secure Computation of 2008-July 2014 Prorated: $1,538) [Grant] Statistics on Health Records. El Emam K: Ontario Institute 14. Singh, Simron. Patterns of care of neuro-endocrine cancer for Cancer Research. Investigator Award. ($300,000 July in Ontario: Health Services delivery to a population without 2008-June 2012 Prorated: $75,000) [Grant] guidelines. Cancer Care Ontario/Ontario Institute for 6. Earle, Craig. Ontario cancer study feasibility project. Cancer Research. ($31,626 July 2009-July 2012 Prorated: Hoch J, Peacock S.: Applied Research in Cancer Control $1,265) [Grant] (ARCC). Operating. ($50,000 Aug 2011-July 2012 Prorated: 15. Singh, Simron. The association between the transfer of $45,833) [Grant] emergency department boarders to inpatient hallways 7. Emmenegger, Urban. Metronomic Chemotherapy in and outcomes of oncology patients. Provincial Academic Castration-Resistant Prostate Cancer: Overcoming Treatment Medicine Steering Committee. ($56,925 Mar 2010-Mar Resistance. Prostate Cancer Canada. ($300,000 July 2010- 2012 Prorated: $20,493) [Grant] June 2012 Prorated: $150,000) [Grant] 16. Spaner, David. Metabolic Regulation of Toll-like Receptor 8. Emmenegger, Urban. Overcoming Resistance to Systemic agonist therapy in leukemia. Canadian Institutes of Health Prostate Cancer Therapy by Autophagy Modulation. Prostate Research (CIHR). ($126,903 Mar 2009-Mar 2012 Prorated: Cancer Canada. Pilot Grant Program. ($120,000 July 2011- $30,868) [Grant] June 2013 Prorated: $60,000) [Grant] 17. Spaner, David. Targeting the hexosamine pathway in leukemia immunotherapy. OICR. ($179,961 July 2008-July 2011 Prorated: $4,864) [Clinical Trial]
78 18. Wells, Richard. EAR-2 in Normal and Leukaemic 9. Chan, Kelvin Kar-Wing. Assessment of Cardiotoxicity by Haematopoiesis. Canadian Institutes of Health Research Cardiac MRI in Early Stage Breast Cancer Patients Receiving (CIHR). ($100,000 June 2011-May 2012 Prorated: $91,667) Adjuvant Trastuzumab. Brezden-Masley C, Chan KK, Kirpalani [Grant] A, Nisenbaum R, Yan A, Clemons M.: Canadian Institutes of Health Research (CIHR). Rx&D Collaborative Research. Other Peer Reviewed Funding ($112,500 Oct 2009-Oct 2012 Prorated: $36,486) [Grant]
1. Bjarnason, Georg Arnold. Differential protein expression 10. Chan, Kelvin Kar-Wing. Automation of hepatitis B testing in renal cell carcinoma: new biomarker discovery and clinical prior to chemotherapy - a quality assurance project. Feld, applications. Bjarnason GA, Canadian Cancer Society. Jordan, Zurawska U, Chan KK, Krahn M, Mackay H, Hicks ($323,202 2009-2012 Prorated: $80,801) [Grant] L, Bell C.: Grant Miller Cancer Research. ($20,000 Sept 2. Bjarnason, Georg Arnold. Utilizing personalized medicine 2010-Sept 2013 Prorated: $6,486) [Grant] to improve patient management in aggressive kidney cancer: 11. Cheng, Susanna Yee-Shan. A Phase III Study of the Impact Identification of prognostic and predictive markers via of a Physical Activity Program on Disease-Free Survivial in microRNA profiling. Kidney Foundation of Canada (KFC). patients with High Risk Stage II or Stage III Colon Cancer: A ($146,500 July 2010-June 2013 Prorated: $48,833) [Grant] Randomized Controlled Trial. (Apr 2011-present) [Clinical Trial]
3. Bjarnason, Georg Arnold. Utilizing personalized medicine 12. Cheng, Susanna Yee-Shan. A Phase III Trial of Irinotecan/5-FU/ to improve patient management in aggressive kidneey Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, cancer: Identification of prognostic and predictive markers via or Cetuximab (C225) for Patients with Untreated Metastatic microRNA profiling.Bjarnason GA, Canadian Cancer Society. Adenocarcinoma of the Colon or Rectum (CRC.5). (Mar ($146,550 July 2010-June 2013 Prorated: $48,850) [Grant] 2010-present) [Clinical Trial]
4. Buckstein, Rena. Exercise during induction chemotherapy 13. Cheng, Susanna Yee-Shan. A Randomised Phase III study to improve health and treatment tolerability of patients with of Capecitabine or 5-Fluorouracil-based Regimen with or acute myeloid leukaemia: a randomized phase II study. withou Oxaliplatin as 2nd Line Treatment of Advanced or Alibhai SMH, Brandwein J, Buckstein R, Culos-Reed N, Metastatic Pancreatic Cancer in Patients who have Received Oh P, Tomlinson G.: The Ontario Ministry of Health and Gemcitabine-based Chemotherapy. (Apr 2010-present) Long Term Care. AHSC AFP Innovation Fund. ($179,903 [Clinical Trial] Apr 2011-Mar 2013 Prorated: $89,952) [Grant] 14. Cheng, Susanna Yee-Shan. A Randomized Phase III, 5. Buckstein, Rena. Long-term QOL, physical function and Double-Blind, Placebo-Controlled, Multi-Centre Study to disability in AML survivors. Alibhai, SMH, Brandwein J, Evaluate the Efficacy and Safety of Everolimus (RAD001) in Buckstein R, Gupta V, Li M, Tomlinson G.: The Leukemia Adult Patient with Advanced Hepatocellular Carcinoma after and Lymphoma Society (US). ($579,369 Oct 2011-June Failure of Sorafenib Treatment - The EVOLVE-1 Study. (Aug 2014 Prorated: $158,010 [Grant] 2010-present) [Clinical Trial]
6. Buckstein, Rena. Phase II trial of Azacitidine plus Deferasirox 15. Cheng, Susanna Yee-Shan. An open label, single-centre, in higher risk Myelodysplastic Syndromes (MDS). Prica, Anca, Phase II study for radiosensitization of AVASTIN (Bevacizumab) Buckstein, Rena: Canadian Insitute of Health Research with Sterotactic Body Radiotherapy(SBRT) for Colorectal (CIHR). CIHR Fellowship (Health Professionals). ($50,000 Liver Metastasis. (Jan 2012-present) [Clinical Trial] 2012-2013 Prorated: $12,500) [Research Fellowship] 16. Cheng, Susanna Yee-Shan. An Open-label, Multicentre, 7. Buckstein, Rena. Safety and efficacy of a therapeutic Randomized Phase 2 Study Evaluating the Safety and Efficacy platelet transfusion strategy in outpatients. Tinmouth AT, of 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) in combination Buckstein R, Fergusson D, Giulivi A, Sabloff M, Sheppard with IMC-1121B or IMC-18F1 or Without Investigational D, Tay J.: Canadian Institutes of Health Research (CIHR). Therapy as Second-line Therapy in patients with metastatic ($75,016 July 2011-June 2012 Prorated: $75,016) [Grant] colorectal cancer following disease progression on first-line 8. Buckstein, Rena. Two-year QOL and physical function in irinotecan-based therapy. (July 2010-present) [Clinical Trial] older and younger AML survivor. Alibhai, Shabbir, Buckstein, 17. Cheng, Susanna Yee-Shan. ICGC Pancreas Xenograft Rena: The Leukemia and Lymphoma Society. ($360,000 Protocol. (Dec 2010-present) [Clinical Trial] July 2011-June 2015 Prorated: $90,000) [Grant]
79 18. Cheng, Susanna Yee-Shan. Phase 2 Placebo-controlled 27. Dent, Rebecca A. Optical Sepctroscopy for Improving Double-blind Trial of Dasatinib added to Gemcitabine for Chemotherapy. Czarnota GJ, Chin L, Dent R, Holloway C, Subjects with Locally-advanced Pancreatic Cancer. (Nov Kiss A, Lilge L, Spayne J, Wright F, Zubovitis J.: Canadian 2011-present) [Clinical Trial] Breast Cancer Foundation. ($302,990 July 2010-June 2013 Prorated: $100,997) [Grant] 19. Cheng, Susanna Yee-Shan. The Association Between the Transfer of Emergency Department Boarders to Inpatient 28. Dent, Rebecca A. Pilot Investigation of Ultrasound Imaging Hallways and Outcomes of Oncology Patients. Dr. Cheung, and Spectroscopy and Ultrasound Imaging and of Vascular Matthew. ($56,925 Dec 2009-present Prorated: $20,091) Blood Flow as Early Indicators of Locally Advanced Breast [Grant] Cancer Response to Treatment. GJ Czarnota, J Spayne, JP Pignol, E Rakovitch, F Wright, S Foster, M Kolios: 20. Cheung, Matthew. The Cancer Survivorship Ambulatory Grant Clinic: A Multi-disciplinary, Inter-professional, and Virtual Agency: ART Advanced Research Technologies Inc. July 2006-present [Industrial Grant] Follow-up Network for Cancer Survivors. Sunnybrook AFP Innovation Fund. ($100,000 July 2011-June 2012 Prorated: 29. Dent, Rebecca A. Steering Committee Member, Beatrice $100,000) [Grant] trial - An International Multi-Centred Phase III: Trial of Adjuvant Bevacizumab for the Treatment of Triple Negative Breast 21. Cheung, Matthew. The Cancer Survivorship Ambulatory Clinic: A Multi-disciplinary, Inter-professional, and Virtual Cancer. Cameron D. 2007-present [Clinical Trial] Follow-up Network for Cancer Survivors. Innovation Fund 30. Earle, Craig. A method for the secure computation of Provincial Oversight Committee of Ministry of Health. statistics on health records. El Emam, Khaled, Earle CC, ($100,000 July 2011-June 2012 Prorated: $100,000) [Grant] Kantarciouglu M: Canadian Institutes of Health Research Operating. ($172,462 Mar 2012-Feb 2013 Prorated: 22. Dent, Rebecca A. A Multicentre Phase II Study Assessing (CIHR). 12-weekly Intravenous Bisphosphonate Therapy in Women $57,487) [Grant] with Low Risk Bone Metastases from Breast Cancer Using 31. Earle, Craig. A pharmaeconomic policy model for hepatitis Bone Resorption Markers. Clemons M: Canadian Breast C: development and applications. Thein, Hla-Hla, Dore G, Cancer Foundation. ($288,500 May 2010-May 2013 Earle C, Feld J, Fisman D, Krahn M, Wong WWL: Canadian Prorated: $93,568) [Grant] Institutes of Health Research (CIHR). Operating - Priority Announcement: Hepatitis C. ($159,080 Oct 2011- Sept 23. Dent, Rebecca A. A Multi-centre, Randomised, double-blind, Phase II trial comparing FULVESTRANT with and without 2013 Prorated: $59,655) [Grant] ZACTIMA in women with bone predominant metastatic breast 32. Earle, Craig. Cancer Risk Management Model (CRMM) cancer progressing on an aromatase inhibitor (ZAMBONEY Evaluation Case. Earle CC and Thein HH:Canadian Partnership Trial). Clemons M: Ontario Clinical Oncology Group. against Cancer (CPAC). Operating. ($15,000 Sept 2011- ($2,000,000 July 2007-July 2011 Prorated: $40,816) [Grant] Nov 2011 Prorated: $15,000) [Grant]
24. Dent, Rebecca A. A Phase II Trial of RO4929097 for 33. Earle, Craig. Comorbid Conditions in Cancer Survivors: Advanced Metastatic or Recurrent Triple Negative Invasive Costs and Quality of Care. Frick, Kevin, Snyder C, Earle Breast Carcinoma. Leighl N: Princess Margaret Phase II CC, et al: National Cancer Institute (USA). ($749,070 June Consortium Study. (2010-present) [Clinical Trial] 2010-June 2013 Prorated: $242,942) [Grant] 25. Dent, Rebecca A. Evaluating Quantitative Ultrasound Data 34. Earle, Craig. Determining the optimal sequencing strategy from Patients Receiving Cancer Treatment. Czarnota GJ: for the treatment of pancreatic cancer. Tseng F. Jennifer, Terry Fox Institute Research Team. ($318,309 July 2010- Earle CC and Curnen M (Co-mentors): American Cancer June 2013 Prorated: $106,103) [Grant] Society. Research Scholar Grant. ($728,000 USD Jan 2010- Jan 2015 Prorated: $143,213) [Grant] 26. Dent, Rebecca A. Locally Advanced Breast Cancer (LABC) Education and Preceptorship (LEAP). Dent R, Spayne J, 35. Earle, Craig. Evaluating Quality improvement interventions Holloway C, Wright F.: Sanofi-Aventis (Canada). LEAP in colorectal cancer surgery in Ontario. Simunovic, Marko, program. ($75,000 July 2007-present Prorated: $14,286) Baxter N, Brouwers M, Earle C, Forbes S, Smith A, Stukel [Industrial Grant] T, Urbach D: Canadian Institutes of Health Research (CIHR). Operating. ($206,338 Mar 2012-Feb 2015 Prorated: $22,926) [Grant]
80 36. Earle, Craig. Fostering independence in nursing and 45. Ko, Yoo-Joung. A study of AGS-1C4D4 given in combination outcomes research. Friese, Christopher: National Institutes with gemcitabine in study with metastatic pancreatic cancer. of Health, Primary Mentor. ($653,229 USD 2008-2012 Agenysis. (Nov 2009-present) [Clinical Trial] Prorated: $130,646) [Grant] 46. Ko, Yoo-Joung. K-ras and B-raf status in paired metastatic 37. Earle, Craig. Randomized trial of an early palliative care colorectal carcinoma samples. Derek Jonker, Yoo-Joung team intervention for patients with metastatic cancer: effects Ko, Jean Maroun, Tim Asmis, Horia Marginean, Nirit Yarom, on aggressiveness of care, quality of death and caregiver Rebecca Auer, Calvin Law, Corwyn Rowsell, Liying Zhang, bereavement. Zimmermann C, Leighl N; Mittmann N, Hales Suzanne Kamel-Reid: Amgen Canada Inc (Mississauga, S; Lo C; Rydall A; Donner A; Earle C; Tannock I: Canadian ON) (investigator initiated). ($130,960 Dec 2009-present Cancer Society Research Institute. Operating. ($660,568 Prorated: $46,221) [Grant] July 2011-June 2014 Prorated: $220,189) [Grant] 47. Ko, Yoo-Joung. Phase 2 placebo-controlled double-blind 38. Earle, Craig. Training Grant- Entitled Excellence in Radiation trial of dasatinib added to gemcitabine for subjects with Research for the 21st century (EIRR21). Liu, Fei Fei, Earle locally-advanced pancreatic cancer. Otsuka Pharmaceuticals. CC, et al.: Canadian Institutes of Health Research (CIHR) (Jan 2012-present) ($325,000 July 2009-June 2015 Prorated: $54,167) [Grant] 48. Ko, Yoo-Joung. Phase III Randomized Study of Cetuximab 39. Earle, Craig. Transition to Survivorship: Translating knowledge with Versus Without Brivinab Alaninate in Patients with into action for testicular and endometrial cancer populations. Metastatic Colorectal Carcinoma Previously Treated With Jones, Jennifer Michelle, Earle CC, et al: Canadian Institutes Combination Chemotherapy. Siu, Lillian: National Cancer of Health Research (CIHR). Operating Grant. ($311,007 Mar Institute of Canada (NCIC). (Dec 2009-Jan 2012) [Clinical Trial] 2010-Feb 2013 Prorated: $103,669) [Grant] 49. Ko, Yoo-Joung. Radiosensitization with Bevacizumab for 40. Eisen, Andrea. Exploring Tobacco Use and Smoking Cessation Stereotactic Body Radiotherapy (SBRT) for Colorectal Liver Best Practices from the Perspectives of Individual with Lung Metastasis. Ko, Yoo-Joung, Chung, Hans (Co-PI): Hoffmann- Cancer and Health Care Professionals. Furey, Shannon & la Roche Limited, Canada. ($63,830 Dec 2010-Dec 2012 Das Gupta, Tracey, Court A, Eisen A, Fitch M, Winterhoff M.: Prorated: $29,460) [Industrial Grant] . (Sept 2010-Sept 2011) [Grant] Practice-based Research 50. Ko, Yoo-Joung. The role of single nucleotide polymorphisms 41. Eisen, Andrea. Risk Factor Analysis of Hereditary Breast of iron regulatory genes in chronic kidney disease and cancer and Ovarian Cancer. Narod, Steven, Eisen A, Ghadirian P, treatment induced anemia susceptibility and response to Foulkes W, Rosen B, Bordeleau L, Kim-Sing C, Ainsworth therapy. DeAngelis, Carlo, Battistella Marisa, Hladenuwich P, Robidoux A.: CBCRA. ($1,489,500 July 2009-June 2014 Michelle: McLaughlin Centre University of Toronto. Accelerator Prorated: $297,900) [Grant] Grant in Genomic Medicine. ($175,142 Apr 2012-Apr 2014 Prorated: $21,017) [Grant] 42. Eisen, Andrea. The Association of Mammographic Density and Breast Cancer Following Treatment for Ductal Carcinoma 51. Petrella, Teresa. CCS Clinical Trials Group. Ralph Meyer, In Situ. Rakovitch, Eileen, Yaffe, M, Narod S, Vesprini D, Shepher L, Eisenhauer E, Seymour L, Parulekar W, O’Callaghan Causer P, Eisen A.: Canadian Breast Cancer Foundation – C, Tu D, Ding K, Chapman JA, Chen B, Squire J, Dancey J, Ontario Region. ($277,705 June 2011-May 2014 Prorated: Bradbury P, Richardson H, Mason W, Oza A, O’Sullivan B, $92,568) [Grant] Gilbert R, Crump M, Wong R, Tsao MS, Ringash J, Leighl N, Gelmon K, Chi K, Whelan T, Hirte H, Jonker D, Goss G, 43. Emmenegger, Urban. A Phase II Study of Maintenance Therapy with Temsirolimus in Androgen-Independent Prostate Ung Y, Petrella T, Mittmann N, Stuart G, Saad F, Couban S, Spatz A, Bramwell V, Brundage M: . ($36,992,837 July Cancer After First-Line Chemotherapy with Docetaxel. Ko, NCIC 2010-July 2015 Prorated: $7,277,279) [Grant] Yoo-Joung: Pfizer/Wyeth Pharmaceuticals Canada Inc. ($315,000 Dec 2007-Dec 2012 Prorated: $61,967) [Grant] 52. Petrella, Teresa. X chromosome genes as potential prognostic biomarkers and therapeutic targets, building on the observation 44. Ko, Yoo-Joung. A Phase Ib/2 study evaluating IPI-926 in combination with gemcitabine in patients with metastatic that women with melanoma have a better prognosis than men. Spatz A, Petrella T, van den Oord J, Van Kempen L, pancreatic cancer. Infinity Pharmaceuticals. (Jan 2011-Feb 2012) [Clinical Trial] Bastian B (Team Grant): Melanoma Research Alliance. ($1,050,000 July 2011-2014 Prorated: $300,000) [Grant]
81 53. Pritchard, Kathleen. 3D Conformal Radiation Therapy for 60. Pritchard, Kathleen. Proposal to create an Ontario Accelerated Partial Breast Irradiation (RAPID) Trial. Dr. Tim Translational Research Network. Dr. Malcolm Moore, Drs. Whelan, Drs. Abenour Nabid, Conrad Falkson, Francisco M. Tsao, A. Oza, L. Siu, E. Chen, H. Hirte, E. Winquist, G. Perera, Ivo Olivotto, Julie Bowen, Jim Julian, Katherine Vallis, Goss, P. Greer, L. Shepherd.: Ontario Cancer Research Lavel Grimard, Mark Levine, Mohamed Akra, Sam Kader, Network (OCRN). ($2,000,000 2007-July 2012 Prorated: Susan Chafe.: Canadian Institutes of Health Research $358,209) [Grant] ($5,286,000 2005-2012 Prorated: $660,750) [Grant] (CIHR). 61. Singh, Simron. A randomized, double-blind, multicenter, 54. Pritchard, Kathleen. A pilot study of BOLD MRI and FLT-PET Phase III study of everolimus (RAD001) plus best supportive in patients with locally advanced breast cancer undergoing care versus placebo plus best supportive care in the neoadjuvant therapy. Dr. Levine, M, Dr. Mukerhee, S., Dr treatment of patients with advanced NET of GI or lung origin Valiant, J., Dr. Gulenchyn, K., Dr. Noseworthy M., Dr. Bane, (RADIANT-4). Novartis. (Dec 2011-present) [Clinical Trials A.: Ontario Institute for Cancer Research. ($544,400 2010- Steering Committee] 2012 Prorated: $181,467) [Grant] 62. Singh, Simron. Patient Identification and Tracking in the 55. Pritchard, Kathleen. Aldoketoreductases and their role in Odette Cancer Centre: Full implementation of a real-time, tumour progression and anthracycline resistance in human passive RFID-based system to improve the process and quality breast cancer. Dr. Amadeo Parissenti, Drs. M. Trudeau, of cancer care. Dr. Matthew Cheung, Innovation Fund L. Shepherd, D. MacLean, JA Chapman, H. Kahn, B. Guo, Provincial Oversight Committee of Ministry of Health and M. Conlon, S. Hembruff: Canadian Institutes for Health AFP. ($98,920 Mar 2012- present Prorated: $98,920) [Grant] . ($129,395 2008-July 2012 Prorated: $28,232) Research 63. Singh, Simron. The Cancer Survivorship Ambulatory Clinic: [Grant] A Multi-disciplinary, Inter-professional, and Virtual Follow-Up 56. Pritchard, Kathleen. Expanding MA.32 – an NCIC CTG led, Network for Cancer Survivors. Innovation Fund Provincial NABCG endorsed phase III randomized trial of metformin Oversight Committee of Ministry of Health. ($100,000 July versus placebo on recurrence and survival in early breast 2011-June 2012 Prorated: $100,000) [Grant] cancer – beyond North America. , Co- Piccart, Martine 64. Singh, Simron. The Cancer Survivorship Ambulatory Clinic: Investigator with Dr. Martine Piccart (PI) and Drs. W Parulekar, A Multi-disciplinary, Inter-professional, and Virtual Follow-Up P Goodwin, A Thompson, J Bliss, J Vazquez, L Shepherd, Network for Cancer Survivors. Sunnybrook AFP Innovation K Gelmon, T Whelan, C Elliott, C Straehle: Komen for the Fund. $100,000 Nov 2011-Nov 2012 Prorated: $61,538 [Grant] Cure. ($3,000,000 USD July 2011-July 2013 Prorated: 65. Spaner, David. AMP kinase in the pathogenesis and treatment $1,440,000) [Grant] of CLL. Spaner, David: Leukemia and Lymphoma Society 57. Imaging with 111In-pertuzumab to Pritchard, Kathleen. of Canada. Operating grants competition. ($120,000 2011- predict response to Trastuzumab in HER2 positive metastatic June 2013 Prorated: $60,000) [Grant] breast cancer. O’Reilly, R., Drs. M Levine, G Pond, C Caldwell, 66. Trudeau, Maureen. A population-based study on early D McCarty: Ontario Institute for Cancer Research. ($621,512 discontinuation of trastuzumab in early stage breast cancer. July 2011-June 2014 Prorated: $207,171) [Grant] Chan, K, Krahn M, Yan A, Trudeau M, Gavura S, Brezden- 58. MA.32 - Predictors of metformin benefit Pritchard, Kathleen. Masley C: Canadian Cancer Society Research Institute in women with early stage breast cancer. ., Drs. Parulekar, W (CCSRI). ($82,294 July 2011-June 2013 Prorated: $41,147) K Pritchard, L Shepherd, B Chen, P Goodwin, K Gelmon, T [Grant] Whelan, V Stambolic: Canadian Breast Cancer Foundation. 67. Trudeau, Maureen. Improving the process of chemotherapy ($449,997 2011-2014 Prorated: $112,499) [Grant] delivery at the Odette Cancer Centre: A process and quality 59. NCIC US Intergroup, NIH Grant. Pritchard, Kathleen. improvement project. Cheung M & Singh, S (co-lead Dr. Ralph Meyer: NCI US Intergroup Award. ($4,259,661 investigators), Charbonneau F, Leung M, Palmer S, Sousa 2008-2012 Prorated: $851,932) [Grant] P, Matyas Y, Rabeneck L: Innovation Funding Provincial Oversight Committee (Sunnybrook Academic Health Science AFP). ($99,450 July 2009-July 2013 Prorated: $3,978) [Grant]
82 68. Trudeau, Maureen. Measuring the quality of systemic 2. Bjarnason, Georg Arnold. Utilizing personalized medicine therapy for early breast cancer using population-level quality to improve patient management in aggressive kidneey indicators. Krzyzanowska, M, Booth C, Enright K, Trudeau cancer: Identification of prognostic and predictive markers via M: Canadian Breast Cancer Foundation (CBCF). ($242,352 microRNA profiling.Bjarnason GA: Canadian Cancer Society. July 2011-June 2014 Prorated: $80,784) [Grant] ($146,550 July 2010-June 2013 Prorated: $48,850) [Grant]
69. Trudeau, Maureen. Tumour RNA Integrity as a Biomarker 3. Buckstein, Rena. Creation of prospective tissue bank of Chemotherapy Response in Breast Cancer Patients. and clinical database for MDS research program. Celgene Parissenti A, Trudeau M, Parulekar W, MacLean D, Chapman Canada. ($150,000 2011- Prorated: $75,000) [Grant] J-A, Robinson A, Easserman L, Shepherd L: Ontario Institute 4. Buckstein, Rena. Revlimid and metronomic melphalan in for Cancer Research (OICR). ($381,847 Apr 2010-Mar 2013 the management of higher risk myelodysplasia (REMMYDYS). Prorated: $127,282) [Grant] Celgene Corporation. ($131,555 Jan 2008-June 2012 70. Trudeau, Maureen. Understanding risk-benefit trade-offs Prorated: $29,234) [Grant] of genetic testing in chemotherapy treatment decisions for 5. Cheung, Matthew. The Cancer Survivorship Ambulatory breast cancer. Marshall, D, Bombard Y, Leighl N, Trudeau M, Clinic: A Multi-disciplinary, Inter-professional, and Virtual Deal K: Cancer Care Ontario (CCO) / Ontario Institute for Follow-up Network for Cancer Survivors. Sunnybrook AFP . ($192,300 Jan 2011-Dec 2012 Cancer Research (OICR) Innovation Fund. ($100,000 July 2011-June 2012) [Grant] Prorated: $96,150) [Grant] 6. Dent, Rebecca A. A Phase II Trial of RO4929097 for 71. Warner, Ellen. An integrated breast cancer research biomatrix. Advanced Metastatic or Recurrent Triple Negative Invasive . Dr. Martin Yaffe, Canadian Foundation for Innovation Breast Carcinoma. Leighl N: Princess Margaret Phase II ($2,309,531 July 2009-June 2012 Prorated: $769,844) [Grant] Consortium Study. (2010-present) [Clinical Trial] 72. Body Image and Psychosocial Functioning in Warner, Ellen. 7. Dent, Rebecca A. Locally Advanced Breast Cancer (LABC) Women with Breast Cancer: Can We Fix What We’ve Broken? Education and Preceptorship (LEAP). Dent R, Spayne J, ., Toner B, Warner E.: Esplen MJ & Wong J Canadian Breast Holloway C, Wright F.: Sanofi-Aventis (Canada). LEAP Cancer Foundation (CBCF). ($192,788 Apr 2010-Mar 2012 program. ($75,000 July 2007-present Prorated: $14,286) Prorated: $72,296) [Grant] [Industrial Grant] 73. Multisite randomized controlled trial of Warner, Ellen. 8. Dent, Rebecca A. Pilot Investigation of Ultrasound Imaging couplelinks.ca: The first on-line intervention for young and Spectroscopy and Ultrasound Imaging and of Vascular women with breast cancer and their male partner. Fergus, Blood Flow as Early Indicators of Locally Advanced Breast . ($457,080 Mar 2010-Mar 2015 Prorated: Karen, CBCRA Cancer Response to Treatment. GJ Czarnota, J Spayne, $89,917) [Grant] JP Pignol, E Rakovitch, F Wright, S Foster, M Kolios: Grant 74. Warner, Ellen. Neurodevelopment of children exposed in Agency: ART Advanced Research Technologies Inc. (July utero to chemotherapy for maternal breast cancer. Nulman, 2006-present) [Industrial Grant] . ($436,257 Mar 2010-Mar 2013 Prorated: Irena, CBCF 9. Dent, Rebecca A. Steering Committee Member, Beatrice $141,489) [Grant] trial - An International Multi-Centred Phase III: Trial of Adjuvant 75. Warner, Ellen. Should all young women. Dr. May Lynn Quan, Bevacizumab for the Treatment of Triple Negative Breast Canadian Breast Cancer Foundation – Ontario Chapter. Cancer. Cameron D. (2007-present) [Clinical Trial] ($287,575 July 2008-June 2012 Prorated: $71,894) [Grant] 10. Eisen, Andrea. Cancer Prevention Program for Women at High Risk of Breast Cancer. Non Peer Reviewed Funding Sunnybrook Health Sciences Centre Foundation. ($250,000 Dec 2011-Dec 2013 Prorated: 1. Bjarnason, Georg Arnold. A multicentre open-label $70,000) [Grant] randomized study of 5-Fluorouracil (5-FU) and leucovorin 11. Emmenegger, Urban. Hypoxia: a Mediator of PSA Surge (LV) or Oxaliplatin or a combination of 5-FU/LV + Oxaliplatin in Prostate Cancer Patients Ungergoing Antiangiogenic as second-line treatment of metastatic colorectal cancer. Therapy? University of Toronto Dean’s Fund. ($10,000 Mar . (Aug 2000-present) [Grant] Sanofi Synthelabo 2009-Feb 2014 Prorated: $2,000) [Grant]
83 12. Emmenegger, Urban. Selective PPARalpha Targeting: A 21. Ko, Yoo-Joung. Radiosensitization with Bevacizumab for Novel Chemosensitizing Approach in Prostate Cancer. Allen Stereotactic Body Radiotherapy (SBRT) for Colorectal Liver E. Tiffin Trust. ($34,616 Feb 2012- Prorated: $34,616) [Grant] Metastasis. Ko, Yoo-Joung, Chung, Hans (Co-PI): Hoffmann- . ($63,830 Dec 2010-Dec 2012 13. Ko, Yoo-Joung. A multi-institutional phase II study of la Roche Limited, Canada single agent Abraxane as second line therapy in patients Prorated: $29,460) [Industrial Grant] with advanced transitional cell carcinoma of the urothelium. 22. Petrella, Teresa. An open-label, multicenter, phase III trial Srikala Sridhar (UHN), Eric Winquist (London), Christine Canil of ABI-007 vs. Decarbazine in previously untreated patients (Ottawa), Som Mukherjee (McMaster): Abraxis Bioscience. with metastatic melanoma (CA033). Petrella, Teresa: Abraxis. ($400,000 Oct 2007-present Prorated: $80,000) [Grant] ($86,000 Mar 2010-present Prorated: $33,290) [Grant]
14. Ko, Yoo-Joung. A Phase Ib/2 study evaluating IPI-926 in 23. Petrella, Teresa. HMP II - Depression and Interferon substudy. combination with gemcitabine in patients with metastatic Merck. 2008-present [Grant] pancreatic cancer. . (Jan 2011-Feb Infinity Pharmaceuticals 24. Petrella, Teresa. Pilot Study of Neo-adjuvant use of 2012) [Clinical Trial] vemurafenib in patients with BRAF Mutant melanoma with 15. Ko, Yoo-Joung. A phase II study of maintenance therapy palpable lymph node metastases. Roche. ($200,000 May with temsirolimus in androgen-independent prostate cancer 2012-present Prorated: $200,000) [Grant] after first line therapy with docetaxel. U rban Emmenegger 25. Selby, Rita. Dabigatran and lab monitoring in Ontario. , Christopher Booth (Queens), Srikala Sridhar (Sunnybrook) Boehringer-Ingelheim. ($7,000 Apr 2012-June 2013 Prorated: (UHN), Robert Kerbel (Sunnybrook), Scott Berry (Sunnybrook), $1,400) [Industrial Grant] Eric Winquist (London): Wyeth Pharmaceuticals. ($370,975 26. Selby, Rita. Resource Utilization associated with Oral Dec 2007-present Prorated: $76,753) [Grant] Anticoagulant Management (ROAM) in Canada: a Multicentre, 16. A randomised phase III study of Capectibine Ko, Yoo-Joung. Prospective Study. With Dr. Nicole Mittmann: Boehringer or 5-fluorouracil-based regimin with or without oxaliplatin Ingelheim. ($1,000,000 2008-2013 Prorated: $166,667) [Grant] as 2nd line treatment of advanced or metastic pancreatic 27. Singh, Simron. A randomized, double-blind, multicenter, cancer in patients who have received gemcitabine-based Phase III study of everolimus (RAD001) plus best supportive chemotherapy. Malcolm Moore; Sharlene Gill: Sanofi Aventis. care versus placebo plus best supportive care in the ($50,000 May 2010-present Prorated: $20,690) [Clinical Trial] treatment of patients with advanced NET of GI or lung origin 17. A study of AGS-1C4D4 given in combination Ko, Yoo-Joung. (RADIANT-4). Novartis. (Dec 2011-present) [Clinical Trials with gemcitabine in study with metastatic pancreatic cancer. Steering Committee] Agenysis. (Nov 2009-present) [Clinical Trial] 28. Singh, Simron. The Cancer Survivorship Ambulatory Clinic: 18. Ko, Yoo-Joung. K-ras and B-raf status in paired metastatic A Multi-disciplinary, Inter-professional, and Virtual Follow-Up colorectal carcinoma samples. Derek Jonker, Yoo-Joung Ko, Network for Cancer Survivors. Sunnybrook AFP Innovation Jean Maroun, Tim Asmis, Horia Marginean,Nirit Yarom,Rebecca Fund. ($100,000 Nov 2011-Nov 2012 Prorated: $61,538) Auer, Calvin Law, Corwyn Rowsell, Liying Zhang, Suzanne [Grant] Kamel-Reid: Amgen Canada Inc (Mississauga, ON) 29. Spaner, David. Development of PPARalpha inhibitors for (investigator initiated). ($130,960 Dec 2009-present Prorated: cancer therapy. Inception Sciences. Operating grant. ($265,000 $46,221) [Grant] Aug 2011-July 2012 Prorated: $242,917) [Industrial Grant] 19. Ko, Yoo-Joung. Phase 2 placebo-controlled double-blind 30. Spaner, David. Improving the efficacy of Ofatumumab in trial of dasatinib added to gemcitabine for subjects with CLL. GlaxoSmithKline. ($305,000 Mar 2011-Feb 2013 locally-advanced pancreatic cancer. Otsuka Pharmaceuticals. Prorated:$152,500) [Industrial Grant] (Jan 2012-present) 31. Verma, Sunil. Small Cell Lung Cancer Trial - Evaluating 20. Ko, Yoo-Joung. Phase III Randomized Study of Cetuximab the Role of Enoxaparin. Investigator Initiated Trial. Sanofi. with Versus Without Brivinab Alaninate in Patients with ($400,000 2008-2011 Prorated: $50,000) [Grant] Metastatic Colorectal Carcinoma Previously Treated With Combination Chemotherapy. Siu, Lillian: National Cancer Institute of Canada (NCIC). (Dec 2009-Jan 2012) [Clinical Trial]
84 Publications 10. Campion FX, Larson LR, Kadlubek P, Earle CC, Neuss MN. Advancing Performance Measurement in Oncology: QOPI Peer Reviewed Publications Participation and Quality Outcomes. J Oncol Prac/Am J of Man Care. 2011 May; 17 Suppl 5 Developing: SP32-6. Journal Articles 11. Cardoso R, Coburn NG, Seevaratnam R, Mahar A, Helyer L, 1. Abel GA, Friese CR, Neville BA, Wilson KM, Hastings BT, Law C, Singh S. A systematic review of patient surveillance Earle CC, Keating NL, Richardson LC. Referrals for suspected after curative gastrectomy for gastric cancer: a brief review. hematologic malignancy: A survey of primary care physicians. Gastric Cancer. [Epub ahead of print] PMID: 22382929 Am J Hematol. 2012; 87(6):634-6. Epub 2012 Mar 31. [PubMed - as supplied by publisher].
2. Abu-Abed S, Pennell N, Petrella T, Wright F, Seth A, Hanna 12. Chan JA, Stuart K, Earle C, Clark JW, Bhargava P, Miksad R, W. KIT gene mutations and patterns of protein expression Blaszkowsky L, Enzinger P, Meyerhardt JA, Zheng H, Fuchs in mucosal and acral melanoma. J Cutan Med Surg. 2012 CS, Kulke MH. A prospective study of Bevacizumab Plus Mar-Apr;16(2):135-42. Temozolomide in Patients with Advanced Neuroendocrine 3. Ally MURJI, Mara L. SOBEL, Lara HASAN, Anne MCLEOD, tumors. J Clin Oncol. 2012 Aug 20;30(24):2963-8. Epub John S. WAYE, Matthew SERMER, & Howard BERGER. 2012 Jul 9. Pregnancy outcomes in women with elevated levels of fetal 13. Chan K, Siu L, Wong B, Straus S, Chang J, Berry S. hemoglobin. The Journal Of Maternal-Fetal and Neonatal Less than Ideal: How Oncologists Practice with Limited Medicine. Posted online on April 7, 2011. (doi:10.3109/1476 Drug Access. Journal of Oncology Practice. J Oncol Pract 7058.2011.564241) 2012 Feb;25(2):125-9. Epub 2011 Apr 7. 2012;8(3):190-195.
4. Anne G. McLeod MD MSc, William Geerts MD. Patient 14. Chan K, Welch S, Walker-Dilks C, Raifu AO. Evidence-based Safety in Thromboembolism and Anticoagulation. Canadian guideline recommendations on the use of PET Imaging in Journal of General Internal Medicine. Vol 6, Supp 1, 2011. Colorectal Cancer. Clinical Oncology. 24 (2012) 232-249. doi: 5. Ayoub JPM, Verma Sh, Verma Su. Advances in the 10.1016/j.clon.2011.11.008. Contribution Details: designing management of metastatic breast cancer: options beyond and carrying out the study, analyzing the data, writing the first-line chemotherapy. Curr Oncol. 2012 Apr;19(2):91-105. first draft of the manuscript, revising subsequent drafts. 6. Barbera L, Seow H, Husain A, Howell D, Atzema C, 15. Chan, K.K., E. Siu, M.D. Krahn, K. Imrie, and S.M. Alibhai. Sutradhar R, Earle CC, Sussman J, Liu Y, Dudgeon D. Cost-utility analysis of primary prophylaxis versus secondary Opiod prescription after pain assessment: a population prophylaxis with granulocyte colony-stimulating factor in based cohort of elderly cancer patients. J Clin Oncol. 2012 elderly patients with diffuse aggressive lymphoma receiving Feb 27 (Epub ahead of print). curative-intent chemotherapy. J Clin Oncol. 2012. 30(10): p. 1064-71. 7. Bergh, J., P.E. Jonsson, E.K. Lidbrink, M. Trudeau, W. Eiermann, D. Brattstrom, J.P. Lindemann, F. Wiklund, and 16. Chau NG, Florescu A, Chan KK, Wang L, Chen EX, Bedard R. Henriksson. FACT: An Open-Label Randomized Phase P, Oza AM, Siu LL. Early mortality and overall survival in III Study of Fulvestrant and Anastrozole in Combination oncology phase I trial participants: can we improve patient Compared With Anastrozole Alone as First-Line Therapy selection? BMC Cancer. 2011. 2011 Oct; 11: 426; doi: for Patients With Receptor-Positive Postmenopausal Breast 10.1186/1471-2407-11-426 Contribution Details: contributing Cancer. J Clin Oncol. Epub ahead of print. 2012 Mar. to the design of the study, carrying out the study, analyzing the data, revising subsequent drafts. 8. Berry S, Evans WK, Strevel EL, Bell CM. Variation and Consternation: Access to Unfunded Cancer Drugs in Canada. 17. Chi KN, Beardsley E, Eigl BJ, Venner P, Hotte SJ, Winquist Journal of Oncology Practice. Volume 8 Issue 1: 35 - 39, 2012. E, Ko YJ, Sridhar SS, Weber D, Saad F. A phase 2 study of Patupilone in patients with metastatic castration resistant 9. Bhatt RS, Werner L, Regan MM, Yannucci J, Ko Y-J, Wang prostrate cancer previously terated with Docetaxel: Canadian H-Y, Rosen S, Genega E, Morrissey M-E, Duggan S, Vazquez Urologic Oncology Study Group P07a. Annals of Oncology. C, Sanda M, DeWolf W, Balk S, Yuan X, Bubley GJ. Possible 2011 Risk Factors Associated with Relapse in Patients Treated with Neoadjuvant Chemohormonal Therapy for High Risk Prostate Cancer. The Open Prostate Cancer Journal. 2011, 4: 6-13.
85 18. Cortes J, Fumoleau P, Bianchi GV, Petrella T, Gelmon K, 24. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Pivot X, Verma Sh, Albanel J, Conte P, Lluch A, Salvagni S, (K. Pritchard, Member of Writing Committee). Effect of Serent V, Gianni L, Scaltriti M, Ross GA, Dixon J, Szado T, radiotherapy after breast-conserving surgery on 10-year Baselga J. Pertuzumab Monotherapy After Trastuzumab-Based recurrence and 15-year breast cancer mortality: meta-analysis Treatment and Subsequent Reintroduction of Trastuzumab: of individual patient data on 10,801 women in 17 randomised Activity and Tolerability in Patients With Advanced Human trials. The Lancet. 378: 1707-1716, 2011. Epidermal Growth Factor Receptor 2-Positive Breast Cancer. 25. Early Breast Cancer Trialists’ Collaborative Group J Clin Oncol. 2012 May;30(14):1594-600. (EBCTCG) (K. Pritchard, Member of Writing Committee). 19. Czuczman MS, Vose JM, Witzig TE, Zinzani PL, Buckstein Relevance of breast cancer hormone receptors and other R, Polikoff J, Li J, Pietronigro D, Ervin-Haynes A, Reeder factors to the efficacy of adjuvant tamoxifen: patient-level CB. The differential effect of lenalidomide monotherapy in meta-analysis of randomized trials. The Lancet. 378:771- patients with relapsed or refractory transformed non-Hodgkin 784, 2011. lymphoma of distinct histological origin. British Journal of 26. El Emam K, Hu J, Mercer J, Peyton L, Kantarcioglu M, Malin Haematology. 2011 Aug; 154(4):477-81. B, Buckeridge D, Samet S, Earle CC. A Secure Protocol for 20. Dhani NC, Emmenegger U, Adams L, Jongstra J, Tannock Protecting the Identity of Providers when Disclosing Personal IF, Sridhar SS, Knox JJ, Day JR, Groskopf J, Joshua AM. A Data for Disease Surveillance. JAMIA. 2011: 18(3):212-217. Phase II Study of Cytarabine in men with docetaxel-refractory, 27. El Emam K, Samet S, Arbuckle L, Tamblyn R, Earle C, castration resistant prostate cancer (CPRC) with evaluation Kantarcioglu M. A secure distributed logistic regression of TMPRSS2-ERG and SPINK1 as serum biomarkers. protocol for the detection of rare adverse drug events. J British Journal of Urology International. doi: 10.1111/j.1464- Am Med Inform Assoc. 2012 Jul 30. (Epub ahead of print). 410X.2011.10922.x. [Epub ahead of print] PMID: 22313860 28. El Emam K, Samet S, Hu J, Peyton L, Earle C, Jayaraman [Pubmed - as supplied by publisher]. G, Wong T, Kantarcioglu M, Dankar F, Essex A. A Protocol 21. Di Leo AD, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, for the secure linking of registries for HPV surveillance. PLoS Pritchard KI et al. HER2 and TOP2A as predictive markers One. 2012;7(7):e39915. Epub 2012 Jul 2. for anthracycline-containing chemotherapy regimens as 29. Esplen MJ, Wong J, Warner E, Toner B, Taylor N. Predictors adjuvant treatment of breast cancer: A meta-analysis of of Body Image Aspects of Quality of Life and Psychosocial individual patient data. Lancet Oncology. 12: 1134-42, 2011. Adjustment in Women Post Breast Cancer Surgery. Psycho- 22. Donald M. Arnold, Nancy M. Heddle, Julie Carruthers, Oncology 20(Suppl.2):74, W-3. 2011 Oct. Deborah J. Cook, Mark A. Crowther, Ralph M. Meyer, Yang 30. Esplen MJ, Wong J, Warner E, Toner B, Taylor N. Body Liu, Richard J. Cook, Anne McLeod, Janet A. MacEachern, Image and Psychosocial Functioning in Women with Breast Joy Mangel, David Anderson, Linda Vickars, Alan Tinmouth, Cancer: Can We Fix What We’ve Broken? A group program Andre C. Schuh, and John G. Kelton. A pilot randomized being tested in a randomized trial. Psycho-Oncology trial of adjuvant rituximab or placebo for nonsplenectomized 20(Suppl.2):47, J-2, 2011 Oct. patients with immune thrombocytopenia. Blood. 2012 119:1356-1362; published ahead of print January 5, 2012, 31. Evans WK, Wolfson M, Flanagan WM, Shin J, goffin JR, doi:10.1182/blood-2011-08-374777. Asakawa K, Earle C, Mittmann N, Fairclough L, Fines P, Gribble S, Hoch J, Hicks C, Omariba WDR, Ng E. The evaluation of 23. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) cancer control interventions in lung cancer risk management (K. Pritchard, Member of Writing Committee). Comparison model. Lung Cancer Manage J. 2012; 1(1):25-33. between different polychemotherapy regimens for early breast cancer: Meta-analysis of effects on recurrence and 32. Fairfield KM, Murray K, Lucas FL, Wierman HR,Earle CC, mortality in 100,000 randomized individuals. The Lancet. Trimble EL, Small L, Warren JL. Completion of Adjuvant 379: 432-444, 2012. Chemotherapy and Health Services Use for Older Women with Epithelial Ovarian Cancer. J Clin Oncol. 2011;29(29):3921-6. Epub 2011 Sept 12.
86 33. Fairfield KM, Murray KM, Wierman HR, Han PKJ, Hallen S, 41. Goodwin, P.J., M. Ennis, K.I. Pritchard, M.E. Trudeau, J. Miesfeldt S, Trimble EL, Warren JL, Earle CC. Disparities Koo, S.K. Taylor, and N. Hood. Insulin- and Obesity-Related in Hospice Care among Older Women Dying with Ovarian Variables in Early-Stage Breast Cancer: Correlations and Cancer. Gynecologic Oncology. 2012; 125(1):14-8. Epub Time Course of Prognostic Associations. J Clin Oncol. 2012. 2011 Dec 1. 30(2): p. 164-71.
34. Furlan JC, Chan KK, Sandoval GA, Lam KCK, Klinger CA, 42. Grunfeld E, Earle C, Stovall E. A framework for cancer Patchell RA, Laporte A, Fehlings MG. The combined use survivorship research and translation to policy. Cancer of surgery and radiotherapy to treat patients with epidural Epidemiology, Biomarkers and Prevention. 2011; 20(10):2099- cord compression due to metastatic disease: a cost-utility 104. analysis. Epub ahead of print. doi: 10.1093/neuonc/nos062. 43. Grunfeld E, Julian J, Pond G, Maunsell E, Coyle D, Folkes A, Neuro-Oncology. 2012 Apr. Joy A, Provencher L, Rayson, Rheaume D, Porter G, Paszat 35. Furness S, Glenny A-M, Worthington HV, Pavitt S, Oliver L, Pritchard KI, Robidoux A, Smith S, Sussman J, Dent S, R, Clarkson JE, Macluskey M, Chan KKW, Conway DI, Sisler J, Wiernikowski J, Levine M. Evaluating survivorship The CSROC Expert Panel. Interventions for the treatment care plans: results of a randomized clinical trial with breast of oral cavity and oropharyngeal cancer: chemotherapy. cancer patients.J Clin Oncol. 29: 4755-4762, 2011. Cochrane Database of Systemic Reviews 2011, Issue 4. 44. Haas JS, Brawarsky P, Iyer A, Fitzmaurice GM, Neville Art No.: CD006386. DOI: 10.02/14651858.CD006386. BA. Earle CC. Association of Area Sociodemographic pub3 Contribution Details: analyzing the data, revising Characteristics and Capacity for Treatment with Disparities subsequent drafts. in Colorectal Cancer Care and Mortality. Cancer. 2011; 36. Gandhi S, Towns K, Verma S. Patient and Physician 117(18):4267-76. Epub 2011 Mar 16. Perceptions on Continuing Aromatase Inhibitors Beyond the 45. Heng DY, Mackenzie M, Vaishampayan U, Knox JJ, Bjarnason 5 Year Mark. Breast J. 2011 Nov-Dec;17(6):620-9. GA, Tan MH, Wood L, Donskov F, Rini B, Choueiri TK. 37. Gill S, Berry S, Biagi J, Butts C, Buyse M, Chen E, Jonker Primary anti-vascular endothelial growth factor (VEGF) re- D, Marginean C, Samson B, Stewart J, Thirwell M, Wong R, fractory metastatic cell carcinoma: clinic characterestics, Maroun JA. Progression-free survival as a primary endpoint risk factors and subsequent therapy. Annals of Oncology. in clinical trials of metastatic colorectal cancer. Current 2011 Nov 5. Epub. Oncology. 2011 Nov, Vol 18 (Supp 2): S5-S10. 46. Hertel PB, Tu D, Ejlertsen B, Jensen MB, Balslev E, Jiang S, 38. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann O’Malley F, Pritchard KI, Shepherd LE, Bartels A, Brunner B, Senn H-J and Panel Members (Pritchard KI et al). Special N, Nielsen T. TIMP-1 in combination with HER2 and TOP2A Article: Strategies for subtypes – dealing with the diversity for prediction of benefit from adjuvant anthracyclines in high of breast cancer: Highlights of the St. Gallen International risk breast cancer patients. J Clin Oncol. 132: 225-234, 2012. Expert Consensus on the Primary Therapy of Early Breast 47. Hill KA, Nadler T, Mandel R, Burlein-Hall S, Librach C, Glass K, Cancer 2011. Annals of Oncology. 22: 1736-1747, 2011. Warner E. The experience of young women diagnosed with 39. Goodwin PJ, Pritchard KI, Trudeau M, Koo J, Taylor S, breast cancer who undergo fertility preservation consultation. Hood N. Insulin and obesity related variables in early stage Clinical Breast Cancer,12(2):127-32, 2012 Apr. breast cancer – correlations and time course of prognostic 48. Ho TH, Barbera L, Saskin R, Lu H, Neville BA, Earle CC. associations. J Clin Oncol. 30: 164-171, 2012. Trends in the Aggressiveness of End-of-Life Cancer Care in 40. Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar the Universal Health Care System of Ontario, Canada. J Clin WR, Gelmon KA, Hershman DL, Hobday DJ, Ligibel JA, Oncol. 2011; 29(12):1587-91. Epub 2011 Mar 14. Mayer IA, Whelan TJ, Rastogi P, Shepherd LE. Pritchard KI, 49. Hoffman K, Neville B, Mamon H, Kachnic L, Katz M, Earle C, Evaulation of metformin in early breast cancer: A modification Punglia R. Adjuvant therapy for elderly patients with resected of the traditional paradigm for clinical testing of anti-cancer gastric adenocarcinoma: population-based practices and agents. Br Cancer Res Treat. 126: 215-220, 2011. treatment effectiveness. Cancer. 2012;118(1):248-57. Epub 2011 Jun 20.
87 50. Hotte SJ, Bjarnason GA, Heng DYC, Jewett MAS, Kapoor 59. Jembere N, Campitelli MA, Sherman M, Feld JJ, Lou W, A, Kollmannsberger C, Mayhew LA, North S, Reaume N, J. Peacock S, Yoshida E, Krahn MD, Earle C, Thein H-H. Ruether JD, Soulieres D, Venner PM, Winquist EW, Wood L, Influence of socioeconomic status on survival of hepatocellular Yong JHE, Saad F. Progression-free survival as a clinical trial carcinoma in the Ontario population: a population-based endpoint in advanced renal cell carcinoma. Current Oncol. study, 1990-2009. PLoS One. 2012;7(7):e40917. Epub 2011;18(2):11-19. 2012 Jul 13. 51. Howell D, Hack TF, Oliver TK, Chalak T, Mayo S, Aubin M, 60. José Baselga, M.D., Ph.D., Mario Campone, M.D., Ph.D., Chasen M, Earle CC, Friedman AJ, Green E, Jones GW, Martine Piccart, M.D., Ph.D., Howard A. Burris, III, M.D., Hope Jones JM, Parkinson M, Payeur N, Sabiston CM, Sinclair S. Rugo, M.D., Tarek Sahmoud, M.D., Ph.D., Shinzaburo S (Cancer Journey Survivorship Expert Panel). Survivorship Noguchi, M.D., Michael Gnant, M.D., Kathleen I. Pritchard, services for adult cancer populations: a pan-Canadian M.D., Fabienne Lebrun, M.D., J. Thaddeus Beck, M.D., guideline. Curr Oncol. 2011; 18(6):e265-81. Yoshinori Ito, M.D., Denise Yardley, M.D., Ines Deleu, M.D., 52. Howell D, Hack TF, Oliver TK, Chulak T, Mayo S. Aubin M, Alejandra Perez, M.D., Thomas Bachelot, M.D., Ph.D., Luc Vittori, M.Sc., Zhiying Xu, Ph.D., Pabak Mukhopadhyay, Chasen M, Earle CC, Friedman AJ, Green E, Jones GW, Jones JM, Parkinson M, Payeur N, Sabiston CM, Sinclair S. Ph.D., David Lebwohl, M.D., and Gabriel N. Hortobagyi, Models of care for post-tratment follow-up of adult cancer M.D. Everolimus in Postmenopausal Hormone Receptor- survivors: a systematic review and quality appraisal of the Positive Advanced Breast Cancer. New England Journal of evidence. J Cancer Surviv. 2012 Jul 10 (Epub ahead of print). Medicine. 366: 520-529, 2012. 53. Howell D, Husain A, Seow H, Liu Y, Kustra R, Atzema C, 61. Keating NL, Landrum MB, Lamont EB, Bozeman SR, Krasnow SH, Shulman LN, Brown JR, Oh WK, Rabin M, Dudgeon D, Earle C, Sussman J, Barbera L. Symptom Earle CC, clusters in a population-based ambulatory cancer cohort McNeil BJ. Quality of Care for Patients with Cancer in the validated using bootstrap methods. Eur J Cancer. 2012 May Veterans Health Administration versus the Private Sector. 25 (Epub ahead of print). Ann Intern Med. 2011; 154:727-736. 62. Khella HW, White NM, Faragalla H, Gabril M, Boazak M, 54. Hudson JM, Williams R, Lloyd B, Atri M, Kim TK, Bjarnason Dorian D, Khalil B, Antonios H, Bao TT, Pasic MD, Honey GA, Burns PN. Improved Flow Measurement Using Microbubble Contrast Agents and Disruption-Replenishment: Clinical RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA, Yousef Application to Tumour Monitoring. Ultrasound Med Biol. GM. Exploring the role of miRNAs in renal cell carcinoma 2011 Aug;37(8):1210-21. progression and metastasis through bioinformatic and experimental analyses. Tumor biology: the journal of the 55. Ichim CV, Atkins HI, Iscove NN, Wells RA. Identification of International Society for Oncodevelopmental Biology and a role for the nuclear receptor EAR-2 in the maintenance of Medicine. 2012 Feb; 33(1): 131-40. clonogenic status within the leukemia cell hierarchy. Leukemia 2011;25(11):1687-96. doi: 10.1038/leu.2011.137. Epub 63. Kinshuk K, Roswell C, Law C, Ko YJ. Coexistence of 2011 Jun 3. gastrointestinal stromal tumour and colrectal adenocarcinoma: Two case reports. J Gastrointest Oncol. 2011; 2: 56. Ichim CV, Wells RA. Generation of high-titer viral preparations by concentration using successive rounds of ultracentrifugation. 64. Knight G, Earle CC, Cosby R, Coburn N, Youssef Y, Journal of Translational Medicine 2011;17;9:137. Malthaner R, Wong RKS, The Gastrointestinal Cancer Disease Site Group. Neoadjuvant or adjuvant therapy for 57. Innominato PF, Giacchetti S, Moreau T, Smaaland R, Focan resectable gastric cancer: a systematic review and practice C, Bjarnason GA, Garufi C, Iacobelli S, Tampellini M, Tumolo guideline for North America. Gastric Cancer. Epub ahead of S, Carvalho C, Karaboue A, Levi F. Schedule-dependent print March 31, 2012. interaction betwenn neutropenia and efficacy outcomes in patients receiving oxaliplatin-5 fluorouracil-leucovorin for metastic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int. 2011 Aug;28(7):586-600.
58. Jacobson M, Earle CC, Newhouse JP. Geographic variation in physicians’ responses to a reimbursement change. N Engl J Med. 2011;365(22):2049-52. Epub 2011 Nov 2.
88 65. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, 73. Li Y, Vecchiarelli-Federico LM, Li YJ, Egan SE, Spaner D, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes Hough MR, Ben-David Y. The miR-17-92 cluster expands MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter multipotent hematopoietic progenitors whereas imbalanced R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. expression of its individual oncogenic miRNAs promotes B-cell depletion and remissions of malignancy along with leukemia in mice. Blood. 2012 May 10;119(19):4486-98. cytokine-associated toxicity in a clinical trial of anti-CD19 Epub 2012 Mar 26. chimeric-antigen-receptor-transduced T cells. Blood. 2012 74. Lipton A, Chapman JA, Wilson C, Han L, Shepherd LE, Mar 22;119(12):2709-20. Epub 2011 Dec 8. Pritchard KI, Pollak M, Ali S. Elevated Bone Turnover 66. Kollmannsberger C, Bjarnason GA, Burnett P, Creel T, Predicts For Bone Metastasis in postmenopausal breast Davis M, Dawson N, Feldman D, George S, Hershman J, cancer: NCIC CTG MA.14. J Clin Oncol. 29: 3605-3610 , Lechner T, Potter A, Raymond E, Treister N, Wood L, Wu S, 2011(accompanied by Editorial: Can We Predict Who’s at Bukowski R. Sunitinib in Metastatic Renal Cell Carcinoma: Risk for Developing Bone Metastases in Breast Cancer? Recommendations for Management of Non-Cardiovascular Larissa A. Korde andJulie R. Gralow; pg 3600-3604). Toxicities. Oncologist. 2011;16(5):543-53. (2nd author on 75. Mack JW, Cronin A, Taback N, Huskamp HA, Keating NL, this review based on a North American expert consensus Malin JL, Earle CC, Weeks JC. End-of-life Care discussions meeting). among patients with advanced cancer: A cohort study. Ann 67. Koroukian S, Bakaki P, Owusu C, Earle CC, Cooper G. Cancer- Intern Med. 2012;156(3):204-10. Outcomes in Low-income Elders: Is there an Advantage to 76. Mackey JR, Kerbel RS, Gelmon KA, McLeod DM, Chia SK, Being on Medicaid. Medicare & Medicaid Research Review. Rayson D, Verma S, Collins LL, Paterson AHG, Robidoux A, 2012;2(3), E1-E22. Pritchard KI. Controlling Angiogenesis in Breast Cancer: A 68. Koroukian SM, Bakaki PM, Beaird H, Earle CC, Cooper Systematic Review of Anti-angiogenic Trials. Cancer Treatment GS. Cancer Stage Comparison between Dual Medicare- Review. Cancer Treat Rev. 2012 Oct;38(6):673-88. Medicaid Eligibles using Medicaid as a Supplemental Health 77. Mayer EL, Gropper AB, Neville BA, Partrodge AJ. Cameron Insurance Program and Low-Income Nonduals. J Pub Health DB, Winer EP, Earle CC. Breast cancer survivors’ perceptions Management Prac. 2011; 17(6):479-491. of survivorship care options. J Clin Oncol. 2012; 30(2):158-6. 69. Kotsopoulos J, Lubisnki J, Salmena L, Lynch HT, Kim-Sing Epub 2011 Dec 12. C, Foulkes WD, Ghadirian P, Neuhausen SL, Demsky R, 78. McGee J, Kotsopoulos J, Lubinski J, Lynch HT, Rosen B, Tung Tung N, Ainsworth P, Senter L, Eisen A, Eng C, Singer C, N, Kim-Sing C, Karlan B, Foulkes WD, Ainsworth P, Ghadirian Ginsburg O, Blum J, Huzarski T, Poll A, Sun P, Narod SA, P, Senter L, Eisen A, Sun P, Narod SA. Anthropometric Hbcc HB. Breastfeeding and the Risk of Breast Cancer Measures and Risk of Ovarian Cancer Among BRCA1 and in BRCA1 and BRCA2 Mutation Carriers. Breast Cancer BRCA2 Mutation Carriers. Obesity, 20(6):1288-92, 2012 June. Research,14(2):R42, 2012 March. 79. McLeod AG, Geerts W. Venous thromboembolism prophylaxis 70. Landaverde D, Verma S. Recent treatment advances in in critically ill patients. Critical Care Clinics. 2011 Oct;27(4):765- HER2-positive metastatic breast cancer: a clinical approach. 80, v. Epub 2011 Sep 13. Clin Pract. 2012 May;9(3):287-99. 80. Mittmann N, Isogai PK, Connors JM, Rebeira M, Cheung 71. Landrum MB, Keating N, Lamont E, Bozeman S, Krasnow MC. Economic analysis of alemtuzumab (MabCampath) in S, Shulman L, Brown J, Earle C, Rabin M, McNeil B. fludarabine refractory chronic lymphocytic leukemia. The Survival of older cancer patients in the Veterans Health Open Pharmacoeconomics and Health Economics Journal. administration versus fee for service Medicare. J Clin Oncol. 2012, 4, 18-25. 2012; 30(10):1072-9. Epub 2012 Mar 5. 81. Nielsen T, Cheung M, Voduc D, Tu DS, Jiang S, Leung S, 72. Lathia N, Isogai P, Walker S, DeAngelis C, Cheung MC, Chia S, Shepherd LE, Levine MN, Pritchard KI, Davies S, Hoch J, Mittmann N. Eliciting Patients’ Preferences for Stijleman IJ, Davis C, Ebbert MTW, Parker J, Ellis M, Bernard Outpatient Treatment of Febrile Neutropenia: A Discrete PS, Perou CM. Responsiveness of intrinsic subtypes to Choice Experiment. Supportive Care in Cancer. DOI 10.1007/ adjuvant anthracycline substitution in the NCIC CTG MA.5 s00520-012-1517-5. randomized trial. Clin Cancer Res 18(8):2402-12. Epub 2012 Feb 20.
89 82. O’Malley F, Chia S, Tu D, Shepherd L, Levine MN, Bramwell 89. Pritchard KI, Tu D, Munro A, Levine MN, Chia S, Shepherd V, Andrulis I, Pritchard KI. An exploratory analysis of LE, O’Malley FP, Li X, Bartlett J. Chromsome 17 centromere Topoisomerase II alpha protein and responsiveness of breast (CEP17) duplication as a predictor of anthracycline response: cancer to adjuvant chemotherapy with CEF compared to Evidence from the NCIC Clinical Trials Group (NCIC CTG) CMF in the NCIC CTG randomized MA.5 adjuvant trial. Br MA.5 Trial. Br Cancer Res Treat. 131: 541-551, 2012. Cancer Res Treat. 128: 401-409, 2011. 90. R. Selby, B.J. Borah, H. P. McDonald, J. Henk, M. Crowther, 83. Parker JL, Zhang Y, Buckstein R. Clinical trial risk in Non- P.S. Wells. Impact of Thromboprophylaxis Guidelines on Hodgkin’s Lymphoma: Endpoint and target selection. Journal Clinical Outcomes Following Total Hip and Total Knee of Pharmacy & Pharmaceutical Sciences. 2011; 14(2)227-35. Replacement. Thrombosis Research. Thromb Res. 2012 84. Passaperuma k, Warner E, Plewes DB, Causer P, Hill KA, Feb 23 [Epub ahead of print]. Messner SJ, Wong J, Jong RA, Wright F, Yaffe MA, Ramsay 91. Rauw J, Ahmed S, Petrella T. Pericardial effusion and E, Balasingham S, Verity L, Eisen A, Curpen B, Sumak tamponade following interferon alpha treatment for locally R, Narod SA. Long-term results if the Toronto magnectic advanced melanoma. Med Oncol. 2012 Jun;29(2):1304-7. resonance imaging (MRI) breast surveillance study in 92. Rauw J, Wells RA, Chesney A, Reis M, Zhang L, Buckstein women with BRCA1 or BRCA2 mutations. British Journal R. Validation of a scoring system to establish the probability of Cancer,107(1):24-30, 2012 May. of myelodysplastic syndrome in patients with unexplained 85. Potosky AL, Han PKJ, Rowland J, Klabunde CN, Smith T, Aziz ctyopenias or macrocytosis. Leukemia Research. 35 (2011) N, Earle C, Ayanian JZ, Ganz PA, Stefanek M. Differences 1335-1338. between primary care physicians’ and oncologists’ knowledge, 93. Rodrigo JA, Hicks LK, Cheung MC, Song KW, Ezzat H, attitudes and practices regarding the care of cancer survivors. Leger CS, Boro J, Montaner JS, Harris M, Leitch HA. HIV- J Gen Intern Med. 2011; 26(12):1403-10. Epub 2011 Jul 22. Associated Burkitt Lymphoma; Good Efficacy and Tolerance 86. Pritchard KI, Julian JA, Holloway CMB, McCready D, of Intensive Chemotherapy including CODOX-M/IVAC Gulenchyn K, George R, Hodgson N, Lovrics P, Perera F, with or without Rituximab in the HAART Era. Advances in Elavathil L, O’Malley FP, Down N, Bodurtha A, Shelley W, Levine Hematology. Volume 2012 (2012), Article ID 735392. doi: MN. A Prospective Study of FDG-PET in the Assessment of 10.1155/2012/735392. Regional Nodal Spread of Disease in Breast Cancer Patients: 94. Saad F, Hotte S, North S, Eigl B, Chi K , Czaykowski P, Wood An Ontario Clinical Oncology Group (OCOG) Study. J Clin L, Pollak M, Berry S, Mukherjee S, Gleave M, Winquist E, Oncol. 30: 1274-1279, 2012. and the Canadian Uro-Oncology Group. Randomized Phase 87. Pritchard KI, Shepherd LE, Chapman JAW, Kook JE, Norris 2 Trial of Custirsen (OGX-011) in Combination with Docetaxel BD, Cantin J, Goss P, Dent S, Walde D, Vandenberg TA, or Mitoxantrone as Second-line Therapy in Patients with Findlay B, O’Reilly SE, Wilson CF, Han L, Piura E, Whelan Metastatic Castrate Resistant Prostate Cancer Progressing TJ, Pollak MN. A Randomized Trial of Tamoxifen versus after First line Docetaxel. Clinical Cancer Research. Accepted Combined Tamoxifen and Octreotide LAR Therapy in the and In Press, May 2011. Adjuvant Treatment of Early Stage Breast Cancer in Post- 95. Saito AM, Landrum MB, Neville BA, Ayanian JZ, Earle CC. menopausal Women: NCIC CTG MA.14. Accompanied by The effect on survival of continuing chemotherapy to near an Editorial. J Clin Oncol. Sep 12, 2011:JCO.2010.33.7006; death. BMC Palliative Care. 2011; 10:14. published online. 96. Saito AM, Landrum MB, Neville BA, Ayanian JZ, Weeks JC, 88. Sousa B. Long term follow-up of women in Pritchard KI, Earle CC. Hospice Care and Survival Among Elderly Lung trials of adjuvant therapy for breast cancer: Is it still important? Cancer Patients. J Pall Med. 2011; 14(8):929-39. Epub On the article entitled: Long-term benefits of five years of 2011 Jul 18. tamoxifen: 10 year follow up of a large randomized trial in women aged at least 50 years with early breast cancer, by Allan Hackshaw, et al. J Clin Oncol. 29, 1651-1652, 2011.
90 97. Sehn, L.H., D. MacDonald, S. Rubin, G. Cantin, M. Rubinger, 106. Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E, B. Lemieux, S. Basi, K. Imrie, R.D. Gascoyne, J. Sussman, Tannock IF, Mukherjee SD, Wang L, Blattler C, Wright JJ, B.E. Chen, M. Djurfeldt, L. Shepherd, S. Couban, and M. Moore MJ. A Phase II Trial of Sorafenib in First-line Metastatic Crump. Bortezomib ADDED to R-CVP is safe and effective Urothelial Cancer: a study of the PMH Phase II Consortium. for previously untreated advanced-stage follicular lymphoma: Investigational New Drugs, 29(5):1045-9, 2011 Oct. a phase II study by the National Cancer Institute of Canada 107. Stukel TA, Fisher ES, Alter DA, Guttmann A, Ko DT, Fung K, Clinical Trials Group. J Clin Oncol. 2011. 29(25): p. 3396-401. Wodchis WP, Baxter NN, Earle CC, Lee DS. Association of 98. Seow H., Barbera L., Sutradhar R., Howell D., Dudgeon hospital spending intensity with mortality and readmissions in D., Atzema C., Liu Y., Husain A., Sussman J., Earle C. The Ontario hospitals [Accompanied by Editorial]. JAMA. 2012; trajectory of performance status and symptom scores in 307(10):1037-1045. cancer patients’ last six months of life. J Clin Oncol. 2011; 108. Trudeau, M., E. Green, R. Cosby, F. Charbonneau, T. Easty, 29(9):1151-8. Y. Ko, P. Marchand, U. David, N. Berger, and S. Hertz. 99. Sheppard, A.J., A.M. Chiarelli, L.D. Marrett, E.D. Nishri, Key components of intravenous chemotherapy labeling: A and M.E. Trudeau. Stage at diagnosis and comorbidity systematic review and practice guideline. J Oncol Pharm influence breast cancer survival in First Nations women in Pract, 2011. 17(4): p. 409-24 (JOPP Best Paper Award - Ontario, Canada. Cancer Epidemiol Biomarkers Prev. 2011. Clinical Practice Category). 20(10): p. 2160-7. 109. Tung S, Spaner DE. A role for Danazol in chronic lymphocytic 100. Shuen AY, Wong BYL, Fu L, Selby R, Cole DEC. Evaluation of leukemia. Leukemia. 2012 Jan 13. doi: 10.1038/leu.2011.386. a warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and [Epub ahead of print] PubMed PMID: 22289992. its effect on dosage algorithms in a genetically heterogeneous 110. Ubel PA, Berry SR, Nadler E, Bell CM, Kozminski MA, Palmer anticoagulant clinic. Clinical Biochemistry. Clin Biochem. JA, Evans WK, Strevel EL, Neumann PJ. In a survey, marked 2012 Apr;45(6):397-401. Epub 2012 Jan 13. inconsistency in how oncologists judged value of high-cost 101. Singh S, Law C. Chromogranin A: A reliable marker cancer drugs in relation to gains in survival. Health Affairs. for the detection and post-treatment monitoring of 31:4, 709-717 2012. gastroenteropancreatic neuroendocrine turmours (GEP 111. van Walraven C, Fergusson D, Earle C, Baxter N, Alibhai NETs). Expert Review of Gastroenterology & Hepatology. S, MacDonald B, Forster AJ, Cagiannos I. Association of 102. Smith IE, Pierga JY, Biganzoli L, Cortes-Funes, Thomssen Diagnostic Radiation Exposure and Second Abdominal-Pelvic C, Pivot X, Fabi A, Xu B, Stroyakovsky D, Franke FA, Malignancies after Testicular Cancer. J Clin Oncol. 2011; Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong 29(21):2883-8. Epub 2011 Jun 20. A, Gonzalex-Trujillo JL, Koza I, Petrakova K, Pereira D, and 112. Verma S, Provencher L, Dent R. Emerging trends in the Pritchard KI on behalf of the ATHENA Study Group. treatment of triple-negative breast cancer in Canada: a First-line bevacizumab plus taxane-based chemotherapy survey. Curr Oncol. 2011 Aug;18(4):180-190. for locally recurrent or metastatic breast cancer: Safety and 113. Villarreal-Garza C, Cortes J, Andre F, Verma S. mTOR efficacy in an open-label study in 2251 patients. Ann Oncol. inhibitors in the management of hormone receptor-positive 22: 595-602, 2011. breast cancer: the latest evidence and future directions. Ann 103. Snyder CF, Frick KD, Herbert RJ, Blackford AL, Neville BA, Oncol. 2012 May 2 [Epub ahead of print]. Carducci MA, Earle CC. Preventive Care in Prostate Cancer 114. Warner E. Clincal practice: Breast cancer screening. New Patients: Following Diagnosis and for Five-Year Survivors. J England Journal of Medicine, 365(11):1025-32, 2011 Sept. Cancer Surviv. 2011; 5(3):283-9. Epub 2011 May 8. 115. White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, 104. Spaner DE. Oral high-dose glucocorticoids and Ofatumumab Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA, in fludarabine-resistant Chronic Lymphocytic. Leukemia. Evans AJ, Gabril M, Yousef GM. miRNA profiling in metastatic 26(5):1144-5, 2012. renal cell carcinoma reveals a tumour-suppressor effect for 105. Spiegel T, Esplen MJ, Hill KA, Wong J, Warner E. Psychological miR-215. Br J Cancer. 2011 Nov 22;105(11):1741-9. impact of recall on women with BRCA mutations undergoing MRI surveillance. Breast, 20(5):424-30, 2011 Oct.
91 116. White NMA, Bao TT, Grigull J, Youseff YM, Girgis A, Diamandis 6. Altwairgi AK, Parulekar W, Chapman J-A, Shepherd LE, M, Fatoohi E, Metias M, Honey R, Stewart R, Pace KT, Pritchard KI, Han L, Goss PE, Whelan TJ. Impact of Bjarnason GA, Yousef GM. MiRNA profiling in clear cell concurrent and sequential radiotherapy with adjuvant renal cell carcinoma: Biomarker discovery and identification of aromatase inhibitors in early-stage breast cancer: NCIC potential controls and consequences of miRNA dysregulation. CTG MA.27. J Clin Oncol. 2012 June; 30: Abstract #500. J Urol. 2011 Sep;186(3):1077-83. 7. Beck JT, Rugo HS, Burris III HA, Baselga J, Noguchi S, 117. Williams R, Hudson JM, Lloyd B, Sureshkumar A, Lueck Gnant M, Pritchard KI, Bennett L, Ricci J-F, Horobagyi GN. G, Milot L, Atri M, Bjarnason GA, Burns PN. Dynamic BOLERO-2: Health-related quality of life in metastatic breast microbubble contrast-enhanced ultrasound (DCE-US) to cancer patients treated with everolimus and exemestane measure tumor response to targeted therapy: A proposed versus exemestane. J Clin Oncol. 2012 June; 30: Abstract. clinical protocol with results from renal cell carcinoma 8. Bjarnason GA, Johnson C, Pili R, Teh B, Rathmell K, Brugarolas patients receiving anti-angiogenic therapy. Radiology. 2011 J, McDermott D, Neckers L, Yousef G, Gudas L, Kerbel R, Aug;260(2):581-90. Foster S, Ebos J, Atkins M, Jewett M, Knox JJ, Hudson J, 118. Wright F, Spithoff K, Easson A, Murray C, Toye J, McCready Pili R. An individualized dose/schedules strategy for Sunitinib D, Petrella T; the Melanoma Disease Site Group of Cancer in metastatic renal cell cancer may improve progression free Care Ontario’s Program in Evidence-based Care. Primary survival: Correlation with dynamic microbubble ultrasound excision margins and sentinel lymph node biopsy in clinically (DCE-US) data. 2nd WNY and Southern Ontario Kidney node-negative cutaneous melanoma of the trunk or extremities. Symposium Buffalo 2012. Poster presentation. Clin Oncol (R Coll Radiol). 2011 Nov;23(9):572-8. 9. Bjarnason GA, Khalil B, Williams R, Hudson JM, Lloyd 119. Yu J, Simmons C, Leighl N, Verma S. Impact of New BA, Milot LM, Atri M, Kiss A, Burns P. An individualized Chemotherapeutic and Targeted Agents on Survival in Stage IV dose/schedule strategy for sunitinib in metastatic renal cell Non-Small Cell Lung Cancer. Oncologist. 2011;16(9):1307-15. cancer (mRCC) may improve progression free survival (PFS): Correlation with dynamic microbubble ultrasound (DCE-US) Abstracts data. ASCO-GU. (poster presentation) 2011.
1. Ali A, Fergus K, Wright F, Pritchard K, Kiss A, Warner 10. Boquiren B, Esplen MJ, Toner B, Wong J, Warner E. The E. Preliminary findings of a survey designed to access the influence of gender-socialization and body consciousness impact of a breast cancer diagnosis on the mother-daughter on body image in breast cancer survivors. Presented at the relationship. Presented at the San Antonio Breast Cancer Annual Meeting of the Canadian Association of Psychosocial Symposium, San Antonio, December 2011. Oncology, April 2012.
2. Ali A, Fergus K, Wright F, Pritchard K, Kiss A, Warner E. 11. Boquiren V, Esplen MJ, Wong J, Warner E, Toner B. An The impact of a breast cancer diagnosis in young women investigation of sexual functioning, marital satisfaction and on their relationship with their mothers. Presented at the social support in breast cancer survivors. Presented at the annual scientific meeting of Canadian Assocaition of Medical Annual Meeting of the Canadian Association of Psychosocial Oncologists, Toronto, April 2012. Oncology, April 2012. 3. Ali A, Fergus K, Wright F, Pritchard KI, Kiss A, Warner E. 12. Bouganim N, Dong B, Hilton JF, Chapman J-AW, Arnaout Pilot Study of a Questionnaire To Assess Impact of a Breast A, O’Malley F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, Cancer Diagnosis in Young Women on Their Relationship with Bramwell V, Whelan T, Pritchard KI, Shepherd L, Clemons Their Mothers. Cancer Research. Vol 71: Poster Presentation M. How Should We Assess Tumour Size (T Stage) in Patients at SABCS 2011, P5-17-06. with Multicentric/Multifocal Breast Cancer? Results from 4. Ali A, Hill K, Warner E. Genetic testing referral, uptake and the NCIC CTG MA.5 Randomized Trial of CEF vs. CMF in results in a program for women. Presented at the ASCO Pre-Menopausal Women with Node Positive Breast Cancer. Annual Meeting, June 2012. Cancer Research. Vol 71: Poster Presentation at SABCS 2011, P2-12-23. 5. Ali A, Hill K, Warner E. Genetic testing referral, uptake and results in program for women < age 40 with breast cancer. Presented at the NYU Hereditary Breast and Ovarian Cancer Conference. New York City, Sept 2011.
92 13. Boyle F, Smith I, O’Shaughnessy J, Ejlertsen B, Kaufmann 20. Collins LC, Gelber S, Marotti JD, Cole K, Kerakoglow S, Ruddy M, Buzdar A, Fumoleau P, Gradishar W, Martin M, Moy B, K, Brachtel EF, Schapira L, Come SE, Borges V, Schendin Piccart M, Pritchard KI, Lindquist M, Amonkar M, Huang P, Warner E, Winer E, Partridge A. Molecular phenotype Y, Williams L, Wang Q, Finkelstein D, Goss P. Lapatinib in of breast cancers in a large cohort of young women with HER2+ early breast cancer (EBC): Quality of Life (QOL) breast cancer according to pregnancy interval. Presented at Analysis. J Clin Oncol. 2012 June; 30: Abstract. the San Antonio Breast Cancer Symposium, San Antonio, 14. Bramwell VH, Tuck AB, Chapman J-A, Anborgh PH, Postenka December 2011. CO, Shepherd L, Pritchard KI, Han L, Wilson C, Pollak M, 21. Cukier M, Nadler A, Singh S, Milot L, Law C. “A novel hepatic Chambers AF. Studies of a Malignancy-Associated Protein, parenchymal preserving technique in the management of Osteopontin, in NCIC CTG MA.14, a Randomized Trial of neuroendocrine tumour liver metastases: a feasible approach.” Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Society of Surgical Oncology (SSO) 2012 Annual Meeting. in Adjuvant Treatment of Women with Early Breast Cancer. 22. D. Y. C. Heng, W. Xie, L. C. Harshman, G. A. Bjarnason, U. Cancer Research. Vol 71: Poster Presentation at SABCS N. Vaishampayan, J. Lebert, L. Wood, F. Donskov, M. H. Tan, 2011, P2-12-28. S. Y. Rha, C. Wells, Y. Wang, C. K. Kollmannsberger, B. I. Rini, 15. Carroll JC, Dicks E, Permaul J, Blaine S, Warner E, Rothemund T. K. Choueiri. External validation of the international metastatic H, Semotiuk K, Esplen MJ. Use of a hereditary colorectal renal cell carcinoma (mRCC) database consortiumprognostic cancer clinical tool by family physicians: a 2-year follow-up. model and comparison to four other models in the era of Presented at the annual meeting of the North American targeted therapy. ASCO 2011. (poster discussion). Primary Care Research Group. Banff, AB. November 2011. 23. Eisen A, Carroll J, Chiarelli A, Heale E, Horgan M, Meschino W, 16. Chan A, Dhesy B, You J, Freeman M, Inculet R, Pritchard KI, Plewes D, Rabeneck L, Shumack R, Warner E. Implementation Dayes I, Chushu G, Julian J, Gulenchyn K, Evans B, Levine of a population-based breast cancer screening program for MN. Positron emission tomography/computed tomography high risk women in Ontario. The Ontario Breast Screening (PET/CT) for the diagnosis of recurrentcancer (PETREC): a Program (OBSP) High Risk Program. Presented at the 4th multicenter, prospective cohort study. J Clin Oncol. Poster International Symposium on hereditary breast and ovarian Presentation, Abstract 23, 2012 June. cancer. BRCA: From Theory to Practice. Montreal, April 2012.
17. Chan LSA, Shapiro R, Buckstein R, Lin Y, Callum J, Chodirker 24. Emmenegger U, Ko YJ, Berry S. Temsirolimus (TEM) L, Lee CD, Lam A, Mamedov A, Wells RA. Initial transfusion maintenance therapy after response of castration-resistant rate predicts survival in MDS. Blood. 118 (21), November prostate cancer (CRPC) to docetaxel (TAX). Journal of Clinical 2011, ASH Annual Meeting. Oncology (ASCO Annual Meeting). ePub: e15177. 2012 June.
18. Chapman JA, Yerushalmi R, Goss P, Pollak M, Bramwell 25. Enright, K. A., M. Trudeau, L. Yun, E. Grunfeld, and M. VH, Levine MN, Pritchard KI, Whelan T, Ingle JN, Parulekar Krzyzanowska. A Population Level Assessment of Emergency W, Shepherd LE, Gelmon K. Differences in efficacy by Room Visits and Hospitalizations for Women Undergoing assessment method: NCIC CTG Adjuvant Breast Cancer Adjuvant Chemotherapy for Early Breast Cancer. San Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis. Antonio Meeting Abstracts, 2011. Cancer Res; 71(24 Suppl.) Poster Presentation at SABCS 2011, P5-14-01. December 15, 2011: Abstract P5-18-02, page 423s. Poster Presentation. 19. Chapman J-AW, Shepherd LE, Le Maitre A, Pritchard KI, Graham BC, Gelmon KA, Bramwell VH. Effect of Treatment 26. Esplen MJ, Wong J, Warner E, Toner B, Taylor N. Predictors Emergent Symptoms on Relapse Free Survival: NCIC CTG of body image aspects of quality of life and psychosocial MA.12 a Randomized Placebo-Controlled Trial of Tamoxifen adjustment in women post breast cancer surgery. Presented after Adjuvant Chemotherapy in Pre-Menopausal Women at the International Psycho-oncology Society Meeting. Turkey. in Early Breast Cancer. Cancer Research. Vol 71: Poster October 2011. Presentation at SABCS 2011, P1-06-08. 27. Esplen MJ, Wong J, Warner E, Toner B, Taylor N. Body image and psychosocial functioning in women with breast cancer: can we fix what we’ve broken? A group program being tested in a randomized trial. Presented at the International Psycho-oncology Society Meeting. Turkey. October 2011.
93 28. Gibson J, Peacock S, Cleghorn M, Maunula L, Berry S, 36. Hilton JF, Dong B, Bouganim N, Chapman J-AW, Arnaout Hoch J. Social media and cancer drug funding: implications A, O’Malley F, Nielsen T, Gelmon K, Yerushalmi R, Levine M, for research and policy. The Canadian Centre for Applied Bramwell V, Whelan T, Pritchard KI, Shepherd L, Clemons Research in Cancer Control (ARCC) Conference. May 2012. M. Simply Adding Together the Diameters of Tumor Foci in Patients with Multicentric or Multifocal Disease Does Not 29. Gnant M, Baselga J, Rugo HS, Shinzaburo N, Pritchard KI, Burris III HA, Piccart M, Hart LL, Eakle JF, Mukai H, Iwata Add Any Additional Prognostic Information: An Analysis from H, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl NCIC CTG MA.12 Randomized Placebo-Controlled Trial of DE, Hortobagyi GN. Effects of everolimus (EVE) on disease Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal progressionin bone and bone markers (BM) in patients with Women with Early Breast Cancer. Cancer Research. Vol 71: bone metastases. J Clin Oncol. 2012 June; 30: Abstract Poster Presentation at SABCS 2011, P2-12-27. #100783. 37. Hortobagyi GN, Piccart M, Rugo H, Burris H, Campone M, Noguchi S, Gnant M, Vittori L, Mukhopadhyay 30. Gore ME, Porta C, Bracarda S, Crinò L, Hawkins R, Bjarnason Pritchard KI, P, Sahmoud T, Lebwohl D, Baselga J. Everolimus for GA, Oudard S, Lee SH, Kim TM, Yuan J, Fly K, Szczylik C. 118. Updated Safety and Efficacy Results for Sunitinib Postmenopausal Women with Advanced Breast Cancer: from a Global, Expanded-access Trial in Metastatic Renal Updated Results of the BOLERO-2 Phase III Trial. Cancer Cell Carcinoma. ESMO/ECCO Stockholm 2011. (Poster). Research. 2011, Vol 71: Abstract S3-7. 31. Goss P, Smith I, O’Shaugnessy J, Ejlertsen B, Kaufmann M, 38. Innominato PF, Giacchetti S, Smaaland R, Focan CNJ, Garufi Boyle F, Buzdar A, Fumoleau P, Gradishar W, Martin M, Moy C, Bjarnason GA, Iacobelli S, Tumolov S, Karaboue A, Levi F. Chemotherapy-induced neutropenia (neutro association B, Piccart-Gebhart M, Pritchard KI, Aktan G, Rappold E, Williams L, Finkelstein D. Results of a Randomized, Double- with survival in metastatic colorectal cancer (MCC): Schedule- Blind, Multicenter, Placebo-Controlled Study of Adjuvant dependency. ASCO. 2011 Lapatinib in Women with Early-Stage ErbB2-Overexpressing 39. Karen A. Moffat, Rita Selby, Michael Keeney, Anne Raby. Breast Cancer. Cancer Research. 2011, Vol 71: Abstract S4-7. International Normalized Ratio – Is there standardization of reporting for the Prothrombin Time in the Province of Ontario? 32. Graham T, Eisen A, Richter S, Haroun I, Warner E. Variants of uncertain significance in BRCA Testing: Impact on risk A retrospective analysis of performance. International Society perception, worry, prevention and counseling. Presented of Laboratory Hematology. May 2012. at the annual meeting of the American Society of Clinical 40. Kochenderfer J, Dudley M, Feldman S, Wilson W, Spaner Oncology, June 2012. D, Devillier L, Carpenter R, Nathan D, Maric I, Morgan R and Rosenberg SA. B-Cell Depletion, Remissions of Malignancy, 33. Hebbard P, Baxter N, Yun L, Rakovitch E, Wright F, Warner E, McCready D, Hodgson N, Quan M. The effect of surgery on and Cytokine-Associated Toxicity in a Clinical Trial of T Cells recurrence and survival of young women with breast cancer. Genetically-Engineered to Express An Anti-CD19 Chimeric Presented at the Canadian Society of Surgical Oncology Antigen Receptor. Blood. (ASH Annual Meeting Abstracts), conference. Toronto. April 2012. Nov 2011; 118: 167. 34. Hertel PB, Tu D, Ejlertsen B, Jensen M-B, Balslev E, Jiang S, 41. Lathia N, Isogai PK, Hoch JS, DeAngelis C, Cheung MC, Walker S, Mittmann N. Deriving health utility values from O’Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO. TIMP-1 in Combination with HER2 and TOP2A a health-related quality of life instrument in non-Hodgkin for Prediction of Benefit from Adjuvant Anthracyclines in lymphoma patients. Blood (ASH Annual Meeting Abstracts) High Risk Breast Cancer Patients. Cancer Research. Vol 71: Nov 2011; 118: 2065. Poster Presentation at SABCS 2011, P1-06-07. 42. Lee Mozessohn, Matthew Cheung, Michael Crump, Rena John 35. Hill KA, Nadler T, Mandel R, Burlein-Hall S, Librach C, Buckstein, Neil L. Berinstein, Kevin R. Imrie, Kuruvilla, and Vishal Kukreti. Rituximab Warner E. The experiene of young women diagnosed with Eugenia Piliotis breast cancer who undergo fertility preservation consultation. resistant follicular lymphoma: Predictors of Rituximab Presented at the 2011 Breast Cancer Symposium of ASCO. resistance, incidence of transformation and prognosis. Blood San Francisco, Sept 2011. (ASH Annual Meeting Abstracts). 2011 118: Abstract 4981 Lymphoma - Therapy with biologic agents, excluding pre clinical model.
94 43. Liedke P, Tu D, Pritchard KI, Shepherd LE, Chavarri-Guerra 50. Mittmann N, Cheung M, Isogai PK, Saskin R, Liu N, Hoch Y. Vasomotor (VM) and musculoskeletal (MSK) symptoms JS, Leighl N, Trudeau ME, Evans WK, Dainty KN, Earle and association with outcomes on extended adjuvant CC. Population-based health care cost estimates related to letrozole therapy: Analyses from NCIC CTG MA.17. J Clin non-Hodgkin lymphoma (NHL). Blood (ASH Annual Meeting Oncol Proceedings. 2012 June; 30: Poster Presentation, Abstracts) Nov 2011;118:Abstract 2068. Abstract 524. 51. Mozessohn L, Cheung M, Crump M, Buckstein R, Berinstein 44. Ligibel JA, Segal R, Pond G, Dion M-J, Pritchard KI, Levine NL, Imrie KR, Kuruvilla J, Piliotis E, Kukreti V. Rituximab M, Goodwin PJ. Impact of the Lifestyle Intervention Study resistant follicular lymphoma: predictors of rituximab resistance, in Adjuvant Treatment of Early Breast Cancer (LISA) Weight incidence of transformation and prognosis. Blood (ASH Loss Intervention upon Physical Activity. Cancer Research. Annual Meeting Abstracts) Nov 2011;118:Abstract 4981. Vol 71: Poster Presentation at SABCS 2011, P4-12-05. 52. Nancy M Pennell, Matthew Cheung, Lisa K. Hicks, Eugenia 45. M. E. Trudeau, L. B. Pritzker, A. M. Parissenti, X. Wang, M. Piliotis, Kevin R. Imrie, Rena Buckstein, Cindy Davidson, Zhu, B. Guo, L.E. Shepherd, J-A. W. Chapman and K.P.H. Mary-Anne Cussen, Zeina Ghorab, Alden Chesney, Neil L. Pritzker. A Novel RNA Test to Guide Primary Systemic Breast Berinstein. First evidence for high incidence of complete Cancer Chemotherapy. IMPAKT Breast Cancer Conference, and sustained molecular remissions and maintenance of Brussels, Belgium, 3-5 May, 2012. Poster Walk (Friday, May immune responses in patients receiving consolidation with 4, 2012). Y90 Ibritumomab Tiuxetan (90Y-RIT) post R-CHOP for newly diagnosed advanced stage high and intermediate risk follicular 46. Martin D, Bahr T, Chi Ming C, Kennedy M, Imrie K, Lalani A, Leung F, Loukes K, Ravitz P, Shapiro H, Glover takahashi lymphoma. Blood (ASH Annual Meeting Abstracts). 2011 118: Abstract 2701 6:24 Lymphoma - Therapy with biologic S. “Easier read than done”: Residents learning CanMEDs communication competencies through a curriculum web agents, excluding pre clinical models: Poster II. initiative. COLLEGE OF PHYSICIANS AND SURGEONS 53. Noguchi S, Masuda N, Ito Y, Mukai H, Horiguchi J, Tokuda OF CANADA, R. International Conference on Residency Y, Kuroi K, Iwase H, Inaji H, Ohsumi S, Piccart M, Hortobagyi Education 2011: Transitions in residency education. Open GN, Rugo HS, Gnant M, Campone M, Sahmoud T, Pritchard Medicine, North America, 5, sep. 2011. Available at: http:// KI, Burris III HA, Baselga J. BOLERO-2: Everolimus with www.openmedicine.ca/article/view/504/423. exemestane versus exemestane alone in Asian patients with 47. Massimo Cristofanilli, Stephen R. D. Johnston, Alexey HER2-negative, hormone-receptor positive breast cancer. Manikhas, Henry Leonidas Gomez, Oleg Gladkov, Zhimin J Clin Oncol. 2012 June; 30: Abstract. Shao, Sufia Safina, Stephen D. Rubin, Sulabha Ranganathan, 54. Pennell N, Cheung M, Hicks L, Piliotis E, Imrie K, Buckstein Suman Lata, Maureen E. Trudeau. A randomized phase R. Davidson C, Cussen, M-A, Ghorab Z, Chesney A, II study (VEG108838) of lapatanib plus pazopanib (L+P) Berinstein N. First evidence for high incidence of complete versus lapatanib (L) in patients with ErbB2+ inflammatory and sustained molecular remissions and maintenance of breast cancer (IBC). J Clin Oncol 30, 2012 (suppl; abstr immune responses in patients receiving consolidation with 531). Poster Discussion. Y 90 Ibritumomab Tiuxetan (90Y-RIT) post R-CHOP for newly diagnosed advanced stage high and intermediate 48. Maureen E. Trudeau, Yvonne Bombard, Linda Rozmovits, Natasha B. Leighl, Ken Deal, Deborah Marsha. The value of risk follicular lymphoma. Blood. 118 (21), December 2011, personalizing medicine: Medical oncologists’ and patients’ ASH Annual Meeting. perspectives on genomic testing of breast tumors in 55. Piccart M, Noguchi S, Pritchard KI, Burris III HA, Rugo HS, chemotherapy treatment decisions. J Clin Oncol 30, 2012 Gnant M, Hortobagyi GN, Melichar B, Petrakova K, Arena (suppl; abstr e11000). FP, Xu C, Cahana A, Taran T, Sahmoud T, Lebwohl DE, Campone M, Baselga J. Everolimus for postmenopausal 49. Meschino WS, Eisen A, Carroll J, Chiarelli A, Plewes D, women with advanced breast cancer: Updated results of Rabeneck L, Shumak R, Warner E. The OBSP High Risk Program: An integrated care model for women at high-risk the BOLERO-2 phase III trial. J Clin Oncol. 2012 June; 30: for breast cancer. Presented at the American College of Abstract #101092. Medical Genetics Meeting, North Carolina, March 2012.
95 56. Pritchard KI, Burris III HA, Rugo HS, Gnant M, Baselga J, 63. T. Di Valentin, Y. Alam, A. Ali Alsharm, S. Arif, F. Aubin, J. Biagi, Piccart M, Noguchi S, Dakhil S, Srimuninnimit V, Puttawibul P, C.M. Booth, S. Bourque, r. Burkes, P, Champion, B. Colwell, Osborne K, Mukhopadhyay P, Taran T, Sahmoud T, Campone C. Cripps, M. Dallaire, M. Dorreen, N. Finn, D. Freschette, S. M, Hortobagyi GN. Safety of everolimus for women over 65 Gallinger, J. Gapski, C. Giacomantonio, S. Gill, R. Goel, R. years of age with advanced breast cancer (BC): 12.5-mo Goodwin, L. Grimard, A. Grothey, N. Hammad, D. Hedley, follow-up of BOLERO-2. J Clin Oncol. 2012 June; 30: Poster K. Jhaveri, D. Jonker, Y. Ko, M. L Esperance, J. Maroun, #3B, Abstract 551. H. Ostic, N. Perrin, M. Rother, E. St-Hilaire, M. Tehfe, M. Thirlwell, S. Welch, N. Yarom, T. Asmis. Eastern Canadian 57. Richter S, Haroun I, Eisen A, Warner E. Variants of uncertain significance in BRCA testing: Cancer risk perception, worry Colorectal Cancer concensus conference: application of and preventive behaviours of patients and impact on genetic new modalities of staging and treatment of gastrointestinal counseling. Presented at the NYU Hereditary Breast and cancers. Current Oncology. 2012 June; Vol 19 pp 169-174. Ovarian Cancer Conference. New York City, Sept 2011. Tam V, Berry S, Hsu T, North S, Neville A, Chan K, Verma S. Oncology Education in Canadian Undergraduate and 58. Riesco-Martinez MC, Berry SR, Ko YJ, Chan K. Optimizing Postgraduate Medical Programs: A survey of educators the sequence of biological agents in advanced colorectal and learners. Canadian Association of Medical Oncologists cancer: A decision analysis. Journal of Clinical Oncology. 2012 Annual Meeting 2012.Tam V, Berry S, Hsu T, North S, Neville ASCO Annual Meeting Proceedings (Post-Meeting Edition). A, Chan K, Verma S. Oncology Education in Canadian Vol 30, No 15_suppl (May 20 Supplement), 2012: e14171. Undergraduate and Postgraduate Medical Programs: A survey 59. Rita Selby, Nicole Mittmann, Pierre K Isogai, Lisa Kaus4, of educators and learners. Journal of Clinical Oncology. 2012 Marika Koo, Faith Sealey. Long-Term Oral Anticoagulant ASCO Annual Meeting Proceedings (Post-Meeting Edition). Management Associated with Routine Medical Care (RMC) Vol 30, No 15 suppl (May 20 Supplement), 2012: e16558. In Patients with Non-Valvular Atrial Fibrillation (NVAF) In 64. Tam VC, Ko YJ, Mittmann N, Kinshuk K, Hassan S, Cheung Canada. Blood. 2011;118(21): abstract # 4192. M, Chan K. Cost-effectiveness of systemic therapies for 60. Sousa BA, Nasim S, Cole D, ong B, Hill K, Vanderberghe H, metastatic pancreatic cancer. ASCO. 2011 Ueng S, Romaschin A, Warner E. First results from a study 65. White NMA, Khella HWZ, Bjarnason GA, Jewett MAS, Yousef analyzing CYP2D6 genotypes and tamoxifen metabolites GM. miRIMA Profiling in Metastatic Renal Cell Carcinoma in a Canadian population with endocrine responsive breast Reveals a Tumour Suppressor Effect for miR-215. The cancer. Presented at the 2011 European Multidiciplinary Canadian Cancer Research Conference, Toronto, Nov 27-30 Cancer Congress. Stockolm, Sept 2011. 2011. Poster presentation. 61. Sousa BA, Nasim S, Cole DE, Wong BY, Hill K, Pritchard 66. Wolpin BM, Hidalgo M, Ko YJ, O’Reilly E, Chan C, Rocha KI, Trudeau M, Verma S, Dent RA, Petrella T, Gandhi Lima C, Hartford A, Jackson L, Reyno L. Global, multicenter, S, Ueng S, Vandenberghe U, Romaschin A, Warner E. open-label, randomized phase II trial comparing gemcitabine Effects of CYP2D6 Phenotype and Drug Adherence on (G) vs. G plus AGS-1C4D4 (A) in patients (pts) with metastatic Tamoxifen Metabolite Levels. Cancer Research. Vol 71: pancreatic cancer (mPC). ASCO. Chicago, Illinois. 2011. Poster Presentation at SABCS 2011, P4-01-04.
62. Szumacher E, Pignol JP, Pritchard KI. Development of a Book Chapters Patient Decision Aid for Women 70 Years and Older with 1. Chan E, Emmenegger U. Bisphosphonates for bone Stage I, Hormonally Sensitive, Breast Cancer Considering metastases. Future Medicine e-Book Series, Advances in Adjuvant Treatment Post-Lumpectomy. Cancer Research. Bone Metastasis Management. 66-79 (2012). Vol 71: Poster Presentation at SABCS 2011, P5-15-03. 2. Cukier M, Gillis A, Rowsell C, Singh S, Law C. Neuroendocrine Tumours (GastroEnterPancreatic). Surgical Oncology Manual - 1st Edition. Division of General Surgery and General Surgical Oncology Fellowship Program. Apr 2012.
96 Editorials as part of the 2011 International Conference on Residency Education, September 23, 2011, Quebec City, Que. Available 1. It takes a village. Journal of Clinical Oncology. Earle CC. at http://icre2011.files.wordpress.com/2011/11/duty-hours- 2012; 30(4):353-4. Epub 2011 Dec 27. symposium-report.pdf. 2. Kelly C, Pritchard KI. Editorial on Rae and Price, A BIG-ATAC on CYP2D6; or is it? J Nat Cancer Inst. 2012 Apr, 104: 1-2. 4. Latest Advances in Pancreatic Neuroendocrine Cancer. Hot Spot, Quarterly Newsletter of the Rapid Radiation Response 3. Kelly CM, Pritchard KI. Personalized medicine: What exactly is it and can we truly measure it? J Clin Oncol. 10.1200/ Program. Aug 2011. JCO.2011.38.5740 (e-pub ahead of press), 2012.
4. Pritchard KI, Sousa B. Long term follow-up of women in Honours and Awards trials of adjuvant therapy for breast cancer: Is it still important? On the article entitled: Long-term benefits of five years of International tamoxifen: 10 year follow up of a large randomized trial in Distinctions and Research Awards women aged at least 50 years with early breast cancer, by Allan Hackshaw, et al J Clin Oncol. 29: 1651-1652. 2011 Nov. Received
5. Pritchard KI. Invited Podcast: “Trastuzumab in the Adjuvant 1. Trudeau, Maureen. Best Paper Award, Journal of Oncology Setting - Sequential versus Concurrent” on paper “Will We Pharmacy Practice. (Best Paper Award). December 2011. Ever Know the Full Answer? Sequential versus concurrent Key components of intravenous chemotherapy labeling: trastuzumab in adjuvant chemotherapy for breast cancer” a systematic review and practice guideline, Journal of by Edith A. Perez, et al. J Clin Oncol. 2012 Mar. Oncology Practice, Volume 17, December 2011. 6. Pritchard, KI. Personalized Therapy for Breast Cancer: Is it 2. Pritchard, Kathleen. 2011 Fellow of the American really happening? on paper “Adoption of Gene Expression Society of Oncology, American Society of Clinical Profile Testing and Association with Use of Chemotherapy Oncology (ASCO). (Distinction, Specialty: Oncology). 2011. among Women with Breast Cancer” by Michael J. Hassett, The Awards recognizes the extraordinary dedication of et al. J Clin Oncol. 2012. Invited Podcast. ASCO members for their voluntary efforts that benefit the Society, the specialty of oncology, and, most importantly, Letters to Editor the patients whom we serve. It is also meant to encourage 1. Chan KK & Tomlinson G. Risk of Mortality in patients with more members to become inv. cancer who experience febrile neutropenia. Cancer. 2011 3. Pritchard, Kathleen. Nobel Conference on Breast Nov, Vol. 117, Issue 22. p.5245. doi: 10.1002/cncr.26141. Cancer, Distinguished Speaker, Karolinska Institutet, Stockholm, Sweden. (Distinction). June 2012. Other Endocrine therapy-first generation of targeted drugs but have we reached a dead end? 1. Eisen A, Carroll J, Chiarelli A, Heale E, Horgan M, Meschino W, Plewes D, Rabeneck L, Shumak K, Warner E. Implementation National of a population-based breast cancer screening program for high risk women in Ontario. Presented at the 4th International Distinctions and Research Awards Symposium on Hereditary Breast and Ovarian Cancer. BRCA Received from Theory to Practice. Montreal, QC, April 2012. 1. Emmenegger, Urban. Prostate Cancer Canada Clinician-Scientist Award, Prostate Cancer Canada, 2. Imrie K, Weston W, Kennedy M. Generalism in Postgraduate Canada. (Research Award). July 2010 – June 2012. Medical Education. -Members of the FMEC PG consortium; 2011. http://www.afmc.ca/pdf/fmec/02_Imrie_Generalism. Total Amount: $300,000.00 CAD. pdf. 2011. 2. Spaner, David. Governor General’s Award, Principle investigator, Leukemia and Lymphoma Society of 3. Imrie, K, Maniatis T, Park A, Reed D and Moss F. Duty Canada. (Research Award). May 2012 – July 2012. hours: Solutions Across Borders. Symposium Report. Held top ranked grant in 2011 competition.
97 Local 5. Verma, Sunil. Medical Oncology Training Program (MOTP) Division Day, Faculty of Medicine, University of Toronto. June 2012. Distinctions and Research Awards 3rd Prize - Research Supervisor: Awarded to Raman Tatla Received for project titled “A Review of Phase III Clinical Trials in Metastatic Breast Cancer: Clinical Endpoints and Quality 1. Trudeau, Maureen. Mentorship Recognition, Women of Life”. Division of Medical Oncology Retreat. in Cancer (WinC). (Mentorship Recognition). April 2012. 6. Senior Investigator Award, Faculty of Medicine, Successful Mentor of April. Earle, Craig. Sunnybrook Health Sciences Centre. (Research Award). 2011. 2. Emmenegger, Urban. 2012 Research Summer Student Award, Sunnybrook Research Institute, Sunnybrook Health Sciences 7. Warner, Ellen. U of T Division of Medical Oncology Investigator Centre. (Research Award). Student Name: Darren Yau. April 2012. Award, Faculty of Medicine, University of Toronto. (Research Award). June 2012. Total Amount: $1,600.00 CAD.
Teaching Awards Teaching Awards Received Received Outstanding Teaching Award, Dept of Medicine, 1. Cheng, Susanna Yee-Shan. 2011 Department of Medicine 1. Verma, Sunil. - Ambulatory Teaching Award, Dept of Medicine, Faculty of Faculty of Medicine, University of Toronto, Division of Medical Medicine, Sunnybrook Health Sciences Centre / University Oncology. 2011. of Toronto, Toronto, Ontario, Canada. (Multilevel Education). July 2011 – June 2012.
2. Ko, Yoo-Joung. Peters-Boyd Academy Teaching Award for MMMD Teaching, No Division, Dept of Medicine, Faculty of Medicine, Peters-Boyd Academy. (Undergraduate MD, Year 2). July 2011 – June 2012.
3. Trudeau, Maureen. 25 Year Service Award, Faculty of Medicine, University of Toronto. May 2012.
Unspecified Scope
Distinctions and Research Awards Received
1. Pritchard, Kathleen. Listed Member, Best Doctors in America. 1991 – present.
2. Pritchard, Kathleen. Senior Scientist, Sunnybrook Research Institute. 2003 – present.
3. Verma, Sunil. ASCO Breast Symposium Merit Award, ASCO. 2011. Research Supervisor: Awarded to Dr. Urszula Zurawska. 4. Verma, Sunil. Best Summer Research Project Poster, Faculty of Medicine, University of Toronto. August 2011. Research Supervisor: Awarded to Raman Tatla for project titled “A Review of Phase III Clinical Trials in Metastatic Breast Cancer: Clinical Endpoints and Quality of Life”.
98 DIVISION OF NEPHROLOGY
Number of Faculty: 6
Grants Number Amount Peer Reviewed Funding Principal Investigator: 1 $5,400 CAD Co-Principal Investigator: 1 $57,823 CAD Co-Investigator / Collaborator: 10 $917,275 CAD Other: 0 $0 CAD 1 $2,032,258 USD Total: 12 $980,498 CAD $2,032,258 USD
Non Peer Reviewed Funding Total: 4 $981,482 CAD 2 $990,000 USD
Publications Number Peer Reviewed Publications Principal Author 9 Co-Principal Author 2 Senior Responsible Author 4 Collaborator / Co-Author 23 Other Role 0 Total 38
Honours and Awards Received International: 2 National: 1 Provincial: 1 Local: 4 Total Honours and Awards: 8
99 Grants, Contracts and Clinical Trials 6. Hladunewich, Michelle Adrienne. The Role of Single Nucleotide Polymorphisms of Iron Regulatory Genes in Peer Reviewed Funding Chronic Kidney Disease and Cancer Treatment Induced Anemia Susceptibility and Response to Therapy. Battistella, Division Member is Principal Investigator Marisa: R. Samuel McLaughlin Foundation (The). Accelerator 1. Tanna, Gemini. The Nephrology CanMEDS OSCE: An Grant in Genomic Medicine. ($40,000 May 2012-Apr 2013 innovative examination designed to assess physician Prorated: $6,667) [Grant] competencies in non-medical expert roles. Department of 7. Hladunewich, Michelle Adrienne. University of Toronto Medicine Education Innovation Fund. ($5,850 June 2011- Hypertension in Pregnancy Program. Gandhi, Shital and June 2012 Prorated: $5,400) [Grant] Ray, Joel: University of Toronto, Department of Medicine. Strategic Planning Innovation Funds. ($57,823 July 2011- Other Peer Reviewed Funding June 2012) [Grant]
1. Hladunewich, Michelle Adrienne. Curcumin to Prevent 8. Oliver, Matthew J. Beta blockers, dialyzability and outcomes. Perioperative Complications after Elective Abdominal Aortic Weir, Matthew: Canadian Institute of Health Research (CIHR). Anuerysm Repair. Amit, Garg: Canadian Institutes for Health ($59,956 Mar 2011-Mar 2012 Prorated: $41,508) [Grant] Research (CIHR). Randomized Controlled Trials Program. 9. Tobe, Sheldon William. CURCUMIN to prevent perioperative ($320,853 July 2011-June 2013 Prorated: $160,427) [Grant] complications after elective abdominal aortic anuerysm repair. 2. Hladunewich, Michelle Adrienne. Rare Diseases Garg Amit: Canadian Institutes of Health Research (CIHR). Consortium for Minimal Change Disease (MCD), Focal & ($322,419 July 2011-June 2012) [Grant] Segmental Glomerulosclerosis (FSGS) and Membranous 10. Tobe, Sheldon William. First Nations Community-Based Glomerulosclerosis (MN) - NEPTUNE Study. Kretzler, Matthias: Chronic Disease System Improvement Strategy. Harris The National Institutes of Health Office of Rare Diseases, Stuart, Brian: Ministry of Health and Long-Term Care. The National Institutes of Diabetes, Digestive and Kidney Primary Health Care System Program (PHCS). ($11,990 Disease, NephCure Foundation and University of Michigan. Oct 2011-Oct 2011) [Grant] Rare Disease Clinical Research Consortia. ($10,500,000 USD July 2010-Aug 2015 Prorated: $2,032,258) [Grant] 11. Tobe, Sheldon William. First Nations Community-Based Chronic Disease System Improvement Strategy. Harris, 3. Hladunewich, Michelle Adrienne. STandard versus Stewart Brian: Canadian Institute of Health Research Accelerated initiation of Renal Replacement Therapy in Acute (CIHR). Planning Grants-PA: Community-based Primary Kidney Injury (STARRT-AKI). Wald, Ron: Canadian Institutes Healthcare. ($24,999 Oct 2011)[Grant] of Health Research (CIHR). Operating Grants. ($227,720 July 2011-June 2013 Prorated: $113,860) [Grant] 12. Tobe, Sheldon William. Heart Outcomes Prevention Evaluation (HOPE-3). Lonn ,Eva, Yusuf, Salim: Canadian 4. Hladunewich, Michelle Adrienne. The Accurate Measurement Institutes of Health Research (CIHR). $(4,565,353 Sept of Glomerular Filtration Rate in Patients with Kidney Disease. 2008-Jan 2013 Prorated: $118,033) [Grant] White, Christine: Canadian Institute of Health Research (CIHR). Operating Grants. ($346,118 Sept 2009-Aug 2012 Non Peer Reviewed Funding Prorated: $115,373) [Grant] 1. Hladunewich, Michelle Adrienne. A pilot study to determine 5. The Prevalence and Hladunewich, Michelle Adrienne. the dose and effectiveness of H.P. Acthar® Gel (Acthar) Predictors of Albuminuria in Women with Polycystic Ovary in treatment-resistant subjects with persistent proteinuria Syndrome (PCOS). Laredo, Sheila: Faculty of Medicine. and nephrotic syndrome due to idiopathic membranous Dean’s Fund. ($10,000 July 2007-June 2012 Prorated: nephropathy (iMN). Fervenza, Fernando: QUESTCOR $2,000) [Grant] Pharmaceuticals. ($780,000 USD July 2010-June 2012 Prorated: $390,000) [Clinical Trial]
100 2. Hladunewich, Michelle Adrienne. A Randomized Controlled 4. Campbell NR, Gilbert RE, Leiter LA, Larochelle P, Tobe SW, Trial of Rituximab Versus Cyclosporin in the Treatment of Chockalingam A, Ward R, Morris D, Tsuyuki RT, Harris SB. Idiopathic Membranous Nephropathy (MENTOR) Study. Hypertension in people with type 2 diabetes: Update on Fervenza, Fernando: Genentech Pharmaceuticals. ($6,000,000 pharmacologic management. Canadian Family Physicians. USD Jan 2012-Dec 2016 Prorated: $600,000) [Clinical Trial] 57(9):997-1002,e347-53, 2011 September.
3. Oliver, Matthew J. Comparison of data sources for identifying 5. Daskalopoulou SS,Khan NA, Quinn RR, Ruzicka M, McKay incident dialysis patients and their characteristics. Oliver, DW, Hackam DG, Tobe SW et al. The 2012 Canadian Matthew; Paterson, J Michael, Co-Investigators: Quinn Hypertension Education Program Recommendations for the RR, Garg AX, Jim SJ, Wald R: Ministry of Health and Long- management of hypertension: blood pressure measurement, term Care, Ontario, Canada. ($15,000 Apr 2011-Mar 2012 diagnosis, assessment of risk, and therapy. Canadian Journal Prorated: $11,250) [Grant] of Cardiology. 2012 May Volume 28, Issue 3, pgs.270-287.
4. Oliver, Matthew J. Peritoneal dialysis catheter placement, 6. Dillon JJ, Hladunewich MA, Haley WE, Reich HN, use and technique failure in Ontario. Perl, Jeff; Oliver Matthew: Cattran DC, Fervenza FC. Rituximab therapy for Type 1 MOHLTC/Ontario Renal Network. ($10,000 Apr 2012-Apr membranoproliferative glomerulonephritis. Clin Nephrol 2013 Prorated: $2,308) [Grant] 2012 Apr;77(4):290-5
5. Tobe, Sheldon William. ENDURE Study. Tobe SW: Servier 7. Goldman J, Fishbane S, Oliver MJ, Blaney M, Jacobs JR, and Canada Inc. ENDURE study. ($47,000 Jan 2010-Dec 2011 Begelman SM. Tenecteplase for the Improvement of Blood Prorated: $11,750) [Clinical Trial] Flow Rate in Dysfunctional Hemodialysis Catheters:TROPICS 3-4. Clinical Nephrology 2012 Jan. 6. Tobe, Sheldon William. Heart outcome prevention evaluation trial( HOPE-3). A large simple randomized trial of combined 8. Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek cholesterol modification and blood pressure lowering in middle N, Massat AE, Hunley TE, Hladunewich MA, Julian BA, aged people at average risk. Eva Lonn and Salim Yusuf: Fervenza FC, Cattran DC. Validation of the Oxford classification AstraZeneca. ($909,482 July 2009-June 2015 Prorated: of IgA nephropathy. Kidney Int 2011 Aug;80(3):310-7. $151,580) [Industrial Grant] 9. Hildebrand AM, Iansavichus AV, Lee CW, Haynes RB, Wilczynski NL, McKibbon KA, Hladunewich MA, Clark WF, Cattran Publications DC, Garg AX. Glomerular disease search filters for Pubmed, Ovid Medline, and Embase: A development and validation Peer Reviewed Publications study. BMC Med Inform Decis Mak 2012 Jun 6;12(1):49.
Journal Articles 10. Hladunewich MA, Kingdom J, Odutayo A, Burns K, Lai V, O’Brien T, Gandhi S, Zimpelmann J, Kiss A, Miller J, Cherney 1. Barbour SJ, Greenwald A, Djurdjev O, Levin A, Hladunewich D. Postpartum assessment of the renin angiotensin system Nachman PH, Hogan SL, Cattran DC, Reich HN. MA, in women with previous severe, early-onset preeclampsia. J Disease-specific risk of venous thromboembolic events is Clin Endocrinol Metab 2011 Nov;96(11):3517-24. increased in idiopathic glomerulonephritis. Kidney Int 2012 11. Hua D, Carter S, Bellerive J, Allu SO, Reid D, Trembley G Jan;81(2):190-5. Tobe SW et.al. Bridging the gap: Innovative knowledge 2. Campbell N, Young ER, Drouin D, Legowski B, Adams MA, translation and the Canadian Hypertension Education Farrell J, Kaczorowski J, Lewanczuk R, Moy Lum-Kwong M, Program. Canadian Journal of Cardiology. 2012 May Volume A Famework for Discussion on How to Improve Tobe SW. 28, Issue 3, pgs.258-261. Prevention , Management and Control of Hypertension in 12. Jain AK, Cuerden MS, McLeod I, Hemmelgarn BR, Akbari A, Canada. Canadian Journal of Cardiology. 2012 May Volume Tonelli M, Quinn RR, and Garg AX. Reporting of 28,Issue 3, pgs.262-269. Oliver MJ, the estimated glomerular filtration rate was associated with 3. Campbell NR, Cappucio FP, Unnecessary controversy Tobe SW. increased use of angiotensin-converting enzyme inhibitors regarding dietary sodium: a lot about a little. Canadian Journal and angiotensin-II receptor blockers in CKD. Kidney Int.81 of Cardiology. Volume 27, Issue 4, pg.404-406 2011 July. (12):1248-1253, Jun 2012
101 13. Kitchlu A, Clemens K, Hackam DG, Gomes T, Juurlink 22. Tobe SW, Stone JA, Brouwers M, Bhattacharrya O, Walker DN, Mamdani M, Manno M, Oliver MJ, Quinn RR, Suri RS, KM, Dawes M, Genest J Jr, Grover S, Gubitz G, Lau D, Wald R, Yan AT, Garg AX. Beta-blockers and Cardiovascular Pipe A, Selby P, Tremblay MS, Warburton DER,Ward R, Outcomes in Dialysis Patients: A Cohort Study in Ontario, Woo V, Leiter LA, Liu PP. Harmonization and integration of Canada. Nephrol.Dial.Transplant 27 (4):1591-1598, Sept 2012. cardiovascular disease prevention and treatment guidelines: The C-CHANGE Initiative. Canadian Medical Association 14. Lionaki S, Derebail VK, Hogan SL, Barbour S, Lee T, Journal. Volume 183, Issue 15, pages E1135-1150 2011 Hladunewich MA, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN. Venous September. thromboembolism in patients with membranous nephropathy. 23. Wald R, Quinn RR, Adhikari NK, Burns KE, Friedrich JO, Garg Clin J Am Soc Nephrol 2012 Jan;7(1):43-51. AX, Harel Z, Hladunewich MA, Luo J, Mamdani M, Perl J, 15. Lok CE, Moist L, Hemmelgarn BR, Tonelli M, Vazquez MA, Ray JG; University of Toronto Acute Kidney Injury Research Group. Risk of chronic dialysis and death following acute Dorval M, Oliver MJ, Donnelly S, Allon M, and Stanley K. Effect of fish oil supplementation on graft patency and kidney injury. Am J Med 2012 Jun;125(6):585-93. cardiovascular events among patients with new synthetic 24. Young KJ, Kim JJ, Yeung G, Sit C, Tobe SW. Physician arteriovenous hemodialysis grafts: a randomized controlled Preferences for Accredited Online Continuing Medical trial. JAMA 307 (17):1809-1816, Jun 2012. Education. Journal of Continuing Education in the Health 16. Mendelssohn D, Beaulieu M, Kiaii M, Jindal K, MacRae J, Professions. Volume 31, Issue 4:256-261 2011 October. Kappel J, Miller L, Lok C, Moist L, Donnelly S, Oliver M, Abstracts Chan C, Ethier J, Delziel C, McKinnon M, Soroka S, Hirsch K, Barrett B. Report of the Canadian Society of Nephrology 1. B Wong, P Ravani, B Manns. X Zhang, R Chin, B Hemmelgarn, Vascular Access Working Group. Seminars in Dialysis. Vol M Tonelli, MJ Oliver3, RR. Quinn. Patterns and Predictors of 25, No 1 (Jan–Feb) 2012 pp. 22–25. Blood Transfusion Among Hospitalized Hemodialysis Patients. Presented at Canadian Society of Nephrology Meeting on 17. Myers MG, Godwin M, Dawes M, Kiss A, Tobe SW, Kaczorowski April April 28th, 1012, St. John’s Newfoundland. J. Conventional versus automated measurement of blood pressure in the office (CAMBO) Trial. Family Practice. 2011 2. B Wong, P Ravani, B Manns. X Zhang, R Chin, B Hemmelgarn, November. M Tonelli, MJ Oliver3, RR. Quinn. Treatment of Anemia in Hospitalized Hemodialysis Patients. Presented at Canadian 18. Nathan Allen, Daniel Schwartz, Paul Komenda, Robert P Pauly, Society of Nephrology Meeting on April April 28th, 2012, St. Deborah Zimmerman, Gemini Tanna, Jeffery Schiff, Claudio John’s Newfoundland. Rigatto and Manish M Sood. International practice patterns and factors associated with non-conventional hemodialysis 3. Barbour S, Levin A, Cattran DC, Wald R, Kim J, Hladunewich utilization. BMC Nephrology 2011 Dec 5; 12:66. MA, Reich H. Asians with IgA nephropathy have an increased risk of progression to ESRD. CSN 2012. 19. Nevis IF, Reitsma A, Dominic A, McDonald S, Thabane L, Akl EA, Hladunewich MA, Akbari A, Joseph G, Sia W, 4. Battistella M, Ho G, Leblanc K, Huh J, Ng J, Selby R, Richardson Iansavichus AV, Garg AX. Pregnancy outcomes in women R, Brien B, Hladunewich MA. Use of Fondparinux in severe with chronic kidney disease: A systematic review. Clin J Am renal impairment and hemodialysis. NKF 2012. Soc Nephrol. 2011 Nov;6(11):2587-98. 5. Clark EG, Barton J, Bouchard J, Friedrich JO, Hladunewich 20. Oliver MJ, Quinn RR, Garg AX, Kim SK, Wald R, Paterson MA, James MT, Lafrance JP, Levin A, Moist L, Pannu N, JM. Likelihood of starting dialysis after incident fistula creation Stollery DE, Wald R, Walsh M, Bagshaw SM. A prospective Clinical Journal of the American Society of Nephrology. Feb multi-centre evaluation of the timing of renal replacement 2012. ePub ahead of print. therapy for acute kidney injury in critically ill patients in Canada. ASN 2011. 21. Tobe SW, Brian Baker, Katie Hunter, Alex Kiss, Nancy Perkins, Lissette Gomez, Yu Feng, Karen Wigg, Cathy L. Barr. 6. Hladunewich MA, Fervenza F, Reich H, Cattran DC. A The impact of andothelin-1 genetic analysis and job strain pilot study to determine the dose and effectiveness of on ambulatory blood pressure. Journal of Psychosomatic H.P. Acthar® Gel (Acthar) in treatment-resistant subjects Research. Volume 71, Issue 2, pgs.97-101 2011, August. with persistent proteinuria and nephrotic syndrome due to idiopathic membranous nephropathy (iMN). CSN 2012.
102 7. Mahoney SL, Derebail VK, Biddle A, Yichun H, Hladunewich 2. Hladunewich, Michelle Adrienne. Fellow, American Society MA, Falk RJ, Cattran D, Reich H, Nachman PH. Factors of Nephrology, United States. (Distinction). 2005 – present. influencing treatment choice in Idiopathic Membranous Nephropathy. ASN 2011. National
8. Nevis I, Hladunewich MA, Garg A, Sia W, Joseph G, Reistsma Student / Trainee Awards A, Iansavitchous A, Akle E, McDonald S, Thabane L, Akbari Received A, Darumoz. Risk of adverse maternal and fetal outcomes in women with chronic kidney disease: A systematic review 1. Naimark, David. Top trainee abstract, Principle and meta-anaylsis. WCN 2011. supervisor, Canadian Society of Nephrology, Newfoundland and Labrador, Canada. Specialty: 9. Odutayo A, Litwin S, Richardson B, Adhikari NA, Barton J, Nephrology. (Awardee Name: Maneesh Sud). April 2012. Friedrich JO, Garg A, Lapinsky S, Moineddin R, Hladunewich Maneesh Sud’s abstract was selected as one of the top MA, Wald R. The epidemiology of acute kidney injury in 8 of all submitted to the CSN Annual Scientific meeting Canadian Critical Care Units. ASN 2011. in St. John’s NFLD, April 26-29, 2012. At the meeting 10. Quinn RR, Ravani P, Zhang X, Garg AX, Blake PG, Verrelli M, his verbal presentation was awarded the top prize. Total Zacharais JM, Johnson JF, Pandeya S, Austin PC, Oliver Amount: $1,500.00 CAD. MJ. Peritoneal dialysis and hemodialysis are associated with similar rates of hospitalization among patients who Provincial/Regional are eligible for both therapies. Presented at the Canadian Society of Nephrology, 2012 Meeting on April 28th, 2012 Distinctions and Research Awards in St. John’s Newfoundland. Received
Letters to Editor 1. Hladunewich, Michelle Adrienne. Renal Professional’s Award, Kidney Foundation of Canada - Ontario Chapter, 1. David MJ Naimark. Warfarin related nephropathy. Kidney Toronto, Ontario, Canada. (Distinction). April 2012. International. 2012 Feb;81(3):322. doi: 10.1038/ki.2011.383. Annual award for patient care and advocacy. Other Local 1. Hladunewich MA, Hercz AE, Keunen J, Chan C, Pierratos A. Pregnancy in end stage kidney disease. Semin Dial. 2011 Student / Trainee Awards Nov;24(6):634-9. Recieved 2. Hladunewich MA, Schaefer F. Proteinuria in special 1. Naimark, David. 3rd place Gallie Bateman and McMurrich populations: Pregnant women and children. Adv Chronic Resident Research Competition, Co-supervisor, Faculty Kidney Dis. 2011 Jul;18(4):267-72. of Medicine, University of Toronto, Department of 3. Hladunewich MA. Pregnancy and the Kidney. Long-term Surgery, Ontario, Canada. Specialty: Urology. (Awardee consequences of placental disease. ASN Kidney News. Name: Nathan Perlis). May 2011 – May 2012. 2011 Jul;Vol.3, Number 7:12-13. Award for a decision analysis: “Role of radical cystectomy and radiation therapy in T2 muscle-invasive bladder cancer: Honours and Awards A decision analysis”. Total Amount: $500.00 CAD. International 2. Naimark, David. First place, resident research competition, Principle supervisor, Faculty of Medicine, Sunnybrook Distinctions and Research Awards Department of Medicine, Ontario, Canada. Specialty: Received Nephrology. (Awardee Name: Maneesh Sud). May 2012. A Competing Risk Model for Death & Progression to 1. Elected Membership, Hladunewich, Michelle Adrienne. End-Stage Renal Disease (ESRD) Among the Sunnybrook American Physiological Society, United States. (Distinction). Chronic Kidney Disease (CKD) Cohort. 2003 – present.
103 Teaching Awards 2. Tobe, Sheldon William. SEAC Education Beyond Received Sunnybrook, Nephrology, Dept of Medicine, Faculty of Medicine, Sunnybrook Education Action Committee. May 2012. 1. Continuing Education Tobe, Sheldon William. In recognition of contribution made by educating Family Teaching Award for 2011, Nephrology, Dept of Medicine, Physicians about Hypertension management through the Faculty of Medicine, Sunnybrook Health Sciences Canadian Hypertension Education Program TTT sessions. Centre-Department of Medicine. September 2011. In recognition of National Leadership in Hypertension Education including prominent position with CHEP.
104 DIVISION OF NEUROLOGY
Number of Faculty: 11
Grants Number Amount Peer Reviewed Funding Principal Investigator: 18 $1,259,534 CAD Co-Principal Investigator: 7 $659,339 CAD 2 $502,390 USD Co-Investigator / Collaborator: 36 $2,972,541 CAD 3 $1,971,196 USD Other: 23 $7,241,258 CAD Total: 84 $12,132,672 CAD 5 $2,473,586 USD
Non Peer Reviewed Funding Total: 33 $567,755 CAD 0 $0 USD
Publications Number Peer Reviewed Publications Principal Author 8 Co-Principal Author 3 Senior Responsible Author 18 Collaborator / Co-Author 40 Other Role 29 Total 98
Honours and Awards Received International: 2 National: 11 Provincial: 10 Local: 10 Total Honours and Awards 33
105 Grants, Contracts and Clinical Trials 7. Gladstone, David. 30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event Peer Reviewed Funding (EMBRACE): A Randomized Controlled Trial. [top-rated CSN stroke prevention grant]. Dorian P, Spring M, O’Donnell M, Division Member is Principal Investigator Mamdani M, Thorpe K, Laupacis A, Kapral M, Aviv R, Blakely 1. Black, Sandra E. A Phase 2 Multicenter, Randomized, Double J, Sharma M, Shuaib A: Canadian Stroke Network – National Blind, Placebo-Controlled Study of the Safety, Tolerability, Award. ($770,000 2008-2011 Prorated: $96,250) [Grant] and Pharmacokinetics of Multiple Doses of PF-04360365 in 8. Gladstone, David. Cardiac Monitoring for Stroke Prevention: Patients with Mild to Moderate Alzheimer’s Disease. Pfizer The EMBRACE Study Program. Dorian P, O’Donnell M, Canada Inc. ($390,192 May 2009-Sept 2011 Prorated: Spring M, Mamdani M, Thorpe K, Laupacis A, Kapral M, $30,237) [Clinical Trial] Aviv R, Blakely J, Cote R, Sharma M, Shuaib A: Canadian 2. Black, Sandra E. Development of the Toronto Dementia Stroke Network – National Award. ($952,718 2010-2013 Research Alliance (TDRA) Database and Creation of an Prorated: $238,180) [Grant] Integrated Discovery System in Neurodegenerative Disorders. 9. Gladstone, David. SPARTACUS: The Ontario Atrial Fibrillation Lang AE, Greenberg B, Tang-Wai D, Freedman M, Keren R, Stroke Prevention Registry. Swartz RH, on behalf of the Pollock B, Strothers S: University of Toronto. Department of UofT Stroke Program Investigators: Ontario Stroke System Medicine: Innovation Fund. ($75,000 Jan 2012- Dec 2012 / Ontario Ministry of Health and Long-Term Care. ($85,000 Prorated: $37,500) [Grant] 2010-2012 Prorated: $28,333) [Grant]
3. Black, Sandra E. Improving EMR uptake using a customizable 10. Masellis, Mario. Orthostatic Hypotension in Lewy Body tool integrated into workflow across the health care system Spectrum Disorders: Cognitive, Structural and Perfusion as a means to optimize knowledge exchange and patient Perspectives. The Consortium of Canadian Centres for Clinical education. Ween J, Saposnik G, Swartz R, Selchen D, Silver Cognitive Research (C5R). Research Grants Initiative Awards. F, Basile V: Sunnybrook Health Sciences Centre. Academic ($19,974 June 2012-May 2013 Prorated: $1,665) [Grant] Health Science Centres AFP Innovation Fund. $50,400 Feb 11. Masellis, Mario. Parkinson’s Related Dementia: A 2011- Feb 2013 Prorated: $24,192) [Grant] Pharmacogenomic Study of Cholinesterase Inhibitors 4. Black, Sandra E. In Vivo Brain Mapping in the Dementias: Investigating Cognitive Benefit, Motor Worsening, and Brain A Longitudinal Brain-Behaviour Study with A Focus on SPECT. Black SE, Freedman M, Tang-Wai D, Kennedy JL, Cerebrovascular Disease. Caldwell C, Gao F, Herrmann N, Chen R, Herrmann N, MacIntosh BJ, Kleiner-Fisman G, Lee Kiss A, Lanctôt K, Lobaugh N, Masellis M, McIlroy W, Rogaeva J, Lang AE: Parkinson’s Society of Canada, Garden Centre E, Stefanovic B, Stuss D, Swartz R: Canadian Institutes of Group Co-Op Corp. New Investigator Award. ($90,000 Sept Health Research (CIHR). ($1,411,055 Oct 2008-Sept 2013 2011-Aug 2013 Prorated: $37,500) [Grant] Prorated: $282,211) [Grant] 12. Masellis, Mario. The GENetic Frontotemporal Dementia 5. Black, Sandra E. Towards Functional Imaging Biomarkers Initiative (GENFI): A New Multi-Centre Platform for the Study of Alzheimer’s Disesase. Grady C, Schwindt G, Stefanovic of Frontotemporal Lobar Degeneration. Black SE, Chow T, B: Canadian Institutes of Health Research (CIHR). ($203,013 Freedman M, Keren R, Tang-Wai D, Tartaglia C: Centres of Oct 2010-Sept 2013 Prorated: $67,671) [Grant] Excellence in Neurodegeneration Initiative: Call for Proposals. 6. Gladstone, David. “Spot Sign” Selection of Intracerebral Canadian Institutes of Health Research (CIHR). International Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT): Collaborative Operating Grant. ($686,959 Oct 2011-Aug A Randomized Controlled Trial. Aviv R, Demchuk A, Hill 2013 Prorated: $39,960) [Grant] MD, Butcher K, Black S, Mamdani M, Thorpe K, Sahlas D, 13. Masellis, Mario. Transforming Dementia Care in Ontario: Spence J: Canadian Institutes of Health Research (CIHR) – Application of Genetic Testing to Treatment of Parkinson’s- National Award (operating grant). ($1,708,141 2010-2015 Related Dementia’s. Ministry of Economic Development and Prorated: $284,690) [Grant] Innovation (MEDI). ($150,000 May 2012-Apr 2017 Prorated: $5,000) [Grant]
106 14. Swartz, Richard H. Improving EMR uptake using a 4. Black, Sandra E. A Phase II, Randomized, Multicentre, customizable tool integrated into workflow across the health Double-Blind, Placebo-Controlled Trial Comparing rFVIIa care system as a means to optimize knowledge exchange to Placebo for Treatment of Subjects with Acute ICH and and patient education. University of Toronto. Division of Contrast Extravasation (the Spot Sign) Identified on CTA. Neurology - New Initiative Fund. ($30,000 July 2011-July Broderick JP and Gladstone D, Aviv R, Black S, Hopyan 2012 Prorated: $27,692) [Innovation Fund] J, John V, Lam B, Swartz R, Ween J: National Institutes of . ($6,749,831 USD May 2008-Apr 2013 15. Swartz, Richard H. Post-stroke triage “DOC”: simple Health (NIH) (USA) screening for Depression, Obstructive. Heart and Stroke Prorated: $1,349,966) [Grant] Foundation of Ontario (The) (HSFO) – Grant in Aid. ($143,598 5. Black, Sandra E. ADNI (Alzheimer’s Disease Neuroimaging June 2012-July 2014 Prorated: $5,523) [Grant] Initiative): ADNI-1, ADNI-Go and ADNI-2. Weiner M, Black SE (Site PI): ($48,999 16. Swartz, Richard H. The CLOQS trial: Countdown Lights to National Institutes of Health (NIH) (USA). Optimize Quality in acute Stroke. Sunnybrook Health Sciences Sept 2005-Aug 2017 Received: $48,999) [Grant] Centre. AFP Innovation Fund. ($84,500 Mar 2010-Feb 2012 6. Black, Sandra E. Apathy in Alzheimer’s Disease Prorated: $28,167) [Grant] Methylphenidate Trial (ADMET). Lanctôt KL, Mintzer JE, Rosenberg PB, Scherer RW (PI’s), Herrmann N, Black SE: 17. Zinman, Lorne H. Clinical Trial of Ceftriaxone in Subjects with Amyotrophic Lateral Sclerosis - Canadian Project National Institutes of Health (NIH) (USA). ($1,770,123 Sept Management. ALS Society of Canada. ($100,000 2009-2012 2009-Aug 2011 Prorated: $147,510) [Grant] Prorated: $25,000) [Grant] 7. Black, Sandra E. Association Between Genetic Markers of Inflammation and Rate of Cognitive Decline in Patients 18. Zinman, Lorne H. Formation of the Canadian ALS Clinical Trials Research Network. ALS Society of Canada. ($30,000 with Vascular Cognitive Impairment – A Pilot Study. Wong B, 2009-2011 Prorated: $5000) [Grant] Chan PC, Pettersen J, Black S: Practice-Based Research Award (Sunnybrook Health Sciences Centre). ($10,775 19. Zinman, Lorne H. Neural Mechanisms of Cognitive and Sept 2009-Aug 2011 Prorated: $898) [Grant] Bulbar Motor Decline in ALS. ALS Society of Canada. ($100,000 2009-2012 Prorated: $25,000) [Grant] 8. Black, Sandra E. Canadian Atherosclerosis Imaging Network (CAIN) - “Hearts and Minds”. Tardif J-C (Project Leader), Other Peer Reviewed Funding Moody A, Black S(site Co-PI), Rutt B, Spence JD, Fenster A, Frayne R, Freidrich M, Lespérance J, Chow B, Beanlands R: 1. Black, Sandra E. “Spot Sign” Selection of Intracerebral Canadian Institutes of Health Research (CIHR). ($1,400,000 Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT): A Apr 2008-Mar 2013 Prorated: $280,000) [Grant] Randomized Controlled Trial. Korngut L, Jette N, Pringsheim T, Black SE: Canadian Institutes of Health Research (CIHR). 9. Black, Sandra E. Canadian Stroke Registry. Kapral M and ($209,496 Oct 2011-Oct 2013 Prorated: $75,419) [Grant] Silver F (Project Leaders), Gladstone DJ (site PI) and Black SE (Co-I) at Sunnybrook. Canadian Stroke Registry: NCE 2. Black, Sandra E. “Spot Sign” Selection of Intracerebral Canadian Stroke Network. ($85,000 Apr 2001-Mar 2013 Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT): Prorated: $7,083) [Grant] A Randomized Controlled Trial. Gladstone DJ, Aviv R and Demchuk, Black S, Butcher K, Dowlatshahi D, Hill M, Mamdani 10. Black, Sandra E. Communication and Imaging Infrastructure M, Sahlas D, Spence J, Thorpe K: Canadian Institutes of for the Canadian Atherosclerosis Imaging Network (CAIN). Health Research (CIHR). ($1,708,140 Apr 2010-Mar 2015 Tardif J-C (Project Leader), Moody A, Black S (Site Co- Prorated: $341,628) [Grant] PI), Rutt B, Spence JD, Fenster A, Frayne R, Freidrich M, Lespérance J, Chow B, Beanlands R: Canada Foundation 3. Black, Sandra E. A Novel Ultrasound Phased Array and for Innovation (CFI). ($5,500,000 July 2009-June 2014 Sonication Method for Stroke Treatments. Hynynen K, Black Prorated: $26,000) [Grant] S, Chopra R, Goertz D, Stanisz G: National Institutes of Health (NIH) (USA). ($2,515,716 USD Sept 2008-Aug 2013 Prorated: $503,143) [Grant]
107 11. Black, Sandra E. Composite Behavioural Markers to Assess 18. Black, Sandra E. Improving Performance in Drivers with and Monitor Alzheimer’s Disease. Poupart P, Roy E, McIlroy Mild Cognitive Impairment: An RCT of Cognitive Training. W, Huissoon J, Zelek J, Black J, Dupuis S, Mann R, Black Naglie, Gary, Binns M, Black S, Bedard M, Dawson D, S(site PI), Rockwood K: Alzheimer’s Association. ($200,000 Fischer C, Freedman M, Herrmann N, Korner-Bitensky N, Nov 2008-Nov 2011 Prorated: $27,027) [Grant] Levine B, Schweizer T, Tang-Wai D: Canadian Institutes of . Operating Grant. ($562,765 Jan 12. Black, Sandra E. Context-Aware Mobile Devices and Health Research (CIHR) Wireless Services as Cognitive Aids for Senior Citizens. 2012-Jan 2017 Prorated: $55,354) [Grant] Baecker R, Black S: NSERC. ($214,260 Sept 2008-Aug 19. Black, Sandra E. Lipidomics of Neurodegenerative Disease: 2011 Prorated: $11,903) [Grant] A Systems Biology Approach to Integrative Research Training. , Figeys D (PI), Tandon A, Fraser PE, Baetz K, 13. Black, Sandra E. Diffuse Brain Damage Effects on Distributed Bennett S Systems: Multimodal Brain Imaging and Rehabilitation. Schlossmacher M, Slack RS, Park DS, Black S, Baenziger J, Couture JF, Messier C, Yao Z, Fai S, Arnason JT, Woulfe Levine B, Alain C, Black SE, Graham S, Gryfe P, McIntosh J, Lanctot KL, Bickel D: AR, O’Connor P, Stuss DT, Turner G, Ween J: Canadian Canadian Institutes of Health . ($1,789,998 June 2009-Mar 2015 Institutes of Health Research (CIHR). ($853,770 Oct 2009- Research Team Grant Sept 2014 Prorated: $170,754) [Grant] Prorated: $306,857) [Grant] 20. Medical Imaging Trial NEtwork of Canada 14. Black, Sandra E. FMRI Neurofeedback Applied to Motor Black, Sandra E. (MITNEC). , Black SE (Co-PI), Beanlands Imagery in Stroke. Graham SJ, Black SE, McIlroy WE, Staines Tardif, Jean Claude R, Benard F, Burrell SC, Evans AC, Rayne R, Friedrich MG, R, Boe S, Cassidy R: Heart and Stroke Foundation of Canada Lal C, Lee, TY, McEwan A, Pibarot PJ, Turcotte E, Valliant JF: (HSFC). ($120,784 2011-2013 Prorated: $40,261) [Grant] Canadian Institutes of Health Research (CIHR). Operating 15. Black, Sandra E. Heart and Stroke Foundation Centre for Grant. ($9,000,000 Jan 2011-Jan 2013 Received Amount: Stroke Recovery. Sandra Black (Site Director, SHSC), Hakim $0) [Grant] AM (Site Director, University of Ottawa), Levine B (Site Director, Baycrest), Mearow KM (Site Director, Memorial University). 21. Black, Sandra E. Neural Mechanisms of Cognitive and SHSC site principal investigators: McIlroy WE, Stefanovic Bulbar Motor Decline in ALS. Zinman L, Yunusova Y, Black B, Graham SJ, Gladstone DJ, Swartz RH, Mochizuki G, SE, Stuss DT, Stanisz G, Kiss A: ALS Society of Canada - Bernice Ramsay Discovery Grants Program. ($100,000 Feb Macintosh BJ: HSFO, University of Ottawa, Baycrest 2010-Jan 2012 Prorated: $29,167) [Grant] Centre for Geriatric Care, Sunnybrook Health Sciences Centre. ($40,000,000 2002-2012 Prorated: $2,500,000) 22. Black, Sandra E. Neuropsychological Profiles and [Centre of Excellence Funding] Neuroanatomic Correlates of Limb Apraxia. Roy EA & Black Dixon M, Danckert J, Park N, Adams S, Hebert D: 16. Black, Sandra E. Impact of music-supported rehabilitation SE, Heart on behavioural and cortical functions in stroke recovery. and Stroke Foundation of Canada (HSFC). ($404,725 July 2007-June 2012 Prorated: $80,945) [Grant] Fujioka, T, Dawson D, Black S, Ross B, Stuss D, Cohen E, Henri-Bhargava A, Lim-Lambie F: Canadian Institutes of 23. Black, Sandra E. Parkinson’s related dementia: A Health Research (CIHR). Operating Grant. ($461,247 Apr pharmacogenomics study of cholinesterase inhibitors 2012-Mar 2015 Prorated: $38,437) [Grant] investigating cognitive benefit, motor worsening and brain SPECT. , Black SE, Freedman M, Tang-Wai D, 17. Black, Sandra E. Impairment of Vascular Autoregulation in the Masellis, M Kennedy JL, Chen R, Hermann N, MacIntosh BJ, Kleiner- Cerebral White Matter Predicts Future Leukoariosis. Mikulis Fisman G, Lee J, Lang AE: . D & Black SE, Mikulis D, Black SE(Co-PI), Silver F, Aviv R, Parkinson Society Canada ($90,000 July 2011-June 2013 Prorated: $45,000) [Grant] Gladstone D, Da Costa L, Fisher J, Crawley A, Kassner A, Tomlinson G, Poublanc J: Canadian Stroke Network. 24. Black, Sandra E. Prediction of Hemorrhagic Transformation ($388,000 Apr 2010-Mar 2013 Prorated: $129,333) [Grant] of Ischemic Stroke with CT Perfusion Derived Blood-Brain- Barrier Permeability Surface Area Product. Lee T-Y, Aviv R, Black S, Gladstone D, Symons S: Heart and Stroke Foundation of Ontario. ($453,370 July 2009-June 2014 Prorated: $90,674) [Grant]
108 25. Black, Sandra E. The ‘Weight Times’ Strategy: A simple, 30. Black, Sandra E. Understanding the Epidemiology of low-cost intervention to improve safety in patients receiving Neurological Conditions and Building the Methodological thrombolysis for stroke. Swartz, Richard, Gladstone D, Foundation for Surveillance. Jetté N, Pringsheim T, de Robles Sahlas DJ, Ween JE, Jaigobin C, Silver FL, Casaubon L, P, Hamilton M, Korngut L, Maxwell C, Oskoui M, Zinman Hopyan J, Del Campo M, Mamdani M, Black SE, Selchen L, Zygun D, Black S, Gallagher C, Hogan D, Holroyd-Leduc DH, Saposnik G, Breaton J: Ontario Ministry of Health and J, Lorenzetti D, Marrie RA, Patten S, Steeves T, Svenson Long-Term Care. ($85,000 June 2010-Mar 2012 Prorated: L, Wiebe S, Wolfson C: Canadian Institutes of Health $34,773) [Grant] Research (CIHR). ($482,400 Sept 2010-Mar 2013 Prorated: $155,613) [Grant] 26. Black, Sandra E. The GENetic Frontotemporal Dementia Initiative (GENFI): a new multi-centre platform for the study 31. Black, Sandra E. Validation of the NINDS VCI of frontotemporal lobar degeneration. Masellis, Mario and Neuropsychological Protocols. Nyenhuis DL, Black SE Rossor, Martin, Frisoni G (site PI), Ayoubi T (site PI), Masellis (Co-PI), Pedelty LL, Beam C, Gao W, Zhou XJ, Stebbins M (site PI), Rohrer J, Warren J, Fox N, Ourselin S, Rowe GT, Stuss DT, Graham SJ, Lobaugh N, Gao FQ, Sahlas D: J, Nestor P, Pievani M, Ghidoni R, Borroni B, Galimberti D, National Institutes of Health (NIH) (USA). ($1,250,000 USD Scarpini E, Fenoglio C, Black SE, Chow T, Freedman M, Nov 2007-Oct 2011 Prorated: $104,167) [Grant] Tang-Wai D, Tartalia C, Keren R: Canadian Institutes of 32. Gladstone, David. Communication and Imaging Infrastructure Health Research (CIHR). Catalyst Grant. ($686,959 Oct for the Canadian Atherosclerosis Imaging Network (CAIN) 2010-Oct 2013 Prorated: $222,798) [Grant] – Magnetic resonance imaging characterization of carotid 27. Black, Sandra E. The Language Impairment In Progressive plaque and prediction of end-organ and clinical outcomes. Aphasia: A Longitudinal Neuropsychological And Imaging Tardif J-C, Moody A, Black S, Rutt B, Spence JD, Fenster Study. Rochon E & Black SE, Levine B, Leonard C, Freedman A, Frayne R, Freidrich M, Lespérance J, Chow B, Beanleands M, Chow T, Tang-Wai D, Graham N: Canadian Institutes of R: Canada Foundation for Innovation (new initiative fund) Health Research (CIHR). ($511,835 Apr 2007-Sept 2013 – National Award. ($21,638,735 2009-2014 Prorated: Prorated: $93,061) [Grant] $3,606,456) [Grant]
28. Black, Sandra E. The Neurotrophic Effects of Lithium 33. Gladstone, David. Effects of Cardiac Rehabilitation for Carbonate Following Stroke: A Feasibility Study. Heart and Individuals After Transient Ischemic Attack. McIlroy WE, Stroke Foundation of Ontario, Lanctot KL, Herrmann N (PI), Brooks D, Oh P, Black S, Ween J, Gladstone D: Heart and MacIntosh B, Gold A, Stefanovic B, Albert B, Swartz R, Stroke Foundation of Ontario – Provincial Award. ($80,000 Black SE, Tennen G, Gao F, Hopyan J: Heart and Stroke 2009-2011 Prorated: $13,333) [Grant] ($130,576 Mar 2011-June Foundation of Canada (HSFC). 34. Gladstone, David. Impairment of Vascular Autoregulation 2013 Prorated: $55,961) [Clinical Trial] in the Cerebral White Matter Predicts Future Leukoariosis. 29. Black, Sandra E. The Ontario Stroke Prevention Registry for Mikulis D, Black S, Silver F, Aviv R, Gladstone D, Da Costa Atrial Fibrillation. Gladstone, David, Swartz RH, Silver FL, L, Fisher J, Kassner A, Tomlinson G, Poublanc J: Canadian Selchen DH, Saposnik G, Geerts W, Mamdani M, Jaigobin C, Stroke Network – National Award. ($194,000 2009-2011 Casaubon L, Del Campo M, Black SE, Ween JE, Mittmann Prorated: $32,333) [Grant] N, Shojania K, Dorian P: Ontario Ministry of Health and 35. Gladstone, David. PARTNERS: Promoting Adherence Long-Term Care. ($100,000 Aug 2010-Mar 2012 Prorated: to Regimen of Risk Factor Modification by Trained Non- $45,000) [Grant] Medical Personnel (Volunteers) Evaluated Against Regular Practice. Chan R, Hachinski V, et al: Canadian Stroke Network – National Award. ($770,000 2008-2013 Prorated: $128,333) [Grant]
109 36. Gladstone, David. Prediction of Hemorrhagic Transformation 43. Hopyan, Julia Jasmine. 30 day event monitor belt for of Ischemic Stroke with CT Perfusion Derived Blood-Brain- recording after acute cerebral event. (EMBRACE). Gladstone, Barrier Permeability Surface Area Product. Lee T-Y, Aviv David, Dorian P, O’Donnell M, Spring M, Mamdani M, Thorpe R, Black S, Gladstone D, Symons S: Heart and Stroke K, Laupacis A, Kapral M, Aviv R, Blakely J, Cote R, Sharma Foundation of Ontario – Provincial Award. ($90,674 2009- M, Shuaib A: Canadian Stroke Network. (2009-present) 2014 Prorated: $15,112) [Grant] [Clinical Trial]
37. Gladstone, David. The ‘Weight Times’ Strategy: A Simple, 44. Hopyan, Julia Jasmine. Canadian Atherosclerosis Imaging Low Cost Intervention to Improve Safety in Patients Receiving Network (CAIN). Black, Sandra, Moody, Alan; Spence, Thrombolysis for Acute Stroke. Swartz RH, Gladstone DJ, David; Tardif, Jean-Claude; Beanlands: Canadian Institutes of on behalf of the UofT Stroke Program Investigators: Ontario Health Research (CIHR). (Apr 2008-Mar 2013) [Clinical Trial] Stroke System / Ontario Ministry of Health and Long-Term 45. Hopyan, Julia Jasmine. Canadian Atherosclerosis Imaging – Provincial Award. ($99,500 2010-2012 Prorated: Care Network Study. Moody, Alan, Black, Sandra; Leung, $33,167) [Grant] General; Milot, Laurent; Aviv, Richard: Canadian Institutes 38. Gladstone, David. The CLOQS Trial: Countdown Lights to of Health Research (CIHR). (Apr 2008-Mar 2013) [Grant] Optimize Quality in Acute Stroke. , Gladstone DJ, Swartz R 46. Hopyan, Julia Jasmine. Granulocyte Colony Stimulating Silver FL, Selchen D, Black SE, on behalf of the UofT Stroke Factor in Ischemic Stroke Trial (GIST). A Pilot Study. Atkins Program: Academic AFP Innovation Fund, Sunnybrook H, Sharma M, Gladstone DJ, Black SE, Hakim A, Hogan . ($84,500 2010-2012 Prorated: Health Sciences Centre M: Heart and Stroke Foundation of Canada (HSFC). Centre $28,167) [Grant] for Stroke Recovery. (2007-present) [Grant] 39. The Role of Cytokine-Serotonin Interactions Gladstone, David. 47. Hopyan, Julia Jasmine. INTERSTROKE: Importance of in Post-Stroke Depression and Cognitive Symptoms. Lanctôt Conventional and Emerging Risk Factors for Stroke in Different KL, Herrmann N, Black SE, Gladstone DJ, Snaiderman A, Regions of the World and in Different Ethnic Groups. A Pilot Gao F, Aviv R and Albert PR: Heart and Stroke Foundation Case Control Study. O’Donnell, Yusuf S, Saposnik G, Kapral – Provincial Award. ($95,400 2008-2011 Prorated: of Ontario MK, Oczowski W, Gladstone DJ: Canadian Institutes of $11,925) [Grant] Health Research (CIHR). (2007-present) [Grant] 40. The Spot Sign for Predicting and Treating Gladstone, David. 48. Hopyan, Julia Jasmine. Promoting Adherence to Regimen ICH Growth Study (STOP-IT Study): A Phase II, randomized, of Risk Factor Modification by Trained Non-Medical Personnel multicentre, double-blind, placebo-controlled trial comparing (Volunteers) Evaluated Against Regular Practice (PARTNERS). rFVIIa to placebo for treatment of subjects with acute ICH Chan, R: Canadian Stroke Network. (2009-present) [Clinical and contrast extravasation (the spot sign) identified on CTA. Trial] Flaherty M and Jauch E: National Institutes of Health (NIH)/ 49. Hopyan, Julia Jasmine. The Neurotrophic Effects of Lithium National Institute of Neurological Disorders and Stroke Carbonate Following Cerebrovascular Accidents: A Feasibility (NINDS). ($1,791,105 2008-2013 Prorated: $298,518) [Grant] Study. Lanctot, Krista, Hermann, N; Swartz, R; Black S; 41. The SPOTLIGHT study: A Multicentre Gladstone, David. Tennen G: Canadian Institutes of Health Research (CIHR). Image-Guided Emergency Treatment Protocol for Patients (Oct 2010-Oct 2013) [Grant] with Intracerebral Hemorrhage. Gladstone DJ, Aviv R and 50. Hopyan, Julia Jasmine. The Spot Sign for Predicting and Demchuk A: Ministry of Health & Long-Term Care, Ontario Treating ICH Growth Study (STOP-IT Study). Flaherty M, Stroke Network. ($85,000 2011-2013 Prorated: $28,333) and Jauch E: National Institutes of Health (NIH) / National [Grant] Institute of Neurological Disorders and Stroke (NINDS). 42. Gladstone, David. The University of Toronto Stroke Innovation (2008-2013) [Clinical Trial] Project. Swartz R, Gladstone DJ, Silver FL, Selchen D, Black 51. Lim, Andrew. Sleep Loss in Aging and Dementia. Saper, SE, on behalf of the UofT Stroke Program: Academic AFP Clifford B: Dana Foundation. Clinical Neuroscience Research Innovation Fund (St. Michael’s Hospital, University Health Grant Program. ($354,260 USD July 2009-June 2012 Network) and Sunnybrook Health Sciences Centre. ($300,000 $118,087) [Grant] 2009-2011 Prorated: 50,000) [Grant]
110 52. Masellis, Mario. Driving and Dementia in Ontario. Rapoport 59. Swartz, Richard H. Improving EMR uptake using a M, Masellis M, Herrmann N, Naglie G, Molnar F, Tang-Wai customizable tool integrated into workflow across the health D, Frank C, Pimlott N: Alzheimer’s Society (Canada). Quality care system as a means to optimize knowledge exchange of Life Research Grants Program. ($78,843 June 2010-May and patient education. Saponsnik, Gustavo: St. Michael’s 2012 Prorated: $36,389) [Grant] Hospital. Innovation Fund. ($14,500 July 2011-July 2012 Prorated: $13,385) [Innovation Fund] 53. Masellis, Mario. In Vivo Brain Mapping in the Dementias: A Longitudinal Brain-Behaviour Study With a Focus on 60. Swartz, Richard H. Improving EMR uptake using a Interactions of Alzheimer’s and Cerebrovascular Disease. customizable tool integrated into workflow across the health Black SE, Caldwell CB, Gao F, Herrmann N, Kiss AJ, care system as a means to optimize knowledge exchange Lanctot KL, Lobaugh N, Masellis M, McIlroy WE, Rogaeva and patient education. Black, Sandra: Sunnybrook Health E, Stefanovic B, Stuss DT, Swartz R: Canadian Institutes of Sciences Centre. Innovation Fund. ($50,400 June 2011- Health Research (CIHR). ($1,411,055 2008-2013 Prorated: May 2013 Prorated: $25,200) [Innovation Fund] $235,176) [Grant] 61. Swartz, Richard H. IMS-III: Interventional Management 54. Murray, Brian. Post-stroke triage “DOC”: simple screening of Stroke Trial. National Institutes of Health (NIH) (USA). for Depression, Obstructive sleep apnea and Cognitive NINDS. (Sept 2010-present) [Clinical Trial] impairment. Swartz, Richard: Heart and Stroke Foundation 62. Swartz, Richard H. In vivo brain mapping in the dementias: of Canada (HSFC). ($71,799 May 2012) [Grant] a longitudinal brain-behaviour study with a focus on 55. Murray, Brian. STAR (Sleep Troubles and Relationship cerebrovascular disease. Black SE, Caldwell C, Gao F, to perinatal outcomes). Stremler, Robyn, Donna Brown, Herrmann N, Kiss A, Lanctôt K, Lobaugh N, Masellis M, Cindy-Lee Dennis, Ellen Hodnett, Kathryn Lee, Charles Morin, McIlroy W, Rogaeva E, Stefanovic B, Stuss D, Swartz R: Brian Murray, Eleanor Pullenayegum, Clogdah Ryan, Rory Canadian Institutes of Health Research (CIHR). ($1,411,055 Windrim: Canadian Institutes of Health Research (CIHR). Sept 2008-Sept 2013 Prorated: $277,585) [Grant] ($198,952 July 2010-present Prorated: $88,423) [Grant] 63. Swartz, Richard H. INTERSTROKE: Importance of 56. Swartz, Richard H. 30-Day Cardiac Event Monitor Belt for Conventional and Emerging Risk Factors for Stroke in Different Recording Atrial Fibrillation After a Cerebral Ischemic Event Regions of the World and in Different Ethnic Groups. A Pilot (EMBRACE): A Randomized Controlled Trial. [top-rated Case-Control Study. O’Donnell M, Yusuf S, Saposnik G, Kapral CSN stroke prevention grant]. Gladstone DJ, Dorian P, MK, Oczkowski W, Gladstone DJ: Canadian Institutes of Spring M, O’Donnell M, Mamdani M, Thorpe K, Laupacis A, Health Research (CIHR). ($112,395 2006-present $16,651) Kapral M, Aviv R, Blakely J, Sharma M, Shuaib A: Canadian [Clinical Trial] . ($770,000 July 2010-Aug 2011 Prorated: Stroke Network 64. Swartz, Richard H. Salary Support Award - Intracranial $110,000) [Clinical Trial] Vessel Wall Imaging with MRI : Improving Stroke Diagnosis 57. Swartz, Richard H. Functional Neurovascular Imaging and Treatment. Heart and Stroke Foundation of Canada Workshop. Mikulis, David: Canadian Institutes of Health (HSFC). Heart and Stroke Foundation of Canada Research Research (CIHR). Meetings, Planning and Dissemination Scholarship. ($100,000 Feb 2010-Feb 2012 Prorated: grant: Neurosciences. ($10,000 Sept 2011-Nov 2011) $32,000) [Salary Support Award]
58. Swartz, Richard H. Improving EMR uptake using a 65. Swartz, Richard H. Spot Sign” Selection of Intracerebral customizable tool integrated into workflow across the health Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT): care system as a means to optimize knowledge exchange A Randomized Controlled Trial. Canadian Institutes of and patient education. Ween, Jon: Baycrest Centre for Health Research (CIHR) – National Award (operating grant). Geriatric Care. Innovation Fund. ($29,200 July 2011-July ($1,708,141 July 2010-June 2015 Prorated: $341,628) [Grant] 2012 Prorated: $26,954) [Innovation Fund] 66. Swartz, Richard H. The ‘Weight Times’ Strategy: A Simple, Low Cost Intervention to Improve Safety in Patients Receiving Thrombolysis for Acute Stroke. Swartz, Richard, Gladstone, David: Ontario Stroke System / Ontario Ministry of Health and Long-Term Care. ($85,506 June 2010-Mar 2012 Prorated: $34,980) [Grant]
111 67. Swartz, Richard H. The Neurotrophic Effects of Lithium 3. Black, Sandra E. A Phase 3, Multicenter, Randomized, Carbonate Following Stroke: A Feasibility Study. Lanctot, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy Krista, Herrmann, Nathan; Gold, Allison; Black, Sandra; and Safety Trial of Bapineuzumab (AAB-001, ELN115727) Tenne, Gayla; Swartz, Rick; Hopyan, Julia; Albert, Paul; in Subjects with Mild to Moderate Alzheimer’s Disease who Gao, Fuqiang; MacIntosh, Bradley; Stefanovix, Bojana; are Apolipoprotein E ε4 Non-carriers. Amount paid to SHSC Kiss, Alexander: Heart and Stroke Foundation of Ontario. in 2011-2012: $91,272, Amount paid to date: $127,852. ($132,364 July 2011-June 2013 Prorated: $66,182) [Grant] Wyeth Research (Pfizer). ($563,688 2010-2016 Prorated: $80,527) [Clinical Trial] 68. Swartz, Richard H. The Ontario Stroke Prevention Registry for Atrial Fibrillation. Gladstone, David, Ontario Ministry 4. Black, Sandra E. A Randomized, Double-Blind, Parallel- of Health and Long-Term Care. ($85,936 June 2010-Mar Group Placebo-Controlled Phase III Study to Evaluate the 2012 Prorated: $35,156) [Grant] Efficacy and Safety of Desmoteplase in Subjects with Acute Ischemic Stroke (DIAS-4). 69. Swartz, Richard H. The SPOTLIGHT study: An Multicentre Gladstone, DJ: Lundbeck. image-guided emergency treatment protocol for patients (2009-present) [Clinical Trial] with intracerebral hemorrhage. Gladstone, David; Aviv, 5. Bui, Esther. Cerebral Metabolic Changes in Thalamic Richard; Demchuk, Adrew, Hopyan, Julia; Ween, Jon; del Stimulation. University of Toronto. ($10,000 2009-present Campo, Martin; Silver, Frank; Casaubon, Leanne; Jaigobin, Prorated: $2500) [Grant] Cheryl, Selchen, Dan; Saposnik, Gustavo; Chan, Richard; 6. Bui, Esther. The Epilepsy Monitoring Unit: Barriers to Access Jin, Al; Mehdiratta, Manu; Dowlatshahi, Dar; Stottts, Grant; and Targets for Improved Epilepsy Care in Ontario. University Sharma, Mike: Ontario Ministry of Health and Long-Term of Toronto. ($15,000 2009-2011 Prorated: $2,500) [Grant] Care. Ontario Stroke Network Research Program. ($97,500 7. Gladstone, David. A Single-Blind Study of the Safety, June 2011-July 2013 Prorated:$45,000) [Grant] Pharmacokinetics and Pharmacodynamics of Escalating 70. Zinman, Lorne H. Bulbar motor deterioration in ALS. Repeat Doses of GSK249320 in Patients with Stroke (MAG . ($2,389,340 USD 2009-2014 Prorated: Yunusova, Yana: NIH 111539). Sponsor: GlaxoSmithKline Inc. (2009-2011) $398,223) [Grant] [Contract] 71. Understanding the epidemiology of Zinman, Lorne H. 8. Gladstone, David. Desmoteplase In Acute Ischemic neurological conditions and building the methodological Stroke (DIAS-4): A randomised, double-blind, parallel-group foundation for surveillance. Jette, Nathalie: Public Health placebo-controlled phase III study to evaluate the efficacy Agency of Canada (PHAC). ($402,000 2010-2013 Prorated: and safety of desmoteplase in subjects with acute ischemic $100,500) [Grant] stroke. sponsor: Lundbeck A/S. (2009-present) [Contract] Non Peer Reviewed Funding 9. Gladstone, David. Public Screen for Atrial Fibrillabtion: The Pulse Check Pilot Study. Sponsor: Heart and Stroke 1. Black, Sandra E. A Dose Ranging, Randomized, Double- Foundation of Ontario. (July 2011-June 2012) [Contract] blind, Parallel-group Placebo-Controlled Multi-centre Study 10. The CLOQS Trial: Countdown Lights of RO5313534 Used as Add-on to Donepezil Treatment in Gladstone, David. to Optimize Quality in Acute Stroke. Swartz R, Gladstone Patients with Mild to Moderate Symptoms of Alzheimer’s DJ, Silver FL, Selchen D, Black SE, on behalf of the UofT Disease. Hoffman-La Roche Ltd. ($84,000 2009-2011 Stroke Program: . ($100,000 2010-2012 Prorated: Prorated: $14,000) [Clinical Trial] Roche $33,333) [Grant] 2. Black, Sandra E. A Phase 2 Multicenter, Randomized, Double 11. A Phase II Prospective, Randomized, Blind, Placebo-Controlled Study of the Safety, Tolerability, Hopyan, Julia Jasmine. Double-Blind, Placebo Controlled Study of NTx™-265: and Pharmacokinetics of Multiple Doses of PF-04360365 in Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) Patients with Mild to Moderate Alzheimer’s Disease. Pfizer in Acute Ischemic Stroke Patients (REGENESIS). Cramer Canada Inc. ($390,192 May 2009-Sept 2011 Prorated: , Hill M, Ehrenreich H, et al: . $30,237 [Clinical Trial] S Stem Cell Therapeutics (2008-present) [Clinical Trial]
12. Hopyan, Julia Jasmine. DIAS (Desmoteplase in Acute Stroke) 4 trial. Lundbeck A/S. (2009-present) [Clinical Trial]
112 13. Lee, Liesly. A Double-Blind, Randomized, Multicenter, 22. Masellis, Mario. A Phase 2 Multicenter, Randomized, Double Placebo-Controlled, Parallel-Group Study Comparing the Blind, Placebo-Controlled Study of the Safety, Tolerability Efficacy and Safety of 0.5mg FTY720 Administered Orally and Pharmacokinetics of Multiple Doses of PF-04360365 Once Daily Versus Placebo in Patients with Primary Progressive in Patients with Mild-to-Moderate Alzheimer’s Disease. Multiple Sclerosis. Novartis Canada Ltd. ($38,051 Feb Study Number: A9951002. Black, Sandra: Pfizer Canada 2011-present Prorated: $26,160) [Clinical Trial] Inc. ($367,000 Mar 2009-Sept 2011 Prorated: $35,516) [Clinical Trial] 14. Lee, Liesly. A Multinational, Multicenter, Randomized, Double- Blind, Parallel-Group, Placebo-Controlled Study, to Evaluate 23. Masellis, Mario. Heterogeneity in Clinical, Neuropsychological, the Safety, Tolerability and Efficacy of Daily oral Administration and Neuroimaging Correlates of Familial Frontotemporal of Laquinimod 0.6 mg in Subjects with relapsing-remitting Dementia due to Progranulin (PGRN) Mutation. Family donation multiple sclerosis. Teva Neuroscience Inc. ($20,000 Jan to Sunnybrook Foundation - FTD research. ($20,000 Apr 2008-present $4,211) [Clinical Trial] 2012- May 2013 Prorated: $4,286) [Donation]
15. Lee, Liesly. A phase III double-blind randomized placebo- 24. Masellis, Mario. Pharmacogenetics of Cholinesterase controlled trial of minocycline in Clinically Isoltaed Syndromes Inhibitors in Alzheimer’s (AD) and Lewy Body Disease (LBD). (CIS). MSS of Canada. ($10,000 Apr 2009-present $2,857) Masellis, Mario: Family donation to Sunnybrook Foundation [Clinical Trial] - Dementia research. ($5,000 Apr 2011-Dec 2011 Prorated: $3,333) [Donation] 16. Lee, Liesly. A Population Study of Risk Factors for Multiple Sclerosis: The Canadian Contribution to an International 25. Masellis, Mario. Pharmacogenetics of Rasagiline in Parkinson’s Study ENVironmental factors in Multiple Sclerosis (EnvIMS). Disease (PD). Masellis M, Lang AE, Lang AE, Kennedy MS Society of Canada. (Sept 2009-present) [Clinical Trial] JL, Macciardi F: Teva Neurosciences Inc. ($143,258 Dec 2011-Nov 2012 Prorated: $83,567) [Investigator - Initiated, 17. Lee, Liesly. A Population Study of Risk Factors for Multiple Sclerosis: The Canadian Contribution to an International Industry-Sponsored Study] Study ENVironmental factors in Multiple Sclerosis (EnvIMS). 26. Perry, James. An Open-Label, Three-Cohort, Phase II MS Society of Canada. ($5,000 Apr 2012-present Prorated: Study of E7080 in Subjects with Recurrent Malignant Glioma $5,000) [Clinical Trial] (HOPE). Eisai Inc. ($30,000 Jan 2012-present Prorated: $5,000) [Clinical Trial] 18. Lee, Liesly. An international, multi-center, randomized, double-blind, placebo-controlled, Parallel group study to 27. Perry, James. Cilengitide for Subjects With Newly Diagnosed evaluate the efficacy and safety of two year treatment with Glioblastoma Multiforme and UnMethylated MGMT Gene teriflunomide 7mg once daily and 14mg once daily versus Promoter (CORE). Merck KGAA. ($27,000 Nov 2010-present placebo in patients with a first clinical episode suggestive of Prorated: $27,000) [Clinical Trial] multiple sclerosis. ($20,000 June Sanofi-Aventis (Canada). 28. Perry, James. Glioblastoma in the Elderly (CE.6). Perry, 2009-present Prorated: $6,000) [Clinical Trial] James: National Cancer Institute of Canada (NCIC). 19. Lee, Liesly. An Open-Label, Survey-Based Multicenter Clinical Trials Group. ($180,000 Oct 2007- present Prorated: Study to Determine Patient Satisfaction with Single-Use $37,895) [Clinical Trial] Prefilled Avonex Pen Autoinjector in Multiple Sclerosis Patients 29. Swartz, Richard H. CLOQS - expansion for UTSP sites. (Avonex PEN Satisfaction and Patients Experience Clinical Swartz, Richard, Gladstone DJ, Silver FL, Selchen D, Black Trial (ASPECT). . ($6,200 Aug Biogen Idec Inc. (Ontario) SE: Roche Limited. ($100,000 Mar 2010-Feb 2012 Prorated: 2011-May 2012 Prorated: $6,200) [Clinical Trial] $33,333) [Grant] 20. Epidemiology of Anti-JCV Antibody Prevalence Lee, Liesly. 30. Swartz, Richard H. Development of an Integrated Stroke in Multiple Sclerosis Patients: JEMS. Biogen Idec Inc. Program Involving Three University Academic Health Science ($39,400 Oct 2011-May 2012 Prorated: $39,400) (Ontario). Centres. Swartz, Richard, Gladstone DJ, Silver FL, Selchen [Clinical Trial] D, Black SE: University of Toronto Department of Medicine 21. Lee, Liesly. Tysabri Retrospective Chart Review Extension and Sunnybrook Brain Sciences Program. ($100,000 2009- Study in Multiple Sclerosis (TysCan). Biogen Idec Inc. 2011 Prorated: $16,667) [Grant] (Ontario). ($35,075 June 2010-Oct 2011 Prorated: $8,253) [Clinical Trial]
113 31. Swartz, Richard H. Effects of Cardiac Rehabilitation for 6. Demchuk A, Dowlatshahi D, Rodriguez DL, Molina CA, Blas Individuals After Transient Ischemic Attack. McIlroy WE, YS, Dzialowski I, Kobyashi A, Boulanger J, Lum C, Gubitz Brooks D, Oh P, Black S, Ween J, Gladstone D: Heart and G, Padma V, Roy J, Kase CS, Kosior J, Bhatia R, Tymchuk Stroke Foundation of Canada (HSFC). ($240,000 2009-2012 S, Subramanian S, Gladstone DJ, Hill M, Aviv R and on Prorated: $60,000) [Clinical Trial] behalf of PREDICT/Sunnybrook ICH CTA study group. Validation of the CTA spot sign for predicting hematoma 32. Swartz, Richard H. Frequency of Fabry Disease in an unselected group of cryptogenic stroke patients: a multi- expansion in patients with intraceerebral hemorrhage in the PREDICT prospective multicenter study. Lancet Neurol. centre cohort study. Canadian Stroke Consortium. Canadian Fabry Stroke Screening Initiative (CFSSI). (2010-present) 2012;11(4):307-14. [Cohort Study] 7. F. M. Coelho, H. Georgsson, B. J. Murray. Benefit of repeat multiple sleep latency testing in confirming a possible 33. Swartz, Richard H. PARTNERS: Promoting Adherence to Regimen of Risk Factor Modification by Trained Non-Medical narcolepsy diagnosis. Journal of Clinical Neurophysiology. Personnel (Volunteers) Evaluated Against Regular Practice. 2011 Aug (40%). Chan R, Hachinski V, et al: Canadian Stroke Network. 8. F. M. Coelho, M. Narayansingh, B.J. Murray. Testing (2008-2013) [Grant] Sleepiness and Vigilance in the Sleep Laboratory. Current Opinion in Pulmonary Medicine. (invited review) (40%). Publications 9. Freedman M, Bar Or A, Oger J, Traboulsee A, Patry D, Young C, Olsson T, Hartung HP, Antel J, Zamvil S, Arnold D, Cutter Peer Reviewed Publications G, DeStefano N, Lublin F, Chad Z, Polman C, Bouchard JP, 1. Ashford JW, Salehi A, Furst A, Bayley P, Frisoni GB, Jack Jr Bahn V, Duquette P, Freedman M, Lee L, Melanson M, Marrie CR, Sabri O, Adamson MM, Coburn KL, Olichney J, Schuff RA, O’Connor P, Oger J, Patry D, Steffanelli M, Bakker J, N, Spielman D, Edland SD, Black S, Rosen A, Kennedy Brunet D, Kremenchutzky M, Young C, Sharrack B, Nicholas D, Weiner M, Perry G. Introduction: Imaging the Alzheimer R, O’Leary C, Constantinescu C, Palace J, Jongen PJ, Brain. Journal of Alzheimer’s Disease. October 2011; Zwanikken CP, Sanders EA, Anten B, van Munster ET, Olsson 26(Suppl 3):1-27. T, Hillert J, Lycke J, Vrethem M, Nilsson P, Svenningsson A, Martin C, Sörensen PS, Erälinna JP, Kuusisto H, Reunanen 2. Burke Mj, Vergouwen MD, Fang J, Swartz RH, Kapral M, Jolma T, Färkkilä A, Hartung HP, Schimrigk S, Chan A, MK, Silver FL, Casaubon LK. Investigators of the registry of Ziemssen T, Stengel M, Heesen C, Gross-Paju K, Kalbe the Canadian Stroke Network. Short term outcomes after I, Metra M, Arbizu T, Arroyo R, Montalbán X, Thibault M, symptomatic internal carotid artery occlusion. Stroke. 2011. Edmond F, Verrrault S, Maxner CE, McKelvey JR, McDougall Sept; 42(9): 2419-24. Epub 2011 Jul 14. AD, Vandorpe R, Bernier GP, Girard JM, Prat A, Mclean H, 3. Chow TW, Graff-Guerrero A, Verhoeff NPG, Binns M, Tang- Rabinovitch H, Simantirakis E, Martin L, Cruce R, Ween JE, Wai DF, Freedman M, Masellis M, Black SE, Wilson AA, Symons S, Murray B, Masellis M, York N, Galimova L, Houle S, Pollock BG. An Open-Label Study of the Short- Burton J, Gray T, Selchen D. A phase III study evaluating the Term Effects of Memantine on FDG-PET in Frontotemporal efficacy and safety of MBP8298 in secondary progressive Dementia. Neuropsychiatric Disease and Treatment. July MS. Neurology. Neurology. 2011 Oct 18;77(16):1551-60. 2011; 7:415-424. Epub 2011 Oct 5. 4. D. Rotstein, P. O’Connor, Multiple L. Lee, B.J. Murray. 10. Freedman MS, Bar-Or A, Oger J, Traboulsee A, Patry D, sclerosis fatigue is associated with reduced psychomotor Young C, Olsson T, Li D, Hartung HP, Krantz M, Frenczi L, vigilance. Canadian Journal of Neurological Sciences. 2012 Verco T, et al., Masellis M (collaborator). A phase III study Mar;39:2, (40%) evaluating the efficacy and safety of MBP8298 in secondary 5. Dandara C, Adebamowo C, de Vries J, Dove ES, Fisher E, progressive MS. Neurology. (2011 Oct). 77(16):1551-60. Gibbs RA, Hotez PJ, Kickbusch I, Knoppers BM, Masellis M, Oestergaard MZ, Pang T, Rotimi CN. An idea whose time has come? An African foresight observatory on genomics medicine and data-intensive global science. Current Pharmacogenomics and Personalized Medicine (2012). 2012 Feb;10(1): 7-15.
114 11. Gao FQ, Swartz RH, Scheltens P, Leibovitch FS, Kiss A, Honjo 19. Kaufman LD, Pratt J, Levine B, Black SE. Executive deficits K, Black SE. Complexity of MRI White Matter Hyperintensity detected in mild Alzheimer’s disease using the antisaccade Assessments in Relation to Cognition in Aging and Dementia task. Brain and Behavior. January 2012; 2(1):15-21. from the Sunnybrook Dementia Study. Journal of Alzheimer’s 20. Krupinski EA, Patterson T, Norman CD, Roth Y, ElNasser Z, Disease. October 2011; 26(Suppl 3):379-388 (also in Ashford Abdeen Z, Noyek A, Sriharan A, Ignatieff A, Black S, Freedman JW, et al (Eds). Handbook of Imaging the Alzheimer Brain: M. Successful Models for Telehealth. Otolaryngologic Clinics Vol. 2 Advances in Alzheimer’s Disease. IOS Press, 2011). of North America. December 2011; 44(6):1275-1288. 12. Gorelick PB, Scuteri A, DeCarli C, Greenberg SM, Black SE, 21. Lazarou J, Hopyan J, Panisko D and Tai P. Neurology for Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, internal medicine residents: working towards a national Petersen RC, Schneider JA. Tzourio C, Arnett DK, Bennett Canadian curriculum consensus. Med Teach. 2011;33(2):e65-8. DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, 22. Leibovitch FS, Vasquez BP, Ebert P, Beresford KL, Black SE. Roman GC, Sellke FW, Seshadri S. Vascular Contributions A Short Bedside Battery for Visuoconstructive Hemispatial to Cognitive Impairment and Dementia: A Statement for Neglect: Sunnybrook Neglect Assessment Procedure Healthcare Professionals From the American Heart Association/ (SNAP). Journal of Clinical Experimental Neuropsychology. American Stroke Association. Stroke. September 2011; April 2012; 34(4):359-368. 42(9): 2672-2713. 23. Mackenzie IR, Ansorge O, Strong M, Bilbao J, Zinman 13. Hurko O, Black SE, Doody R, Doraiswamy PM, Gamst A, L, Ang LC, Baker M, Stewart H, Eisen A, Rademakers R, Kaye J, Obisesan TO, Rusinek H, Scharre D, Sperling R, Neumann M. Pathological heterogeneity in amyotrophic Weiner MW, Green RC, for the ADNI Data and Publication lateral sclerosis with FUS mutations: two distinct patterns Committee. The ADNI Publication Policy: Commensurate correlating with disease severity and mutation. Acta recognition of critical contributors who are not authors. Neuropathol. 2011 Jul;122(1):87-98. Epub 2011 May 21. NeuroImage. February 2012; 59(4):4196-4200. PubMed PMID: 21604077. 14. J. Oh, A. Saghal, P. Sanghera, MN Tsao, P. Davey, K. Lam, 24. Mandell DM. Matouk CC, Rarb RI, Krings T, Agid R, Terbrugge S Symons, R. Aviv, J.R. Perry. Glioblastoma: Patterns of K, Willinsky RA, Swartz RH, Silver FL, Mikulis DJ. Vessel Wall Recurrence and Efficacy of Salvage Treatments. Can J Neurol MRI to Differentiate between reversible cerebral vasoconstriction Sci. 2011 Jul;38:621-625. syndrome and central nervous system vasculitis: preliminary 15. J. Keith JL, Zinman L, Cohen S, Young B, Bilbao J. Paraspinal result. Stroke. 2011 Dec 08. [Epub ahead of print]. myopathy with novel shard-like compact aggregates of thin 25. Morrison LJ, Baker AJ, Rhind S, Kiss A, MacDonald R, filaments. Muscle Nerve. 2011 Jul;44(1):145-6. doi: 10.1002/ Schwartz B, Perreira T, Simitciu M, Trompeo A, Black SE, mus.22093. Epub 2011 Jun 9. PubMed PMID: 21660984. Stuss DT. The Toronto Prehospital Hypertonic Resuscitation- 16. Juurlink DN, Gomes T, Mamdani MM, Gladstone DJ, Kapral Head Injury and Multi Organ Dysfunction Trial (TOPHR HIT) MK. The safety of proton pump inhibitors and clopidogrel in – Feasbility Study of a Randomized Controlled Trial. Journal patients after stroke. Stroke. 2011;42:1-5. of Critical Care. August 2011; 26(4):363-372. 17. Kalia LV, Mozessohn L, Aviv R, Da Costa L, Lang AE, Shadowitz 26. Naglie G, Hogan DB, Krahn M, Beattie BL, Black SE, S, Masellis M. Hemichorea-hemiballism associated with MacKnight C, Freedman M, Patterson C, Borrie M, Bergman hyperglycemia and a developmental venous anomaly (DVA). H, Byszewski A, Streiner D, Irvine J, Ritvo P, Comrie J, Neurology. (2012). 78(11): 838-839. Kowgier M, Tomlinson G. Predictors of Patient Self-Ratings 18. Kamal SM, Warnich L, Ferguson LR, Srivastava S, Ray S, of Quality of Life in Alzheimer’s Disease: Cross-sectional Avard D, Joly Y, Huynh ML, Page M, Masellis M, Dove ES, Results from the Canadian Alzheimer’s Disease Quality of Gurwitz D, Özdemir V. Forward look: Tenth anniversary of the Life (CADQOL) Study. Journal of Geriatric Psychiatry. October human genome sequence and 21st century postgenomics 2011; 19(10):881-890. global health — A close up on Africa and women’s health. 27. Özdemir V, Fisher E, Dove ES, Burton H, Wright G, Zimmern Current Pharmacogenomics and Personalized Medicine. RL, Masellis M, Warnich L. End of the beginning and public (2011). 9(3):148-155. health pharmacogenomics: Knowledge in ‘mode 2’ and P5 medicine. Current Pharmacogenomics and Personalized Medicine (2012) 10(1):1-16.
115 28. Park NW, Lombardi S, Gold DA, Tarita-Nistor L, Gravely M, 36. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson Roy EA, Black SE. Effects of Familarity and Cognitive Function S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, on Naturalistic Action Performance. Neuropsychology. March Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, 2012; 26(2):224-37. Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, 29. Patterson KK, Nadkarni NK, Black SE, McIlroy WE. Gait symmetry and velocity differ in their relationship to age. Gait Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen & Posture. April 2012; 35(4):590-594. IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden 30. Protzner AB, Mandzia JL, Black SE, McAndrews MP. Network J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Interactions Explain Effective Encoding in the Context of Isoviita VM, Kaivorinne AL, Hölttä-Vuori M, Ikonen E, Sulkava Medial Temporal Damage in MCI Patients. Human Brain R, Benatar M, Wuu J, Chiò A, Restagno G, Borghero G, Mapping. July 2011; 32(8):1277-1289. Sabatelli M; ITALSGEN Consortium, Heckerman D, Rogaeva 31. R. Rasquinha, A. Moszczynski, B. J. Murray. A modern E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler artifact in the sleep laboratory. Journal of Clinical Sleep EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy Medicine. 2012 Apr;8(2) 225-226, (40%). J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, 32. R.I. Aviv, P.L. Francis, R. Tenenbein, P. O’Connor, L. Zhang, A. Morris HR, Tienari PJ, Traynor BJ. A hexanucleotide repeat Eilaghi, L. Lee, T.J. Carroll, J. Mouannes-Srour, A. Feinstein. expansion in C9ORF72 is the cause of chromosome 9p21- Decreased Frontal Lobe Gray Matter Perfusion in Cognitively linked ALS-FTD. Neuron. 2011 Oct 20;72(2):257-68. Epub Impaired Patients with Secondary Progressive Multiple 2011 Sep 21. PubMed PMID: 21944779; PubMed Central Sclerosis Detected by the Bookend Technique. American PMCID: PMC3200438. Society of Neuroradiology. AJNR Am J Neuroradiol; 2012 Apr. 37. Sheppard YD, Middleton D, Whitfield Y, Tyndel F, Haider S, 33. Rapoport MJ, Weaver B, Kiss A, Sarracini CZ, Moller H, Spiegelman J, Swartz RH, Nelder MP, Baker SL, Landry Herrmann N, Lanctot K, Murray B, Bédard M. The effects L, Maceachern R, Deamond S, Ross L, Peters G, Baird M, of donepezil on computer-simulated driving ability among Rose D, Sanders G, Austin JW. Intestinal toxemia botulism healthy older adults: A pilot study. Journal of Clinical in 3 adults Ontario, Canada 2006-2008. Emerg Infect Dis. Psychopharmacology. 2011 Aug (10%). 2012 Jan;18(1):1-6.
34. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer 38. Sperling RA, Jack CR, Black SE, Frosch MP, Greenberg SM, JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Hyman BT, Scheltens P, Carrillo MC, Thies W, Bednar MM, Onyike C, Hillis A, Josephs KA, Boeve BF, Kertesz A, Seeley Black RS, Brashear HR, Grundman M, Siemers ER, Feldman WW, Rankin K, Johnson JK, Gorno-Tempini M-L, Rosen HH, Schindler RJ. Amyloid-Related Imaging Abnormalities H, Latham C, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer J, in Amyloid-Modifying Therapeutic Trials: Recommendations Rossor M, Warren J, Fox N, Galasko D, Salmon DP, Black from the Alzheimer’s Association Research Roundtable SE, et al. Sensitivity of Revised Diagnostic Criteria for the Group. Alzheimer’s and Dementia. July 2011; 7(4):367-385. Behavioural Variant of Frontotemporal Dementia. Brain. 39. Stamenova V, Black SE, Roy E. A model-based approach September 2011; 134(9):2456-2477. to long-term recovery of limb apraxia after stroke. Journal 35. Reardon D, Perry JR, Brandes A, Jalali R, Wick W. Advances of Clinical and Experimental Neuropsychology. November in Malignant Glioma Drug Discovery. Expert Opinion on Drug 2011; 33(9):954-971
Discovery. Jul 2011, Vol. 6, No. 7, Pages 739-753: 739-753. 40. Tippett WJ, Sergio LE, Black SE. Compromised visually guided motor control in individuals with Alzheimer’s disease: Can reliable distinctions be observed? Journal of Clinical Neuroscience. May 2012; 19(5):655-660.
41. Vergouwen M, Silver F, Mandell D, Mikulis D, Swartz RH. Symptomatic middle cerebral artery stenoses show eccentric narrowing and enhancement in patients with recent ischemic stroke. Archives of Neurology. 2011;68(3):338-342.
116 42. Vergouwen M, Silver F; Mandell D, Mikulis D, Krings T, 5. Boulos MI, Pettersen JA, Nguyen L, Jewell DR, Shammi Swartz RH. Fibrous Cap Enhancement in Symptomatic P, Black S, Murray BJ. Nocturnal Limb Movements are Atherosclerotic Basilar Artery Stenosis. Archives of Neurology. Correlated with Cerebral White Matter Hyperintensities and 2011;68(5):676. Fronto-Executive Deficits. Sleep. May 2012; 35(Abstract Suppl):A261 Abstract presented at SLEEP 2012 - 26th 43. Vergouwen MD, Casaubon LK, Swartz RH, Fang J, Stamplecoski M, Kapral MK, Silver FL, on behalf of the Annual Meeting of the Associated Professional Sleep Societies Investigators of the Registry of the Canadian Stroke Network. (Boston, MA, June 9-13, 2012). Subtherapeutic Warfarin Is Not Associated With Increased 6. Boyko M, Kosior R, Dowlatshahi D, Kosior J, Rodriguez- Hemorrhage Rates in Ischemic Strokes Treated With Tissue Luna D, Molina CA, Silva Blas Y, Dzialowski I, Kobayashi Plasminogen Activator. Stroke. 2011;42:1041-1045. A, Boulanger JM, Lum C, Gubitz G, Padma V, Roy J, Kase 44. Xiao S, Sanelli T, Dib S, Sheps D, Findlater J, Bilbao J, CS, Gladstone DJ, Smith E, Aviv RI, Demchuk AM, on behalf of the PREDICT/Sunnybrook ICH CTA study group. Keith J, Zinman L, Rogaeva E, Robertson. RNA targets of TDP-43 identified by UV-CLIP are deregulated in ALS. J. Coregistration and 3D comparison reveal a variable trajectory Mol Cell Neurosci. 2011 Jul;47(3):167-80. Epub 2011 Mar of intracerebral hemorrhage expansion in relation to spot 21. PubMed PMID: 21421050. sign location: analysis from the PREDICT study. Stroke 2011 (abstract entry for the 2012 International Stroke Conference, 45. Yunusova Y, Green JR, Greenwood L, Wang J, Pattee New Orleans, Louisiana). GL, Zinman L. Tongue movements and their acoustic consequences in amyotrophic lateral sclerosis. Folia Phoniatr 7. Carling-Rowland A, Black S, McDonald A, Kagan A. Logop. Folia Phoniatr Logop. 2012;64(2):94-102. Adaptation of the capacity evaluation process to make admission decisions: increasing access for people with stroke Abstracts and aphasia. Stroke. November 2011, 42(11):e590 Abstract presented at 2nd Canadian Stroke Congress (Ottawa, ON, 1. Black S, McNeely A, Ramirez J, Scott C, Szilagyi G, Kiss October 2-4, 2011). A, Stuss D. Left Temporal Lobe Subcortical Hyperintensities Correlate with Verbal Learning and Memory in Alzheimer’s 8. Chow T, Fam D, Graff-Guerrero A, Verhoeff N, Tang-Wai D, Disease and Normal Elderly. Neurology. April 2012;78(Meeting Masellis M, Black S, Wilson A, Houle S, Pollock B. FDG- Abstracts 1):P03.087 Abstract presented at 64th Annual PET in Semantic Dementia after 6 Months of Memantine: Meeting of the American Academy of Neurology (AAN) (New an open-Label Pilot Study. International Journal of Geriatric Orleans, LA, April 21-28, 2012). Psychiatry. Jan 2012.
2. Black SE, Ganda A, Gao F, Gibson E, Graham S, Honjo K, 9. Coelho FM, Parekh N, Narayansingh M, Danells C, McIlroy Lobaugh NJ, Marola J, Pedelty L, Rangwala N, Scott CJ, W, Black S, Murray BJ. Subjective Sleep Characteristics in Stebbins GT, Stuss DT, Zhou XJ, Nyenhuis D. Validation of the Stroke Patients. Sleep. May 2012; 35(Abstract Suppl):A286 NINDS-CSN Harmonization VCI Neuropsychology Protocols Abstract presented at SLEEP 2012 - 26th Annual Meeting in an Ischemic Stroke Sample. Stroke. November 2011, of the Associated Professional Sleep Societies (Boston, MA, 42(11):e608 Abstract presented at 2nd Canadian Stroke June 9-13, 2012). Congress (Ottawa, ON, October 2-4, 2011). 10. Crane DE, MacIntosh BJ, Aviv R, da Costa L, Ganda 3. Boulos M, Pettersen J, Jewell D, Black S, Murray B. Nocturnal A, Howard PR, Mikulis DJ, Pham D, Sam K, Black SE. Limb Movements are Correlated with Cerebral White Matter Evaluating compromised white matter cerebrovascular Hyperintensities. Neurology. April 2012;78(Meeting Abstracts reactivity in individuals with CADASIL. Stroke. November 1):P05.001 Abstract presented at 64th Annual Meeting of 2011, 42(11):e593 Abstract presented at 2nd Canadian the American Academy of Neurology (AAN) (New Orleans, Stroke Congress (Ottawa, ON, October 2-4, 2011). LA, April 21-28, 2012).
4. Boulos MI, Pettersen JA, Jewell DR, Black SE, Murray BJ. Objective Markers of Nocturnal Limb Movements are Correlated with Cerebral White Matter Hyperintensities. Neurology. New Orleans USA.
117 11. Cummings J, Frolich L, Black S, Bakchine S, Bellelli G, 16. Eitzen A, Walker L, Atkins H, Stotts G, Hogan M, Hakim A, Molinuevo J, Kressing R, Downs P, Caputa A, Strohmaier Black S, Gladstone D, Sharma M. Change in cognition C. A new option to reach maximum dose efficacy with following GCSF therapy to treat ischemic stroke. Canadian rivastigmine patch in the treatment of Alzheimer’s disease: Journal of Neurological Sciences. May 2012; 39(3 Suppl results of a 48-week, randomized, double-blind evaluation of 3):S40 Abstract presented at 47th Annual Congress of the the comparative efficacy, safety and tolerability of 9.5 mg/24 Canadian Neurological Sciences Federation (CNSF) (Otttawa, h and 13.3 mg/24 h. Neurology. April 2012;78(Meeting ON, June 5-8, 2012). Abstracts 1):P04.193 Abstract presented at 64th Annual 17. Fernando Morgadinho Santos Coelho, Neal Parekh, Marc Meeting of the American Academy of Neurology (AAN) (New Narayansingh, Cynthia Daniels, Matt Curie, William McIlroy, Orleans, LA, April 21-28, 2012). Sandra Black, Brian James Murray. Subjective sleep 12. Cummings J, Frolich L, Black S, Bakchine S, Bellelli G, characteristics in stroke patients. Sleep. June 2012. Molinuevo J, Kressing R, Downs P, Caputa A, Strohmaier 18. Ganda A, Nyenhius D, Rizkalla M, Gao F, Marola J, Scott C. Managing Functional and Cognitive Decline in Patients CJ, Honjo K, Rangwala N, Pedelty L, Lobaugh NJ, Graham with Mild-to-Moderate Alzheimer’s Disease: A 48-week, S, Gibson E, Zhou XJ, Stebbins GT, Stuss DT, Black SE. Randomized, Double-blind Evaluation of 13.3 mg/24 h (15 Sensitivity and Specificity of Four Neuropsychological Screening cm2) versus 9.5 mg/24 h (10 cm2) Rivastigmine Patch. Measures in an Ischemic Stroke Sample. Stroke. November Neuropsychopharmacology. December 2011, 36(S1): S223-4 2011, 42(11):e610-611 Abstract presented at 2nd Canadian Abstract presented at 50th Annual Meeting of the American Stroke Congress (Ottawa, ON, October 2-4, 2011). College of Neuropsychopharmacology (ACNP) (Waikoloa, 19. Gao F, Shield KD, Kiss A, Rockwood K, Black SE. Do Lesion HI, December 4-8, 2011). Burden and Atrophy Predict Responsiveness to Donepezil 13. Danells CJ, Van Kessel MA, Cohen EJ, Mansfield A, Black Treatment in Patients with Vascular or Mixed Dementia: SE, McIlroy WE. Developing a Comprehensive Database of The Canadian VASPECT Study. Stroke. November 2011, Stroke Recovery: The Heart & Stroke Foundation Centre for 42(11):e596 Abstract presented at 2nd Canadian Stroke Stroke Recovery Rehabilitation Affiliates Program. Stroke. Congress (Ottawa, ON, October 2-4, 2011). November 2011, 42(11):e609 Abstract presented at 2nd 20. Gladstone D on behalf of the EMBRACE Steering Canadian Stroke Congress (Ottawa, ON, October 2-4, 2011). Committee and Investigators. 30-Day Cardiac Event 14. Dowlatshahi D, Aviv RI, Rodriguez-Luna D, Molina CA, Silva Monitor Belt for Recording Paroxysmal Atrial Fibrillation Blas Y, Dzialowski I, Kobayashi A, Boulanger JM, Lum C, After a Cerebral Ischemic Event (EMBRACE): Randomized Gubitz G, Padma V, Roy J, Kase CS, Stewart T, Bhatia Controlled Trial. Canadian Stroke Congress. Ottawa City. R, Boyco M, Kosior J, Gladstone DJ, Hill MD, Demchuk 2011 Oct 3. Prevention and Treatment P.34. AM, on behalf of the PREDICT/Sunnybrook ICH CTA study 21. Gladstone D. “Spot Sign” Selection of Intracerebral group. Small intracerebral hematomas have a low spot sign Hemorrhage to Guide Hemostatic Therapy (SPOTLIGHT): prevalence and are unlikely to expand: analysis from the A Randomized Controlled Trial. Canadian Stroke Congress. PREDICT study. Stroke 2011 (abstract entry for the 2012 Ottawa City. 2011 Oct 3. Prevention and Treatment P.33. International Stroke Conference, New Orleans, Louisiana). 22. Gladstone DJ, Aviv R, Demchuk A, Hill MD, Flaherty M, 15. Eilaghi A, Lee TY, Jakubovic R, Swartz R. Djalilvand A, Butcher K, Black S, Mamdani M, Thorpe K, Sahlas DJ, Aviv RI. Gray and White Matter CT Perfusion Threholding Spence J, Dowlatshahi D, Shamy M, De Masi S, Hall J, for Outcome Prediction in 114 patients with acute ischemic and the SPOTLIGHT Steering Committee and Investigators. stroke. American Society of Neuroradiology 50th annual “Spot Sign” Selection of Intracerebral Hemorrhage to Guide meeting. April 21-26, 2012. New York, United States. Hemostatic Therapy (SPOTLIGHT): Design of a Canadian Image-Guided Randomized Controlled Trial of Recombinant Factor VIIa. Stroke. November 2011, 42(11):e597 Abstract presented at 2nd Canadian Stroke Congress (Ottawa, ON, October 2-4, 2011).
118 23. Graham NL, Tang-Wai DF, Black S, Leonard C, Jokel R, 30. Ramirez J, Scott CJ, Black SE. Subcortical Hyperintensity Schwindt G, Rochon E. Non-Fluent Progressive Aphasia Sub-types in a Cross-Sectional Sample of Alzheimer Disease Without Agrammatism or Apraxia of Speech. Procedia - and Normal Elderly. Stroke. November 2011, 42(11):e602 Social and Behavioral Sciences. 2011; 23:223-224 Abstract Abstract presented at 2nd Canadian Stroke Congress presented at Academy of Aphasia 2011 (Montreal, QC, (Ottawa, ON, October 2-4, 2011). October 16-18, 2011). 31. Rascovsky K, Hodges JR, Knopman D, Mendez MF, 24. Honjo K, Scott CJ, Nyenhius D, Gao F, Zhou XJ, Graham SJ, Kramer JH, Xie S.,van Swieten JC, Seelaar H, Dopper EGP, Rangwala N, Stebbins GT, Gibson E, Ganda A, Lobaugh NJ, Onyike C, Hillis A, Josephs K, Boeve BF, Kertesz A, Seeley Marola J, Stuss DT, Black SE. Thalamic Volume is Related WW, Rankin K, Johnson JJ, Gorno-Tempini ML, Rosen H, to Side of Stroke, Stroke Volume and Post-Stroke Cognitive Neuhaus J, Latham C, Lee A, Kipps CM, Lillo P, Piguet O, Impairment. Stroke. November 2011, 42(11):e619 Abstract Rohrer J, Rossor M, Warren JD, Fox NC, Galasko G, Salmon presented at 2nd Canadian Stroke Congress (Ottawa, ON, DP, Black SE, et al. Determinants of Survival in Autopsy- October 2-4, 2011). Confirmed Patients with Behavioural Variant Frontotemporal Dementia (bvFTD): Second Report of the International bvFTD 25. Jokel R, Anderson N, Black S, Rochon E, Freedman M, Chow T, Tang-Wai D. Neuroplasticity in dementia following Criteria Consortium (FTDC). Alzheimer’s and Dementia. July language intervention: illusion or possibility? Alzheimer’s and 2011;7(4-Suppl 1):S758-9 Abstract presented at Alzheimer’s Dementia. July 2011;7(4-Suppl 1):S751-2 Abstract presented Association International Conference (AAIC) 2011 (Paris, at Alzheimer’s Association International Conference (AAIC) France, July 16-21, 2011). 2011 (Paris, France, July 16-21, 2011). 32. Russell Rasquinha, Alex Moszczynski, Brian James Murray. Automated Quantification of Axial EMG Tone in Sleep Identifies 26. JR Perry, C O Callaghan, K Ding, W Roa, W Mason, G Cairncross, A Brandes, J Menten, C Phillips, M Fay, R Patients with REM Sleep Behavior Disorder, New Orleans Nishikawa, C Winch, N Laperriere. A phase III randomized USA. Neurology. Apr 2012. controlled trial of short-course radiotherapy with or without 33. Sam K, Poublanc J, Crane D, Ganda A, Mandell DM, Black concomitant and adjuvant temozolomide in elderly patients S, Mikulis D. Cerebrovascular autoregulation and cerebral with glioblastoma (NCIC CTG CE.6, EORTC 26062-22061, perfusion are reduce white matter hyperintensities compared TROG 08.02). Can J Neuro Sci. Jan 2012; V39:S1 pg 16. to normal appearing white matter. Stroke. November 2011, 27. Kalia LV, Mozessohn L, Aviv R, Da Costa L, Shadowitz 42(11):e603 Abstract presented at 2nd Canadian Stroke Congress (Ottawa, ON, October 2-4, 2011). S, Masellis M. Hemichorea-hemiballism associated with hyperglycemia and a basal ganglia developmental venous 34. Schwindt GC, Chaudhary S, Crane D, Ganda A, Janik R, anomaly. Movement Disorders. (2011). 26(2): S32. Masellis M, Grady CL, Stefanovic B, Black SE. State- Dependent Modulation of the Default Mode Network 28. Mandell D, Matouk C, Swartz R, Silver F, Mikulis D. Vessel Wall MR imaging to differentiate between reversible in Alzheimer’s Disease. Alzheimer’s and Dementia. July cerebral vasoconstriction syndrome and central nervous 2011;7(4-Suppl 1):S36, S222 Abstract presented at Alzheimer’s system vasculitis: Preliminary results. American Society of Imaging Consortium (AIC) 2011 (Paris, France, July 16, 2011) Neuroradiology 50th annual meeting. April 21-26, 2012. and Alzheimer’s Association International Conference (AAIC) New York, United States. 2011 (Paris, France, July 16-21, 2011). 29. Middleton L, Brooks D, Oh P, Lanctot K, Turner G, MacIntosh 35. Shield KD, Gao F, Kiss A, Rockwood K, Black SE. Centralized Standardized Analysis of CT Scans in a Multi-Center Clinical B, Black S. Cardiac Rehabilitation: Benefits to People with MCI and Alzheimer’s Disease. Alzheimer’s and Dementia. July Trial of Donepezil Treatment in Patients with Vascular or 2011;7(4-Suppl 1):S611-2 Abstract presented at Alzheimer’s Mixed Dementia in the Canadian VASPECT study. Stroke. Association International Conference (AAIC) 2011 (Paris, November 2011, 42(11):e596 Abstract presented at 2nd France, July 16-21, 2011). Canadian Stroke Congress (Ottawa, ON, October 2-4, 2011).
119 36. Skarpathiotakis M, Mandell D, Swartz R, Tomlinson G, Editorials Mikulis D. Intracranial vessel wall imaging; atherosclerotic 1. Saper CB. Sleep, circadian rhythms, and dementia. plaque enhancement; ischemic stroke. American Society Lim AS, Ann Neurol. 2011 Nov; 70:677-9. of Neuroradiology 50th annual meeting. April 21-26, 2012. New York, United States. Letters to Editor 37. Smith EE, O’Donnell M, Teo K, Dagenais G, Lear S, Wielgosz A, 1. Mark I. Boulos, Jennifer Singerman, Brian J. Murray. Recurrent Sharma M, Stotts G, Black S, Modi J, McCreary CR, DeJesus Hypersomnia Due to Occult Hepatic Encephalopathy. Journal J, Rangarajan S, Yusuf S. Rationale, Design and Preliminary of Clinical Sleep Medicine. 2012 Mar;13(3):321-2 (40%). Findings of the Prospective Urban-Rural Epidemiologic Mind (PURE-MIND) MRI Study. Stroke. November 2011, Other 42(11):e587 Abstract presented at 2nd Canadian Stroke 1. Laperriere N, Weller M, Stupp R, Perry JR, Brandes AA, Congress (Ottawa, ON, October 2-4, 2011). Wick W & vanden Bent MJ. Optimal management of elderly 38. Stamenova V, Black SE, Roy EA. Dissociation between patients with glioblastoma. Cancer Treatment Reviews. June Input and Output of the Conceptual Praxis System. Stroke. 19, 2012 epub ahead of print November 2011, 42(11):e620 Abstract presented at 2nd Canadian Stroke Congress (Ottawa, ON, October 2-4, 2011). Honours and Awards 39. Swartz R, Breaton J, Silver F, Selchen D, Gladstone D, Zwarenstein M. The CLOQS study: countdown lights to International optimize quality in stroke CLoq study. Canadian Stroke Congress 2011 (Ottawa, Ontario). Oct 2011. Student/Trainee Awards Received 40. Verhoeff N, Honjo K, Kaye E, Petrovic-Poljak A, Wilson A, Rusjan P, Houle S, van Reekum R, Freedman M, Black 1. Black, Sandra E. Wayne Hening Young Investigator S. Amyloid Imaging with [11C]SB-13 PET in Patients with Award, International Restless Legs Syndrome Study Group Mild Alzheimer’s Disease: A Test-Retest Reliability Study of (IRLSS). (Awardee Name: Boulos, Mark). June 2012. Distribution Volume Ratio Estimates. Alzheimer’s and Dementia. Total Amount: $1,000.00 USD. July 2011;7(4-Suppl 1):S63, S724-5 Abstract presented at 2. Murray, Brian. Wayne Hening Young Investigator Award, Alzheimer’s Imaging Consortium (AIC) 2011 (Paris, France, International RLS Study Group (IRLSSG). Specialty: Sleep July 16, 2011) and Alzheimer’s Association International Medicine. (Awardee Name: Mark Boulos). July 2011 – June 2012. Conference (AAIC) 2011 (Paris, France, July 16-21, 2011). Total Amount: $1,000.00 USD.
Book Chapters National 1. Gao FQ, Swartz RH, Scheltens P, Leibovitch FS, Kiss A, Honjo Distinctions and Research Awards K, Black S. Complexity of MRI white matter hyperintensity assessments in relation to cognition in aging and dementia Received from the Sunnybrook Dementia Study. Handbook of imaging 1. Black, Sandra E. Irma M Parhad Award for Excellence, the Alzheimer brian, Advances in Alzheimer’s disease. Volume Consortium of Canadian Centres for Clinical Cognitive 2 679-688. 2011. Research (C5R). (Distinction). 2. Overview of Stroke diagnoses, treatments Gladstone DJ. 2. Swartz, Richard H. Focus on Stroke Research and preventions. International public education video series. Scholarship, Heart and Stroke Foundation of Canada, Feb 2012. CIHR, Canadian Stroke Network. (Distinction). 2010 – 2012. Case Reports peer-reviewed research salary support award. Total Amount: $100,000.00 CAD. 1. Wiseman-Hakes, C., Victor, J. C., Brandys, C., Murray, B. 3. Swartz, Richard H. Summer Studentship, Canadian Stroke Impact of post traumatic hypersomnia on functional recovery Network (CSN). (Research Award). May 2012 – August 2012. of cognition and communication: A case study. Brain Injury. Total Amount: $7,000.00 CAD. 2011 Dec;25(12), 1256-1265, (33%).
120 4. Zinman, Lorne H. Queen Elizabeth II Diamond Jubilee Provincial/Regional Medal, Faculty of Medicine. (Research Award). 2011. ALS Research and Leadership Activities. Distinctions and Research Awards
Student/Trainee Awards Received
Received 1. Black, Sandra E. Order of Ontario (O.Ont.), Government of Ontario, Ontario, Canada. (Distinction). January 2012. 1. Black, Sandra E. Vanier Doctoral Research Award, Canadian Institutes of Health Research, Canada. (Awardee The Order of Ontario is the province’s highest official Name: Schwindt, Graeme). May 2009 – April 2012. honour. Awarded to Dr. Sandra E. Black of Toronto, one of Total Amount: $150,000.00. the world’s pre-eminent cognitive neurologists specializing in stroke and dementia, and the visionary leader behind 2. Black, Sandra E. Canada Graduate Scholarship - the Ontario Stroke System. Frederick Banting and Charles Best Doctoral Award, Canadian Institutes of Health Research, Ontario, Canada. 2. Gladstone, David. HSFO Phase II Clinician-Scientist (Awardee Name: Nestor, Sean). May 2011 – April 2014. Award ($65,000/year; 3 years), Heart and Stroke Foundation of Ontario. (Research Award). 2009 – 2012. Total Amount: $90,000.00 CAD. Project title: “Improving the Detection and Treatment of 3. Black, Sandra E. Canadian Stroke Network Summer Research Atrial Fibrillation Following Transient Ischemic Attack and Scholarship, Faculty of Medicine, Sunnybrook Health Sciences Stroke”. Centre. (Awardee Name: Gravely, Mark). May 2011 – August 2011. 3. Early Researcher Award Total Amount: $7,000.00. Gladstone, David. ($50,000/year; 3 years), Ontario Ministry of Research 4. Black, Sandra E. Focus on Stroke Research and Innovation. (Research Award). 2011 – 2014. Fellowship, Heart and Stroke Foundation of Ontario/ “Stopping Bleeding in the Brain: Developing an Innovative Canadian Institute of Health Research, Canada. Image-Guided Emergency Treatment Protocol for Patients (Awardee Name: Boulos, Mark). July 2011 – June 2014. with Intracerebral Hemorrhage”. Total Amount: $150,000.00. 5. Black, Sandra E. MD/PhD Scholarship, Faculty of Medicine, Student / Trainee Awards McLaughlin Centre for Molecular Medicine, University of Toronto. Received (Awardee Name: Schwindt, Graeme). May 2012 – April 2015. 1. Black, Sandra E. HSF CSR Sunnybrook Research Fellowship, Total Amount: $18,000.00. Heart and Stroke Foundation Centre for Stroke Recovery, Canada. 6. Black, Sandra E. MD/PhD Scholarship, Canadian (Awardee Name: Herlihey, Tracey). July 2010 – June 2012. Institutes of Health Research. (Awardee Name: Total Amount: $25,000.00. Schwindt, Graeme). May 2012 – April 2015. 2. Black, Sandra E. Ruth Taylor Research Studentship Fund Total Amount: $72,000.00 CAD. - Summer Studentship, Queen’s University at Kingston. 7. Black, Sandra E. Training Program in Neurodegenerative (Awardee Name: Dossa, Fahima). May 2011 – August 2011. Lipidomics, Canadian Institute of Health Research, Ontario, Total Amount: $5,000.00 CAD. Canada. (Awardee Name: Lam, Benjamin). May 2012 – April 2013. 3. Black, Sandra E. HSFCSR Summer Student Award, Total Amount: $20,000.00 CAD. Heart and Stroke Foundation Centre for Stroke Recovery. (Awardee Name: Climans, Seth). June 2011 – August 2011. Total Amount: $2,500.00. 4. Black, Sandra E. Early Researchers Award, Ontario Ministry of Economic Development and Innovation, Ontario, Canada. (Awardee Name: Masellis, Mario). 2012 – 2017. Total Amount: $140,000.00 CAD.
121 5. Black, Sandra E. MITACS Accelerate Research Student / Trainee Awards Internship, MITACS & HSF CSR, Canada. (Awardee Received Name: Herlihey, Tracey). March 2012 – June 2012. Total Amount: $15,000.00 CAD. 1. Black, Sandra E. SRI Research Summer Student Award, Faculty of Medicine, Sunnybrook Research Institute. 6. Black, Sandra E. MITACS Accelerate Research Internship, MITACS & HSF CSR, Canada. (Awardee (Awardee Name: Nastis, Sofia). May 2011 – July 2011. Name: Gonzalez, David). April 2012 – July 2012. Total Amount: $1,600.00. Total Amount: $15,000.00 CAD. 2. Black, Sandra E. SRI Research Summer Student Award, Faculty of Medicine, Sunnybrook Research Institute. 7. Black, Sandra E. HSFCSR Summer Student Award, Heart and Stroke Foundation Centre for Stroke Recovery. (Awardee Name: Muir, Ryan). May 2012 – July 2012. (Awardee Name: Dmytriw, Adam). June 2012 – August 2012. Total Amount: $1,600.00. Total Amount: $2,500.00. 3. Black, Sandra E. IMS Summer Undergraduate Research Award, Faculty of Medicine, Institute of Medical Science Local (University of Toronto) & Sunnybrook Health Sciences Centre. (Awardee Name: Nastis, Sofia). June 2012 – August 2012. Distinctions and Research Awards Total Amount: $4,800.00 CAD. Received 4. Black, Sandra E. Brain Sciences Summer Studentship, 1. Gladstone, David. Department of Medicine Research Faculty of Medicine, Sunnybrook Health Sciences Centre. Committee (competitive, peer-reviewed research salary (Awardee Name: Au, Kelvin ). June 2012 – August 2012. support) ($50,000), Sunnybrook Health Sciences Centre. Total Amount: $2,000.00. (Salary Support). 2011. 5. Masellis, Mario. Sunnybrook Brain Sciences Summer 2. Black, Sandra E. Sibbald Mentorship Award for Excellence, Studentship, Primary Supervisor, Dept of Medicine, Faculty of Medicine, Sunnybrook Health Sciences Centre, Faculty of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Department of Medicine. (Distinction). Toronto, Ontario, Canada. Specialty: Neurology. (Awardee July 2011. Name: David Dongkyung Kim). May 2011 – August 2011. Total Amount: $2,000.00 CAD. 3. Black, Sandra E. Deborah Ivy Christiani Brill Chair in Neurology, Faculty of Medicine, Dept. of Medicine and SHSC Foundation, 6. Masellis, Mario. Sunnybrook Brain Sciences Summer University of Toronto, Canada. (Distinction). 2006–present. Studentship, Faculty of Medicine, Sunnybrook To advance research in cerebrovascular disease. Award Health Sciences Centre, Toronto, Ontario, Canada. Renewed Jan 2012. Total Amount: $2,000,000.00. (Awardee Name: Zhe Yu). May 2012 – August 2012. Total Amount: $2,000.00 CAD. 4. Swartz, Richard H. Junior Investigator Award, Faculty of Medicine, Sunnybrook Health Sciences Centre, Canada. (Research Award). 2011.
122 DIVISION OF REHABILITATION MEDICINE
Number of Faculty: 1
Grants Number Amount Peer Reviewed Funding Principal Investigator: 0 $0 CAD Co-Principal Investigator: 0 $0 CAD Co-Investigator / Collaborator: 0 $0 CAD Other: 0 $0 CAD Total: 0 $0 CAD
Non Peer Reviewed Funding Total: 0 $0 CAD
Publications Number Peer Reviewed Publications Principal Author 3 Co-Principal Author 1 Senior Responsible Author 0 Collaborator / Co-Author 0 Other Role 0 Total 4
Honours and Awards Received National: 4 Total Honours and Awards 4
123 Publications Honours and Awards
Peer Reviewed Publications Provincial/Regional
Journal Articles Distinctions and Research Awards
1. Annaswamy TM, De Luigi AJ, O’Neill B, Keole N and Berbrayer Received D. Emerging Concepts in the Treatment of Myofascial Pain: 1. Berbrayer, David. Ontario Medical Student Bursary A Review of Medications, Modalities, and Needle-based Fund- AWARDS Sustainer, Ontario Medical Assocaition, Interventions. Clinical Review: Current Concepts. PM&R; Canada. (Distinction). May 2007 – June 2012. Oct 2011. 3(10): 940-961. Ontario Medical Student Bursary Fund- AWARDS Received 2. Dr. David Berbrayer. Plantar Fasciitie. Knowledge Now - Sustainer 2006. Total Amount: $20.00 CAD. part of American Academy of Physical Medicine and 2. Berbrayer, David. Ontario Medical Student Bursary Fund- rehabilitation online articles. www.aapmr.org click knowldge AWARDS Benefactor, Ontario Medical Association, Canada. now - click MSK - click plantar fasiitis- peer reviewed online (Distinction). Specialty: PMR. May 2008 – June 2012. review. Nov 2011. Ontario Medical Student Bursary Fund- AWARDS Received Abstracts Benefactor 2008. Total Amount: $25.00 CAD. 3. Berbrayer, David. Ontario Medical Association Physiatry 1. Dr. David Berbrayer. Weight and Image Related Barriers Section Service Award, Service to OMA advancing role of to Employment in Spina Bifida. Abstracts annual meeting Physiatry in the medical profession, Ontario Medical Association, AAPMR-PMR journal. Nov 2011. Ontario, Canada. (Distinction). Specialty: Physiatry. May 2012. Criteria: The Section Service Award is awarded in” recognition Case Reports of significant service to the OMA, medical profession, or 1. Dr. D. Berbrayer. Pain and Spasticity in Child With Cerebral public within a Section.” Nominations Process: Nominations Palsy. AAPM&R’s Online Case Study Program Berbrayer,D: may be made through a Section by universities, hospitals “Pain and Spasticity in Child with Cerebral Palsy” AAPM&R and community medi. Case of the Month, Pediatric Case #1 Dec 2011. First published online Pediatric case report endorsed by the Teaching Awards American Academy of Physical Medicine and Rehabilitation Received Peer reviewed with editor and also subeditor blinded review 1. Berbrayer, David. Ontario Medical Student Bursary of project over several months. Fund- AWARDS Builder 2006, Ontario Medical Assocation, Ontario, Canada. Specialty: PMR. (Undergraduate Education, All Ontario medical students). May 2006 – June 2012. Ontario Medical Student Bursary Fund- AWARDS Received Builder 2006. Total Amount: $10.00 CAD.
124 DIVISION OF RESPIROLOGY AND CLINICAL IMMUNOLOGY
Number of Faculty: 4
Grants Number Amount Peer Reviewed Funding Principal Investigator: 2 $185,867 CAD Co-Principal Investigator: 0 $0 CAD Co-Investigator / Collaborator: 5 $1,665,800 CAD Other: 0 $0 CAD Total: 7 $1,851,667 CAD
Non Peer Reviewed Funding Total: 5 $8,204,272 CAD
Publications Number Peer Reviewed Publications Principal Author 8 Co-Principal Author 0 Senior Responsible Author 6 Collaborator / Co-Author 10 Other Role 0 Total 24
Honours and Awards Received National: 1 Provincial: 2 Local: 1 Total Honours and Awards 4
125 Grants, Contracts and Clinical Trials 5. Gershon, Andrea. Measuring and improving the quality of ambulatory care for people with cardiovascular risk factors Peer Reviewed Funding and/or chronic cardiovascular diseases. Tu, Jack, Alter D, Booth G, Hillmer M, Lee D, Stukel T, You J, Atzema C, Division Member is Principal Investigator Garg A, Hogg W, Lewis M, Tu K, Austin P, Gershon AS, 1. Gershon, Andrea. Impact of pulmonary function testing Kapral M, Manuel D, Walton N, Bhatia S, Glazier R, Ko D, on health outcomes of individuals with chronic obstructive Palmer L, Wijeysundera H: Canadian Institutes of Health pulmonary disease. To T, Aaron S: Ontario Lung Association Research (CIHR). Team Grant: Chronic Disease Risk and & Pfizer Canada. ($50,000 Aug 2011-July 2012 Prorated: Intervention Strategies. ($1,998,744 Apr 2012-Mar 2017 $45,833) [Grant] Prorated: $99,937) [Grant]
2. Gershon, Andrea. Respiratory Research Response Program: Non Peer Reviewed Funding Providing Evidence to Support Chronic Obstructive Pulmonary 1. Chronic Obstructive Pulmonary Disease Disease Drug Policy. To T, Upshur R, Stukel T: Ontario Ministry Gershon, Andrea. Surveillance Program. of Health and Long-Term Care. Drug Innovation Fund. Gershon, Andrea, To T: Ontario ($641,824 Sept 2009-Mar 2014 Prorated: $140,034) [Grant] Ministry of Health and Long-Term Care. ($384,183 Nov 2010-Mar 2014 Prorated: $112,444) [Grant] Other Peer Reviewed Funding 2. Gershon, Andrea. Chronic Respiratory Disease in the Metis 1. Geerts, William H. Prospective evaluation of long-term Nation of Ontario. Gershon, Andrea: Public Health Agency outcomes after pulmonary embolism. Dr. Susan Kahn (McGill of Canada (PHAC). ($24,823 Jan 2011-Jan 2012 Prorated: University) Drs. A Hirsch, J Granton, C. Dennie, E. Lang, $13,366) [Grant] W. Geerts, C Holcroft, et al. Canadian Institutes of Health 3. Gershon, Andrea. Ontario Asthma Surveillance Information Research (CIHR). Operating Grant. ($479,053.00 Apr 2009- System - Renewal. Gershon AS, To T: Ontario Ministry of Mar 2013 Prorated: $119,763) [Clinical Trial] Health and Long-Term Care. ($150,000 Apr 2012-Mar 2013 2. Gershon, Andrea. A pragmatic evaluation of telehomecare Prorated: $37,500) [Grant] for patients with congestive heart failure or Chronic Obstructive 4. Gershon, Andrea. Ontario Asthma Surveillance Information Pulmonary Disease. Henry, David and Stern, Anita, Krahn System - Renewal. Gershon, Andrea: Ontario Ministry of M, Alter D, Gershon AS, Liu P, Jaakkimainen L, Shah B, Health and Long-Term Care. ($150,000 Apr 2011- Mar Zwarenstein M, Booth R, Browne G, Bowles K, Donnelle L, 2012 Prorated: $112,500) [Grant] Franek J, Jadad A, Mitsakakis N, Pham B, Paulden M, Ritvo 5. Gershon, Andrea. Pulmonary Function Testing in Ontario. P, Scott RE, van der Velde G, Ladak N: Ontario Ministry Gershon, Andrea: Ontario Ministry of Health and Long-Term of Health and Long-Term Care. ($990,203 Aug 2011-July Care. ($252,135 Apr 2011-Mar 2013 Prorated: $126,068) 2014 Prorated: $302,562) [Grant] [Grant] 3. Gershon, Andrea. Canadian Cohort Obstructive Lung Disease (CanCOLD). Bourbeau, Jean and Tan, Wan, Aaron SD, Publications Atherton JK, Baglone C, Benedetti A, Chapman KR, Cowie RL, Coxson HO, Daskalopoulou S, Despres J-P, Fitzgerald Peer Reviewed Publications JM, Gershon AS, Goldstein RS, Hernandez P, Lacasse Y, Lavoie K, Maltais F, Marciniuk DD, Meidinger D, O’Donnell Journal Articles DE, Rabasa-Lhoret R, Sin D: Canadian Institutes of Health 1. Brian M Wong, Khalil Sivjee et al. Getting the message: Research (CIHR). Operating Grant: Industry-partnered a quality improvement initiative to reduce pages sent to the Collaborative Research. ($1,108,844 Jan 2011-June 2013 wrong physician. BMJ. 2012 Feb. Prorated: $443,538) [Grant] 2. Bucci C, Geerts WH, Sinclair A, Fremes SE. Comparison of 4. Gershon, Andrea. Canadian Network for Observational Drug the effectiveness and safety of low-molecular-weight heparin Effect Studies (cNODES). Suissa S: Canadian Institutes of versus unfractionated heparin anticoagulation after heart Health Research (CIHR). ($3,500,000 Jan 2011-Dec 2015) valve surgery. Am J Cardiol. 2011;107:591-594. Prorated: $700,000) [Grant]
126 3. Cook D, Meade M, Guyatt G, Walker SD, Heels-Ansdell D, 14. To T, McLimont S, Daly S, Moores G, Gershon AS, Lougheed Geerts W, Warkentin TE, Cooper DJ, Zytaruk N, Vallance S, D. Is it feasible to use indicators to collect data on asthma care Berwanger O, Rocha M, Qushmaq I, Crowther M. PROphylaxis performance in the primary care setting? A feasibility study. for ThromboEmbolism in Critical care Trial protocol and Primary Care Respiratory Journal. 2011 Dec;20(4):452-453. analysis plan. J Crit Care. 2011;26:223.e1-223.e9. 15. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, 4. Gandhi R, Salonen D, Geerts WH, Khanna M, McSweeney Cruz AA, Boulet LP. Global asthma prevalence in adults: S, Mahomed NN. A pilot study of CT detected asymptomatic findings from the cross-sectional world health survey. BioMed pulmonary filling defects following hip and knee arthroplasty. Central Public Health. 2012 Mar;12:204. J Arthroplasty. 2012;27(5):730-735. 16. Victor JC, To T, Wilton A, Guan J, Ho MH, Gershon AS. 5. Gershon AS, Dolmage TE, Stephenson A, Jackson B. The feasibility of COPD surveillance in Ontario: a population Chronic obstructive pulmonary disease and socioeconomic study. HealthCare Quarterly. 2011 Oct;14(4): 25-9. status: a systematic review. Journal of Chronic Obstructive Abstracts Pulmonary Disease. 2012 Apr;9:216–226.
6. Gershon AS, Guan J, Victor JC, Wang C, To T. The course 1. Gershon AS, Cascagnette P, Croxford R, Stanbrook M, To T, of asthma activity: a population study. The Journal of Allergy Upshur R, Stephenson A, Stukel T. Comparative effectiveness and Clinical Immunology. 2012 Mar;129:679-686. of inhaled, long-acting beta agonists with and without inhaled corticosteroids in older individuals with chronic obstructive 7. Gershon AS, Guan J, Wang C, Victor JC. Describing and quantifying asthma comorbidity: a population study. PLoS pulmonary disease (COPD). Am J Respir Crit Care Med 2012 ONE. 2012 May; 7(5): e34967. May;185;2012:A3714.
8. Gershon AS, Victor JC, Guan J, Aaron SD, To T. Pulmonary 2. Gershon AS, Victor JC, Cascagnette P, Aaron SD, To T. function testing in the diagnosis of asthma: a population Use of pulmonary function testing in the diagnosis of chronic study. Chest. 2012 May;141(5):1190-1196. obstructive pulmonary disease (COPD). Am J Respir Crit 9. Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Care Med 2012 May;185:A3712. Lifetime risk of developing chronic obstructive pulmonary disease (COPD). Lancet. 2011 Sept;378(9795):991 - 996. 3. Gershon AS, Warner L, Cascagnette P, Croxford R, Stanbrook M, To T, Upshur R, Stephenson A, Stukel T. Disparity in access 10. Iron K, Lu H, Manuel D, Henry D, Gershon AS. Using linked health administrative data to assess the clinical and healthcare to medications for chronic obstructive pulmonary disease system impact of chronic diseases in Ontario. Healthcare (COPD). American Journal of Respiratory and Critical Care Quarterly. 2011;14(3):23-27. Medicine. 2012 May;185:A3713. 11. Nanwa N, Mittmann N, Knowles S, Bucci C, Selby R, 4. To T, Foty R, Dell S, Stanojevic S, Gershon AS, Lisckai C. Shear N, Walker SE, Geerts W. The direct medical costs The impact of air quality on chronic obstructive pulmonary associated with suspected heparin-induced thrombocytopenia. disease (COPD) morbidity: a population-based study. PharmacoEconomics. 2011;29:511-520. American Journal of Respiratory and Critical Care Medicine. 12. Smith SD, Sivjee K. Defining training needs, core competencies 2012 May;185:A1727. and future certification for Canadian hospitalists. CMAJ. 2012 Jan. 5. To T, Stanojevic S, Dell S, Lougheed D, Zheng H, McLimont S, Gershon AS. The prevalence of severe asthma in Ontario, 13. Stephenson A, Seitz DP, Fischer HD, Gruneir A, Bell CM, Canada from 2001 to 2009. American Journal of Respiratory Gershon AS, Fu L, Anderson GM, Austin PC, Rochon PA, and Critical Care Medicine. 2012 May;185:A5228. Gill SS. Cholinesterase inhibitors and adverse pulmonary events in older people with chronic obstructive pulmonary 6. Vozoris N, Fischer H, Fang X, Anderson G, Bell C, Gershon disease and concomitant dementia: a population-based AS, Gill S, Rochon P. Benzodiazepine medication use among cohort study. Drugs and Aging. 2012 Mar;29(3):213-223. older adults with chronic obstructive pulmonary disease (COPD) in Ontario, Canada. American Journal of Respiratory and Critical Care Medicine. 2012 May;185:A3996.
127 Other Provincial
1. Stanbrook MB, Gershon AS. Inhaled long-acting β-agonists Distinctions and Research Awards versus anticholinergics in older patients with chronic Received obstructive pulmonary disease. Annals of Internal Medicine 2011 Oct;155(8):561-562. 1. Gershon, Andrea. Ontario Career Scientist Award, Government of Ontario, Nunavut, Canada. (Research Award). July 2009 – September 2011. Honours and Awards Originally granted for $70,000 per year for 5 years but ended early due to program terminiation. $70,000.00 CAD. National 2. Gershon, Andrea. The Ontario Lung Association/Pfizer Distinctions and Research Awards Canada Smoking Cessation and COPD Award 2011, Ontario Lung Association, Ontario, Canada. (Research Award). 2012. Received
1. Gershon, Andrea. Pharmacologic Management of Chronic Local Disease in Older Adults II New Investigator Award, CIHR New Distinctions and Research Awards Emerging Team in Pharmacologic Management of Chronic Received Disease in Older Adults. (Research Award). January 2012 – December 2012. 1. Sivjee, Khalil Y. 2011 Feldman Patient Safety Award for TRAPP Clinic, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. (Distinction). Specialty: Department of Medicine. September 2011.
128 DIVISION OF RHEUMATOLOGY
Number of Faculty: 2
Grants Number Amount Peer Reviewed Funding Principal Investigator: 2 $42,511 CAD Co-Principal Investigator: 2 $33,700 CAD Co-Investigator / Collaborator: 1 $0 CAD Other: 0 $0 CAD Total: 5 $76,211 CAD
Non Peer Reviewed Funding Total: 0 $0 CAD
Publications Number Peer Reviewed Publications Principal Author 1 Co-Principal Author 0 Senior Responsible Author 2 Collaborator / Co-Author 3 Other Role 0 Total 6
Honours and Awards Received International: 1 National: 4 Local: 0 Total Honours and Awards 5
129 Grants, Contracts and Clinical Trials Publications
Peer Reviewed Funding Peer Reviewed Publications
Division Member is Principal Investigator Journal Articles
1. Bell, Mary. Physician’s Tool to Evaluate Joint and Bone 1. Bell MJ, Veinot P, Embuldeniya G, Nyhof-Young J, Sale J, Complaints. Taveres, Mary Aisen: Canadian Initiative For Sargeant J, Tugwell P, Brooks S, Ross S, Tonon R, Richards Outcomes in Rheumatology Care (CIORA). ($47,808 Dec D, Boyle J, Knickle K, Sandhu S, Britten N, Bell E, Webster F, 2011-Aug 2013 Prorated: $15,936) [Grant] Cox-Dublanski M. Peer to Peer Mentoring for Individuals with Early Inflammatory Arthritis: Peer Mentor Training. # OP04. 2. Bell, Mary. Peer-to-Peer Mentoring For Individuals with Early Inflammatory Arthritis: An Effective Study (Pilot RCT). Excellence in Rheumatology. Madrid, Spain. (Awarded 4th Ed Keystone, Sydney Lineker, Joanna Sale, Sharron Sandhu: best abstract) 2012. Canadian Initiative For Outcomes in Rheumatology Care 2. Oswald AE, Bell MJ, Wiseman J, Snell L. The impact of (CIORA). ($46,506 Dec 2010-Aug 2012 Prorated: $26,575) trained patient educators on musculoskeletal clinical skills [Grant] attainment in pre-clerkship medical students. BMC Med Educ. 2011 Sep 23;11(1):65. Other Peer Reviewed Funding 3. Oswald AE, Wiseman J, Bell MJ, Snell L. Musculoskeletal 1. Bell, Mary. Improving patient outcomes: mapping practice examination teaching by patients versus physicians: how are boundaries and intersections between the domains of they different? Neither better nor worse, but complementary. Continuing Education, Knowledge Translation, Patient Med Teach. 2011;33(5):e227-35 Safety and Quality Improvement. Kitto S, Bell M, Reeves S, 4. Ruben Tavares, Janet E. Pope, Jean-Luc Tremblay, Carter Sargeant J, Etchells E, Silver I: . ($20,000 AFMC SCCPD Thorne, Vivian P. Bykerk, Juris Lazovskis, Kenneth L.N. May 2011-June 2012 Prorated: $17,143) [Grant] Blocka, Mary J. Bell, Diane Lacaille, Carol A. Hitchon, 2. Bell, Mary. Getting a Grip on Arthritis Online. The Arthritis Avril A.Fitzgerald, Wesley K. Fidler, Arthur A.M. Bookman, Society. Lineker (Brooks), Sydney Dr. Sydney Cecile Lineker, James M. Henderson, Dianne P.Mosher, Dalton E. Sholter, Lynn Moore, Dr. Mary Jane Bell, Dr. E. Badley, Dr. V. Curran, Majed Khraishi, Boulos Haraoui, Hong Chen, Xiuying Mrs. K. Drouin, Ms. L. Fleet, Mrs. B. Hajdu, Mr. C. Hogben, Li,Andreas Laupacis, Gilles Boire, George Tomlinson and Mrs. F. Kirby, Mr. J. McCarthy, Dr. P. Tugwell, Dr. J. Wootton Claire Bombardier. Arthritis and Its Predictors: A National, (SRPC): Canadian Institutes for Health Research Planning Multicenter, Retrospective Cohort Time to Disease-modifying and Dissemination Grant (CIHR). ($198,680 May 2012-Apr Antirheumatic Drug Treatment in Rheumatoid. The Journal 2014 Prorated: $16,557) [Grant] of Rheumatology 2012; 39:11; doi:10.3899/jrheum.120100 3. CME Bias Management Process Project - Part 2 Bell, Mary. Abstracts Project. Takhar J, Marlow B, Bourgeoi, Campbell C, Cemone C, Dixon D, Lockyer E, Bell M, Davis P, Rebel M: RCPSC 1. Bell MJ, Veinot P, Embuldeniya G, Nyhof-Young J, Sale J, Medical Education Research Grant. (Mar 2008-2011) [Grant] Sargeant J, Tugwell P, Brooks S, Ross S, Tonon R, Richards D, Boyle J, Knickle K, Sandhu S, Britten N, Bell E, Webster F, Cox-Dublanski M. Peer to Peer Mentoring for Individuals with Early Inflammatory Arthritis: Peer Mentor Training. # OP04. Excellence in Rheumatology. Excellence in Rheumatology, Madrid, Spain. (Awarded 4th best abstract) 2012.
130 Other 2. Bell, Mary. Consumer Champion Award, 2011 Canadian Arthritis Network Annual Scientific Conference., Quebec, Canada. 1. Ruben Tavares, Janet E. Pope, Jean-Luc Tremblay, Carter (Consumer Champion Award - Canadian Arthritis Network Thorne,Vivian P. Bykerk, Juris Lazovskis, Kenneth L.N. Annual Scientific Conference). October 2011 – October 2012. Blocka, Mary J. Bell, Diane Lacaille, Carol A. Hitchon, Consumer Champion Award. Avril A. Fitzgerald, Wesley K. Fidler, Arthur A.M. Bookman, James M. Henderson, Dianne P. Mosher, Dalton E. Sholter, Student/Trainee Awards Majed Khraishi, Boulos Haraoui, Hong Chen, Xiuying Received Li,Andreas Laupacis, Gilles Boire, George Tomlinson And 1. Bell, Mary. Summer Res Prog Med & Allied Health Claire Bombardier. Early Management of Newly Diagnosed Prof Students, Dept of Medicine, Faculty of Medicine, Rheumatoid Arthritis by Canadian Rheumatologists: A University of Toronto. Canadian Arthritis Network National, Multicenter, Retrospective Cohort. The Journal (CAN), Toronto, Ontario, Canada. (Awardee Name: of Rheumatology. 2011;38;2342-2345 The Journal of Sicong (Selena) Huang). May 2011 – August 2011. Rheumatology 2011; 38:11; doi:10.3899/jrheum.110249 Total Amount: $6,000.00 CAD. Honours and Awards 2. Bell, Mary. Abbott Summer Studentship, Dept of Medicine, Faculty of Medicine, University of Toronto. Canadian International Rheumatology Association (CRA), Toronto, Ontario, Canada. (Awardee Name: Joseph Moran). May 2011 – July 2011. Distinctions and Research Awards Total Amount: $5,000.00 CAD. Received Local 1. Bell, Mary. 4th best abstract award, 2012 Excellence in Rheumatology Conference, Madrid, Spain. (Excellence Distinctions and Research Awards in Rheumatology 4th Best abstract award). Specialty: Nominated Peer to Peer Mentoring. January 2012 – January 2013. Bell, Mary. Department of Medicine, Mentoring Award, University Awarded 4th best abstract for 2012 conference - Bell MJ, of Toronto, Toronto, Ontario, Canada. (Mentoring). 2010 – 2011. Veinot P, Embuldeniya G, Nyhof-Young J, Sale J, Sargeant J, Tugwell P, Brooks S, ross S, Tonon R, Richards D, Boyle J, Knickle K, Sandhu S, Britten N, Bell E, Webster F, Cox- Dublanski M. ( January 2.
National
Distinctions and Research Awards
Received
1. Bell, Mary. Best Poster award for the consumer category, 2011 Canadian Arthritis Network Annual Scientific Conference., Quebec, Canada. (“Best Poster” award in the consumer category - Canadian Arthritis Network Annual Scientific Conference.). October 2011 – October 2012. “Best Poster” award in the consumer category - Richards D, Boyle J, Veinot P, Bell M. ( October 27 -29, 2011). Consumer Involvement in the Development of a Peer to Peer Mentoring Intervention for Individuals with Early Inflammatory Arthritis. Canadian Art.
131 MISSION, VISION & VALUES STATEMENTS MISSION VISION VALUES
Sunnybrook’s Department of Medicine Optimal care for every patient • Clinical excellence: leadership in quality promotes and delivers the highest quality through leadership in clinical and safety of the patient experience care, provides an innovative learning and practice, education and research. • Academic excellence: innovation, critical practice environment, engages in research, inquiry and effective knowledge exchange. and supports knowledge exchange • Supportive and energizing environment: between clinicians, researchers and collegiality and inter-professional educators to achieve the best possible collaboration; an environment where every health outcomes for local and global faculty member is supported and valued populations. • Accountability
ORGANIZATION CHART
Physician-in-Chief
Deputy Physician-in-Chief
Committees Executive Committee Division Heads • Education • Cardiology • Faculty Well-Being • Clinical Pharmacology & • Finance Toxicology • Research • Dermatology • Endocrinology • Gastroenterology • General Internal Medicine • Geriatric Medicine • Infectious Diseases • Medical Oncology/ Hematology • Nephrology • Neurology • Obstetrical Medicine • Rehabilitation Medicine • Respirology & Clinical Immunology • Rheumatology
132 Annual Report July 1, 2011 – June 30, 2012
Sunnybrook Health Sciences Centre 2075 Bayview Avenue, Room D474 Toronto, ON, Canada M4N 3M5 T: 416.480.4592 F: 416.480.6191